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Abstract
Lessons in Modeling, Preventing, and Treating Neural Injury: Improving Bench-toBedside Translation
Ryan Coddington Turner
The translation of therapeutic agents for ischemic stroke and traumatic brain injury from
the preclinical laboratory to clinical trials has been fraught with failure as evident by the
1,000+ preclinical studies that have failed to translate to a proven therapeutic clinically.
Numerous potential reasons for these shortcomings have been identified and include the
use of animal models that fail to capture clinically relevant risk factors or injury
parameters, targeting of pathological events occurring rapidly after injury but before the
likely time of patient presentation for treatment, emphasis on acute rather than chronic
outcome measures, and mismatch in outcome measures used between preclinical and
clinical studies. To address these shortcomings, we describe the use of aged animals in
a clinically relevant model of ischemic stroke produced through thrombus insertion and
reperfusion mediated via administration of tissue plasminogen activator (tPA), the only
FDA-approved pharmacologic agent for treatment of ischemic stroke.
Using this
ischemic stroke model with tPA administered at 2 hours post-stroke, we demonstrate the
neuroprotective properties of bryostatin-1, a protein kinase c (PKC) modulator.
Specifically, bryostatin-1 treated animals displayed an improved survival rate, reduced
infarct volume, and diminished functional impairment following ischemic stroke. As tPA
administration is limited clinically by the time of presentation, extending the therapeutic
window will be therapeutically advantageous. We show, in our aged model of ischemic
stroke, that administration of a recombinant human apyrase (APT 102), a novel form of
the naturally occurring human apyrase/ADPase, improves the safety and efficacy of tPA
administration at 6 hours post-stroke based on functional and histological endpoints.
Furthermore, we characterized behavioral and functional deficits following ischemia at
numerous time points in order to more closely replicate clinical studies that emphasize
behavioral outcomes rather than the use of infarct volume or other histological measures
as an experimental endpoint. These studies demonstrate a significant correlation
between infarct volume and functional ability, particularly with regards to striatal infarcts.
Similar paradigms were applied to a diffuse axonal injury model and revealed no
substantive deficits between injured and non-injured animals within one week of trauma.
This indicates the challenge of identifying injury severity in preclinical trauma models as
the lack of deficits is more representative of subconcussive injury rather than concussion
or more substantive brain injury. Using this diffuse axonal injury model, we also explore
preventative measures drawing on biologically inspired discovery. We show for the first
time, the ability to reduce intracranial injury through manipulation of the vasculature
through an externally applied device. Data from these studies demonstrate potential
advances addressing the shortcomings associated with neural injury research, namely
the development and use of clinically relevant animal models, selection of appropriate
experimental endpoints, and varied approaches to both improving neural injury
prevention and treatment.

This work is dedicated to my loving and supportive family and the many others
that have helped and encouraged me along the way.
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CHAPTER 1
BACKGROUND AND OBJECTIVES
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The overall goal of this work is to better understand neural injury in an effort to develop
improved treatment for patients suffering neural injury. Neural injury takes numerous
forms ranging from ischemic stroke to hemorrhagic stroke to traumatic brain injury to
drug abuse. Consequently, numerous tools exist for studying neural injury and include
animal models of ischemic stroke and traumatic brain injury, both of which are explored
in greater detail throughout this work as these animal models are utilized as tools for the
study of neural injury.
1.1 Types of Neural Injury
Neural injury represents a leading cause of death and disability in the developed world,
likely due to the diverse and highly prevalent nature of neural injury. While neural injury
has historically been categorized as a product of ischemic or hemorrhagic stroke and
trauma, further sub-classifications and other forms of neural injury require consideration.
Traumatic brain injury, for example, can be classified as open or closed, linear or
rotational, and can occur from a traditional impact or from blast exposure. Other forms
of neural injury include toxicant exposure and drug abuse, each of which may result in
not only acute pathological changes but also persistent neuroinflammation, not unlike
more traditionally considered forms of neural injury such as stroke and trauma.
1.2 Pathophysiology of Neural Injury
While the diversity of conditions and causes associated with neural injury leads to
various inciting injurious elements, the pathophysiology of neural injury often shares
many similar events. Using ischemia as an example, the cessation of blood flow is
associated with a rapid decoupling of oxidative phosphorylation and hypoglycemia that
leads to decreased ATP production and failure of ionic pumps. Ionic imbalance leads to
membrane depolarization and subsequent glutamate release from the pre-synaptic
neuron 1. Excess glutamate can lead to prolonged opening of Ca2+ channels and a
number of damaging events ranging from free radical production to activation of
Ultimately, these events may lead to
proteases, lipases, and endonucleases 2.
irreversible cell damage and death. While these events occur rapidly following injury,
others demonstrate a delayed onset or persist for prolonged periods. Perhaps the best
example of a delayed but persistent event following injury is that of inflammation 3.
Induction of the inflammatory process remains under investigation but emerging
evidence indicates a role for not only signaling molecules released from the damaged
tissue directly (proteases, DAMPs, ATP, etc) but also a disruption in communication
between neurons and glial cells essential for homeostasis as well as the response to
injury, namely microglia and astrocytes. How exactly these glial cells contribute to injury
as well as repair is not entirely clear and consequently remains a topic of investigation 3.
Other forms of neural injury exhibit similar pathophysiological processes as ischemic
stroke. For example, traumatic brain injury, particularly open head injury, results in
vascular disruption and therefore produces similar pathological events to ischemic stroke
acutely. Traumatic brain injury, particularly closed head injury, also produces diffuse
axonal injury (DAI). DAI leads to microstructural changes in connectivity and excess
glutamate release, a finding that frequently correlates with injury severity 4, and initiates
a pathological cascade similar to that observed in ischemic stroke 5. Furthermore,
trauma induces significant glial activation as evident by astrocyte reactivity, microglial
activation, and corresponding events such as cytokine release and formation of the glial
scar 6,	
   7. Glial activation, a hallmark of neuroinflammatory processes, is shared amongst
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most, if not all, forms of neural injury and represents a critical pathological process in
drug abuse and neurotoxicant exposure as well.
1.3 Modeling Ischemic Stroke
One of the tools developed and honed by the Rosen lab at West Virginia University for
the study of neural injury is that of ischemic stroke in a clinically-relevant animal model
utilizing aged rodents and a thromboembolic mechanism of ischemia. This model,
surgical technique, and some of the finer points required for experimental success are
detailed in the following section.
This work was published in TRP Channels in Drug Discovery: Volume II, Methods in
Pharmacology and Toxicology.
Citation: Turner RC, Elliott AS, Huber JD, Rosen CL (2012) A Clinically Relevant
Thromboembolic Stroke Model in the Aged Rat. Edited by Arpad Szallasi and Tamás
Bíró. TRP Channels in Drug Discovery: Volume II. Methods in Pharmacology and
Toxicology.
ABSTRACT
Animal models have been an integral component of scientific discovery concerning
ischemic stroke pathophysiology and the accompanying therapeutic targets.
Unfortunately, the knowledge gleaned from these studies has failed to translate to
enhanced therapeutics in the clinical environment 8. We argue that this failed translation
is a direct result of inadequate animal models that fail to address the greatest risk factor
for stroke, age 9. Herein we provide comprehensive step-by-step instructions for a
clinically-relevant thromboembolic stroke model in aged rats 10. This technique, utilizing
the only FDA approved therapeutic agent for the treatment of stroke, tissue plasminogen
activator (tPA), allows for pathophysiologic studies in addition to testing potential
therapeutic agents in combination with the currently approved treatment regime.
1.3.1. INTRODUCTION
The desire to model stroke in the preclinical environment remains relevant due to the
immense societal impact of stroke. Stroke remains the world’s second leading cause of
Worse yet, survivors often
mortality, resulting in ~6,000,000 deaths annually 11.
experience significant morbidity. These factors necessitate the development of improved
therapeutic agents that can be applied to a greater percentage of those afflicted with
stroke.
In spite of more than 100 agents that have progressed from what appeared to be
successful preclinical studies to clinical trials, tissue plasminogen activator remains the
only FDA approved treatment and can be used in a relatively small number of patients
due to contraindications and a limited window of opportunity 8. The question of why so
many agents have failed to translate successfully remains largely unanswered.
Assessing this failed translation, it is clear that one key difference exists between the
animal models and the clinical realm – the consideration of age.
The average stroke patient is elderly – approximately 72% of patients are over the age
of 65 yet the vast majority of preclinical studies are completed in 3 month old rats which
equates to essentially a young-adult 9. Additionally, 52% of stroke victims are female but
most preclinical studies utilize male animals. Furthermore, 87% of strokes are ischemic
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and caused by a thrombus or embolus occluding a vessel, most often being the middle
cerebral artery. Despite this fact, many preclinical studies utilize other methods of
occlusion ranging from a suture to endothelin-1 to photothrombosis.
The stroke model described in this work seeks to model the clinical scenario as closely
as possible by utilizing aged, female rats and a thrombus to occlude the middle cerebral
artery 10. While this is but one model of ischemia in terms of technique and animal type
used, we believe it is the most clinically relevant for studying the pathophysiology of
stroke and assessing various proposed pharmacologic agents.
1.3.2. MATERIALS
1.3.2.1. Equipment
Equipment described below is used in our laboratory. Alternatives are available and may
be substituted where appropriate.
1. VetEquip RC2 (Rodent Circuit Controller) anesthesia machine (VetEquip;
Pleasanton, California)
2. Harvard Apparatus Homeothermic Blanket Control Unit with Probe(Harvard
Apparatus; Holliston, Massachusetts)
3. Harvard Apparatus Homeothermic Blanket (Harvard Apparatus; Holliston,
Massachusetts)
4. Oster GOLDEN A5 with #10 clip for hair removal (Oster; McMinnville,
Tennessee)
5. Leica M400-E Operative Microscope (Leica Microsystems Inc; Buffalo Grove,
IL)
6. Moor Instruments DRT4 Laser Doppler Perfusion Monitor (Moor Instruments
Inc; Wilmingtown, Delware)
7. Aitecs SEP-215 Plus syringe pump for administering saline (Aitecs; Vilnius,
Lithuania)
8. Harvard Apparatus Pump 11 for administering tissue plasminogen activator
(Harvard Apparatus; Holliston, Massachusetts)
9. Integra 2.7 mm twist drill bit with adjustable safety stop (Integra; Plainsboro,
New Jersey)
10. Integra Camino Bolt (cranial bolt for insertion of Doppler probe) (Integra;
Plainsboro, New Jersey)
11. ISMATEC Reglo Peristaltic Pump for cardiac perfusion of the animal
(ISMATEC; Wertheim-Mondfeld, Germany)
12. -80 °C freezer
13. Autoclave (for sterilizing surgical equipment)
14. Incubator (for thrombus preparation)
1.3.2.2. Supplies for Thrombus Preparation
1. INTRAMEDIC CLAY ADAMS Brand NON-RADIOPAQUE POLYETHYLENE
TUBING (BD; Franklin Lakes, New Jersey)
a. PE 50 – I.D. 0.58 mm and O.D. 0.965 mm
b. PE 10 – I.D. 0.28 mm and O.D. 0.61 mm
2. Petri dish
3. 1 ml syringe
4. Bunsen Burner
5. 0.9% Physiologic Saline
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1.3.2.3. Surgical Instruments and Supplies
1. Kendall Curity Gauze Sponges (for making gauze pillow) (Covidien;
Mansfield, Massachusetts)
2. VWR Laboratory Labeling Tape (for making gauze pillow) (VWR International;
Radnor, Pennsylvania)
3. Puritan Cotton Tipped Applicators (VWR International; Radnor, Pennsylvania)
4. Kendall MonoJect 20 ml syringe (Covidien; Mansfield, Massachusetts)
5. Ethicon 3-0 Coated Vicryl Suture (Ethicon; Somerville, New Jersey)
6. Syneture 5-0 Sofsilk Suture (Covidien; Mansfield, Massachusetts)
7. Forceps (sharp & dull; different sizes)
8. Surgical scissors (large and small sizes)
9. Surgical scalpel
10. Bard-Parker Stainless Steel Surgical Blade #15 (BD; Franklin Lakes, New
Jersey)
11. Micro-scissors
12. Micro-vascular clips (x 2)
13. Micro-vascular clip holder
14. Hemostat
15. Needle Driver
16. Bone Rongeur for craniotomy
17. 2 mm brain block
18. Razor blades
19. Sterile surgical gowns
20. Sterile surgical gloves
21. Sterile surgical drapes
22. Instrument pouch for autoclave
23. Micro-syringe for thrombus injection
1.3.2.4. Drugs/Chemicals
1. Baxter 0.9% Sodium Chloride Injection USP 1000 mL (Baxter; Deerfield,
Illinois)
2. 2,3,5 – Triphenyl tetrazolium chloride (Sigma-Aldrich; St. Louis, Missouri)
3. Activase (tissue plasminogen activator) (Genentech; San Francisco,
California)
4. Phosphate-buffered Saline (PBS)
5. Scrub Care® Providone Iodine Cleansing Solution (Cardinal Health; Dublin,
Ohio)
6. Dechra VETROPOLYCIN veterinary ophthalmic ointment (Dechra Veterinary
Products; Overland Park, Kansas)
7. Isoflurane
1.3.3. METHODS
The following sections describe all steps of the thromboembolic stroke model beginning
with chemical and surgical preparation through achieving reperfusion.
1.3.3.1. Chemical Preparation
1.

Activase (tissue plasminogen activator)
a. Add 100 mL of physiologic saline to 100 mg bottle of Activase,
creating a concentration of 1 mg/ml.
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b. Dissolve the mixture by gentle shaking.
c. Aliquot 1.5 mL in 2 mL Eppendorf tubes and store at -80 °C until
needed. To achieve the final dose of 5 mg/kg, 5 ml/kg is given.
For example, a 300 gram rat receives 1.5 ml of the 1 mg/ml
mixture.
2.

2% Triphenyl tetrazolium chloride
a. Weight 2 grams of 2,3,5 - Triphenyl tetrazolium chloride.
b. Place in a 100 mL Pyrex round media storage bottle with screw
cap.
c. Fill to 100 mL with phosphate-buffered saline.

1.3.3.2. Surgical Preparation
1.

Preparation of Sterile Surgical Instruments
a. Place clean instruments in autoclave pouch. Instruments should
be in the open position when applicable to ensure proper
sterilization.
b. Place autoclave pouch containing instruments in the autoclave.
c. Ensure autoclave is filled with deionized water.
d. Run autoclave (most cycles are at least 20 minutes).
e. After cycle is complete and pressure reduced, crack the autoclave
door slightly (Note 1).
f. Run drying cycle (per manufacturer instructions).
g. Allow temperature to normalize with room temperature.
h. Remove pack.

2.

Anesthesia Induction
a. Place rat in the anesthesia induction chamber.
b. Induce anesthesia for 10 minutes with the gas valve set at 4.0%.
c. Remove rat from induction chamber and place the nose of the rat
in the nose cone.
d. Maintain anesthesia via nose cone with the gas valve set at 2.0%
for remainder of procedure.

3.

Aseptic Surgical Preparation
a. Shave the hair of the rat in the proper position (see below).
b. Apply sterile surgical drapes around the surgical site.
c. Ready these areas for surgery using a surgical preparation
solution such as betadine.
d. Place a drop of eye ointment in each eye to prevent post-surgical
ophthalmic infections.

4.

Preparation of Gauze Pillow
a. Roll gauze pads together creating a 2.5 cm diameter by 5 cm long
cylinder.
b. Secure with laboratory labeling tape.
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1.3.3.3. Creation of Thrombus
1. Position rat on the homeothermic heating pad in a supine position while
placing the lower limbs in the down position, exposing the groin region (Note

Figure 1.1. Femoral artery dissection in preparation for blood draw to create
thrombus. Note space between suture and microvascular clip – this is where femoral
artery lumen will be exposed to insert PE50 tubing.
8).
2. Prepare the right groin area for aseptic surgery (see above).
3. Using a surgical scalpel, make a 4 cm incision parallel to the midline in the
groin.
4. Using blunt dissection techniques, dissect down to the femoral artery and
vein. Passing through the layers of fat and connective tissue, the inferior
epigastric artery will become visible, arising from the femoral artery and
coursing towards the superficial layers of the lower abdomen.
5. Using a 3-0 suture, retract the external oblique muscle overlying the femoral
artery using a hemostat in order to widen the field of view.
6. Isolate the femoral artery from the surrounding femoral vein and nerve.
7. Using a 5-0 suture, ligate distal portion of femoral artery.
8. Place microvascular clip (aneurysm clip) proximally to ligated portion of the
femoral artery. Leave sufficient space (approximately 2 cm) between suture
and clip. This process is visualized in Figure 1.
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9. Once microvascular clip and suture are in place, effectively ceasing blood
flow through this portion of the femoral artery, use microscissors to make a
small cut in the top portion of the femoral artery. Use caution to not sever the
entire vessel so that the base of the artery remains intact despite an opening
in the top portion.
10. Cut a 15 cm long segment of PE50 tubing. Bevel one end of the cut segment
at approximately 45°.
11. Insert beveled end of PE50 tubing into opening of the femoral artery. With
application of light pressure, artery circumference will stretch to
accommodate the tubing.
12. Once beveled end of PE50 tubing is entirely inside the artery lumen (0.5 cm
inside), release the microvascular clip briefly.
13. PE50 tubing should rapidly fill with blood. Upon filling, the microvascular clip
is replaced.
14. Remove blood-filled PE50 tubing and bipolar coagulate the femoral artery
proximal to incision, in order to prevent bleeding.
15. Remove microvascular clip and remove traction on overlying muscles.
16. Suture wound with 3-0 suture.
17. Place blood-filled PE50 tubing in an incubator at 37°C for 120 minutes.
18. Store thrombus in refrigerator overnight.
1.3.3.4. Preparation of Thrombus for MCAO
1. Remove thrombus from refrigerator.
2. Add saline to petri dish to wash thrombus.
3. Affix a 20 cm segment of PE10 tubing to a 1 ml syringe via a sharp 27 gauge
needle.
4. Insert free end of PE10 tubing into lumen of thrombus-filled PE50 tubing.
5. With slow but constant pressure, eject thrombus into saline-filled petri dish.
6. Visually assess thrombus diameter and appearance for uniformity using the
microscope. A well-formed thrombus should appear consistent throughout (a
smooth exterior with no missing pieces).
7. Wash clot by drawing into PE10 tubing attached to a syringe and expelling
repeatedly back into saline. Upon initial expulsion, red cells will become
detached from thrombus resulting in a cloudy appearance within saline.
When clot is washed thoroughly it should appear ~25% narrower and no
additional cloudiness produced.
8. Prepare modified PE50 tubing for injection of the thrombus. This is done by
heating the PE50 tubing over a bunsen burner, removing from the heat, and
then stretching the heated portion quickly, reducing the diameter.
9. You should now have a piece of PE50 tubing that is regular in diameter on
the left and right end and much thinner in the middle. Cut tubing in the
middle of the thin portion creating two pieces of the modified PE50 tubing.
10. Set a micrometer to 0.3 mm. Pull the modified PE tube between the jaw
blades, starting at the thinnest portion and progressing to the thicker
segment. Where blades ‘catch’ the tubing is where the tubing is then cut.
This creates a modified PE50 segment of tubing with an outer diameter of 0.3
mm.
11. When ready to inject thrombus, draw clot into modified PE50 tubing either
directly or indirectly (via PE10 tubing).
1.3.3.5. Measurement of Cerebral Blood Flow
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When performing middle cerebral artery occlusion, confirmation of proper thrombus (or
suture in other models) placement is essential for verifying the induction of ischemia as
well as for monitoring tissue plasminogen activator-induced reperfusion (Note 2). Briefly,
a cranial bolt with accompanying laser Doppler cerebral blood flow (CBF) probe is
inserted into the cranium above the area corresponding to the vascular region supplied
by the middle cerebral artery (MCA). This provides continual readings to document CBF
at baseline as well as during and after insertion of thrombus and during reperfusion.
1. Position rat on homeothermic heating pad such that it is on its left side, with
the right side exposed.
2. Prepare region between ear and eye for aseptic surgery (see above).
3. Using a surgical scalpel, make an incision that is 2 cm medial and cephalic to
right ear to 2 cm lateral and cephalic to right ear.
4. Temporalis muscle should now be exposed. Using scalpel, make a 1 cm
incision along right edge at the point where temporalis muscle inserts into
skull.
Make another 1 cm incision parallel to the first incision in cephalic
direction. Now to complete temporalis flap, cut along medial insertion. Use
the bipolar at low setting (i.e. 15-20 Malis units) to control bleeding.
5. Reflect temporalis flap using 3-0 suture and a hemostat to expose Bregma.
6. After removing excess tissue to clearly expose sutures, use tip of scalpel
blade to start a small burr hole approximately 3 mm caudal to Bregma and 3
mm medial to the linea temporalis (twirl the scalpel with attached blade in
your fingers, similar to a drill bit).
7. Once a starting groove has been made in skull with scalpel blade, switch to
drill bit (approximately 7/64 of an inch) and continue making burr hole. Do
this part slowly and remove bone fragments frequently, particularly once dural
surface is exposed (Note 3).
8. When the burr hole is finished, it should be a perfect circle and dura mater
should be exposed such that you can see vasculature (Figure 2).
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Figure 1.2.

Burr hole ready for insertion of cranial bolt and laser Doppler

9. Affix cranial bolt over middle cerebral artery by carefully screwing it into
parietal bone surrounding burr hole (Note 4).
10. Insert laser Doppler probe into cranial bolt opening for monitoring cerebral
blood flow (Note 5).
11. Remove hemostat providing traction and withdraw suture from temporalis
muscle.
12. Rat is now ready to be positioned for middle cerebral artery occlusion
procedure.
1.3.3.6. Middle Cerebral Artery Occlusion
The thromboembolic model described herein is advantageous in that it most closely
mimics the clinical scenario. This is accomplished by administering a thrombus created
from a donor rat into the middle cerebral artery, the vessel most frequently occluded in
the human population. Additionally, proper placement can be verified through the use of
the laser Doppler cerebral blood flow recording discussed previously.

10

1. Place rat in supine position on homeothermic heating pad being careful not to
disrupt laser Doppler probe that has been inserted previously for monitoring
purposes.
2. Place a small pillow (see above) under head of rat such that anterior portion
of head and neck are parallel to operating table. This is important as it brings
anatomical structures of interest (carotid artery and its branches) more

Figure 1.3. Vessels prepared for insertion of thrombus. The external
carotid artery stump, seen ligated by the suture, is the site of insertion.
This stump can be manipulated such that it is in line with the internal
carotid artery, allowing for a straight shot from the ECA stump into the ICA
and subsequently the MCA.

3.
4.
5.
6.

7.
8.
9.

superficial. This allows increased access to the bifurcation of the carotid
artery and visualization of the internal carotid artery.
Place forelimbs of rat in traction such that chest is fully exposed, enhancing
visualization during dissection.
Using surgical scalpel, make a midline cervical incision running from near
mandible to the sternum.
Dissect through superficial connective tissue to visualize mandibular glands
and muscles overlying the trachea.
Focusing to right (the rat’s right side) of the midline, a triangle formed by
three different muscles should be apparent (Figure 3). The medial border of
this triangle is created by the sternohyoid, the inferior lateral border by the
sternomastoid, and the superior lateral by the inferior portion of the digastric.
Separate these muscles by dissecting through connective tissue between the
muscles.
Use care to avoid damaging muscles as this can result in
unnecessary trauma and excessive bleeding.
Retract superior lateral border of triangle (inferior portion of digastric) by
encircling muscle with 3-0 suture and providing traction using a hemostat.
Common carotid artery should now be visible in center of the triangle.
Carefully isolate common carotid artery from surrounding connective tissue.
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10. Follow common carotid artery superiorly to its bifurcation into external and
internal carotid arteries.
11. Carefully isolate external carotid artery, the more superficial of the branches
from the common carotid artery. The other branch from bifurcation is the
internal carotid artery.
12. Following external carotid artery cephalically until the superior thyroid artery
(first anterior-oriented branch off of external carotid) comes into view (Figure
4). The superior thyroid artery may be attached underneath the superior
angle of the triangle, between the digastric muscle and sternohyoid muscle.
13. Bipolar coagulate superior thyroid artery and cut in the center of bipolared
portion, separating superior thyroid artery from external carotid artery.
14. Ligate external carotid artery near origin from common carotid artery. Use a
single tie that can be untied easily as this is a temporary ligation.
15. Bipolar coagulate external carotid artery in the most distal region possible,
above where the superior thyroid artery branched off.
16. Cut external carotid artery in middle of the bipolared segment, creating the
external carotid artery stump at the bifurcation of the common carotid artery.
This stump should move freely while attached to the common carotid artery at
this point – if not, dissect more thoroughly such that the stump can be moved
such that it is inline with the internal carotid artery.
17. Isolate internal carotid artery. While isolating, a branch originating near the
ECA-ICA bifurcation becomes apparent called the occipital artery.
18. Isolate the portion of the occipital artery nearest the internal carotid artery and
bipolar this vessel. Once the vessel is bipolared sufficiently, cut this vessel in
the bipolared segment. The external carotid artery stump can be seen in
Figure 3. Also visible in this figure is the common carotid artery and the
internal carotid artery.
19. Finish isolating the internal carotid artery down to the next branch
(pterygopalatine artery). Ensure that both the ICA and the pterygopalatine
artery can be seen at this bifurcation (Figure 4) as it is essential that the
tubing can be visualized in the proper vessel when inserted in subsequent
steps.
20. Apply two microvascular clips – one on the common carotid artery and one
on the internal carotid artery. These are to occlude blood flow temporarily
while inserting the thrombus. A drop in CBF in the MCA territory, as
measured with the laser Doppler monitoring system, should be observed at
this point (Figure 5).
21. Mark the modified PE50 tubing prepared previously with a permanent marker
at 18 mm from the modified end. This mark will allow for visualization
through the artery as the clot is inserted in subsequent steps.
22. Draw the clot into the modified PE50 tubing using the micro-syringe. If the
clot cannot be drawn into the modified tubing, wash the clot more in the
saline until small enough to be drawn into the modified tubing (Note 6 & 7).
23. Position the micro-syringe with attached modified PE50 tubing filled with the
clot such that the modified tubing is in line with the external carotid artery
stump. To do this, use modeling clay positioned in the groin of the rat as the
mounting point for the micro-syringe and adjust this superiorly or inferiorly
such that the modified tubing and clot are in the proper location.
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Figure 1.4. Diagramatic representation of vasculature in the neck and
brain relevant for middle cerebral artery occlusion (MCAO). It is important
to note the location of the superior thyroid artery and the occipital artery as
these must be dissected and bipolared prior to thrombus insertion. When
inserting the thrombus, ensure the modified tubing is placed from the
external carotid artery stump into the internal carotid and then the middle
24. Cut the bipolared segment off of the external carotid artery stump so that the
lumen can be visualized.
25. Loosen the suture placed around the external carotid artery and begin to
insert the modified tubing containing the clot while bending the external
carotid artery stump towards the syringe, inline with the internal carotid artery.
Once the tubing is inserted beyond the suture, tighten the suture once again
around the tubing.
26. Remove the micro-vascular clip from the internal carotid artery but leave the
other micro-vascular clip on the common carotid artery at this time.
27. Continue inserting the modified tubing containing the clot into the internal
carotid artery. Ensure that the tubing remains in the internal carotid artery
and does not enter the pterygopalatine artery by observing the tubing inside
the vessel.
28. When the 18 mm mark approaches the bifurcation, slow the insertion process
and watch the laser Doppler monitor for changes in cerebral blood flow.
29. When the laser Doppler number drops, indicating blood flow to the MCA is
disrupted, the tubing is in the correct place (Figure 5).
Pull back
approximately 1 mm on the modified tubing and watch the cerebral blood flow
be restored, as indicated by the laser Doppler recording (Figure 5). This is a
confirmatory step for ensuring no hemorrhage was caused.
30. When the cerebral blood flow is restored, inject 5 µl of saline to eject the
blood clot from the modified tubing.
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Figure 1.5. Laser Doppler recording of CBF during MCAO procedure. 1)
Baseline CBF recording, 2) Occlusion with modified tubing prior to clot
injection, 3) Verification by withdrawing catheter approximately 1 mm, 4)
Injection of clot and CBF reduction to 20% or less of baseline, 5) Reperfusion
from tPA administration.
31. Once the clot is injected, the cerebral blood flow should drop again to a value
similar to that seen previously when occluding with the tubing only (Figure 5).
32. After injecting the clot, wait 5 minutes to ensure clot stability prior to slowly
removing the modified tubing.
33. When removing the modified tubing, a micro-vascular clip will need to be
placed on the internal carotid artery prior to withdrawing the modified tubing
entirely.
34. Once the clip is placed, remove the modified tubing the rest of the way and
use the remaining suture around the external carotid artery stump to ligate
the stump permanently. The stump can also be bipolar coagulated to ensure
proper closure and prevent bleeding.
35. Remove both micro-vascular clips at this time. The CBF in the MCA territory
should remain decreased at 20% or less of baseline (Figure 5).
36. Cover the exposed tissues with a saline-soaked gauze pad while the animal
remains under anesthesia prior to closing the wound using a 3-0 suture.
1.3.3.7. Achieving Reperfusion

14

In this thromboembolic model, reperfusion is obtained via administration of tissue
plasminogen activator, the same compound that is utilized clinically. This allows for the
study of new therapeutics in conjunction with the presently approved agent – a
combination therapy approach. Briefly, tissue plasminogen activator can be given
intravenously via the same catheter used to administer saline in the femoral vein.
1.
2.
3.
4.

Follow the procedure for ‘Creation of Thrombus’, found above.
Isolate the femoral vein from the artery and nerve.
Using a 5-0 suture, ligate the distal end of the exposed femoral vein.
Using a 5-0 suture, prepare a loose ligation more proximally. This will be to
hold the intravenous catheter in place but cannot be tightened until the
catheter is inserted.
5. Insert the 22-gauge catheter proximal to the total ligation of the femoral vein
but distal to the loose suture.
6. Secure the intravenous catheter with the previously prepared 5-0 suture.
7. Connect the intravenous catheter to a syringe pump loaded with saline.
8. Administer saline at a rate of 1 ml/hour to maintain proper fluid balance.
9. At 2 hours after induction of ischemia by injecting the clot, administer tissue
plasminogen activator via a syringe pump at a dose of 5 mg/kg. A 30% bolus
should be given and the remaining administered over a period of 30 minutes.
This is done via the same intravenous catheter used for saline administration
and is done simultaneously.
10. While administering tissue plasminogen activator, closely observe the rat for
bleeding from open wounds and stop via bipolar.
11. Observe the cerebral blood flow measurement, as blood flow should be
restored following tissue plasminogen activator administration (Figure 5).
12. Once complete, carefully remove the intravenous catheter and either suture
or bipolar this open segment of the femoral vein.
13. Remove the laser Doppler probe and cranial bolt.
14. Suture all wounds using a 3-0 suture.

1.3.3.8. Post-stroke Assessment
Assessment of animals post-stroke in the past has largely focused on volumetric
measurements and the ability of the compound being tested to alter infarct volume. In
recent years the focus has begun to shift towards behavioral outcomes to increase
clinical relevancy 12. This shift has been largely predicated on the failure of compounds
to translate from preclinical models to clinical trials. Despite the hundreds of clinical
trials initiated for pharmacologic agents to treat ischemic stroke, tissue plasminogen
activator remains the only FDA approved compound.
As such, we will discuss briefly both aspects of assessment post-stroke: functional and
volumetric.
1.

Functional Assessment
1.1. Modified Neurological Severity Score (MNSS)

The MNSS has long been utilized as a functional assessment for stroke as it is proposed
to assess both motor and sensory deficits after ischemia 13. This scale, while simple
when applied to the young animal, is fraught with challenges when applied to the aged
animal. The aged animal is fundamentally unique in that motor activity, even prior to
injury, is greatly reduced as well as balance and sensory perception. Therefore, the
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utility of this scale in the aged population may simply be more of a qualifier for whether
or not stroke occurred rather than an accurate assessment of stroke severity.
Raising rat by tail (normal = 0; maximum = 3)
Flexion of forelimb
Flexion of hindlmb
Head movement >10° to vertical axis within 30 seconds
Placing rat on floor (normal = 0; maximum = 3)
Normal walk
Inability to walk straight
Circling toward the paretic side
Falls down to paretic side
Sensory tests (normal = 0; maximum = 2)
Placing test (visual and tactile test)
Proprioceptive test (deep sensation, pushing paw against table
edge to stimulate limb muscles)
Beam balance tests (normal = 0; maximum = 6)
Balances with steady posture
0
Grasps side of beam
Hugs beam and one limb falls down from beam
Hugs beam and two limbs fall down from beam, or spins on
beam (>60 seconds)
Attempts to balance on beam but falls off (>40 seconds)
Attempts to balance on beam but falls off (>20 seconds)
Falls off; no attempt to balance or hang on the beam (<20 seconds)
Reflex absence and abnormal movements (normal = 0; maximum = 4)
Pinna reflex (head shake when auditory meatus is stimulated)
Corneal reflex (eye blink when cornea is lightly touched with cotton)
Startle reflex (motor response to a brief auditory stimulus)
1
Seizures, monoclonus, and myodystony
Maximum points

(3)
1
1
1
(3)
0
1
2
3
(2)
1
1
(6)
1
2
3
4
5
6
(4)
1
1
1
(18)

*Points are assessed for inability to perform specified task or for absence of reflex,
resulting in more severely impaired animals receiving a higher score. The following
ranges have been used to categorize injury severity: 1-6 mild injury, 7-12 moderate
injury, and 13-18 severe injury.
1.2. Sensorimotor Assessment
Assessment of sensorimotor activity can be done as part of scoring systems such as the
aforementioned MNSS but can also be done using other techniques such as open-field/
locomotor activity, rotarod, staircase test, the cylinder test, grip-strength, adhesive label
test, and others 14. While the intent of this work is not to review all functional tests, it is
important to consider the variety of factors that impact the assessment of motor ability.
Perhaps most important are the inherent differences seen from animal to animal at
baseline. Therefore, it is important to either normalize to baseline or provide adequate
training to meet a preset criterion. Additionally, age must be considered. Young adult
animals behave differently than aged animals and have significantly more mobility before
and after ischemia. Furthermore, alterations in the methodology used to induce MCAO
produces highly variable results depending on occlusion type, location, duration, and
strain of animals used.
1.3. Cognitive Assessment
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Cognitive assessment of rodents post-stroke remains a widely debated topic, similar to
other behavioral assessments. There is little agreement as to the most appropriate
measures or expected results as past work has been highly variable. Some commonly
utilized techniques include the Morris Water Maze, radial maze, passive avoidance, and
active avoidance 15. Each of these tests has been designed to assess some aspect of
learning or memory but requires significant motor ability and baseline ability may vary
from strain to strain and with age.
2. Volumetric Assessment
1. At time of sacrifice, anesthetize the rat as described previously.
2. Once anesthetized, place the rat in a supine position.
3. Make a horizontal incision, approximately 2 inches wide, in the upper
abdomen of the rat.
4. Cut vertically at each end of this incision, cutting through the diaphragm and
rib cage.
5. A flap has now been created consisting of the sternum and the anterior
portion of the rib cage that can be retracted using a large hemostat.
6. Quickly remove any fascia remaining around the heart and aorta so that both
structures can be visualized clearly.
7. Insert the peristaltic pump needle into the left ventricle and into the aorta.
Visualize the needle in the aorta to confirm proper placement (Note 9).
8. Start the pump and set to a rate of approximately 10 mL/min for 10 minutes
using physiologic saline to perfuse the animal.
9. Cut the right atrium to allow for the blood to drain out of the animal. Over
time the fluid should become clear and the tissues/organs should become
pale (particularly liver and eyes), indicating a successful perfusion.
10. After 10 minutes (and 100 mL of saline), turn off the pump and remove the
needle from the aorta.
11. Decapitate the animal.
12. Extract the brain, being careful not to damage the cortex.
13. Place the brain in the 2 mm brain block.
14. Place in -80 °C freezer for approximately 5 minutes.
15. Remove from freezer and slice using razor blades.
16. Place each slice in a separate well in a 12 well plate.
17. Add 2 mL of 2% TTC in PBS to each slice.
18. Place in incubator for 20 minutes.
19. Remove plate from incubator and scan into an image file (jpg, tif, etc).
20. Calculate lesion volume using previously described techniques (Photoshop,
ImageJ, etc)	
  16.
1.3.3.9. NOTES
1. If the instrument pouch is wet upon removal from the autoclave, it is likely that
the door was not opened/cracked appropriately and/or the drying cycle did
not run properly. Do NOT open the door to the maximum extent immediately
as this allows colder room air to rush in and create condensation on the
instruments.
2. We strongly recommend relying on CBF measurements throughout the
procedure. CBF changes can be seen with each step, ranging from the initial
brief reduction seen when placing microvascular clip on the CCA to those
corresponding to duration of ischemic episode.
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3. Creating a high quality burr hole without damaging the brain is vital for
confirming ischemia and reperfusion but is often challenging, even for the
experienced surgeon. After initiating the hole with the scalpel and switching
to the drill bit, be sure to frequently remove bone fragments to prevent forcing
them into the brain. Also, try applying enough downward force to engage the
drill bit in the cranium but then apply slight upward force to prevent the bit
from entering the dura and brain. This upward force also assists in directing
bone fragments out of the cranium rather than inside.
4. Our group, as well as others in the field, has experimented with different
methods of recording cerebral blood flow such as extracranial measurements
from the cranium surface. While it is possible to obtain readings from this
position, we have not found consistent success at ensuring proper occlusion
and reperfusion. One of the primary obstacles encountered is the ability to
achieve preset criteria for assessing ischemia/reperfusion.
We define
ischemia as a drop of 80% or more from baseline laser Doppler recording
and define reperfusion as a return to 80% or greater of the baseline value or
visual absence of thrombus upon craniotomy.
5. Prior to inserting the cranial bolt, verify the position of the Doppler probe
within the bolt. Depending on the supplies/equipment used, the probe may
be longer than the bolt. In this case, it may be helpful to apply a moldable but
somewhat rigid material (such as bone wax) to the probe to prevent the probe
from extending beyond the bolt.
6. Washing the clot properly is one of the most critical steps of the process.
Wash too little and reperfusion becomes unreliable, wash too much and
spontaneous reperfusion occurs. The proper amount of washing requires
practice and a trained eye – this can be acquired with attention to detail and
some basic experience.
7. We have found significant variance in the PE 50 tubing used to form the clot
when purchased from various manufacturers. In addition to slight variances
in size, lumen texture is also variable with some appearing smoother while
others are slightly ribbed. For this reason, we utilize the INTRAMEDIC listed
in the materials section. We have found the most success with this tubing as
it conforms to rigid tolerances and as such is consistent from reel to reel.
8. We have also found that the method of anesthesia used influences volume of
the clot. Isoflurane may result in smaller diameter clots than using Ketaject.
For this reason, it may be advantageous to utilize Ketaject for blood-draws
from the donor animal.
9. When perfusing the animal, it may be desirable to use a dulled needle. Often
a sharp needle may penetrate the aorta leading to poor quality perfusions. If
you experience this problem, file the tip of the needle to create a dulled tip.
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1.4. Role of Aging in Neural Injury
One of the greatest shortcomings of prior work in neural injury is the failure to consider
the effect of aging on pathophysiology and subsequent therapeutic targets. This is
particularly alarming when considering subsets of neural injury such as ischemic stroke,
a disease predominately affecting the elderly population. The following work explores
the importance of aging as an experimental parameter in neural injury research using
ischemic stroke as a fundamental example.
This work was published in the Journal of Aging Research.
Citation: Popa-Wagner A, Buga AM, Turner RC, Rosen CL, Toescu E (2012)
Cerebrovascular Disorders: Role of Aging. Journal of Aging Research. Article ID 128146.
doi: 10.1155/2012/128146.
Therapeutic development for neurological diseases, whether cerebrovascular disease,
vascular dementia, or Alzheimer’s disease (AD), has been largely unsuccessful. Despite
the apparent success of numerous pharmacologic agents in preclinical animal models,
few have translated successfully from bench to bedside. As such, a vast need remains
unmet and additional investigation is required.
Speculation concerning the reasons for this failed translation from bench-to-bedside
often highlights either the lack of reproducibility or a poor choice of the outcome
measure parameters. However, in most of the literature, the lack of clinical relevance of
the animal model used often goes unnoticed. The role of age in neurologic disease
development is well known, in fact, age is the greatest risk factor for development of AD
as well as stroke. In sharp contrast to this clinical reality, the vast majority of preclinical
studies utilize young or young-adult animal models of neurologic disease, despite the
suggestion of collaborative advisory groups such as the Stroke Therapy Academic and
Industry Roundtable (STAIR).
The aging process affects various biological axes, from the status of the cardiovascular
system to the status of the inflammatory responsiveness and finally to the changes in the
ability of the neural systems to handle pathological insults and a significant reduction in
the recovery capability.
At one end of this spectrum of changes in cerebral
cardiovascular status are the morphological changes in vasculature, manifested as large
increases in the vascular path due to increased tortuosity of arterioles in the deep white
matter 	
   17 and an age-associated decrease in capillary number and length, leading to a
significant increase (25%) of the inter-capillary distance in both the hippocampus and
cortex	
   18 and white matter	
   19. Such processes would lead to tissular hypoxia that in
young or adult brain would trigger an angiogenesis response, mediated by HIF-1 as a
transcription factor for VEGF. However, in the aged brain, there is a reduction in the
angiogenesis response, due to decreased responsiveness to HIF-1.
Such ageassociated changes in the blood vessels architecture are even more relevant to the
brain, because of the specifics of vascularization: the system of feeding arteries is
situated near the surface of the brain, from where end arteries are penetrating through
the gray and white matter in a network that terminates in a capillary bed but with very
few shunts	
  20.
As a result of such anatomical changes, there is little surprise that in the aged brain
there is a significant reduction in the cerebral blood flow (CBF), affecting mainly the
cortex, and more sparingly the subcortical regions, as revealed by a variety of imaging
techniques, from positron-emission tomography (PET) and single-photon emission
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computed tomography (SPECT) to high-resolution, contrast-enhanced MRI and arterialspin labeling (ASL) 21. However, as it has been pointed out	
   22, CBF is aff ected not only
by morphological changes, but it is also modulated by a variety of functional parameters
such as perivascular innervation	
   23, astroglial control of arteriolar constriction	
   24, and
autocrine endothelial signaling in response to rheostatic forces and neural environment	
  
25.
For the clinical category of cerebrovascular diseases, the stroke is, by a distance, the
most significant entity, both in terms of prevalence and consequences. The stroke can
result from either an occlusion of the vessel (ischemia), which can be either transient
(e.g., the transient ischemic attack, TIA) or of longer duration; or from the rupture of a
vessel, leading to regional hemorrhage, either within the cortical matter or in the dural
cavities. While the biological and medical consequences of a stroke are significant at
any age, the incidence and the severity of a stroke are significantly increased with age.
The paper from Russo et al. provides a systematic review, looking at the first stroke
incident and shows that the trend continues for the very old (older than 80 years old)	
  26.
Several factors are likely contributors to this increased severity of stroke with age. One
such factor is a metabolic decrease in the capacity of neural cells to counteract extreme
stressors and/or neurotoxic challenges (decreased metabolic reserve)	
   27 that appear in
the penumbra region of a stroke, in which a combination of hypoxia and resulting
decrease in ATP provisions will lead to the generation of a hyperexcitable environment,
posing significant metabolic challenges.
Stroke in the very old is a very frequent condition, with an unfavorable outcome, and
makes a relevant contribution to the social burden of stroke and may require more
efficient dedicated stroke services 26. Aged individuals recover less well from stroke,
and rehabilitation aims at improving the physical and cognitive impairments and
disabilities of patients with stroke. Therefore, studies on behavioral recuperation after
stroke in aged animals are necessary. Various experimental settings have been used to
assess the recovery of sensorimotor functions, spontaneous activity, and memory after
ischemia in aged rats. Overall, the results indicate that aged rats have the capacity to
recover behaviorally after cortical infarcts, albeit to a lesser extent than their young
counterparts 	
  28,	
   29. It should be kept in mind, however, that before stroke aged rats are
already impaired as compared to young animals and show significantly decreased
performance in some tests like spontaneous activity 	
   30. Accelerated glial reactivity to
stroke in aged rats correlates with reduced functional recovery 30 including Morris water
maze	
  31. Behavioral and histological effects of chronic antipsychotic and antidepressant
drug treatment in aged rats with focal ischemic brain injury are discussed in the work by
Zhao and colleagues	
  31.
Another crucial component of the brain tissue response to stroke is the inflammatory
response. As reviewed in the article by Shah and Di Napoli 32 the age-associated
changes in the immune function determine that in the aged and individuals, the response
to an acute stroke involves a more intense inflammatory reaction in the first phase of
acute ischemia, involving cytokine activation and chemokine expression that lead to an
early scar formation and fibrosis. In agreement with previous observations	
   33, the article
also points out the fact that the biology of the aged brain is different from that of the
young brain, and this has significant implications for the current translational efforts to
define effective therapies, since a large majority of interventional studies are performed
on young and young-adult animals.
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Another important perspective in asserting new potential therapeutical interventions for
stroke is to assess if the differences in responsiveness between young adult and old
brains are due only to functional changes or if they involve more elaborate changes in
protein expression. Recent detailed analyses of the genomics data from adult and aged
animals indicate changes in the balance of the various systems and regulatory
processes. Using categorized DNA arrays, we found inappropriate gene regulation in
response to stroke both in the ipsilateral and the contralateral hemisphere of aged rats.
The gene expression profile in the brains of post-stroke aged rats is indicative of
increased cell death due to DNA damage and apoptosis, especially in the first week after
stroke. Similarly, we reported persistent down-regulation of genes that are required for
neurogenesis after stroke in aged rats	
  34.
However, the category of cerebrovascular diseases is not restricted to the pathologies
involving the large vessels. Cerebral small vessels disease (cSVD) is a group of
pathological processes associated with established vascular risk factor such as
hypertension, atherosclerosis, diabetes mellitus, and atrial fibrillation. The consequences
of small vessel disease on the brain parenchyma are mainly lesions located in the
subcortical structures such as lacunar infarcts, white matter lesions, large hemorrhages,
and microbleeds. This compendium of tissue lesions has been compiled in the last
decade or so by the ever-expanding use of more powerful and sensitive brain imaging
technologies, rather than by a better understanding or direct assessment of actual small
vessels territories. As a result, the cerebral small vessels diseases are now invoked in
explaining a variety of clinical syndromes, and van Uden and collaborators discuss in
their paper the possibility that such vascular pathology is underlining the clinical
manifestations of the late onset depression in the aged people 	
   35. Even more daring,
Teggi et al. propose that cSVD might also explain some forms of the Meniere disease	
  36.
Another area of neuropathology in which small vessel disease has a well-established
role that gathers ever increasing recognition in both the clinical and basic research world
is that of being a leading cause of cognitive decline and functional loss in the elderly.
Vascular dementia is a broad concept that has evolved slowly. While general anecdotal
references linking putative cerebral vascular events with reductions in cognitive
performance have existed for long time, it is the articles of Binswanger and Alzheimer
around the turn of the 20th century describing in detail the various types of vascular
lesions that could be encountered in human brains that set the field on a strong
morphopathological footing, and it took another 70 years until Hachinski suggested that
dementia of vascular origin was a consequence of multiple strokes 	
  37. Subsequently, the
concept continued to evolve to include multiple mechanisms related to deficiencies in
cerebral blood supply, including large vessel disease, small vessel pathology,
consequences of cerebral hypoperfusion and hemorrhage.
While the risk factors for vascular diseases are relatively well established, much less
consensus exists on the specific risk factors for vascular dementia, that is, apart, from
the acknowledged role of increased age. Ongoing interest in cerebrovascular diseases
research has provided data showing that Alzheimer’s proteins and other factors may be
involved in the pathogenesis of gradual ischemic brain injury. Thus, both focal and global
brain ischemia in rodents produce a stereotyped pattern of selective neuronal
degeneration, which is just the same as in Alzheimer’s type dementia. As hypothesized
in the article by Enciu et al.	
   38, there is an overlap of events between chronic hypoxia
and AD on several levels, such as hypoxic-triggered cellular pathways, inflammatory
environment, growth factor signaling, and calcium homeostasis. A reduction of CBF and
a series of molecular events precede the major ischemic events in vascular cognitive
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impairment. Based on these subtle changes, intervention at early stages could prevent
the full-blown development of dementia, which might represent a “point of no return” for
the neurovascular units and neuronal networks with few chances for efficient treatment.
In their extensive review, Enciu and her colleagues also discuss some of the molecular
mechanisms that are triggered by the cerebrovascular diseases and that lead to
overcognitive dysfunction and argue convincingly the case for an early intervention at
the point at which the dysfunction of the neurovascular units is still potentially reversible	
  
38.
However, it is important to keep in mind that the genetic makeup is a hugely important
factor, from the subtle alterations in the function of various proteins (e.g., ApoE4) to the
overt cerebrovascular diseases with a genetic control, as the cerebral autosomal
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) that involves
mutations in Notch-3 protein. Equally important is the discovery that fundamental genetic
changes may occur with aging, such as the CLOCK genes, as discussed by Thome et
al. 	
   39. Taken together, aging may result in fundamental changes throughout the body,
beginning at a gene level and progressing to protein expression or posttranslational
modification level.
It is clear that the quest for improved therapeutics will require increased understanding
of disease pathophysiology and, in particular, the changes induced by the aging process.
Similarly, neurologic disease research has often maintained a “neurocentric” focus, in
which the role of the neuron was emphasized. This is unlikely to result in successful
development of therapeutics due to the intimate relationship evident between neurons,
surrounding glia, and the neurovascular unit—in both health and disease. The effect of
aging on astrocyte and microglial response to injury and how this process can be
manipulated successfully for therapeutic development must be considered.
Similarly, preclinical studies of neurologic disease utilizing aged animals must
incorporate functional outcome measures in addition to histological measures. Clinically,
the primary assessment remains functional outcome and presence/absence of
significant disability yet preclinical studies often emphasize histological outcomes such
as infarct volume. The difficulty of identifying high fidelity functional studies in aged
animals remains a vexing problem.
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1.5. Improving Preclinical Models of Ischemic Stroke
Research in neural injury, particularly ischemic stroke, has largely failed to advance
proposed therapeutic agents successfully from bench-to-bedside. Reasons for this lack
of success are primarily speculative in nature at this point but have frequently focused
on the use of inadequate animal models, failure to address the role of age and
comorbidities in disease pathophysiology, and the pursuit of hyperacute injury
mechanisms rather than those more likely present at the time of patient presentation. In
these works, we explore each of these topics to varying degrees in an effort to shed light
upon what may be more promising directions for future investigations.
This work was published in part in Journal of Neurosurgery and the Yale Journal of
Biology and Medicine.
Citations:
Turner RC, Dodson SC, Rosen CL, Huber JD (2013) The science of cerebral ischemia
and neuroprotection: navigating past failure to future success. Journal of Neurosurgery
118(5): 1072-1085.
Lucke-Wold BP, Turner RC, Lucke-Wold AN, Rosen CL, Huber JD (2012) Age and the
Metabolic Syndrome as Risk Factors for Ischemic Stroke: Improving Preclinical Models
of Ischemic Stroke. Yale Journal of Biology and Medicine 85: 523-539.
Abstract
Ischemic stroke represents a leading cause of morbidity and mortality in the developed
world. This disabling and sometimes fatal event puts an ever-increasing burden on the
family members and medical professionals who care for stroke victims. Preclinical
ischemic stroke research has predominantly utilized young adult, health animals, a
clear discrepancy when considering the clinical population affected by stroke. A broad
spectrum of risk factors such as age, obesity, diabetes, and hypertension has been
associated with an increased stroke risk. The effect of these comorbidities on both
stroke pathophysiology and outcome has not been emphasized and has been
recognized as a shortcoming of preclinical studies. By addressing these conditions in
experimental models of ischemic stroke, it may be possible to more accurately
represent the clinical scenario and improve therapeutic translation from bench-tobedside. In this work, we review many of the risk factors associated with increased
stroke risk, particularly as each risk factor relates to inflammation. Additionally, we
explore potential animal models that could be utilized in identifying the contribution of
these risk factors to stroke outcome. By investigating the risk factors for stroke and
how these may alter stroke pathophysiology, the present discrepancies between
preclinical studies and the clinical reality can be reconciled in an effort to improve
therapeutic development and translation from bench-to-bedside.
1.5.1. INTRODUCTION
Stroke is the second largest contributor to mortality worldwide and the primary cause of
disability among the elderly in Western Europe and the United States	
   40,	
   41. Among the
various types of stroke, ischemic stroke is the most prominent and accounts for the most
long-term disability	
  42. This review will deal only with preclinical models of ischemic stroke.
It is widely accepted that age is the greatest risk factor for stroke. The process of aging
results in a large number of inflammatory changes. It is predicted that the number of
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people in the United States past the age of 65 will double within the next 30 years 	
   43.
Thus, the need for new treatments and therapeutic options for stroke is a pressing concern
as the population ages. Current available therapeutics are limited to thrombolytics such as
recombinant tissue plasminogen activator (r-tPA) and mechanical means of thrombolysis	
  
44. Although r-tPA drastically improves patient outcome when used within the suggested
time period, only a small percentage of presenting patients are candidates to receive rtPA due to an extensive list of contraindications. As such, a large medical need remains
unmet for the vast majority of patients afflicted with ischemic stroke.
As more than 100 potential therapeutic agents have progressed from pre-clinical studies
with young animals to unsuccessful clinical trials, the need for improved pre- clinical
models is clear 45. These failures call into question the validity of the models being used
to represent ischemic stroke. An area of specific concern is how the age and health of
the animals used in these experiments replicates disease pathogenesis and
pathophysiology observed in the clinic. Previously, stroke work was done principally with
young adult, healthy animals despite the fact that the people most susceptible to stroke
are older and are often overweight, diabetic, and hypertensive	
   46. Recent
recommendations from the Stroke Therapy Academic and Industry Roundtable (STAIR)
encourage research to be performed with healthy, young adult, male animals first and
then proceed to aged, diabetic, hypertensive, and female animals 	
   47. Currently, these
recommendations have not been broadly implemented. In the following sections,
physiologic changes associated with aging, obesity, diabetes, and hypertension will be
examined for their roles in predisposition to stroke. It will be argued that more accurate
models are necessary to improve the applicability of future research endeavors and to
adhere to the suggestions made by STAIR. We identify potential models allowing for
investigation of ischemic stroke in relation to a given comorbid condition and, in
particular, identify pathophysiologic changes associated with each respective disease
state that may represent therapeutic targets. By better understanding pathologic
alterations induced by common comorbid conditions as related to ischemic stroke, it is our
hope that therapeutics may more successfully move from preclinical studies to
accepted treatments clinically.
We specifically focus on molecules associated with inflammatory processes and
cascades, as not only does inflammation represent a potentially promising therapeutic
target but is also heightened or altered in aging and various comorbid conditions associated with ischemic stroke. Pharmacologic agents targeting inflammation have been
developed and, in the case of minocycline, appear promising for the treatment of
ischemic stroke. Inflammation involves interplay between cellular and molecular
components that results in brain tissue loss. Leukocytes, microglia, astrocytes, and
neurons are but a few cell types involved in inflammation related to stroke. On the
molecular side, a broad range of chemokines, cytokines, and adhesion molecules play a
role in infarct development and subsequent deficits. The activity of these components
can be altered by the presence of various disease states, aging, and lifestyle factors 48.
These factors have not been emphasized in most preclinical models of ischemic stroke
and may represent a potential reason for the lack of successful therapeutic translation
from bench-to-bedside. This review addresses the importance of considering other
comorbid processes and how they relate to stroke.
1.5.2. Aging and Stroke
Age: The Greatest Risk Factor
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Age is the greatest risk factor for stroke yet is rarely considered in preclinical models 9,
49. The aged brain is fundamentally different and responds to pathologic insults in a
detrimental manner, resulting in increased infarct volume and worsened functional
outcome, when compared to young-adult animals 9, 50-52. This is particularly evident
when considering inflammatory processes and astrocyte activation 30, 53-56.
The aged brain is believed to exist in a state of chronic, low-grade inflammation that
diminishes the ability of the aged brain to respond appropriately to pathologic stimuli,
such as ischemia. Throughout normal aging, microglia, the primary immune cell of the
brain, are primed following peripheral inflammation. This priming, characterized by
morphologic changes and by cell-surface protein expression, leads to increased proinflammatory molecule release following additional pathologic insult 53. While the
release of pro-inflammatory results in a wide array of downstream effects beyond the
scope of this review, the effect of aging on pro-inflammatory molecule expression has
been well-documented 56. Furthermore, work in an aged animal model has shown
differences, when compared to young-adult animals, in regulation of the JAK2/STAT3
pathway 51. Notably, young-adult and aged animals differ in inflammatory response
across a variety of time-points post-stroke. Badan, et al showed a gradual activation of
microglia and astrocytes in the young-adult animal, peaking 14 to 28 days after
ischemia. Alternatively, aged animals exhibit rapid activation of these glial cells, peaking
within the first week post-ischemia 30. This is consistent with the findings of DiNapoli, et
al in which morphologic differences in astrocytes and microglia were seen when
comparing young-adult and aged animals after stroke 51.
The mitigation of oxidative stress using free radical scavengers has proven successful in
preclinical studies but failed to translate in clinical trials 57, 58. This may be related to
methodology differences such as time of administration after stroke, type of stroke,
delivery method, and others, or differences in downstream effects associated with age.
An example of age-related effects was seen with apocynin, an inhibitor of the NOX2
isoform of NADPH oxidase, which has contrasting effects when used in young-adult or
aged animals. Apocynin was shown to be neuroprotective in young-adult animals but
worsened stroke outcome in aged animals 59.
While the precise downstream consequences of these differences remain to be
elucidated, it is clear that age and the aging process fundamentally alter the response to
pathologic stimuli. To truly address the lack of translation from bench-to-bedside, and
increase the clinical relevance of preclinical models, utilizing aged animals may prove
fruitful. In the following sections, we attempt to briefly discuss implications of aging,
how aging changes the response to an injurious event, and the benefits and limitations
of aged animal models.
The Aged Brain: Fundamentally Different
Aging has been well documented to be associated with an overall dysregulation of the
immune system hallmarked by a shift to- ward a pro-inflammatory condition 	
   60-‐63. Age
causes an increased secretion of tissue necrosis factor-alpha (TNF-a), a proinflammatory cytokine, and decreased inter- leukin-10 (IL-10), an anti-inflammatory
cytokine	
   61. These cytokines act on specific cells in the central nervous system.
Numerous cell types throughout the body can release cytokines, and these cells can
change with age. The concept of “inflamm-aging” (inflammation increasing with age) has
been attributed to chronic macrophage stimulation	
   60. Despite the mechanistic details
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being unclear, aging clearly results in inflammatory variations that are especially obvious
in the brain. Some of these variations are due to genetics, lifestyle, and the envi
ronment as seen in Figure 1. These alterations in inflammation are common to agerelated diseases and serve to prime the central nervous system. This often leads to an
exaggerated response and worsened outcome following a systemic challenge	
   61,	
   62.
Consistent with the link between age-related diseases and inflammatory changes are
recent findings in humans and animals alike in which inflammation has been linked to
cognitive impairment and altered brain structure and metabolism	
   64. In fact, high levels of
interleukin-6 (IL-6), a pro-inflammatory cytokine, have been described as exhibiting a
strong correlation with morbidity and mortality in the aged population. Some
discrepancy does exist as even “healthy” centenarians possess a highly elevated IL-6
level 60. Cell-specific changes in the CNS mediate how the brain responds to and alters
the immune system following injury. These cell-specific changes and the brain’s global
response to injury will be discussed below.

Figure 1.6. Aging and Stroke. A schematic diagram of the factors contributing to the
aging process and how aging alters both the function and structure of the brain. These
changes contribute to an altered and generally more deleterious response to injury when
compared to the young adult brain.
Age and Cell-Specific Changes
Astrocytes
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With increased awareness of the role of glia in neurologic injury and the neurovascular
unit, modulation of astrocytes and their associated functions have been identified as a
potential target for ischemic stroke. Astrocytes are implicated in many functions
associated with injury pathophysiology such as buffering of potassium ions and
maintaining the integrity of the blood-brain barrier (BBB)	
   65. Despite increased
understanding of astrocyte functions pre- and post-injury, the effect of age on astrocyte
function is not entirely clear. Inflammatory cytokines do, however, alter astrocyte ability
to respond to injury. Recent studies have shown that astrocytes do express markers
consistent with senescence in both aged humans and rodents. These markers include
increases in glial fibrillary acidic protein (GFAP), cytokine release, and protein
aggregates thought to induce cellular death	
   66. Therefore, it is evident that astrocyte
function changes with aging and may influence both normal homeostatic mechanisms as
well as the response to injury. It will be important for future work to elucidate how agerelated inflammatory cytokines modify astrocytes.
Endothelial Cells: A Source of Inflammatory Regulators
Since stroke is a vascular disease, it is important to understand the effect of aging on the
vasculature system. One of the primary components of the vasculature system is
endothelial cells. Studies in aged rats that were designed to correspond to a 70- to 75year-old human have revealed a marked increase in pro-inflammatory cytokine
expression. This increase in cytokines from endothelial cells may be responsible for
altering vascular function and increasing permeability in the CNS. Key cytokines
identified include TNF-α, interleukin-1β (IL-1β), IL-6, interleukin-17 (IL-17), and
interleukin-6Rα (IL-6Rα). Aging was also associated with decreased expression of
endothelial nitric oxide synthase (eNOS) and increased production of inducible nitric
oxide synthase (iNOS), factors that clearly alter vascular function	
  67.
Microglial Cells
Microglia, the resident immune cells of the central nervous system (CNS), undergo
significant functional changes with aging ranging from altered iron storage to cytokine
production and accumulation of lipofuscin 	
   68. These age-related altercations are
exemplified by morphologic changes and are likely involved in the transition of microglia
from a neuroprotective phenotype in the young brain to a neurotoxic and destructive
form in the aged brain. The destructive form of microglia is known to secrete increased
amounts of IL-6 and TNF-α in the aged brain	
   69,	
   70. Interestingly, microglial senescence
occurring during the aging process may mediate the transition from protective to
deleterious effects. This transition is consistent with findings of senescent microglia in
close proximity to degenerating neural cells 	
  63-‐69. Furthermore, recent work by Baker and
colleagues demonstrated that increasing removal of senescent cells results in delayed
acquisition of age-related disorders. Microglial senescence may perhaps be a promising
therapeutic target for many neurodegenerative conditions 	
  71. Microglia in aged subjects
possess altered surface markers such as major histocompatibility complex II (MHCII)
and ED1. How exactly age-associated changes are induced in microglia remains to be
elucidated, but it is clear that microglia in the aged brain are basally activated and
respond differently to stimuli such as lipopolysaccharide (LPS) and Nogo B 63,	
  72-‐74.
Neuron-Microglia Interaction
One method of regulating microglial activation in the healthy, young adult brain is
through neuron-microglia communication. Disruptions in this signaling mechanism may
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explain the age-associated shift of microglia from a protective to a destructive phenotype	
  
75. Neurons can communicate and regulate microglia in multiple ways with ligandreceptor binding via the CD200-CD200R and CX3CL1-CX3CR1 pathways. CD 200,
when bound to its receptor (CD200R), is commonly expressed on cells of the myeloid
lineage such as microglia. This binding results in microglia being maintained in the
quiescent state. As previous works have demonstrated, targeting CD200-CD200R
interaction represents a potential therapeutic target to modulate microglial activation with
age. In fact, Cox and colleagues have demonstrated that administration of CD200 fusion
protein (CD200fc) restores microglia from a quiescent state and results in improved
long-term potentiation (LTP) in aged animals 76. Fractalkine (CX3CL1), a protein
expressed by neurons, has been identified as playing a role in neuroimmune modulation
by binding to the corresponding receptor, CX3CR1, on microglia. Consistent with the
shift to a proinflammatory state seen in the aged brain, fractalkine levels are reduced in
the aged rat hippocampus as early as 12 months of age. By correcting this fractalkine
deficiency exogenously, hippocampal progenitor cell proliferation and neurogenesis is
largely restored. This further illustrates the ability to modulate inflammation for
neurologic benefit	
  77.
Global Changes in Neural Proliferation and Architecture
The aged brain exhibits decreased neurogenesis in the subventricular zone (SVZ) and
subgranular layer of the hippocampus in comparison to young adult animals. Proteins
such as ubiquitin and GFAP are altered in the aged brain and may play a role in
ageassociated effects 78,	
   79. It is currently unknown whether diminished regenerative
capabilities are the product of stem cell impairment or, rather, changes in the
surrounding environment due to age	
   29. Besides changes in neurogenesis, the structure
of neuron spines is altered as well. The aged brain is characterized by a loss up to
nearly 50 percent of thin spines. No change in mushroom or stubby spine quantity has
been noted	
  80. Experiments assessing changes in the hypothalamus have gone as far as
implicating the G protein-coupled receptor and cytoskeletal-associated protein, GIT2, as
a critical regulator of the aging process	
  81.
Responding to Injury: Role of Brain Aging
Age not only affects risk, but also has a profound impact on recovery	
   29. Following
ischemic injury, for example, aged animals exhibit a rapid development of the glial scar
and an increased release of associated signaling molecules. The rapid progression
demonstrates a dysregulated cellular and inflammatory response	
   33. This altered
response is likely a product of physiologic differences prestrike and also an associated
increase in oxidative stress. The inflammation predisposes to a more deleterious
response after injury 	
  77,	
  82,	
   83. The contribution of each of these factors and the role aging
plays in the pathophysiologic differences is expanded upon below.
Disruption of the Blood-Brain Barrier
Aging has been associated with diminished BBB integrity following ischemic stroke 84,	
   85.
The precise mechanism leading to this altered permeability is unclear, but an increase in
matrix metalloproteinase-9 (MMP-9) has been associated with increased permeability.
Similarly, claudin-5, a protein integral in BBB structure, is decreased in the aged brain
following injury 	
   85. A disrupted BBB allows an influx of inflammatory cells that are
responsible for most of the damage seen following stroke. Modulating BBB integrity
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therefore represents a promising therapeutic target because BBB disruption precedes
neuronal damage and often correlates with the extent of injury	
  84.
Cell Survival and Degradation
The altered response to injury exhibited by the aged brain results in diminished cell
survival and the potential for changes in other key cellular processes such as autophagy.
Work in various neural injury models utilizing aged rodents has demonstrated an
increase in apoptotic cell death attributed to inflammatory processes and heightened
oxidative stress 	
  86,	
  87. Besides apoptosis, cellular autophagy represents another pathway
for degradation. The pathway remains under investigation with respect to aging and
deleterious injuries. It might represent yet another potential therapeutic target	
  88.
Inflammation
Following injury, inflammatory responses differ between young adult and aged subjects.
In ischemic stroke, suppressor of cytokine signaling 3 (SOCS3) is elevated in aged
animals in the subacute period. It mitigates the effects of an elevated phosphorylated
signal transducer and activator of transcription 3 (pSTAT3) 51. This is consistent with
other reports in aged animals. On the other hand, microglia are activated more quickly
following ischemic stroke and contribute to the release of deleterious cytokines and
reactive oxygen species 	
   33. Other studies of inflammatory diseases utilized young and
aged animals to investigate microglial phenotype and demonstrated age-dependent
differences. Specifically, microglia expressed a pro-inflammatory phenotype
characterized by ED1 and IL-1β in older rats but not young adult rats in an adjuvant
arthritis model	
  89. IL-1β is involved in cell proliferation, differentiation, and apoptosis.
Oxidative Stress
Oxidative stress has long been recognized as a potential contribution to the aging
process and associated pathologies, but the precise origin of oxidative stress has not
been entirely clear. In addition to the changes in metabolism and energy production
discussed previously, recent studies demonstrate an association between aging and
NADPH oxidase (NOX). NOX is a key enzyme in producing reactive oxygen species.
NOXs and their associated subunits appear to vary with the aging process. Similarly,
lifestyle choices such as diet may influence the production of reactive oxygen species in
the aged population 	
   90. A proposed neuroprotective agent apocynin, a NOX2 inhibitor,
demonstrates contrasting effects in young adult and aged animals. While protective in
young adult animals, apocynin worsened outcome from ischemic stroke in aged animals.
This further proves the importance of utilizing aged animals in preclinical studies	
  59.
Preclinical Models of Aging
Assessing the role of aging in preclinical models of ischemic stroke has been
accomplished using both in vitro and in vivo models. While neither model system has
resulted in the successful translation of therapeutics from bench-to-bedside, preclinical
studies using aged rats have demonstrated findings in opposition to similar studies in
young adult animals. Aging is one of many components that may lead to improved
models.
The primary in vivo models for studying the effects of the aging process on ischemic
stroke employ aged rats. These studies generally report the use of animals as disparate
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as 12 to 28 months old. However, female rats typically undergo reproductive senescence
around 9 months of age. Therefore, 9 months of age can been equated to a period
similar to the late 40s or early 50s in humans. Studying animals around 18 months of
age may equate to a similar period in humans of 75+ years old. In humans, this is the
period of greatest stroke risk. Utilizing aged animals, 18 to 20 months of age, typically
requires the establishment of an aging colony either by the investigator or the animal
supplier.

An alternative to aging animals in the traditional fashion described above is made
possible by the development and selection of Senescence-Accelerated Mouse (SAM)
strains. These mice originate from inbred strains suffering from early onset of agerelated diseases and demonstrate other pathologic features consistent with aging such
as dysregulation of the immune system. The SAMP10 strain in particular experiences
both histologic (loss of spines, synapses, and neurons) and functional (impaired learning
and memory, depressive-like behavior) changes. Notably, this strain exhibits many of the
pro-inflammatory characteristics observed in the aged brain of both humans and
rodents.
Limitations
Despite the potential for clear benefit not only in investigation of disease
pathophysiology but also therapeutic development, models of aging have some
drawbacks that must be considered. For example, due to per diem costs for housing and
caring for animals, aging can be prohibitively expensive for many groups. Despite the
expense, research with this model has been conducted successfully by groups in both
North America and Europe. Conversely, SAMs may represent a quicker and more costefficient method of studying the aged brain, but the question of how well SAMs correlate
with normal aging remains to be answered. It will be important for future work to
investigate how closely SAMs replicate the process of aging.
1.5.3. THE METABOLIC SYNDROME AND STROKE
Obesity: Inflammatory Mechanisms Driving the Epidemic
The number of overweight and obese people in the United States has doubled within the
past 30 years 91. Obesity dramatically increases the risk for stroke, and several groups
have proposed mechanisms to explain this phenomenon. The first mechanism is a
decrease of the cytokine called adiponectin. Low adiponectin levels can cause an
increase in inflammation, insulin resistance, and vascular degradation 	
   92. Savopoulos
and colleagues showed that the cytokine resistin is altered with obesity. Resistin causes
endothelial dysfunction by augmenting the release of endothelin-1	
   93. Endothelin-1
constricts blood vessels and links obesity to hypertension. Still further, the Hishinuma
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group has shown that visceral
fat increases TNF-α as shown
in Figure 1.7. TNF-α acts on
pathways that initiate
appropriate responses to
inflammation and some others
that cause apoptosis 94. TNF-α
in association with lymphotoxin
induces macrophages to
adhere to endothelial cells and
exit the blood vessel by
diapedesis.
These
Figure 1.7. Obesity and Stroke. Obesity causes a
macrophages engulf
decrease in adiponectin and an increase in resistin
pathogens and release
and TNF-alpha. These molecular changes predispose
inflammatory cytokines
the body to increased inflammation. The inflammation
following an ischemic injury.
leads to increased stroke risk.
Furthermore, a phenomenon
known as the obesity paradox
has been reported during vascular surgery. Obesity decreases the risk of post-operative
stroke compared to the risk seen in non-obese individuals 	
   95. Further work has shown
that even though obesity elevates the risk for stroke in the general population, it
increases survival rates following stroke. Two prevailing theories about this paradox are
an excess nutrient reserve available in obese and overweight individuals following stroke
as well as an upregulation of TNF-α receptors in adipose tissue following infarct	
   96. The
activation of TNF-α receptors might increase the likelihood of stroke in obese individuals
but it also provides greater neuroprotection following stroke. This occurs because TNF-α
is known to activate apoptotic pathways through tissue necrosis factor receptor 1
(TNFR1) and neuroprotective pathways through tissue necrosis factor receptor 2
(TNFR2) 97.
Animal Models of Obesity
In order to elucidate the role of obesity in stroke infarct damage, researchers have
sought to develop appropriate models of obesity. Two primary forms of obesity exist in
the general public. The first is uncontrollable genetic disorders such as leptin insensitivity
and the second is obesity caused by poor diets. A model of the genetic form of obesity is
the obese Zucker rat. Zucker rats are insensitive to satiety signals relayed to the
hypothalamus ventromedial nucleus and also have deficient leptin receptors 	
   98. The
model has been used to gather important data regarding the release of vasodilator and
vasoconstrictor hormones associated with stroke development 	
   99. A model for the dietinduced obesity uses high fat diets in rats. Rats are fed these high-fat diets from 3 weeks
of development onward. After these animals become obese, transient middle cerebral
artery occlusion (tMCAO) is induced through a fibrin clot. Infarct damage is increased in
these animals compared with non-obese controls	
   100. This elevated level of damage is
due to neurovascular matrix degradation and BBB disruption mediated by increases in
MMP-9 	
   101. Furthermore, matrix metalloproteinase 2 (MMP-2) is upregulated and
causes degradation of type IV collagen, which is then replaced by inappropriate collagen
type I deposits 	
   102. Since obesity is associated with many vascular disorders, it will be
important in the future to investigate how other stroke risk factors such as age, diabetes,
and hypertension interact with obesity.
Diabetes: A Growing International Problem
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Diabetes mellitus type 2 has become the most common serious metabolic disorder not
only in the United States but across the world	
   103. One research group estimates that
171 million people across the globe were inflicted with diabetes mellitus in the year 2000
and that number is projected to double by 2030	
   104. The most recognizable aspect of
type 2 diabetes mellitus is the uncontrolled levels of hyperglycemia. Hyperglycemia can
stimulate the formation of advanced glycosylated end-products (AGEs). In the clinical
setting, diabetes mellitus is diagnosed as a fasting plasma-glucose of 110 mg/dL or
more, or a random plasma-glucose of 200 mg/dL or more	
   105. The pathophysiology of
diabetes mellitus, however, is more complex than a simple elevation in serum glucose
levels. Clinical manifestations also include glycosuria, polydipsia, polyuria, and renal
failure from AGEs. Perhaps the most interesting aspect of the disease is the starvation of
body tissues despite the fact that glucose remains abundant in the blood stream. This
phenomenon is due to peripheral cells being either completely or partially resistant to the
effects of insulin 105. The body shifts from primarily receiving energy from glucose to
receiving energy from lipids. Consequentially, this leads to ketone buildup in the body
and a lowered pH level	
  103.
Causes of Diabetes: An Unknown Conglomeration of Many Factors
A few theories have been proposed regarding the causes of diabetes. In reality, little is
known about the causes, and like many other diseases, it is likely multifactorial. Many
clinicians point to certain habits, such as sedentary lifestyle and high calorie and fat
intake, as the main culprit of diabetes 103. Interventions focusing on weight loss, diet
modifications, and regular physical exercise of at least 150 minutes per week reduce the
incidence of diabetes in at-risk patients. These activities also reduce hemoglobin A1C
levels in type 2 diabetics 	
  106. Genetic links have likewise been recognized. Researchers
discovered at least 36 genes associated with diabetes 	
   107. A high concordance level
among identical twinsshows that type II diabetes is heritable 108.
Diabetes: Role in Chronic Inflammation and Ischemic Stroke Risk/Outcome
Additionally, many groups began to focus on the influence of inflammation and innate
immunity in diabetes. It is uncertain at this point if inflammation occurs prior to or after
the onset of diabetes. Specific cytokines such as TNF-α, IL-6, and C-reactive protein
(CRP) are elevated in type 2 diabetic patients in comparison to non-diabetic controls 	
  109.
TNF-α and IL-6 cause generalized systemic responses such as fever and increased
vascular permeability while CRP is a key player in complement-mediated immunity.
CRP is the foundational block of the classical pathway. CQ binds to the pathogen, and
CR and CS cleave C4 and C2 to make the convertase C4bC2a. The convertase then
marks the pathogen for phagocytosis by cleaving C4 to C4b and C4a, which allows C4b
to become membrane bound. Another innate immune response is driven by toll-like
receptors (TLR). TLRs are activated by LPS or lipoteichoic acid on cell membranes or by
DNA or RNA in endosomes. TLRs trigger nucleus specific changes that often lead to
increased release of acute phase reactants 110. These acute phase reactants are
beneficial in situations in which the body’s immune system is compromised with an
infection or after an acute trauma. Over a longer period of time, these reactants become
destructive to the systemic vascular system and cause damage to tissues throughout the
body	
   109. This destruction of the vascular system contributes to other diseases and
injuries such as hypertension, cerebrovascular diseases, renal disease, and ischemic
stroke	
   111,	
   112. The damage is mediated through numerous pro-inflammatory pathways.
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The signaling produces enhanced oxidative stress and the toxic build-up of degraded
cells, proteins, and molecules	
  112.
Although the role of inflammation in diabetes is still under investigation, it is important to
consider which pathways may be targeted therapeutically. For example, TNF-α induces
pathways that lead to increased insulin resistance throughout the body 113. Insulin
resistance is a strong risk factor for ischemic stroke	
   112. Targeting TNF-α pathways may
therefore be useful for preventing strokes in diabetic patients. Ultimately, any
inflammatory trauma to the vascular system will have a large effect on the vasculature of
the brain. If the inflammatory changes of diabetes can be controlled, it might greatly
reduce the incidence of stroke in this population.
Diabetes in Animal Models
Many well-established rat models are used in type 2 diabetes research. This section will
address three of the most prominent models as mentioned in Figure 1.8. The Israeli
sand rat model focuses on the dietary factors of diabetes mellitus. As mentioned
previously, an increased caloric intake can intensify the occurrence of diabetes mellitus
type 2. When the normal vegetarian diet is changed to a specific high-calorie laboratory
diet, the rats eventually develop obesity, glucose intolerance, and hyperinsulinemia	
   114.
With time, the rat’s intact pancreatic islet cells begin to degrade and die, thus leading to
overt diabetes	
   115,	
   116. Essentially, this model relies on nutritional means to develop
diabetes mellitus type 2 in the animals. The model is beneficial because it mimics the
excessive calorie and glucose levels found in the human population. One limitation is
that it does not address the genetic factors of diabetes. Many genetic factors have been
identified in the human population and lead to activation of different pathways. These
pathways present different therapeutic intervention opportunities. Therefore, genetic
factors of diabetes are essential in the development of a proper diabetic model.
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Figure 1.8. Rat Models of Diabetes Type II. Three well-known models of diabetes
include the Israeli Sand Rat, Otsuka Long-Evans Tokushima Fatty Rat, and
Ventromedial Hypothalamus Lesion (VMH) Dietary Obese Rat. Each of these models
represents different characteristics of diabetes such as obesity, glucose intolerance,
hyperinsulinemia, polyphagia, and hepatic lipogenesis.
The Otsuka Long-Evans Tokushima fatty (OLETF) rat is one example of a diabetic
model that incorporates genetic factors. This rat model is developed by selective
breeding from an outbred rat colony of Long-Evan rats. Although selective breeding is
used, it is important to note that this is not a transgenic population. At 16 weeks of age,
the OLETF rats’ differentiating characteristics are thoroughly developed. This rat model
demonstrates the following physical manifestations: glucose intolerance,
hyperinsulinemia, mild obesity, and polyphagia	
   115. The combination of polyphagia,
obesity, and impaired glucose intolerance is a more accurate syndrome of the Western
diabetic population. The polyphagia is assumed to be partially explained by a null allele
coding for the cholecystokinin A receptor 	
   114. A problem with this model is that the
diabetic characteristics are induced by breeding instead of the actual pathophysiology of
diabetes mellitus. Using such models explains why current treatments of diabetes
mellitus focus only on eliminating physical manifestations of diabetes instead of treating
the underlying cause of the disease.
Another interesting model combines the use of a lesion in the ventromedial
hypothalamus region of the brain and a high-fat/highsucrose diet. This is known as the
ventromedial hypothalamus lesion (VMH) dietary obese rat model	
   117. The lesion itself is
thought to cause the development of hyperphagia, obesity, decreased glucose
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metabolism, defective regulation of insulin, and increased hepatic lipogenesis 	
   115. As
already discussed, the high-fat and high-sucrose diet is a key factor in exacerbating the
lesion’s effects. Within 3 weeks, these rats are found to have fasting hyperinsulinemia,
hypertriglyceridemia, and impaired glucose tolerance 	
   117. Although this model is
beneficial in studying the effects of the lesion and the diet on diabetes, it again does not
accurately portray the entire pathophysiology of diabetes. Some diabetic pathways are
highlighted while others are completely ignored. It is clear that these models do not
accurately represent the pathophysiology of diabetes. A more comprehensive model will
be necessary to elucidate the mechanisms of diabetes and how these altered pathways
increase risk for stroke. Fan and colleagues studied stroke in a streptozotocin diabetic
rat model. The model they used is limited because it represents type I diabetes mellitus
and hemorrhagic stroke instead of the more common type II diabetes and ischemic
stroke. Furthermore, this study focused only on tPA activity instead of investigating other
mechanisms and pathways	
  118.
Hypertension and Stroke: Increasing Prevalence in the United States
Two broad classifications of hypertension include primary hypertension and secondary
hypertension. Primary hypertension is not caused by an independent disease, such as
athersclerosis, but it can lead to higher risk for vascular and heart problems and
predispose individuals to disease. The prevalence of primary hypertension is increasing
in the United States due to the rise of obesity rates 	
  119. Three subcategories for primary
hypertension are systolic and diastolic hypertension (SDH), isolated systolic
hypertension (ISH), and isolated diastolic hypertension (IDH). SDH and ISH are risk
factors for ischemic stroke as shown in Figure 1.9	
  120.
Hypertension as a Contributing Factor in Stroke Outcome: An Inflammatory Process
Hypertension causes an increase in cell adhesion molecules, vascular adhesion
molecules, and selectins. Subsequently, these molecules induce inflammatory
responses by increasing the affinity of binding between immune cells and damaged
tissue. The molecules also increase the build-up of atherosclerotic plaques in blood
vessels through similar binding mechanisms. If a cerebral vessel becomes completely
occluded, an ischemic event ensues leading to a cascade of inflammatory responses
and still further immune cell binding	
   121. Many of these responses are time-specific and
depend on precise pathway activation. For example, Interleukin- 6 (IL-6) and MMP-9 can
paradoxically lead to either neuroprotection or neurotoxicity depending on the specific
period of observation	
   122. IL-6 also causes a systemic fever useful for disrupting
pathogen viability. It is therefore necessary to use models that relate well with human
pathology and to observe changes at multiple time points post-ischemia.
Hypertension in Animal Models
Since hypertension is the largest factor in predicting stroke severity, it is essential that
models of stroke incorporate the issue of hypertension	
   123. It was proposed that 9
percent to 16 percent of ischemic strokes could be avoided if hypertension were kept
under control in the general population	
   124. A model that addresses the issue of
hypertension and stroke is known as the spontaneous hypertensive rats-stroke prone
(SHR-SP). These rats have spontaneous increases in blood pressure, and upward of 80
percent develop stroke when placed on normal diets 	
   125. Not surprisingly, some groups
have found that diets high in sodium chloride accelerate the time to first infarct in these
animals	
   126. A primary reason why this model works well is that it allows researchers to
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investigate how inflammation changes from a baseline state of hypertension to a postischemic state. Inflammation triggered by the sheer on an atherosclerotic vessel
facilitates an increase in oxidative stress and the activation of the ubiquitin-proteasome
system. Initially this leads to small vessel remodeling, but as long as the pressure
remains elevated, these changes eventually result in occlusion and infarct	
   127. Since this

Figure 1.9. Hypertension and Stroke. Primary hypertension, specifically systolic and
diastolic (SDH) and isolated systolic (ISH), increases inflammation and the risk for
stroke. Improved treatments for all classifications of hypertension are necessary to
manage the increasing rate in the population.
process is progressive, it also allows for measurement of time-specific changes.
Unfortunately this model also has some limitations since the animals die before 1 year of
age 128. Since age is the biggest risk factor for stroke, it is important to consider how
hypertension changes with age. The majority of people past the age of 65 will eventually
develop hypertension due to age-related arterial changes 129. It will therefore be
beneficial for future models to use animals that develop hypertension later in their lives
similar to when most humans develop it.
1.5.4. OTHER CONSIDERATIONS
In addition to use of clinically relevant animal models employing aged animals and those
with comorbidities, other considerations need to be taken into account to improve the
likelihood of translation from bench-to-bedside. This includes but is certainly not limited
to the role of gender in outcome following ischemic stroke, occlusion methodology,
combination treatment, time of treatment administration, and outcome measures utilized.
Each of these topics is explored briefly below.
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Role of Gender
Another risk factor for stroke rarely considered is the role of gender. Females are more
likely to be afflicted with ischemic stroke yet the vast majority of preclinical studies are
conducted in young-adult, male animals 9. This fails to account for the role genderrelated hormones may play in stroke outcome 49. While numerous studies have
illustrated a neuroprotective effect of gender-associated hormones, such as estrogen, on
stroke outcome, these studies have been conducted in young-adult animals 130, 131.
There remains no indication that these same hormones, when administered to the aged
animal, will be neuroprotective. In fact, clinical experience from hormone replacement
therapy (HRT) would indicate an increased stroke risk with estrogen replacement in the
aged individual 132.
Occlusion Methodology & Combination Treatment
Methodology for inducing ischemia has been discussed at length in the literature, with
each technique having distinct advantages and disadvantages 133-136. While suture
occlusion remains the prevalent technique for inducing ischemia and is advantageous in
ease and reproducibility, the 100% reperfusion that occurs immediately upon suture
withdrawal lacks clinical relevance. Additionally, reperfusion in clinical stroke occurs with
administration of tissue plasminogen activator (tPA) and this is a gradual reperfusion as
the thrombus is broken down. This reperfusion profile seen clinically is replicated in
preclinical models utilizing a thrombus and subsequent tPA administration. By failing to
utilize one of the only approved treatments for stroke in the vast majority of preclinical
models, it is difficult to study combination therapies. While combination therapies result
in potentially more intricate experimental paradigms, it seems unlikely that any potential
neuroprotectant can be entirely successful without some degree of reperfusion.
Similarly, the ischemic cascade, as described above, is a complex process and may
require multiple steps to be targeted simultaneously. Therefore, it seems plausible that
future studies need to investigate combinatorial therapy, particularly with administration
of tPA to achieve reperfusion 137.
Treatment Administration
To increase the translation from bench-to-bedside, potential therapeutic agents need to
be administered at extended time points in preclinical studies, time points more
consistent with patient presentation. In the past decade since regulatory approval of
tPA, less than 5% of patients receive intravenous tPA. The lack of use is related
primarily to time-of-presentation, in that only 46% of patients present within 3 hours, and
an extensive list of contraindications 138. This reality necessitates that therapeutics
capable of extending the thrombolytic window that can be administered safely, perhaps
by first responders, need to be developed.
Selecting Appropriate Outcome Measures
Preclinical models of stroke emphasize volumetric assessments of stroke outcome
whereas clinical assessment is based almost entirely on functional outcome. This
discrepancy may play a role in the failed translation of therapeutics from bench-tobedside.
Furthermore, functional assessment may prove to be a more sensitive
indicator of recovery in preclinical models, raising the possibility that compounds
previously thought to be a failure based on volumetric assessment, may be
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advantageous functionally. Commonly used functional evaluations in preclinical work,
such as the modified Neurological Severity Score (mNSS), were developed in youngadult animals. If aged animals are to be utilized to increase clinical relevance, it will be
important to obtain baseline assessments and determine the most appropriate functional
and behavioral outcome measures for aged animals, as aged animals may require a
unique battery of tests for detailed functional outcome assessment.
1.5.5. CONCLUSION AND FUTURE DIRECTIONS
Although it has been challenging to find therapeutics that translate successfully from
bench-to-bedside, animal models are still a valuable and promising tool for therapeutic
development. Animals experience several of the same physiological changes that
humans encounter. With the use of transgenic animals and careful breeding, it is
possible to simulate the majority of risk factors seen in complex human diseases 	
   139.
Age, obesity, diabetes, and hypertension were examined in this review as they relate to
stroke risk and inflammation. The models that represent these individual risk factors
have been used successfully in relation to other disease states and furthermore have
provided helpful insights into important components of stroke. The question that remains
is how all of these risk factors fit together. In order to answer this question, it will be
necessary to design a more comprehensive model that incorporates most of these risk
factors.
In human diagnosis, the factors of obesity, dyslipidemia, glucose intolerance, and
hypertension have all been linked into a single metabolic syndrome. Until recently, these
factors were viewed as separate components and risk elements. Since they often occur
together in individual patients, researchers and clinicians were encouraged to propose
the idea of the metabolic syndrome	
   140. Some cardiovascular researchers have adopted
the idea of the metabolic syndrome and now use a transgenic rat model SHR/NDcp,
which spontaneously develops obesity, hypertension, hypderlipidemia, and insulin
resistance	
   141. If such a model could be adapted to stroke research, it may offer a more
comprehensive approach necessary to isolate the important pathways. Another
possibility is to use the high-fat diet mentioned in the obesity section but initiate it at a
later time point in development. This high-fat diet has been deemed the western diet in
animal research and has consistently resulted in the development of the metabolic
syndrome	
   100. The results from this comprehensive model can then be compared with
previous work in the other models. Other models have been used to isolate key
inflammatory pathways important in stroke morbidity and mortality. A good starting point
for using the more comprehensive model would be to look at common pathways
consistently showing changes in most of the previous less-sophisticated models.
When looking through the literature, a few inflammatory pathways appear to be activated
consistently post-ischemia and would be worth investigating with this comprehensive
model. For example, some of the cytokines released post-ischemia such as IL-6,
oncostatin M, and ciliary neurotrophic factor bind to the gp130 receptor 	
   142. These
cytokines cause increased inflammation and the recruitment of immune cells. Not
surprisingly, these same cytokines are altered by age and the factors of the metabolic
syndrome	
   51,	
   143. Once the gp130 receptor is activated, it induces downstream Janus
kinase 2 (JAK2) phosphorylation of the tyrosine residue on STAT3. STAT3 is unique in
its capacity to activate different genes in different cell types 	
   144. Another pathway that
looks promising is TNF-α’s activation of secretory phospholipase A2 IIA (sPLA2 IIA).
sPLA2 IIA activation leads to a destruction of phosphatidylcholine in membranes and
also to an increase in inflammation-dependent infarct size	
   145. The cytokine TNF-α
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specifically causes endothelial widening and diapedesis of macrophages. As mentioned
previously, TNF-α levels are altered by obesity, age, and other factors of the metabolic
syndrome. Finally, protein kinase C (PKC) is a well-known modulator of inflammatory
pathways. PKC has 12 different isoforms, many of which are altered by the metabolic
syndrome and age 	
   146,	
   147. These responses can sometimes work against each other
depending on which isoform of PKC is active. PKCδ is associated with neurotoxicity
where PKCε initiates neuroprotection 	
  148.
Although much remains to be discovered about stroke, the use of a comprehensive
animal model has been a useful tool for translational research in other disease states
and may prove useful for ischemic stroke research as well. It will allow investigators to
highlight neurotoxic and neuroprotective pathways and discover how they function with
consideration to age and the metabolic syndrome. With increased therapeutic options, it
may be possible to increase survival and recovery following an ischemic event.
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1.6. Neuroprotection in Ischemic Stroke
In this work we explore the concept of neuroprotection and potential therapeutic targets
for future research and development.
This work was published in the Journal of Neurosurgery.
Citation:
Turner RC, Dodson SC, Rosen CL, Huber JD (2012) The science of cerebral ischemia
and neuroprotection: navigating past failure to future success. Journal of Neurosurgery
118(5):1072-1085.
Abstract:
Ischemic stroke remains a leading cause of morbidity and mortality for which few
therapeutic options are available. The development of neuroprotective agents, a once
promising field of investigation, has failed to translate from bench-to-bedside
successfully. This work reviews the ischemic cascade, agents targeting steps within the
cascade, and potential reasons for lack of translation. Additional therapeutic targets are
highlighted and areas requiring further investigation discussed. It is clear alternative
targets need to be pursued such as the role glia play in neurologic injury and recovery,
particularly the interactions between neurons, astrocytes, microglia, and the vasculature.
Similarly, the biphasic nature of many signaling molecules such as matrix
metalloproteinases (MMPs) and high mobility group box 1 (HMGB1) protein must be
further investigated to elucidate periods of detrimental versus beneficial activity.
1.6.1. INTRODUCTION
Decades of research on ischemic stroke have produced a heightened understanding of
the pathophysiology, providing an extensive array of potential therapeutic targets. While
many of these proposed targets have been manipulated through various pharmacologic
compounds, many of which have progressed to clinical trials, there remains an unmet
need for alternative, or supplemental, treatments besides tissue plasminogen activator
(tPA) for stroke. In addition to the complex pathophysiology of stroke, the lack of
successful translation from bench-to-bedside has resulted in controversy concerning the
most appropriate preclinical models of ischemic stroke and assessment of potential
therapeutics. This work highlights the pathophysiology of stroke with an emphasis of the
time-dependent nature of the ischemic cascade and pharmacologic agents tested
preclinically and/or clinically targeting events within the cascade. Preclinical modeling
and alternative therapeutic approaches/targets are discussed at length with the goal of
improving the likelihood of successful translation from bench-to-bedside.
1.6.1.1. Significance of Stroke
Stroke remains a leading cause of morbidity and mortality in the developed world with
the only approved pharmacologic treatment being tPA. Due to many risks associated
with tPA use, stringent guidelines must be followed, most specifically, treatment within
three hours of symptom onset resulting in less than 5% of patients receiving tPA
treatment 149. As such, the development of alternative treatments is highly desirable.
1.6.1.2. Concept of Neuroprotection
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The notion that neuroprotection may be possible following neurologic injury, and more
specifically ischemia, is based largely on the findings of Astrup, et al 150. The onset of
ischemia produces a ‘core’ region in which flow is severely reduced, by almost 90%.
This sharp reduction in blood flow results in deficient ATP levels and subsequent ionic
disruption and metabolic failure, progressing to cell death via necrosis within minutes.
Surrounding this ‘core‘ region lies the ‘penumbra‘ in which flow is less severely reduced,
typically in the range of 35% of baseline 150. This territory is characterized by the loss of
action potential firing but maintenance of proper resting membrane potential. Upon
restoration of blood flow to the penumbra, normal function returns. If flow is not restored
acutely, tissue originally in the penumbral region dies and the core infarct region evolves
to encompass what was previously penumbral tissue 151. While the general consensus
remains that the infarct core is not salvageable, it is believed that penumbral tissue can
be salvaged through flow restoration and/or restoration of cellular homeostasis through
manipulation with pharmacologic compounds. Potential neuroprotective agents target a
variety of aspects of cellular physiolology ranging from membrane integrity to
mitochondrial function to the regulation of apoptosis.
1.6.1.3. Current Treatment Options
This concept resulted in the development of intravenous tissue plasminogen activator
(IV-tPA), the most widely used therapeutic option for ischemic stroke treatment.
Unfortunately, IV-tPA can only be applied to a relatively small subset of those afflicted
with ischemic stroke, less than 5%, as a consequence of numerous contraindications
and the late presentation time after stroke onset of most patients 146. In an attempt to
provide thrombolytic therapy to a broader patient population, other therapeutic
techniques have been developed. These include intra-arterial delivery of tPA, the
Penumbra System, and the MERCI clot retrieval device. Each of these alternative
techniques, while expanding the therapeutic window of opportunity, require specialists
found primarily at advanced academic medical centers and are rarely available at
smaller community hospitals, making them less than an ideal therapeutic option.
1.6.1.4. Targeting the Ischemic Injury Cascade
Pharmacologic agents selected to interrupt the ischemic injury cascade that can be
administered safely to a larger patient population are therefore desirable. Numerous
compounds have been investigated as potential neuroprotective agents.
These
compounds have targeted events primarily occurring rapidly after ischemic onset. After
cerebral blood flow is reduced, energy failure occurs due to a decoupling of oxidative
phosphorylation, resulting in a series of events including glutamate release and ionic
imbalance which subsequently causes membrane depolarization 1. Calcium rapidly
enters the cell causing the induction of various enzymes and mitochondrial damage.
Further downstream, apoptotic mediators are released, free radicals produced, and
The events of the injury cascade, and the
inflammatory mediators released 2.
pharmacologic agents designed to prevent them, will be discussed in further detail in
subsequent sections.
1.6.1.5. Current Status of Neuroprotectant Development
To date there have been over 1000 preclinical studies identifying neuroprotective
compounds with over 100 progressing to clinical trials. Of those progressing to clinical
trials, none have proved efficacious in the human population 8. Consequently, funding
for the field has declined from both pharmaceutical corporations as well as government
agencies.
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The prospect of neuroprotection remains at the forefront of the stroke field, despite the
aforementioned failures, with the vast majority of researchers still believing it has merit
as a potential therapeutic option. There is simply too great a need for addtional
treatments and development of
neuroprotective agents due to the
economic burden of stroke with an
estimated $28.3 billion in direct costs
and $25.6 billion in indirect costs in
the United States in the year 2010
152.
The failed translation from bench-tobedside of therapeutic agents has
resulted in much speculation about
the requirements for achieving
success.
This work seeks to
summarize the ischemic cascade
(Figure 1.10), agents that have
targeted a given step yet failed in
clinical trials, and potential reasons
for past failures.
Additional
discussion highlights potentially
promising therapeutic targets and
areas or topics in need of further
investigation.
0

1.6.2.
PATHOPHYSIOLOGY OF
STROKE & CORRESPONDING
THERAPEUTICS – ACUTE PERIOD
1.6.2.1.
Glutamate-mediated
Excitotoxicity
Blood flow cessation as a result of
ischemia onset induces a shortage
of oxygen and glucose delivery. As
the main sources of energy
production via oxidative
Figure 1.10. A diagrammatic representation
phosphorylation, diminished oxygen
of the ischemic injury cascade from the onset
and glucose supply results in a
of ischemia to cell death.
decoupling of oxidative
phosphorylation and subsequently,
reduced ATP production and disruption of ionic pump function. These events occur
rapidly after onset of ischemia; in fact, ATP levels are decreased substantially within 2
minutes 153. Diminished levels of ATP impedes the functioning of Na-K ATPase,
preventing the maintenance of normal ionic gradients. As such, elevations in cytosolic
Na+ and a decrease in cytosolic K+ is seen, leading to a depolarization of the neuronal
membrane 153. Voltage-gated calcium channels are activated by depolarization, allowing
for rapid influx of Ca2+ which results in release of excitotoxic amino acids such as as
glutamate. Under normal homeostatic conditions, glutamate is rapidly cleared from the
synapse via presynaptic and astrocyte uptake but this response is altered in ischemia.
In ischemia, the excess glutamate within synaptic cleft binds ionotropic N-methyl-D-
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aspartate (NMDA)
and α-amino-3hydroxy-5-methyl-4isoazole propionic
acid
( A M PA )
receptors on the postsynaptic membrane,
p r o m p t i n g
depolarization of the
post-synaptic neuron
and propagating the
wave
of
depolarization 1.
1.6.2.2.
Blocking
Excitotoxic Events
Attempts to mitigate
excitotoxicity have
A representation of targets pursued for
encompassed a wide Figure 1.11.
preventing
neuronal
excitotoxicity, often attributed to
array of targets, ranging
excessive
glutamate
release.
These targets include the
from prevention of
glutamate release to
blocking glutamate
receptors to facilitating the opening of ion channels that counteract the excitotoxicity
(Figure 1.11). One of the most widely investigated targets is antagonism of the NMDA
receptor on the post-synaptic membrane. The NMDA receptor is activated by the
binding of both glutamate and glycine to their respective sites and is further modulated
by an allosteric site 154. Once activated, the NMDA receptor acts as a non-specific
cation channel, allowing the passage of Ca2+, Na+, and K+ into the cell 155. By
preventing activation of the NMDA receptor, cation flux through the ion channel is
reduced, preventing depolarization. Numerous agents have been investigated for this
purpose and include non-competitive antagonists such as Aptiganel Hydrochloride
(Cerestat; CNS-1102) 154, 156, 157, Dextrorphan Hydrochloride 154, 158-160, and Magnesium
161-163; competitive antagonists such as Selfotel (CGS-19755) 154, 164, 165; glycine-site
antagonists like Gavestinel (GV-150,526) 154, 166-168; and indirect blockers exemplified by
Lubeluzole (Prosynap) 154, 169, 170.
The AMPA receptor, an ionotropic receptor for glutamate, is another well-documented
target in the search for neuroprotection via reducing excitotoxicity. The AMPA receptor
has multiple glutamate binding sites that when bound activate the receptor and open the
cation channel, allowing passage of cations non-specifically 171. Logic in targeting the
AMPA receptor is similar to that of the NMDA receptor in that antagonizing the AMPA
receptor should prevent cation influx and subsequent depolarization.
One widely
investigated therapeutic antagonizing the AMPA receptor is Zonampanel (YM872) 154,
172.
In addition to targeting glutamate-binding receptors and preventing substrate-receptor
binding, another alternative is to counteract the increase in cation influx. One way of
doing this is to increase the influx of anions such as Cl-. Clomethiazole (Zendra®), a
GABAA receptor agonist, was evaluated for this purpose 173-175. Similarly, activation of
the neuronal 5-HT1A receptor has been shown to elicit hyperpolarization due to
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TABLE 1.1. Examples of proposed neuroprotectants attempting to mitigate excitotoxicity, and the progression from
preclinical experimental stroke models to clinical trials*

increasing inward K+ current. A compound activating the 5-HT1A receptor that has been
evaluated in not only preclinical
experimental stroke studies but also
clinical trials is Repinotan (Bay x
Maxipost
3 7 0 2 ) 176-178.
(BMS-204352), a potassium channel
opener, has also been evaluated for
the treatment of ischemic stroke.
Once again, the logic behind
application of this compound was
that an increase of potassium influx
would hyperpolarize the membrane,
preventing depolarization 154, 179, 180.
A final target for preventing
excitotoxicity is the opiate receptor,
the kappa receptor in particular. This
receptor results in the initiation of a
G-protein signaling cascade when
stimulated 181. While the details of
this cascade are not entirely
elucidated, it is clear that the
pathway is involved in the release of
excitatory neurotransmitters, release
of free fatty acids, and the presence
of antioxidants.
The agent
Nalmefene (Cervene) was a kappa
receptor antagonist investigated for
the treatment of stroke 182, 183.
The target, preclinical development,
clinical evaluation, and results of
these agents is highlighted in Table
1.1. Notably, each of these agents
failed when reaching clinical trials.
The precise reason for each of these
failures is unlikely to be identified but
numerous weaknesses in preclinical
design and the translation from
bench-to-bedside are evident. For
example, most preclinical studies
utilize young-adult animals despite
the role of age in the clinical stroke
population. Furthermore, preclinical
work often involves drug
administration prior to, or shortly
after, onset of ischemia yet clinical
trials often have a much longer
exclusion window in order to increase
the number of eligible patients.
Other potential shortcomings of
studies are discussed in greater
detail below.
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1.6.2.3. Effects of Intracellular Calcium
The excessive calcium influx results in activation of a multitude of enzymes including
phospholipases and proteases, mediated through calcium serving as a messenger
Activation of
molecule for numerous downstream signaling pathways 184, 185.
phospholipases and proteases results in membrane and protein degradation, decreasing
cellular integrity and survival. Endonucleases are also activated, cleaving DNA and
leading to further cellular changes and potentially cell death. Calcium influx also
potentiates glutamate-mediated excitotoxicity as depolarization occurs and additional
glutamate released.
The release of excessive amounts of glutamate results in
propagating waves of depolarization, termed peri-infarct depolarization, originating in the
core and spreading to the peripheral penumbra 186. Peri-infarct depolarization, at least
in the initial 3 hours of ischemia, has been shown to correlate with final infarct volume in
preclinical studies 187. Other studies have shown wave propagation for at least 6-8
hours after ischemic onset, although the correlation with infarct volume at these later
time points is unestablished 188. Agents interrupting the waves of depolarization through
targeted blockade of glutamate receptors (AMPA and NMDA) prevent progression of the
penumbra to infarct in experimental models of ischemic stroke. In contrast, the creation
of additional waves of depolarization through administration of potassium chloride
While manipulation of peri-infarct
causes expansion of the infarct core 188.
depolarization has occurred in preclinical models, the propagating waves of
depolarization have been shown to occur in humans afflicted with stroke and equally
important, each wave has been shown to correlate with expansion of the infarct 188. It is
unclear as to whether the spreading depolarization may have some beneficial effects
though as it may induce release of protective factors.
In addition to roles in protease, phospholipase, and endonuclease activation, and
serving as an intermediary in downstream signaling, calcium influx is involved in
mitochondrial damage and subsequent reactive oxygen species (ROS) generation 51.
Following a rise in intracellular cytosolic calcium concentration, occurring following
ischemia, calcium enters the mitochondria 189. Calcium balance in the mitochondria is
achieved via intake through the uniporter and output through 2Na+-Ca2+ exchange. This
balance is disrupted in ischemia with calcium entering via the uniporter far more quickly
than the 2Na+-Ca2+ exchanger can function 185. Accumulation of excess calcium within
the mitochondria most often results in opening of the permeability transition pore (PTP)
found on the inner mitochondrial membrane. The PTP opening is associated with loss of
membrane potential and subsequent osmotic swelling, leading to outer membrane
rupture and release of cytochrome c 190. While the mechanism has not been elucidated
entirely, calcium influx and associated mitochondrial dysregulation may result in initiation
of apoptosis and generation of reactive oxygen species. This process plays a role in not
only initial ischemic injury but also subsequent reperfusion and reperfusion-associated
injury (Figure 1.12).
1.6.2.4. Blocking Actions of Excess Calcium
Nimodipine, a calcium channel blocker frequently utilized in other forms of
cardiovascular disease, was assessed as a potential therapeutic in the phase III trial
Very Early Nimodipine Use in Stroke (VENUS) 191. Preclinical studies, as well as
previous clinical trials, reported mixed findings regarding the efficacy of Nimodipine
192-194. A subgroup analysis of a previous clinical trial employing Nimodipine suggested
improvement in outcome when drug administration occurred within 18 hours of symptom
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onset, hence the VENUS
trial was initiated.
Unfortunately, the VENUS
trial failed to show
improved outcome, in both
primary and secondary
measures, at trial
termination 191.
1.6.2.5. Oxidative Stressinduced Damage
Oxidative stress has long
been recognized as a
potential target for
therapeutic development
following ischemia.
Oxidative stress, induced
by the production of
reactive oxygen species
(ROS), can be attributed
largely to mitochondrial
dysfunction 189. In addition Figure 1.12. Schematic showing that ischemia results in
t o P T P o p e n i n g a n d increased intracellular calcium levels through not only the
release of cytochrome c, NMDA and AMPA receptors but also through a slow Ca++
i n h i b i t i o n o f n o r m a l channel. Increased cytosolic calcium results in activation
respiration occurs, along of endonucleases and phospholipases as well as
w i t h t h e r e l e a s e o f proteases.
The MPTP allows calcium to enter the
189.
nucleotides
mitochondria, which causes production of ROS and further
Furthermore, glutathione damage.
Calcium in the mitochondria also causes
necessary for neutralization swelling and eventual rupture, release cytochrome c, long
of reactive oxygen species known to play a role in apoptosis.
is reduced.
Free radical
production leads to
peroxidation of plasma membranes and intracellular organelle membranes 187. Release
of biologically active free fatty acids, such as arachidonic acid, is a direct consequence
of free radical production. ROS production also leads to damage of intracellular
organelles such as the endoplasmic reticulum, mitochondria, and induce DNA
fragmentation.
Disturbances to homeostasis induced by ROS contribute to the
progression of downstream injury pathways and apoptosis, often similar to those
induced by excess calcium influx 187.
1.6.2.6. Free Radical Scavenging
Tirilazad mesylate, a compound inhibiting lipid peroxidation, was evaluated for treatment
of stroke in a total of 6 trials (4 of which were published) 57. Tirilazad failed to reduce
morbidity or mortality in acute ischemic stroke. Reasons for failure remain unknown but
preclinical evaluation of the drug produced mixed findings, often depending on time of
drug administration 195, 196. When administered prior to ischemia, tirilazad appeared
efficacious in preclinical studies but when administered post-stroke, no positive effect
was found 195, 196.
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The most recent well-documented failure of a proposed neuroprotective agent is that of
Disufenton Sodium (Cerovive; NXY-059), a free-radical spin trapping agent. Believed by
many to have undergone the most rigorous preclinical assessment of a potential
therapeutic agent, Disufenton Sodium progressed to clinical trials (SAINT I & II) 58. In
SAINT I, Disufenton Sodium appeared to be neuroprotective as disability, assessed with
the modified Rankin scale, was reduced in the treatment group 197. In the confirmatory
trial, SAINT II, Disufenton Sodium failed to reduce disability when administered within 6
hours of ischemic onset 198. This lack of efficacy was also true for subgroup analysis
and hemorrhage associated with tPA administration 199. A critical review of not only
preclinical studies but also design of the clinical trials reveals numerous discrepancies
between studies, ranging from inconsistent time of administration to inadequate animal
models and insufficient functional assessment 58.
1.6.3. PATHOPHYSIOLOGY OF STROKE & CORRESPONDING THERAPEUTICS –
SUBACUTE PERIOD
1.6.3.1. Apoptosis
Evolution of the infarct does not occur based on necrosis or apoptosis individually but is
rather a complex interplay between the aforementioned forms of cell death 1, 200-202. In
the infarct core, where ATP is severely depleted, necrosis may be the predominating
form of cellular death whereas in the penumbra, apoptosis may be the predominant form
of cell death 200. The onset of ischemia induces apoptosis through two primary methods,
one of which is through altered gene expression of apoptotic mediators such as Bax,
Bad, Bid, Bcl-2, Bcl-XL, etc and the second being the influx of calcium and subsequent
mitochondrial damage, ultimately resulting in opening of the PTP. Mitochondrial damage
and changes in mitochondrial membrane integrity can cause release of toxic mediators
such as cytochrome c and apoptosis inducing factor (AIF). This process, termed the
intrinsic arm of the apoptosis program, leads to the activation of proteolytic caspases
and ultimately, cell death. The extrinsic arm of the apoptosis program, in contrast,
utilizes a series of interactions between cell-death factors, such as Fas ligand, and celldeath receptors, such as the Fas receptor. After binding of ligand and receptor, an
adaptor protein (FADD) is recruited, resulting in the activation of the caspase cascade
200, 203.
1.6.3.2. Inhibiting Apoptosis
As a result of the previously discussed cell stressors produced following ischemia, many
of which are involved in mediating apoptosis, the pro- vs. anti-apoptotic protein balance
is shifted towards the induction of apoptosis. One of the pro-apoptotic proteins, Bax, has
been demonstrated to play an essential role in permeabilization of the outer
mitochondrial membrane 204. By preventing the Bax-mediated disruption, the release of
pro-apoptotic proteins can be avoided. When a Bax-inhibiting peptide was used in a
neonatal model of ischemia, outcome was improved 204.
Inhibition of caspases is another alternative target in the attempt to reduce apoptosis
and thus, improve outcome from cerebral ischemia 205. Caspases are proteases, first
synthesized in the pro-caspase form, that are rapidly activated in response to earlier
events in the apoptotic cascade such as apoptosome formation or death receptor
signaling 206. Caspase activation ultimately results in DNA fragmentation via cleavage
and inactivation of inhibitor of caspase activated DNase (ICAD), producing the hallmark
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‘DNA ladder’ of apoptotic cells 207. In experimental neonatal focal ischemia, application
of a pan-caspase inhibitor failed to reduce infarct volume, despite cell death shifting
towards necrosis 207.
While attempts to improve outcome after ischemia through the modulation of apoptosis
have failed to progress to clinical trials and successful therapeutics, investigation of the
apoptotic cascades in neonate, as well as young-adult animals, has revealed
fundamental differences associated with age.
For example, caspase-3 has been
described as being highly involved in apoptosis in the immature brain but plays a minor
role in adult brain 207. Similarly, the mitochondrial permeability often responsible for
inducing apoptosis may be mediated via different age-related mechanisms. In neonatal
hypoxic-ischemic injury, permeability is largely Bax-dependent but in adult brain, the
cyclophilin D transition pore plays a prominent role 204.
Besides appreciating age-related differences in apoptotic mechanisms, another
challenge that must be overcome in the pursuit of pharmacologic apoptotic mediators is
the variety of pathways resulting in the same end result - apoptotic cell death. Many
studies focusing on one specific apoptotic pathway may delay cell death but not entirely
prevent it. Rather, a pan-apoptotic inhibitor may be required 208.
1.6.3.3. Inflammation
Onset of ischemia results in a rapid activation of inflammatory cells residing in the brain,
termed microglia 209. This is followed by influx of circulating inflammatory cells such as
granulocytes, leukocytes, T cells, monocytes, etc 210. Similarly, over the first few hours,
an array of pro-inflammatory mediators such as cytokines and chemokines are released
from the damaged tissue, inducing adhesion molecule expression and subsequent
transendothelial migration of circulating inflammatory cells 210. Infiltration of leukocytes
from the bloodstream into brain tissue results in release of additional cytokines and
chemokines, ultimately leading to excessive oxidative stress and activation of matrix
metalloproteinases (MMPs) 209. MMP activation subsequently causes enhanced bloodbrain barrier (BBB) disruption, leading to further inflammatory cell recruitment and
associated inflammation 211. The inflammatory cascade is complicated by evidence that
the initiating microglia can also produce neuroprotective and neurotrophic factors 212.
1.6.3.4. Mitigating Inflammation
An extensive variety of targets exist in the effort to manipulate the inflammatory
response to achieve neuroprotection (Figure 1.14). Pharmacologic agents modulating
inflammation fall into a few general classes. This includes astrocyte modulators,
blockade of inflammatory cell receptor complexes, inhibitors of microglia, and general
immunosuppressive/anti-inflammatory agents.
The precise role of the astrocyte in ischemic stroke research has received much less
emphasis than the neuron. This neuron-centered approach fails to consider the intimate
relationship between neurons and supporting glia 213. Astrocytes have been credited
with contributing to formation of the blood-brain barrier, modulating neurotransmitter
levels in the synaptic cleft, regulating ion homeostasis, and also may alter inflammation
via microglial influence. Furthermore, the neuron-astrocyte interaction is responsible for
controlling the microcirculation of the brain 214, 215. The influence of astrocytes can be
seen both in homeostasis as well as both the acute and chronic injury response via
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astrogliosis 216. Modulating astrocyte activity, via either fluorocitrate or Arundic Acid
(ONO-2506), has produced mixed results 217-220. Arundic Acid, administered at up to 48
hours after stroke onset, appears promising based on early results yet fluorocitrate
treatment at 5 days after ischemia resulted in decreased vascular remodeling and
worsened functional status 217, 220. Arundic Acid has advanced to clinical trials and its
development highlighted in Table 1.2 154, 218.
Following ischemia, peripheral inflammatory cells such as neutrophils are recruited to
the region of infarction. Multiple attempts have been made to target adhesion molecules
on neutrophils, as well as other inflammatory cells, to prevent infiltration following
ischemic stroke. Examples include Hu23F2G (LeukArrest), an antibody recognizing the
CD11/18 integrin, and Enlimomab (R6.5) which targets intercellular adhesion molecule-1
(ICAM-1) 221-224. More information on the preclinical development and results of clinical
trials utilizing these compounds can be found in Table 1.2 154.
Modulating general inflammation after stroke is another potential, and promising,
therapeutic target.
The effects of non-specific immunosuppressive agents, like

Figure 1.13. Inflammation has been identified as a promising avenue of therapeutic
development. Multiple aspects can be inhibited, including release of inflammatory
mediators from microglia, preventing adhesion, and blocking migration of inflammatory
cells outside of the vasculature and into the parenchyma.
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Table 1.2. Examples of pharmacological agents tested preclinically (and many clinically), seeking to modulate

Tacrolimus (FK-506), as well as microgliaspecific inhibitors such as minocycline are
highlighted in Table 1.2 225-231.
1.6.4. PATHOPHYSIOLOGY OF STROKE &
CORRESPONDING THERAPEUTICS –
CHRONIC PERIOD
1.6.4.1. Inflammation
While inflammation is initiated in the subacute
period after onset of ischemia, inflammation has
been shown to persist for an extended period,
out to greater than 30 days 3. Inflammation is
generally thought of as a detrimental process,
exerting further tissue damage but recent
findings, particularly those associated with matrix
metalloproteinases (MMPs), indicate a
restorative role of inflammation in these
extended time periods 2.
As much of preclinical stroke models focus on
the acute period, many questions remain
unanswered regarding pathologic events
occurring in the chronic period, particularly in
terms of inflammation. Future work needs to
elucidate the role of inflammation in repair and
m o r e s p e c i f i c a l l y, h o w a l t e r i n g a c u t e
inflammation impacts chronic inflammation that
may, in some cases, be required for recovery/
repair.
Furthermore, determining the time
course of expression of inflammatory mediators,
and how this is altered with age and/or
comorbidity, across both the acute and chronic
periods may lead to additional insight into the
role inflammation plays in not only injury but also
recovery.
1.6.4.2. Repair
Recent work has focused on the development of
stem cell therapies for post-stroke treatment.
Early studies have appeared promising and
shown effects ranging from inhibition of cell
death, vasculature regrowth, modulation of
inflammation, and induction of plasticity and
neurogenesis. The use of stem cells, of which
there are many subtypes, remains a promising
future avenue of work with many questions
remaining to be elucidated. Future studies will
likely need to ascertain the precise cell types
most likely to demonstrate success (exogenous,
neural, embryonic, induced pluripotent, etc) and

50

the optimal delivery of these cells. Furthermore, other questions remain such as how
these cells integrate within the remaining intact neurologic structures and the prevalence
of long-term side-effects such as tumor formation, etc. Additionally, how these implanted
cells exert effects on the vasculature, surrounding neurons and glia, and the
inflammatory process all remain to be elucidated 232.
1.6.5. FUTURE DIRECTIONS
1.6.5.1. A Shifting Approach - From Neurons to Neurovascular Unit
For years, stroke research has emphasized neural survival and hence coined the term
‘neuroprotection’. Perhaps ‘neuroprotection’ is simply not enough for clinical success
and rather the focus needs to shift towards full ‘cerebroprotection’ in which glial cells and
the vasculature are also considered (Figure 1.15) 137, 233. Not only has the neuro-centric
approach failed to deliver clinically successful therapeutics but disregards the fact that
glia outnumber neurons and play an integral role in maintaining homeostasis in the
health brain and restoring neurologic function in the injured brain. Furthermore, it has
been shown that glial cells play an integral role in protecting neurons from ischemia and
can also lead to detrimental downstream consequences 216. In fact, the question of
whether neurons can even survive in the absence of supporting glia has been asked and
remains to be addressed, further necessitating the need to consider and investigate the
role of glia in injury more thoroughly.

Figure 1.14. The concept of neuroprotection is perhaps misguided; the neurocentric
approach has failed to produce effective therapeutic agents. Cerebroprotection is
needed, and for that the entire neurovascular unit must be considered. Also, supporting
glia play a crucial role in health and disease, necessitating inclusion in therapeutic
development.
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Astrocytes, long recognized for having a role in neurologic homeostasis via actions on
neurotransmitter and ionic balance, have also been implicated in control of the brains
microcirculation through signaling with neurons 215. Responding to synaptic release of
glutamate from neurons, increases in intracellular calcium concentration within the
astrocyte are observed, ultimately resulting in release of ATP, the primary signaling
molecule through which astrocytes communicate with other cells of the CNS 213. The
release of ATP by astrocytes has been demonstrated following injury and results in
microglial activation. Considering the proximity of astrocytic processes with neural
synapses and cerebral arterioles, forming a possible relay from neuron to vasculature, it
is easy to envision how astrocyte compromise as a consequence of ischemia may be
deleterious neurologically. Similarly, neuronal dysfunction following ischemia results in
excitotoxicity via glutamate release, which may then signal microglial activation through
the astrocytic response.
The role astrocytes play in homeostasis and response to injury is likely increased in the
aged animal due to an increased content of astrocytes, as well as pericytes, with age.
Pilegaard, et al suggested an increase of 20% in astrocyte and pericyte population in the
aged brain 234. Besides an increase in number, astrocytes in the aged brain exhibit
hypertrophy (associated with increase in glial fibrillary acidic protein expression) and
altered expression of surface markers, intracellular antigens, and growth factors.
Notably, these differences exist in the absence of neurologic injury, providing further
indication that the aged brain is a fundamentally different entity in comparison to the
young-adult brain, furthering the need to consider age in preclinical stroke models 50.
Understanding the precise role of microglia, in both acute and chronic periods, after
ischemia and how microglia influence not only neuronal function but that of the
neurovascular unit is another area of investigation that may lead to successful
therapeutic development. Microglia comprise approximately 12% of cells in the brain
and potentially exert both detrimental and beneficial effects in the ischemic brain,
necessitating further investigation and elucidation of these mechanisms 235. While
generally existing in an inactivated state in the young-adult brain, normal aging has been
shown to produce increasing numbers of activated microglia as well as phagocytic
microglial subtypes 53. Similarly, microglial reactivity is increased in response to a
numerous types of injury in the aged brain, ranging from neurotoxin (MPTP) exposure to
traumatic brain injury (TBI) to ischemia. Microglial activation ultimately results in the
production of many pro-inflammatory factors such as PGE2, IL-1β, TNFα, NO, NOO-,
O2*-, and H2O2, furthering the damage initiated by initial pathologic stimuli 235.
Besides release of inflammatory mediators, microglia likely play a role in oxidative
stress-induced damage. As microglia are activated, cytosolic subunits of the NADPH
oxidase enzyme translocate to the cell membrane and assemble the active form of the
enzyme, resulting in superoxide production. In addition to the oxidative damage caused
by extracellular ROS, such as superoxide, these molecules often can act intracellularly,
serving to amplify the inflammatory response 235.
The inflammatory response, mediated primarily through effects of astrocytes and
microglia, represent a more logical target clinically as inflammation persists for an
extended period and consists of beneficial and detrimental effects. Therefore, upregulation of the beneficial aspects of the inflammatory response may be a target as well
as decreasing the detrimental components. Similarly, evidence indicates that events
occurring later in the ischemic cascade such as apoptosis and neuroinflammation
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account for most of the penumbral tissue death, the region of interest in therapeutic
development 1.
Lack of therapeutic translation from bench-to-bedside may partially be explained by the
neurocentric approach taken towards investigating and ischemia and subsequent cell
death.
It is clear there is continual communication between neurons-astrocytes,
neurons-microglia, and neurons-vasculature. This communication, likely bi-directional in
nature, is responsible for normal homeostasis as well as responding to injury. The
previous focus on neuronal response alone fails to consider the complex relationships
amongst the various elements of the neurologic system. Shortcomings of the field led to
formation of the Stroke Progress Review Group by National Institutes of Neurological
Disorders and Stroke (NINDS). One of the primary points of emphasis of this group is
the need for cerebroprotection, in which the entire neurovascular unit and neurologic
structure is considered, rather than solely neuroprotection. As such, future work needs
to address the temporality and mechanistic details of signaling events within the
neurovascular unit.
1.6.5.2. Understanding Biphasic Signaling
A significant challenge in therapeutic development is that of various messenger
molecules having divergent actions temporally. For example, matrix metalloproteinases
(MMPs), have been tied to hemorrhagic transformation in the acute period following
ischemic injury yet also are essential for long-term recovery 2. Similarly, high-mobility
group box 1 (HMGB1) protein promotes necrosis and inflammatory cell infiltration
immediately after ischemia yet is influential in the recovery phase 236. Not only is it
important to identify these biphasic pathways, but it is also important to elucidate how
pharmacologic manipulation alters outcome. If inhibition is possible in the acute phase,
preventing further damage, will the beneficial activity still occur later on?
1.6.6. CONCLUSION
The dearth of success in translation of proposed therapeutic agents for ischemic stroke
from bench-to-bedside necessitates a reassessment of experimental methodology.
Proposed therapeutics have too often targeted events occurring rapidly after the onset of
ischemia such as glutamate excitotoxicity, calcium release, and oxidative stress.
Investigating pathologic events occurring at more delayed periods, such as inflammation
and apoptosis, may prove more realistic targets and consequently, translate more
effectively from bench-to-bedside. Notably, early results of minocycline clinical studies
appear promising. Minocycline acts via targeting inflammation which occurs later after
the onset of ischemia than many of the previously unsuccessful pharmacologic agents.
Additionally, protection afforded by minocycline is not neuro-centric in nature and rather
acts via effects on surrounding glia. Modulating the response of glia to injury, much like
targeting the neurovascular unit, is more likely to translate to effective therapeutic
development due to the large role glia play in both health and disease. Ischemic stroke
is a vascular disease impacting all cellular types within the nervous system, not just
neurons. Similarly, the only approved therapeutic, tPA, exerts its effects through the
vascular system rather than direct effects on neurons. This alone indicates the potential
to improve outcome without a neuro-centric focus.
Future studies must more closely replicate the clinical environment to increase the
likelihood of translational success.
This includes incorporating aged animals in
preclinical studies as well as animals with comorbidities typically seen in the clinical
stroke population such as diabetes and hypertension. Furthermore, models can be
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improved by incorporating tPA for combination therapy. Agents extending the window of
opportunity for tPA treatment would represent a significant improvement in stroke
treatment.
Despite past failures, stroke research must press forward based on the immense need.
By thoroughly reassessing reasons for the previous lack of success and pursuing new
avenues and approaches to treatment, new advances are likely possible.
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1.7 Jak2/Stat3-mediated Signaling in Ischemic Stroke
One area identified as a weakness in preclinical neural injury research is the largely
‘neurocentric’ focus in which other cell types, such as glia, and how these cell types
contribute to injury and/or repair, has not been a point of emphasis. In this work, we
explore the Jak2/Stat3 signaling pathway that has clear implications in numerous cell
types such as neurons and astrocytes. Furthermore, this pathway serves as a prime
example of the potential for biphasic signaling in which a signaling pathway may
contribute to both protective and detrimental effects depending on the duration and
target of signal.
This work was published in Neurological Disorders: New Research.
Citation: Turner RC, Lucke-Wold B, Miller DB, O’Callaghan JP, Rosen CL, Huber JD
(2012) Neuropoietic Cytokines and Neural Injury: Alterations in JAK2/STAT3 Signaling
Associated with Aging. Edited by Chloe E. Thomas and Jayden R. Moore. Neurological
Disorders: New Research. Chapter II. Nova Science Publishers, Inc.
Abstract:
Neuropoietic cytokines have long been recognized as playing a role in neural injury with
recent work implicating the janus-kinase 2/signal transducer and activator of
transcription 3 (JAK2/STAT3) signal-transduction pathway. Released in response to
neural injury, neuropoietic cytokines modulate a diverse array of processes ranging from
apoptosis to vascular remodeling to inflammation. Neural injury, particularly in the case
of ischemic stroke, often is associated with advanced age yet the aging process is rarely
taken into account in preclinical models. Notably, aging has been linked with
inflammation through the ‘inflam-aging’ hypothesis in which dysregulation of the immune
system and an inability to successfully handle pathologic stimuli occurs with aging.
Therefore, the ability to modulate the effects of inflammation-related cytokines and
cytokine-associated signaling is an attractive therapeutic target and has resulted in
promising therapeutics for non-neural disease processes such as arthritis and
autoimmune conditions. Here, we highlight the role of neuropoietic cytokines in neural
injury and more specifically, those that mediate their effects through the JAK2/STAT3
signaling pathway.
The consequences of STAT3 signaling and phospho-STAT3
(pSTAT3) activation are empahsized as well as factors that modulate signaling via this
pathway, in particular the age-dependent regulation of suppressor of cytokine signaling 3
(SOCS3), and potential therapeutic targets discussed.
1.7.1. INTRODUCTION
The role of inflammation in neural injury, regardless of whether the injurious event is a
stroke or traumatic brain injury, has long been recognized and represents a possible
option for therapeutic development. Neuropoietic cytokines, such as the IL-6 family, are
produced in response to ischemia. Release of neuropoietic cytokines occurs in a variety
of cell types ranging from endothelial cells to those more commonly associated with the
inflammatory response such as macrophages and microglia. Regardless of origin, these
cytokines mediate much of the neuronal, glial, and immune response to injury through
signaling cascades such as the Janus-activated kinase-signal transducer activator of
transcription (JAK-STAT) and the mitogen-activated protein kinase (MAPK) pathway
initiated by the gp130 receptor complex 237. This work focuses on the JAK-STAT
pathway (specifically, the JAK2/STAT3 variation) – its activation, downstream effects,
and regulatory processes.
Furthermore, the age-dependent effects after injury
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associated with the pathway are discussed based on work conducted in the laboratory of
the authors.
1.7.1.1. Neuropoietic Cytokine Family
Cytokines represent a varied group of small autocrine and paracrine signaling proteins,
previously associated primarily with the immune response, but more recently a role in
development, disease, and injury has been recognized 237,	
  238. Cytokines are produced
by multiple cell types and often exert diverse effects that are dependent on not only the
stimuli resulting in secretion but also the timing of stimulation 238. As such, the study of
cytokines and downstream signaling effects is inherently complex but provide extensive
opportunities for intervention and modulation for possible therapeutic benefit.
In this work we focus on the neuropoietic cytokine family as these cytokines have been
identified as playing a central role in the inflammatory response to stroke and central
nervous system (CNS) trauma 239. This cytokine family includes interleukin-6 (IL-6),
interleukin-11 (IL-11), neuropoietin, ciliary neurotrophic factor (CNTF), leukemia
inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), and cardiotrophin-like
cytokine (CLC) 237,	
  240,	
   241. Members of the neuropoietic cytokine family share a signaltransducing receptor, glycoprotein-130 (gp130), and consequently exhibit similar
structures, particularly secondary, as well as overlapping activities 239.
Structurally, cytokine ligands are composed of two pairs of anti-parallel α-helices that are
connected by polypeptide loops. This arrangement results in the presence of a shared
protein fold termed the ‘four-helix bundle’. Each family of cytokines is delineated
primarily by the length, and in some cases number, of the α-helices. For example,
interleukins (IL)-2, -3, and -4 have shorter α-helices (8-10 residues long) in comparison
to neuropoietic cytokines which exhibit α-chains composed of 10 to 20 residues. Lastly,
the number of α-helices can vary which is demonstrated by the presence of eight αhelices in IL-5 and interferon γ 242.
1.7.1.2. Role of the gp130 Cytokine Receptor Complex
Signal transduction involving members of the neuropoietic cytokine family involves the
initial formation of a ligand-receptor complex at the cell surface. These receptors often
consist of multiple subunits, creating a receptor complex, with the subunit composition
dictating the affinity for various extracellular ligands, in this case, the binding potential of
different members of the neuropoietic cytokine family.
Furthermore, neuropoietic
cytokine family receptors are transmembrane in nature with ligand binding resulting in
formation of a protein-signaling complex on the intracellular surface of the membrane.
Based on the multi-subunit composition of the gp130 cytokine receptor complex and
transmembrane nature of the overall signaling complex, an extensive number of signals
can be integrated in terms of both initiating molecules binding to the various receptor
complexes but also the induced intracellular signaling cascade. The numerous receptor
complexes incorporating the gp130 receptor are highlighted in Table 1.3.
Table 1.3.
signaling
Ligand

Sites for neuropoietic cytokine binding for activation of JAK/STAT
Site I

Site II

Site III

LIF

-

gp130

LIF-R

OSM

-

gp130

LIF-R/OSM-R
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CNTF

CNTF-R

gp130

LIF-R

CT-1

?

gp130

LIF-R

IL-6

IL-6R

gp130

gp130

IL-11

IL-11R

gp130

gp130

CLC

?

gp130

LIF-R

The multi-subunit nature of the receptor complex is required for intracellular signaling as
only gp130, LIF-R, and OSM are capable of binding the corresponding ligand and
inducing the intracellular signaling cascade. The other receptors are capable of binding
the ligand but do not directly associate with intracellular signaling mediators due to either
shortened cytoplasmic domains, in the case of IL-6R and IL-11R, or are bound to the
extracellular membrane surface by lipid anchors, as is the case with CNTF-R.
Therefore, these molecules must bind the ligand and then associate with gp130 for
intracellular signaling to ensue (Figure 1.1.6) 242.

Figure 1.15. Receptor subunits required for neuropoietic cytokine signaling. Each
cytokine pictured requires a minimum of one gp130 receptor subunit to exert intracellular
effects through this pathway.
Below we review Janus kinases and STAT3 as key downstream effectors of neuropoietic
cytokines signaling through gp130 receptors. While beyond the scope of this brief
review, it is important to note that other trophic signaling molecules can affect Jak/STAT3
signaling via crosstalk from other receptors and pathways (e.g MAPK, interferons,
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erythropoietin, etc.). These effects can occur at the level of Jak and/or STAT3 and can
involve neuronal and glial responses to injury 243.
1.7.1.3. Role of Janus Kinases (Jaks)
The ability of the various cytokine receptor families to exert biological effects via the
induction of tyrosine phosphorylation following ligand binding has long been recognized
244. The Janus family of protein kinases (Jaks) have been identified as the primary
means via which this initially extracellular signal results in intracellular effects. A variety
of Jaks exist, many of which are expressed ubiquitously in mammals. These include
Jak1, Jak2, and Tyk2. Others, such as Jak3, have also been identified but expression is
not ubiquitous and in the case of Jak3 is localized primarily to hematopoietic cells. The
specific Jak used for cytokine-based signaling depends upon the cytokine receptor
utilized and more specifically, an interaction between the non-catalytic domain of the Jak
with the membrane-associated region of the cytokine receptor chain 245. The remainder
of this work will focus specifically on JAK2.
Following ligand-receptor binding and associated conformational changes in the
cytoplasmic portion of the receptor, Jak2 is rapidly phosphorylated, activating its kinase
activity 246. This initial phosphorylation has been attributed to ligand-receptor binding
resulting in a transfer of g-phosphate of ATP to the tyrosine hydroxyl group on the
receptor, which then causes an aggregation of the receptor and the associated Jaks,
This
allowing for a transphosphorylation to occur amongst the Jaks 245,	
   247,	
   248.
transphosphorylation is necessary for kinase activity amplification as previous work has
identified 10 major autophosphorylation sites with some being required for kinase
activity. More specifically, the contribution of phosphorylation at the Y1007 and Y1008 have
been studied in greater detail with mutation to Y1008 revealing little effect on kinase
activity while mutations in Y1007 almost entirely eliminate kinase activity 245. The varying
kinase activity associated with mutated Jak phosphorylation sites illustrate the
importance of protein phosphorylation as a regulatory mechanism in cell signaling and
the role it likely plays in both homeostatic and pathologic processes.
1.7.1.4. Activation of Signal Transducer and Activator of Transcription 3 (STAT3)
Following activation, Jaks phosphorylate specific tyrosine residues of the receptor
endodomains, allowing the binding of signal transducer and activator of transcription 3
(STAT3). The family of STAT proteins share structurally and functionally similar domains
that include an amino-terminal domain (NH2), the coiled-coiled domain (CCD), the DNA
binding domain (DBD), the linker domain, and the SH2/tyrosine activation domain. The
key difference amongst individual members of the STAT protein family lies in the
carboxy-terminal transcriptional activation domain (TAD) 246. It is the SH2 domain,
shared amongst the various STAT proteins, that allows binding to specific
phosphotyrosine motifs.
Consequently, the SH2 domain is described as being
responsible for not only recruitment to the membrane-associated cytokine receptor but
also for association with the activating Jak 246,	
   249,	
   250. Once bound to the Jak, STAT
undergoes phosphorylation and subsequent activation. At this point, STAT dissociates
from the receptor complex forming homo- or heterodimers. This process is once again
dependent on the SH2 domain and interactions amongst phosphorylated tyrosine
residues. The dimers then translocate to the nucleus where binding of response
elements and gene transcription occurs 247.
1.7.1.5. Effects of phospho-STAT3 (pSTAT3)
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The effects mediated by pSTAT3 in the nucleus appear to be widespread and influenced
by a number of factors ranging from the cell-type to the phosphorylation site. We will
review some of the effects most commonly associated with the nervous and circulatory
systems, particularly as they relate to neurologic disease. Some of these pathways are
visualized in Figure 1.17.
Cell Survival
While initially identified as being involved in the acute-phase response associated with
the inflammatory response, perhaps the most extensive research concerning STAT3 has
been conducted in relation to cancer cell biology. Multiple works have illustrated the
involvement of STAT3 in tumor transformation via regulation of suggested target genes
such as c-myc, Bcl-XL, and Fas 251. As such, inhibition of STAT3 signaling has been
suggested as a target for cancer therapy and appeared promising based on preclinical
studies using malignant glioma cells both in vitro and in vivo. Application of a selective
inhibitor of STAT3 phosphorylation suppressed additional tumor cell replication and
promoted apoptosis through activation of Bax and suppression of c-myc, Bcl-XL, and
Mcl-1 252. Anti-apoptotic effects of STAT3 signaling, via effects on Bcl-2, have also been
observed in cardiovascular studies. In a myocardial ischemia post-conditioning study,
administration of AG490, a potent Jak2 inhibitor, resulted in reduced p-STAT3 and
increased apoptosis following post-conditioning 253. Furthermore, attempts have been
made to generate Stat3 knockouts but this leads to early embryonic lethality 254.
Consequently, utilization of ‘floxed’ STAT3 alleles has been pursued generating tissue
specific knockouts, allowing the role of STAT3 to be studied with regards to numerous
processes 246,	
  255,	
  256.
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Figure 1.16. Complexity associated with the STAT3 pathway. Numerous pathways
converge to act on STAT3 to modulate the cellular response. Notice the ability of
different pathways to phosphorylate STAT3 at different sites. This change in structure
induced by pohosphorylation may be responsible for the contrasting effects observed.
Remodeling the Cellular Environment
In addition to its possible oncogenic role in the regulation of cell survival, STAT3
activation may lead to a remodeling of the extracellular environment through effects on
vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and matrix
metalloproteinase-2 (MMP-2) 257. While this work was initially conducted in glioblastoma
cell lines, it is likely applicable to other neurologic disease conditions due to some
similarities in the cellular stress experienced. Glioblastoma, the most common and
malignant primary brain tumor, is characterized by a relatively unique pseudopalisading
necrosis in which a necrotic core is surrounded by a hypercellular zone. Notably, the
pseudopalisading cells experience greater levels of hypoxia than surrounding regions
and consequently, genes regulated by hypoxia are overexpressed in these areas 257.
These genes include hypoxic inducible factor-1 (HIF-1) and the aforementioned VEGF
and MMP-2 258-‐260.
Besides vascular and extracellular matrix remodeling associated with oncogenic-induced
changes in STAT3 signaling, vascular injury and associated neointima formation has
been linked to STAT3 signaling as well. More specifically, following vascular injury,
angiotensin II (Ang II) induces proliferation of vascular smooth muscle cells (VSMC).
This process results in neointima formation and the deposition of extracellular matrix
mediated through the rennin-angiotensin system.
Seki and colleagues further
investigated this work and the role of STAT3 signaling showing an induction of STAT3
phosphorylation through Ang II type 1 receptors. Inhibition of STAT3 signaling via
AG490 administration resulted in reduced neointima formation in the injured artery 261.
Regulating Oxidative Stress
A key element associated with inflammation and disease, as well as the aging process,
is the regulation of oxidative stress. As such, Manea and colleagues investigated the
role of the JAK/STAT pathway in the regulation of oxidative stress via NADPH oxidase in
aortic smooth muscle cells. It was discovered that STAT3 is involved in controlling the
transcription of p47phox and p67phox, two key subunits contributing to NADPH oxidaseassociated oxidative stress 262. Regulation of NADPH oxidase function by STAT3 has
also been demonstrated in a model of retinopathy of prematurity (ROP) rat model and
more specifically, the contribution of oxidative stress in the development of intravitreous
neovascularization 263. Furthermore, IL-6 and associated signaling via STAT3 controls
the transcription of antioxidant enzyme promoters, mainly manganese-containing
superoxide dismutase (Mn-SOD) 264-‐266. This finding is consistent with others in the
literature identifying increased oxidative stress after focal brain injury in IL-6-deficient
mice 267. Conversely, inhibiting IL-6 has been identified as potentially therapeutic through
a reduction in oxidative stress, specifically that generated by inducible nitric oxide
synthase 268.
Immune Tolerance
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The regulation and response of the immune system to both acute and chronic
neurodegenerative diseases has garnered increasing attention in the scientific
community in recent years. This is likely due to the promise offered by modulating these
processes for potential therapeutic benefit. Pharmacologic agents such as minocycline,
described as an anti-inflammatory and protease inhibitor, have reached clinical trials for
the treatment of stroke yet little remains known about how precisely these agents work
269. In attempting to better understand regulatory processes of inflammation, STAT3 has
been identified as a candidate pathway 270. In fact, STAT3 has been shown to prevent
macrophage activation in vitro, limiting the inflammatory response 254,	
   271-‐273. Inhibition of
STAT3, in an attempt to reverse immunotolerance seen in many tumor studies, results in
increased production of IL-12 by macrophages and a reversal of systemic
immunotolerance. This principle of restoring immune tolerance was shown by Hussain,
et al in patients afflicted with glioblastoma multiforme, illustrating the potential of such
approaches not only for cancer patients but also other neurologic diseases involving a
significant immune component 270.
Besides playing a clear role in the immunoregulation and tolerance associated with
CNS-based malignancies, STAT3 has been implicated in cardiovascular conditions.
Inflammation induced via lipopolysaccharide (LPS) administration resulted in increased
cardiomyocyte apoptosis in animals with cardiomyocte-restricted knockout of STAT3.
Similarly, while young animals with the restricted knockout exhibited no outwardly visible
signs of heart failure, aging of these animals resulted in spontaneously developing
cardiac dysfunction 274. As such, it is clear that STAT3 plays an essential role in
modulating inflammation and cell survival, processes that may become even more
important with aging based on the ‘inflam-aging’ hypothesis 60.
Role of the Phosphorylation Site
STAT3 possesses multiple phosphorylation sites but the two primary sites implicated in
modulating its functional activity are tyrosine 705 (Y705) and serine 727 (S727). Thus,
STAT3 DNA-binding activity appears to be regulated by the phosphorylation status of
these key residues, once again illustrating the importance and regulatory control
exhibited by site-specific protein phosphorylation state. For example, Wen et al reported
serine phosphorylation controlled transcription but did not affect DNA-binding in both
STAT1 and STAT3 275. The role of serine phosphorylation appears controversial though
as others have shown a range of effects including potentiating tyrosine phosphorylation
and DNA binding, inhibiting tyrosine phosphorylation, or having no effect on either
activity. Therefore, it has been proposed that the effects of serine-727 phosphorylation
likely vary across cell types and in response to various stimuli 276,	
   277. This site also is
one source of interaction/overlap amongst various pathways with others identifying roles
of mTOR and MAPK in regulating S727 phosphorylation 278,	
   279. Given that mulitple other
phosphoryaltion sites exist on STAT3, their phosphorylation status likely could affect
tyrosine 705 (Y705) and serine 727 (S727) phosphorylation. Moreover, based on findings
for other key signaling modules in the CNS, regulation of the phosphorylation of tyrosine
705 (Y705) and serine 727 (S727) likely would be affected in a tissue and cell-type specific
fashion 280.
1.7.1.6. Regulating pSTAT3: Role of Negative Regulators
In addition to understanding the transcriptional events regulated by pSTAT3, much work
has been completed regarding the regulation of Jak2/Stat3 signaling. Three classes of
negative regulators exist. These include SOCS (suppressors of cytokine signaling),
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PIAS (protein inhibitors of activated stats), and PTPs (protein tyrosine phosphatases)
281. Each of these inhibitory pathways has been extensively reviewed elsewhere and
details beyond those required for a basic understanding of the material are beyond the
scope of this work 282.
Suppressors of Cytokine Signaling (SOCS)
The SOCS family of regulatory proteins consists of eight plus members, each of which
shares a common SH2 domain and in some cases, a small kinase inhibitory region.
SOCS is somewhat different in comparison to the other regulatory proteins as it is a
clear negative feedback loop in which cytokine stimulation results in increased
transcription of SOCS, consequently downregulating cytokine-induced signaling 281.
Protein Inhibitors of Activated Stats (PIAS)
The PIAS family of negative regulators remains somewhat of a mystery as only one
conserved motif, a zinc-binding motif, has been identified. PIAS3, the STAT3-specific
PIAS, appears to only interact with p-STAT3. The precise interaction is not clear but it
may bind monomers, preventing dimmer formation or may facilitate the degradation of
aforementioned dimers 283.
Protein Tyrosine Phosphatases (PTP)
In addition to the activated gp130 receptor attracting cytoplasmic STAT, it also attracts
PTP SHP2, a cytoplasmic PTP that binds the active site of the receptor and unfolds the
protein. Numerous other PTPs are frequently available as a range of subtypes, some of
which alter the kinetics of STAT3 activation whereas SHP2 is thought to regulate the
total amount and amplitude of STAT3 activation 284. This is notable in that modulation of
the kinetics may partially be responsible for differences in downstream effects
associated with other molecules, besides those in the neuropoietic cytokine family, that
also signal through STAT3.
1.7.2. DISCUSSION
1.7.2.1. Changes in Neural Injury
While it is likely STAT3 signaling is altered in the vast majority of neurologic and
neurodegenerative diseases due to the large number of potential signaling events
relayed through this transducing element, most work focusing on STAT3 has been
conducted with an emphasis on stroke and traumatic brain injury. For this reason, we
will limit our discussion to these two conditions.
Stroke
In the past 10 years vast strides have been made in attempting to elucidate the role of
STAT3 signaling on both the outcome from ischemia as well as the role played in
modulating the benefit of ischemic preconditioning. We will first discuss findings in
ischemia and then identify potential roles of STAT3 signaling in modulating the protective
responses seen in ischemic preconditioning.
In the year 2000, one of the first papers related to STAT3 and ischemia was published by
Justicia, et al. In this work, STAT3 was shown to be activated following ischemia,
evidenced by translocation to the nucleus. This response was particularly pronounced in
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reactive astrocytes, identifying a possible role for regulation of astrocyte growth and
expression of glial fibrillary acidic protein (GFAP). Importantly, changes in STAT3
regulation were seen in the neuron and microglial cells as well 285. One substantial
weakness of this preliminary work was the lack of STAT3 phosphorylation status data.
This issue was remedied in the work of Wen and colleagues. In a mouse model of
ischemia, phosphorylated STAT3 was found to be upregulated as early as 6 hours after
ischemia. This increase though was found in peripheral regions of the ischemic territory
and was constrained to neurons only – not astrocytes or microglia. Importantly, p-STAT3
positive neurons were identified as also being TdT-mediated biotinylated UTP nick end
labeling (TUNEL)-positive, illustrating a potential role of p-STAT3 in modulating
ischemia-induced neuron death 286. Following up on these developments, Yamashita
and colleagues assessed the effect of IL-6 inhibition on STAT3 activation and survival in
a mouse model of ischemia. An IL-6 receptor antibody was administered immediately
following ischemia and while successfully decreasing p-STAT3, IL-6 signaling blockade
lead to increased apoptosis and subsequently an increased infarct size as well as
deterioration in neurologic function 287. This work illustrated the potential role of IL-6 as a
neuroprotectant, particularly in the acute phase following injury. Similarly, more recent
work identifying the contribution of p-STAT3 in regulating oxidative stress via the
expression of antioxidants such as Mn-SOD, has shown IL-6 to be neuroprotective 264,	
  
266. Notably, both of these studies are in contrast to the findings of Satriomoto, et al in
which inhibition of STAT3 signaling, whether it be via non-specific JAK2 phosphorylation
inhibitor AG490 or siRNA, resulted in improved outcome as determined using infarct
volume, functional assessments, and histologic studies. Recent work investigating the
roles and regulation of p-STAT3 in a clinically relevant, thromboembolic rodent model of
stroke has been conducted in our laboratory. This work will be described in greater
detail in subsequent sections concerning age-related effects.
Preconditioning has been recognized in numerous injury modalities as a protective
technique. Generally, the mechanisms through which preconditioning is believed to
work are poorly elucidated. Common themes identified as potentially mediating the
effects of preconditioning typically center around inflammation and a ‘priming’ of the
immune response. Recent work by Yagi and colleagues sought to identify the role of
STAT3 in a rodent model of global ischemic preconditioning. STAT3 phosphorylation at
S727 was shown to be protective and necessary for modulating the effects of ischemic
preconditioning.
Notably, phosphorylation at S727 in preconditioning studies is
associated with protein kinase C (PKC) ε-Raf-mitogen-activated protein kinase (MAPK)/
extracellular signal-regulated kinase kinase (MEK)-p44/42 MAPK signaling pathway 288.
In addition to preclinical studies implicating the role of neuropoietic cytokines in the
response to injury, Shakarishvili and colleagues assessed the correlation of numerous
inflammatory cytokines with outcome from stroke in both young and aged patient
populations. Elevated levels of IL-6 following the onset of ischemia, particularly in the
acute period, were found to be a strong predictor of poor outcomes in the aged patient
population 289. Therefore, it appears likely that neuropoietic cytokines and associated
STAT3 signaling may play a role in influencing clinical outcomes as well.
Traumatic Brain Injury
Less controversy appears to exist in the TBI literature concerning the role of p-STAT3
signaling. Numerous studies have been completed characterizing the expression of pSTAT3 following TBI as well as neuropoietic cytokines, such as IL-6, that would lead to
p-STAT3 activation. The knock-out of IL-6 or application of a STAT inhibitor both result in
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worsened outcome following TBI 267,	
   290-‐292. One controversy does exist though in terms
of the cell-type(s) in which p-STAT3 signaling is localized with astrocyte expression
being more well-accepted and neuronal expression appearing slightly more controversial
291,	
   292. The conditional deletion of STAT3 in a mouse model of spinal cord injury results
in enhanced inflammatory responses, increased lesion volume and reduced functional
recovery, effects associated with astrocyte-specific responses related to scar formation
255.
While clinical studies have not begun to elucidate the role of STAT3-associated
signaling, the emphasis on biomarker discovery has led to identification of numerous
cytokines following injury at an extensive list of time-points. These cytokines include
those such as IL-6, which in fact, has been shown to correlate with intracranial pressure
elevation following injury in the clinical population 293.
1.7.2.2. JAK2/STAT3 Regulation Altered With Aging
The role of aging in neurologic disease has long been recognized, particularly as it
relates to stroke, AD, and Parkinson’s Disease (PD).
Similarly, aged individuals
generally fare far worse following neurologic injury, whether it be stroke or traumatic in
origin, when compared to a younger population. As such, it has been hypothesized that
the aged brain is fundamentally different than the young-adult brain. This hypothesis, in
conjunction with our past work and reports of altered cytokine expression in the aged
brain, is what led to our initial investigation of the Jak2/Stat3 pathway 32,	
  56,	
  84.
In our investigation of the effect of age on STAT3-associated signaling, we confirmed
previous reports demonstrating increased p-STAT3 as early as 6 hours and persisting to
72 hours in young-adult animals. When using aged animals, a scenario we believe far
more representative of the aged patients afflicted with stroke, we found increased
SOCS3 expression in comparison to young-adult animals. While the mechanism for this
change in SOCS3 expression remains to be elucidated, it is clear that alterations pSTAT3 signaling may account for differences in outcome between young-adult and aged
animals. One possibility is changes in STAT3 isoform expression associated with aging
as the IL-6-mediated induction of SOCS3 is entirely dependent on STAT3α 144. A second
possibility is alterations in an overlapping pathway or stimulus such as interferon-gamma
(IFNgamma). IFNgamma has been shown to be capable of regulating SOCS3 and
furthermore, is increased with age, raising the possibility that increased levels of
IFNgamma are ultimately responsible for these age-related changes in SOCS3
expression and subsequent pSTAT3 signaling 294,	
  295.
The notion that aging alters not only the initially inflammatory stimulus but also the
response is consistent with findings by Liu and colleagues related to development and
regeneration, furthering the concept that the response of the aged brain is altered in
comparison to the young or young-adult brain 296.
1.7.2.3. Significance of Phosphorylation Site
Studying STAT3 is significantly complicated by the multiple phosphorylation sites present
on the molecule and the potential significance of each site in eliciting transcription
following DNA binding (discussed above). As described previously, the C terminus
contains the TAD segment responsible for transcriptional regulation. It remains unclear
exactly how these domains regulate activity, numerous works have shown a promotion
of transcription following serine phosphorylation (S727) 297,	
   298. Notably, the serine site is
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a mitogen-activated protein kinase (MAPK) phosphorylation motif, illustrating the
complex nature of STAT3 signaling and the simultaneous interaction of multiple
pathways 275,	
   299. Nevertheless, at least for the case of neurotoxic injury of the CNS,
STAT3 can translocate to the nucleus of astrocytes via phosphorylation of tyrosine 705
(T705) in absence of a change in phoshorylation of serine 727 (S727) 300. Importantly, the
effects of phosphorylation at S727 have not been widely considered in vivo and remain to
be clearly elucidated, particularly in relationship to neural injury. Whether high-quality
antibodies allowing such investigation are available remains to be clearly shown and
may be a limiting factor currently.
1.7.3. FUTURE DIRECTIONS
1.7.3.1. Elucidate the Role of STAT3 Across Cell Types
Advances in therapeutics related to STAT3 signaling are likely to require an increased
understanding of the response of various cell types to STAT3 signaling.
More
specifically, the timing and downstream effects must be elucidated in each cell type. The
investigation into cell type specific responses has been recognized by others in the
literature and is exemplified by the work of Haroon and colleagues. They showed, in an
experimental autoiummune encephalomyelitis study, that loss of gp130 on astrocytes
resulted in increased astrocyte apoptosis. Interestingly, the lack of gp130 expression in
neurons did not alter the course of the disease in comparison to the control condition 301.
In addition to possible discrepancies in the benefit/detriment of STAT3 signaling
associated with different cell types, the timing of responses may also prove critical. This
notion was reviewed by Dziennis and colleagues and notably, STAT3 phosphorylation
tends to occur at earlier time points, namely 30 minutes to 24 hours, in neurons following
injury but tends to arise later in astrocytes, microglia, and endothelial cells 302. As such,
perhaps there is some form of biphasic response in which STAT3 signaling and
associated effects are beneficial in certain cell types during the acute period and
detrimental in the chronic period. The opposite may be true for other cell types,
therefore conveying both a cell-specific and time-dependent response.
This concept appears consistent with the multi-factorial role of STAT3 signaling and it’s
presence in development and disease.
In the neuron, phosphorylated STAT3 is
increased following ischemia and correlates with TUNEL-positive neurons 286. On the
other hand, STAT3 has been identified as playing a key role in synaptic plasticity, an
important factor in not only normal development but also recovery from injury 303. The
complex role of astrocytes and implications of STAT3 signaling following neurologic
injury provide yet another example of the cell- and time-dependent effects. Astrocyte
activation and associated glial fibrillary acidic protein expression has been recognized as
a consequence of neural injury and subsequent induction of gp130-related cytokines 300.
Activation of astrocytes results in the potentiation of astrogliogenesis and may also be
involved in regulating other neurologic functions such as pain 304,	
   305. Perhaps most
importantly, spinal cord injury studies have indicated the time-dependent effects of
reactive astrocytes. In the acute phase, astrocytes have been implicated in tissue repair
and functional restoration yet in the chronic phase, astrogliosis impairs axonal
regeneration via both physical and chemical barriers 256. Other studies in spinal cord and
peripheral nerve injury identified a rapid induction of JAK2/STAT3 signaling, primarily in
microglial cells, following injury.
Blockade of this signal, via SOCS3, attenuates the
development of mechanical allodynia, a common symptom associated with impactinduced neuropathic pain 306. The prevention of STAT3 activation in microglia following
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electromagnetic field stimulation results in decreased release of nitric oxide (NO) and
other inflammatory mediators such as TNFα. Taken together, these studies indicate
widespread effects of STAT3 signaling across cell types and the likely time-dependent
response.
1.7.3.2. Modulating Beneficial vs. Detrimental Effects
One of the many challenges in understanding the role of STAT3 signaling, and
potentially targeting the pathway therapeutically, is determining when, where, and to
what extent STAT3 serves beneficial versus detrimental effects. Much like has been
demonstrated in other inflammatory pathways associated with injury, such as matrix
metalloproteinase activation, the initial response to injury may be damaging whereas the
chronic response may be essential for recovery 151. This phenomenon is certainly not
unique to activation of matrix metalloproteinases and has been described in relation to
astrocyte reactivity as well 256,	
   307. Interestingly, one of the primary regulators of STAT3
signaling, SOCS3, has been implicated in the modulation of Wallerian degeneration
following peripheral nerve injury. In addition to regulating STAT3, SOCS3 may decrease
expression of the associated cytokines such as IL-6 and in doing so may prevent
continual high levels of expression associated with inflammation 308. The timing of
SOCS3 expression is important though as IL-6 and LIF play a role in both neuronal
survival and regeneration following injury, further indicating a need to understand the
precise timing of signaling events post-injury.
It is this dynamic between the potential beneficial results of neuroinflammation and the
detrimental effects of sustained or excessive inflammation that must be more clearly
elucidated. IL-6, and subsequent activation of STAT3, has been implicated in the acute
phase response to inflammation, which may be beneficial, and also injury but the overall
effects remain unclear 300,	
  309.
1.7.3.3. Identifying Injury-Associated Changes
Many neurologic disease conditions involve a vascular component and remodeling of the
neurovascular unit, both during the aging process and as a consequence of injury. This
is particularly true in stroke and traumatic brain injury and has implications for both injury
and repair of the neurovascular unit and in particular, the blood-brain barrier. Proteases
are commonly involved in this process with matrix metalloproteinases being the most
well-described. STAT3 signaling has been implicated in this process in through work in
ischemia as well as cancers such as glioblastoma through a link with microRNA-21
310-‐313. MicroRNAs have been recognized for their role in attenuation of protein
expression via complementary binding to target mRNA and in doing so exert numerous
potential effects both directly and indirectly. As such, the interaction of these various
signaling pathways and intervening molecules likely requires greater investigation and
understanding for proper therapeutic development.
1.7.3.4. Understanding & Manipulating Regulatory Processes for Therapeutic Benefit
As discussed previously, the regulation of STAT3 signaling is a dynamic process
involving not only ligand-receptor binding but also a series of downstream effectors such
as SOCS, PIAS, and PTP. How these processes are altered with respect to various
disease states, likely in a cell-specific and time-dependent nature, remains to be clearly
elucidated. Furthermore, how these processes are altered by aging, which is the
greatest risk factor for many neurologic diseases, remains to be seen. We have shown
in our initial work that SOCS3 is upregulated following ischemia in the aged rodent
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producing a decrease in phosphorylated STAT3 not seen in the young-adult rodents 51.
Consequently, it seems not only plausible but likely that the response of the aged brain
to injury is fundamentally unique and requires further investigation. Once again, the celltype and time-dependent nature of these processes, and how it impacts STAT3
signaling, may be fundamentally altered with aging and disease.
1.7.3.5. The IL-6 & IL-10 Signaling Dynamic
Despite IL-6 and IL-10 both exerting effects primarily through modulation of STAT3, the
response to each cytokine is notably unique. In macrophages, both cytokines have
been recognized as anti-inflammatory in nature with IL-10 acting as the more potent antiinflammatory cytokine relative to IL-6. Three key elements emerged from this work in
macrophages by Niemand, et al. First, pretreatment of macrophages with inflammationinducing substances such as LPS resulted in blockade of IL-6 induced STAT3 activation.
This was not true of IL-10 signaling. Secondly, the order and timing of cytokine
expression appears to dictate STAT3 signaling based upon pretreatment of
macrophages with IL-10 impairing future IL-6-induced signaling via STAT3. Importantly,
when IL-6 was administered first, IL-10 signaling was not affected. Lastly, the regulation
of signaling via each cytokine differs. IL-6, and the associated gp130 receptor, attracts
SOCS3, producing a negative feedback loop. This is in contrast to IL-10 and its
associated receptor does not interact with SOCS3. 314 Importantly, some discrepancy
does exist concerning the effect of inflammation induced via LPS administration on IL-6
and STAT3 levels as others have shown increases following inflammation. As such, it is
important to consider the effect of priming or preconditioning on cellular response 315.
Understanding the surely complex interaction between cytokines such as IL-6 and IL-10,
particularly the similarities and differences present, may lead to breakthroughs in the
development of therapeutics targeting this pathway. Furthermore, many questions
remain concerning the relationship between IL-6 and IL-10 such as whether the
signaling dynamic described above holds true for all cell types, does STAT3 undergo
identical phosphorylation regardless of its inducing cytokine, what is the role of prior
inflammation, and are these effects consistent across time points? Are acute phase IL-6
mediated increases in pSTAT3 distinct, perhaps in brain region and cell type from injury
related increases in IL-6 and pSTAT3? Perhaps the most important question raised by
studies concerning the effect of prior inflammation on IL-6 and IL-10 induced STAT3
signaling is how this may relate to models of disease involving an inflammatory
component. For example, the aged brain is known to exist in a state of low-grade
inflammation and how this reality alters STAT3 signaling is only beginning to be
uncovered. Interestingly, our laboratory has shown an attenuation of STAT3 signaling
associated with increased SOCS3 expression in the aged rodent following MCAO, a
finding consistent with that described above in which prior inflammation leads to an
attenuation of IL-6-induced STAT3 signaling 51,	
   314. How this finding may apply to other
models of neurologic disease commonly affecting the aged population remains to be
seen.
Numerous challenges are likely to arise in attempting to address the questions stated
previously. These included the complexity of phosphoprotein regulation, the presence of
multiple STAT3 isoforms, isolation of effects in a given cell type in a biologicallymeaningful environment, and overlapping/intersecting pathways creating a complicated
dynamic of both redundancy and abundance of effects. Phosphoprotein regulation,
particularly when multiple sites are present, is inherently more difficult to study
appropriately.
Furthermore, depending on the inhibitor chosen, one or both
phosphorylation sites may be blocked. For example, the use of AG490 has been shown
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to inhibit Y705 phosphorylation of STAT3 but not S727 in an in vitro astrocyte-stress model,
possibly due to overlapping pathways 316. The notion of intersecting pathways further
complicating studies is expanded upon by Planas, et al. In this work, STAT1 and STAT3
are discussed highlighting the ability of anti-inflammatory cytokines like IL-10 to activated
STAT3 but not STAT1 whereas pro-inflammatory cytokines like IFN-gamma induce
STAT1 but not STAT3. IL-6 on the other hand activates both pathways 317. Lastly, work
concerning STAT3 may need to focus on isoform-specific events. STAT3 is found in two
isoforms: α and β. STAT3β, long thought to be the dominant negative isoform, has been
shown to exert a negative effect on the synthesis of inflammatory cytokines and may
actually increase synthesis of anti-inflammatory cytokines. The α isoform on the other
hand has been implicated in control of SOCS3 144. As such, it is clear that while current
and past studies have greatly expanded our knowledge of STAT3 and associated
signaling, many questions remain unanswered, particularly those related to the study of
neurologic disease.
1.7.3.6. Therapeutic Development: Challenges of Inhibition
The challenges of developing therapeutics to modulate proinflammatory pathways,
particularly for neurologic disease, are numerous and consist of course of timing,
dosage, and delivery challenges. For example, IL-6 antibodies have been developed for
the successful treatment of rheumatoid arthritis in preclinical models but are complicated
by issues such as delivery across the BBB and immunogenicity challenges 318. Other
challenges include the use of inhibitors that can’t penetrate the blood-brain barrier and
inhibit aspects of the signaling cascade upstream of STAT3, such as AG490 319.
Perhaps the greatest challenge to the development of therapeutics targeting STAT3
signaling is when to administer them, for how long, and to what cells. It appears that
STAT3-induced effects likely vary from cell-type to cell-type, making cell-specific
inhibitors desirable.
Furthermore, methods of inhibition utilizing SOCS3 are now
available.
These include genetic overexpression or downregulation as well as
pharmacologic mimetics 320.
Brain inflammatory responses signaling through STAT3 represent promising therapeutic
targets. STAT3 signaling, while complex in nature, seems to have powerful effects on a
variety of cell types important for the study of neurologic disease and allows for targeting
of multiple aspects of pathophysiology ranging from ECM modification to angiogenesis
to apoptosis. Similarly, STAT3 signaling plays a role in not only initial injury but also
represents a promising therapeutic avenue for repair and recovery via effects on neural
stem cells and the modulation of neuroplasticity 237,	
  303.
1.7.4. CONCLUSION
The effects of STAT3 signaling are diverse and likely play a significant role in modulating
the body’s response to neural injury. While STAT3 has been implicated in vascular
remodeling, control of apoptosis, and regulation of oxidative stress, much remains
unknown concerning its regulation in response to injury. Following stroke and traumatic
brain injury, STAT3 signaling is altered across a range of cell types, with each
undergoing time-dependent changes. The precise role STAT3 plays in the initial injury
and subsequent recovery phase remains to be elucidated but represents a potentially
promising therapeutic target. Similarly, aging is associated with the development of
many neurologic diseases and alters the STAT3 signaling pathway in response to injury,
once again demonstrating the need to consider age in the study of neurologic disease.
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1.8 Protein Kinase C as a Therapeutic Target for Ischemic Stroke
Another potential therapeutic target that appears promising in a variety of neural injury
models (ischemic stroke, traumatic brain injury, and Alzheimer’s disease) is regulation of
protein kinase C. In this work, we explore the current status of protein kinase C
research and promising future directions. Much of this work sets the stage for one of our
publications discussed later in this dissertation relating to bryostatin-1 for ischemic
stroke.
This work was published in Ischemic Stroke: Symptoms, Prevention and Recovery.
Citation: Turner RC, Lucke-Wold B, Tan Z, Rosen CL, Huber JD (2013) Modulation of
Protein Kinase C Isoforms: A Potential Therapeutic for Ischemic Stroke? Chapter 6.
Ischemic Stroke: Symptoms, Prevention and Recovery. Edited by Virag Lakatos and
Balazs Somogyi. Nova Biomedical. Pgs. 171-190.
ABSTRACT
Manipulation of the protein kinase C (PKC) signaling pathway has been recognized as a
potential therapeutic target for numerous disease states, the most well-investigated
being cardiovascular disease. Recent discoveries in preclinical models of neurologic
disease ranging from Alzheimer’s disease (AD) to traumatic brain injury (TBI) to stroke
have identified changes in PKC expression and in some cases, successfully targeted
this pathway therapeutically. The effects of altered PKC expression following injury
remain under investigation with some studies implicating PKC in the regulation of
oxidative stress, apoptosis, inflammation, and vascular remodeling. Additionally, various
PKC isoforms may be involved in both beneficial and detrimental processes following
injury as evident in the role of PKC mediating neuroprotection in hypoxic preconditioning
but also being associated with blood-brain barrier (BBB) disruption in other studies.
Furthermore, preclinical studies of neurologic injury and disease often fail to emphasize
the effect of aging, despite the fact that age is the greatest risk factor for numerous
neurologic diseases such as stroke and AD. This is of particular relevance in the
regulation of PKC function as aging has been shown to alter enzyme translocation, thus
altering function. This work reviews the location and pathways associated with various
PKC isoforms, the role of PKC isoforms in the aging process, as well as implications of
PKC signaling following neurologic or cerebrovascular injury. We provide insight into
potential downstream pathways of interest and the potential role of PKC modulation as a
therapeutic target for ischemic stroke based on findings in not only preclinical studies of
stroke but also studies of other neurologic and cardiovascular diseases.
1.8.1. INTRODUCTION
1.8.1.1. PKC Isoforms – A Lesson in Structure-Function Relationships
The PKC family is a series of threonine/serine kinases. Up to twelve different isoforms
exist each with their own actions and specific pathways of activation. All isoforms are
present in some form or another within the brain 321. These isoforms have been grouped
into three classifications: conventional, novel, and atypical. The classification is based
on the unique polypeptide chains and the cofactors associated with each group. The
NH2-domain is specific for the membrane phospholipids that interact with PKC during
translocation. The COOH-domain is specific for the activating cofactors, and the C2
domain has binding capacity for receptors for activated C kinases (RACKs).
Conventional isoforms (cPKCα, -βI, -βII, and γ) require calcium, phosphotidylserine (PS),
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and diacylglycerol (DAG) for activation. The novel isoforms (nPKCδ, -ε, -η, -θ, and –µ)
require PS and DAG but not calcium.
The atypical isoforms (aPKCζ, -λ) are
unresponsive to DAG, PS, and calcium (Figure 1.18). Both cPKCs and nPKCs activate
the extracellular signal-regulated kinase (ERK) and mitogen-activated protein kinase
(MAPK) cascade among other pathways 322. These pathways will be discussed in detail
in later sections. In investigating PKCs, it was discovered that a panel of nine genes
express the phospholipid-kinases. These genes produce the PKCs in various tissues
throughout the body and account for their broad distribution and functions. PKCγ,
PKCδ, PKCα, and PKCε are the most predominant isoforms associated with neurologic
diseases. Other isoforms play more predominant roles in other organ systems such as
the heart.

Figure 1.17. Schematic of typical protein sequence for PKC showing the variations
between conventional, novel, and atypical subgroups. cPKC requires diacylglycerol,
phorbolester, and calcium for activation. nPKC requires diacylglycerol and phorbolester
but not calcium for activation. aPKC is not dependent on diacylglycerol or phorbolester
but activates quicker in their presence which is represented by the black lines.
1.8.1.2. Expression of PKC Isoforms – Systemic and Cellular Considerations
PKCs have been found in a large number of organs such as the heart, brain, lungs,
kidneys, and organs of the gastrointestinal tract as well as in cells of the hematopoietic
system 323-‐326. Different isoforms are located in a tissue-specific manner. PKCα is highly
expressed in β cells of the pancreas, but has also been linked to pathological tissue
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such as breast cancer and malignant gliomas 327. PKCγ is endogenous to the α cells in
the pancreas. PKCζ has been linked to matrix metalloproteinase (MMP) regulation in
smooth muscle cells 328. PKCδ is upregulated in endothelial cells following ischemia 329.
PKCε is present in large quantities in the hippocampus and olfactory tubercle 330. PKCβII
is present in both normal and pathological B-cells 331. Other isoforms such as PKCθ and
PKCα work together and have important roles in T-cell regulation and IL-2 activation 332.
All PKCs are originally localized in the cytosol of specific cells and must undergo a
translocation to a membranous site.
Depending on the isoform or tissue, this
membranous site could be the nucleus, golgi apparatus, endoplasmic reticulum,
mitochondria, or even the cell membrane 333,	
  334.
1.8.1.3. Activation of PKC Isoforms
PKCs are completely phosphorylated following translation but are inactive due to
pseudosubstrate interference with the binding domain. The pseudosubstrate domain
keeps the PKC polypeptide in a folded configuration. PKCs are localized in the cytosol
of specific cells and must be activated by removing the pseudosubstrate domain. After
activation, PKCs must then be translocated to membranous sites in order to
phosphorylate downstream pathways 335. Lipopolysaccharide (LPS) in the presence of
the aforementioned endogenous cofactors (DAG, Ca++, and PS) induces activation of
PKCβ, -ε, and -ζ 336. Phorbolesters such as tissue plasminogen activator (tPA) and even
the β-adrenergic system have also been shown to activate PKCs 337. A variety of growth
factor receptors can activate PKCs as well. The increase in growth factors during
cancer is one of the reasons PKCs have become ideal targets for therapeutic
The translocation
interventions 338. Once activated, PKCs can be translocated.
mechanism is initiated through PKC binding with RACKs. RACKs are 30-36 kilo-Dalton
proteins that are located in cytoskeletal compartments. They interact with a C2 domain
on the PKC polypeptide and thus do not interfere with the substrates binding site. Each
isoform of PKC has a specific RACK. RACKs also have other functions besides binding
PKCs such as anchoring phosphodiesterase and integrin, and contributing to vesicle
release and cell-to-cell communication 339,	
   340. After PKC binds to its isoform specific
RACK, the entire unit will translocate from the cytoplasm to the membranous sites
previously mentioned.
1.8.1.4. Regulating PKC Activation
In general, PKCs are self-regulated proteins.
When PKCs are activated, the
pseudosubstrate dissociates. Eventually, the PKC loses one of its three phosphate
groups at a site known as the activation loop. When this occurs, the cofactor separates
from the active site and the PKC is no longer functionally active. The pseudosubstrate
reattaches and the PKC is in its inactive state. In order for the PKC to return to a state
where it can activate again, it must regain the phosphate group that it has lost. A
phosphoinositide-dependent kinase 1 (PDK-1) phosphorylates the PKC at the activation
loop. This additional phosphorylation causes the other remaining phosphate groups to
reconfigure and realign. In some PKCs, PDK-1 does not directly phosphorylate the
activation loop but instead induces autophosphorylation. Once all phosphate groups
have been restored and the other phosphate groups have been reconfigured, the PKC
can undergo activation 341.
1.8.1.5. PKC – A Role in Disease Processes?
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PKCs typically regulate important functions such as cell growth and differentiation,
secretion of hormones, and normal membrane functioning. They also play a key role in
the regulation of the Na/K/2Cl-cotransporter (NKCC) and neuronal sodium and
potassium transport. Several of the PKC isoforms contribute to the pathology of
neurologic and cardiovascular disease sometimes in direct contrast to one another. In
stroke, the PKC isoforms -α, -βI, and -ε contribute to the activation of NKCC at the
blood-brain-barrier (BBB). This leads to the protectant mechanism of increased K+
transport across endothelial cells and an increased K+ flow back into the blood stream.
342 PKCβI also acts as a neuroprotectant for astrocytes by inducing phosphorylation and
increasing the activation of excitatory neurotransmitter transporters. Similarly, PKCα
acts as a neuroprotectant for neurons by activating the adenosine signaling pathway 343.
In contrast to these neuroprotectant roles, PKCδ in conjunction with amplified Ca++ influx
has been shown to cause increased constriction of the middle cerebral artery (MCA)
prior to and during ischemic stroke 329,	
   344. Following ischemia, PKCβII has been linked
to increased endothelial permeability and inflammation 345. Stroke is not the only
neurologic disease where PKCs are active.
The isoform PKCδ also regulates
mitochondrial-induced apoptosis and has been linked to diseases such as Alzheimer’s
disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and
Traumatic Brain Injury (TBI) 346-‐349. PKCδ is cleaved by caspase-3 and translocates to
specific cells via the appropriate RACK. It then enters the mitochondria of these target
cells, and eventually phosphorylates a series of enzymes such as the GTPase Drp1.
This signaling cascade ultimately leads to mitochondrial-mediated apoptosis 350. PKCs
also play a critical role in cardiovascular disease. PKCε provides cardioprotection
through activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2). PKCε is
originally found in the cytosol and translocates to the cell particulate fraction following
hypoxia preconditioning. In addition to an interaction with the appropriate RACK, PKCε
associates with heat shock protein 90 (HSP90) before it translocates 351. Similar to the
brain, PKCδ leads to reperfusion injury following the initial onset of myocardial infarction.
Importantly, cardiovascular-based studies have revealed an increase in PKC
translocation by over 50% following injury. When inhibited, injury is significantly reduced
through attenuation of the pro-apoptotic pathway in mitochondria 352. If an animal is preconditioned to ischemia before injury, the protectant isoform PKCε will be upregulated
and the harmful isoform PKCδ will be downregulated 353,	
   354. As more is discovered
about PKCs, it is becoming increasingly apparent that they have important functions in a
broad spectrum of diseases. This is particularly true when considering the greatest risk
factor for the development of neurologic disease is aging. Since age in and of itself
alters the dynamics of PKC signaling, it is important to realize that unique modifications
occur in aged animals even before the onset of disease 355.
1.8.2. EFFECT OF NEURAL DISEASE & INJURY ON PKC ACTIVITY
Numerous disease states, both neurologic and non-neurologic in nature, have been
associated with changes in both PKC isozyme activity and translocation. The following
sections highlight the role of common neurologic disease states in modulation of PKC
activity but it’s important to consider that much of what is known concerning the role of
PKC in pathophysiology is derived from work in other organ systems, namely
cardiovascular. Many comprehensive reviews focusing on the general role and effects
of PKC following injury, as well as specific isozyme-mediated effects, have been
published by the Mochly-Rosen group and others, often in reference to cardiovascular
disease, a disease process that likely shares many similarities with cerebral ischemia.
As such, the cardiovascular literature and the aforementioned reviews provide insight
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into the role of PKC in neural injury and can serve as further reference for material not
covered herein 356.
The interest in PKC isozyme modulation following neurologic injury appears warranted
due to the identification of deficits and abnormalities in PKC-mediated signaling
cascades, particularly in relation to learning and memory deficits, in the brain that occur
acutely in patients with Alzheimer’s disease and/or ischemic stroke 148. Of particular
interest is the role of the epsilon isozyme as PKCε is expressed more highly in the brain
than most other tissue, suggesting a critical role in nervous system homeostasis. This
notion is consistent with the role of PKCε in various functions including perhaps most
notably, neurotransmitter release and ion channel function 330. Furthermore, contrasting
viewpoints concerning the effect of neural injury on PKC activity exist and therefore,
additional investigation is required to understand both these effects and how PKC can
be manipulated pharmacologically for therapeutic benefit 326.
1.8.2.1. Alzheimer’s Disease (AD)
Of the neurologic disease states in which PKC has been investigated in relationship to
disease pathophysiology, AD comprises the vast majority of reported studies and
importantly, deficient PKC isozyme function has been described as a key component of
disease pathogenesis and consequently, raised the prospect of PKC as a promising
therapeutic target 357. Pathologic studies conducted on the brains of AD patients reveals
a close correlation between dementia and synaptic loss. The precise mechanism
leading to synaptic loss have been poorly elucidated until recent work of Hongpaisan, et
al in which a reduction in synaptogenic PKC isozymes, particularly α and ε, and
associated substrates was found to occur in conjunction with increased soluble beta
amyloid but prior to both plaque development and corresponding neuronal loss. These
findings were consistent with clinical autopsy results in which age-matched, nondemented control patients exhibited a higher level of PKC expression and activity in
comparison to patients afflicted with AD 358.
Mechanistic studies have revealed a role for PKC activation in activation of α-secretase,
an enzyme responsible for converting amyloid precursor protein (APP) to soluble
sAPPα, potentially preventing amyloid beta (Aβ) production. Besides altering production
of Aβ, PKC-mediated pathways have been reported to increase the degradation of Aβ,
further altering the ratio of production and degradation in a beneficial manner 359. In
addition to providing a potential therapeutic approach to AD, these studies have also
demonstrated clear roles for many PKC isozymes in learning and memory-associated
tasks that are affected in many neurologic disease states such as ischemia and
traumatic brain injury 357.
1.8.2.2. Ischemia
Conflicting evidence exists concerning the effect of ischemia on PKC expression and
activity 322,	
   326,	
   345,	
   360,	
   361. This is thoroughly reviewed by Bright and colleagues and
perhaps most importantly, only recently have the effects of various isozymes been
recognized as frequently divergent, necessitating the consideration of disease-isozyme
relationships rather than consideration of PKC activity/expression as a whole 321. We
attempt to identify these often different, if not opposing, roles of various isozymes as
related to disease pathophysiology and therapeutic development in the remainder of this
work.
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In addition to consideration of potentially contrasting izoyme effects, the impact of
preclinical model and corresponding severity of ischemia has often gone unrecognized.
Importantly, Sun and colleagues investigated this precise issue, demonstrating that while
PKC activity is increased with mild ischemia, severe ischemia results in diminished PKC
activity 148. Besides severity of ischemia, the location of both ischemia and sample must
be taken into account. Cortical and striatal tissue may respond differently to ischemia
due to unique metabolic demands and cellular composition. Whether tissue samples
analyzed are from infarct core or penumbral regions may further influence PKC-related
findings 362. Other factors to consider include the time of analysis post-onset of
ischemia, the role of isozyme phosphorylation in activation and downstream-signaling,
and discrepancies between in vitro and in vivo studies. Contrasting results between cellbased and animal-based studies, as reported by Fleegal and colleagues, indicate the
potential for cell-specific effects, further complicating the study of PKC-mediated
pathways 345. Whether manipulation of PKC in response to injury has similar effects
across the various cell-types found within the brain remains to be seen.
Regardless of the aforementioned issues in comparing results across studies, it is clear
that PKC is involved in both the initial, acute response to ischemia as well as more
delayed effects throughout the subacute and chronic periods. This is consistent with
work showing PKCδ increased throughout both infarct core and penumbra regions 148.
Likewise, PKCε has been shown to be up-regulated rapidly following onset of ischemia
and remains elevated in both in vitro and in vivo studies 322,	
   363. Most importantly,
preclinical studies targeting specific PKC isozymes using either pharmacologic agents or
genetic modifications have demonstrated the ability to reduce cerebral injury 321,	
  364,	
  365.
1.8.2.3. Ischemic Preconditioning
In addition to the effect of ischemia on PKC and modulation of PKC for therapeutic
benefit discussed above, PKC is also involved in the beneficial effects associated with
ischemic preconditioning 148,	
   330,	
   366. Historically, the PKCε isozyme has been most
frequently recognized as essential in ischemic preconditioning 148,	
   330,	
   367. The protective
effects associated with PKCε activation that occurs with preconditioning have been
ascribed to the role of PKCε in the adenosine/NMDA-activated signal transduction
pathway 148. Recent work in mice undergoing hypoxic preconditioning (HPC) prior to
middle cerebral artery occlusion (MCAO) has implicated PKCβII.
This finding is
consistent with observed increases in PKCβII membrane translocation in the acute
phase of HPC, but further work remains to clearly elucidate the mechanism of protection
366,	
   367. Other isozymes such as PKCδ, a pro-apoptotic kinase, have been identified as
being decreased with HPC in cardiac tissue, which may lead to the protective effects
associated with HPC 354.
1.8.2.4. Traumatic Brain Injury
Relatively little work has been done investigating the effect of TBI on PKC activity with
the exception of that by Yang and colleagues and Zohar and colleagues. Yang, et al
demonstrated significant changes in PKC activity at 1 and 3 hours after TBI but not at 5
minutes or 24 hours post-injury. At the 3 hour time point, PKC translocation to
membrane fractions was elevated 326. While Zohar, et al did not assess activity or
translocation, administration of bryostatin-1, a potent PKC activator, resulted in
diminished learning and memory deficits following TBI. The reduction in learning and
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memory deficits was consistent with improved maintenance of synapses as evident by
pre-synaptic synaptophysin and post-synaptic spinophylin immunohistochemistry 349.
1.8.3 ROLE OF PKC IN NEURAL INJURY OUTCOME
The effect of altered PKC activity observed in many of the aforementioned neurologic
disease and injury states has not been entirely elucidated but many recent works have
tied various PKC isozymes to oxidative stress, regulation of apoptosis, blood-brain
barrier (BBB) breakdown, and processes associated with recovery/repair.
In the
following sections we expand upon work investigating the role of PKC in these diseaseassociated events by again linking work completed across multiple organ systems,
mainly neurologic and cardiovascular.
1.8.3.1. Modulation of Response to Oxidative Stress
Oxidative stress has frequently been cited as a potentially precipitating factor in many
pathologic states, particularly those associated with the aging process resulting in the
theory of ‘inflamaging’ 368. A reduction or loss of PKC activity has previously been
correlated with injury severity but how PKC modulated this response was unclear.
Emerging evidence implicates PKC in the modulation of oxidative stress-induced
apoptosis, generation of oxidative stress through NADPH oxidase, and mitochondrial
function.
Oxidative stress leads to PKCδ translocation to the mitochondria, termed mitochondrial
targeting, ultimately causing loss of mitochondrial transmembrane potential and release
of cytochrome c that leads to apoptosis 352,	
   369. PKCδ also appears to be somewhat
unique in the response to oxidative stress in that it may also further amplify the apoptotic
cascade via caspase activation and subsequent feedback 370. Importantly, previous work
has shown these processes can be inhibited using PKCδ inhibitors 369,	
   371. These
inhibitors may also prevent upregulation of NOX1, part of the NADPH oxidase complex,
via PKCδ that contributes to oxidative stress and has been identified previously as a
potential therapeutic target 372-‐374.
1.8.3.2. Effect of PKC on Cell Survival
Consistent with divergent effects of PKC isozymes on other cellular functions, PKC
isozymes have been characterized as pro- or anti-apoptotic in nature. Consequently,
work utilizing non-specific PKC modulators has shown both protective and deleterious
effects in response to injury, likely due to isozyme-specific effects 375. PKC isozymes
identified as suppressing apoptosis include α, β, ε, and ζ while those acting as proapoptotic are δ and θ 148. Most work investigating PKC-mediated effects on cell survival,
namely apoptosis, has centered on the role of PKCδ and PKCε.
Inhibition of PKCδ has been found to be universally protective regardless of organ
system following onset of ischemia as evident by diminished pathologic features of
apoptotic processes such as DNA laddering and fragmentation 352,	
  376. Similarly, proteins
involved in apoptotic signaling cascades such as cytochrome c, caspase 3, and Bcl-2
assocaited death protein (BAD) were reduced following inhibition 352,	
   376-‐379. Perhaps
most importantly, at least from a therapeutic development standpoint, is that
administration of PKCδ inhibitors results in improved outcome following ischemic stroke,
even when administered up to 6 hours after onset 377. How exactly PKCδ mediates the
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aforementioned effects remains to be clearly elucidated but numerous pathways have
been proposed in which glycogen synthase kinase-3B (GSK-3B) and Akt signaling
pathways are altered 376,	
   377. Others have shown a role for Drp1, a mitochondrial fission
protein to which PKCδ binds, that is phosphorylated upon binding resulting in enhanced
mitochondrial fragmentation 379. Furthermore, PKCδ may be partially responsible for
mediating the protective effects of hypothermia following ischemia 360.
Investigation of PKCε is more limited and the effects not as clearly elucidated as those
associated with PKCδ modulation. Bright and colleagues demonstrated a protective role
of ψεRACK and associated PKCε-mediated effects when activator peptide is
administered near the time of stroke onset, implicating PKCε in acute pathophysiologic
events. When given 24 hours before ischemia or at the onset of reperfusion, ψεRACKmediated activation did not improve nor worsen outcome 363. In other work, activation of
PKCε restores the phosphorylation state of endothelial nitric oxide synthase (eNOS),
increasing cell survival 380.
1.8.3.3. Regulating BBB Integrity through Matrix Remodeling
Neural injury and degeneration often involves transient periods of blood-brain barrier
(BBB) disruption. Improving the maintenance of BBB integrity has been identified as a
promising therapeutic target for neurologic disease, particularly ischemic stroke. Much
of the previous work into mechanism of BBB breakdown after injury has focused on the
role matrix metalloproteinases (MMPs) play in both acute breakdown, associated with
deleterious processes, as well as chronic regulation required for recovery/repair. While
regulation of MMP activity has largely remained unclear and complicated, emerging
evidence indicates a clear role for PKC signaling. Fleegal and colleagues have shown
that PKC inhibition with chelerythrine chloride reduces BBB permeability, which lends
credence to the idea that PKC may control expression and function of junctional proteins
345. This is consistent with the suggestion that PKC may regulate other junctional
proteins associated with the epithelial barrier 381. The attempt to identify the role of
specific isozymes involved in BBB permeability has produced multiple candidates
depending on the model used, time points, and severity of injury utilized. In a global
ischemia model, analysis of cortical microvessels demonstrated changes in PKC
distribution, particularly that of PKCθ and PKCζ, as well as phosphorylation activity of
these isozymes. This suggests that these signaling molecules may further mediate tightjunction strength 382. Others have suggested a role for PKCζ in MMP regulation as well
with Hussain and colleagues showing that PKCζ activity is required for cytokine-induced
activation of MMP-1, -3, and -9 328.
Other isozymes identified as contributing to BBB regulation include PKCδ and PKCε 381,	
  
383,	
   384.
Notably, some proposed neuroprotective agents, such as doxycycline, have
reduced BBB breakdown and improved neurologic outcome while downregulating PKCδ,
suggesting protective effects may be mediated via PKC isozyme modulation 385.
How PKC activation and translocation leads to MMP activation is not well elucidated but
indications are that it may involve downstream signaling cascades mediated through the
NF-κB or MAP/ERK pathways 386,	
   387. Work in other organs such as the kidney has
shown other pathways and molecules may be involved in regulating MMP gene
expression such as c-Fos and c-Jun, two cellular proto-oncogenes 387. Other studies
indicate potential modulation of cytokine-induced effects on MMP expression by PKC
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isozymes as well as identify a possible role of PKC-mediated phosphorylation of MMP-2
that then alters the activity of the protease 388-‐390.
In addition to the role the BBB serves in regulating solute passage and preventing
vascular dysfunction, it also is responsible for maintaining the immunoprivileged state.
PKCδ activation in endothelial cells studied in vitro revealed diminished neutrophil
migration following stimulation with leukotriene B4 (LTB4) or tissue necrosis factor-α
(TNF-α) without altering endothelial barrier integrity 391. This would appear to be in
contrast with previous findings in which PKCδ inhibition reduces endothelial dysfunction
and improves BBB integrity 329,	
  379,	
  392.
1.8.3.4. Role in Recovery & Repair following Neural Injury
Understanding the mechanisms associated with recovery and repair from neural injury
remains the subject of intense investigation due to the potential promise for therapeutic
development for a number of neurologic disease states ranging from ischemic stroke to
TBI. Recovery/repair involves a complex array of simultaneously occurring processes
including neural migration and angiogenesis. Recent work highlights roles for PKCmediated signaling in each of these repair-associated components.
One of the greatest challenges in recovery/repair events is overcoming inhibitory activity
attributed to the glial scar found at the lesion site. Much of the inhibition resulting from
myelin and other molecules composing the glial scar is regulated by cPKC activity. By
blocking PKC activity, neurite outgrowth has been stimulated both in vitro and in vivo
despite the normally prohibitive presence of myelin 148. This process likely requires a
series of protease and metalloprotease-mediated steps, which may be regulated by PKC
as discussed above. A prime example is that of semaphoring 3A (Sema3A), a guidance
molecule that activates MMP-2 in a PKCα-dependent fashion 393. Besides involvement
in axonal guidance, PKC activation using bryostatin has been shown to increase
mushroom spine number on neurons in a memory-specific manner 394.
Actual neurite outgrowth has been shown to be PKCε-dependent in nature with an
increase in PKCε promoting nerve growth factor-induced growth whereas a decrease
inhibits the process 330. This overall pro-repair event appears consistent with work
completed in the cardiovascular system in which sustained PKCε inhibition following
heart failure prolonged survival while reducing dysfunction through a variety of
mechanisms, many of which are associated with the regulation of inflammatory
pathways and inflammatory cell migration 334.
PKCδ, often thought of in a negative light with regards to impact on neural injury in the
acute period, has been shown to modulate critical aspects of repair/regeneration such as
angiogenesis and cell cycle modulators, making PKCδ activation potentially beneficial in
the chronic period post-injury. Specifically, Kim and colleagues demonstrated that PKCδ
activation promotes NADPH oxidase activity and increases HIF-1α levels, leading to
angiogenesis 395. PKCδ is also involved in cell cycle events based on actions on Cdk5
via p35 and consequently regulates cortical radial migration of neurons 396.
1.8.3.5. Effect of PKC Modulation on Learning and Memory
In addition to the role of PKC in neural migration and repair following injury, the effect of
PKC on learning and memory has been well established in both healthy and injured
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animals. In Hermissenda, bryostatin was found to enhance memory acquisition at lowdoses consistent with up-regulation of specific PKC isozymes but at high doses,
bryostatin resulted in down-regulation and no recall of the associative training task 397.
One of the major cellular mechanisms associated with learning and memory, long-term
potentiation (LTP), seems to require PKC-mediated signaling based on previous findings
assessing the effect of phorbol esters and PKC inhibitors on LTP. While PKC has been
described as necessary, but not sufficient, to induce LTP, it is clear that PKC isozymes
such as PKCε contribute to presynaptic control 330. Furthermore, PKC modulators such
as bryostatin have been shown to induce synthesis of proteins associated with memory
consolidation, a fact that makes PKC modulators a potentially promising therapeutic
target for conditions associated with memory impairment like Alzheimer’s disease 398.
1.8.4. STUDYING PKC ISOFORM-SPECIFIC EVENTS: USING AVAILABLE TOOLS
Work in other organ systems, such as the cardiovascular system, has illustrated the
importance of elucidating isozyme-specific events for the development of therapeutic
agents. For example, Chen and colleagues showed that various isozymes may have
similar effects with regard to one cellular function and opposing effects on another
function, explaining contrasting findings often reported due to use of non-isozyme
selective pharmacologic agents. Furthermore, the isozyme-dependence of cellular
functions is of particular interest considering the elevation of multiple isozymes following
injury and the idea that it is the balance struck between various isozymes that determine
the overall outcome post-injury 353.
The elucidation of isozyme-specific events can be accomplished via genetic
manipulations such as knockouts or through the use of pharmacologic inhibitors. Of the
isozymes identified, at least four have been successfully mutated to produce null mice.
This includes the γ, β, ε, and θ isozymes. While null mice may provide insight into
neurologic effects associated with a respective isozyme, animals are affected
systemically as evidenced by β and θ-null mice, which have shown phenotypes
consistent with immunologic changes 399. One of the advantages of null mice though is
the ability to target a given isozyme specifically, a significant challenge observed in
studies using pharmacologic inhibitors that often inhibit one isoform class rather than a
specific isozyme. For example, Go6976 has been described as inhibiting classical Ca2+dependent isozymes whereas Go6850 inhibits both conventional and novel isozymes 381,	
  
393. Other agents such as Ro 31-8220 have been shown to inhibit PKCα more
selectively at low concentrations than high concentrations where additional PKC
isozymes may be affected 394. More recently, isozyme specific inhibitors have become
available as well as the development of peptide-based specific inhibitors 321,	
   358,	
   376. In
addition to inhibitors of PKC, activators are also available and include promising
therapeutic candidates, such as bryostatin, for a host of neurologic disorders 349,	
  358,	
  364.
1.8.5. FUTURE DIRECTIONS
Modulation of PKC using isozyme-specific pharmacologic and peptide-based inhibitors
has yielded positive results in many preclinical studies, particularly in models of
neurologic diseases such as stroke, TBI, and AD. Despite the apparent success of
these studies and progression to early phase clinical trials in some cases, further studies
are required to elucidate effects of common disease comorbidities such as aging,
hypertension, and diabetes that have not been addressed in early preclinical studies.
Similarly, many of the early preclinical studies have been conducted in vitro on neurons
and have not addressed the potential of cell-specific or time-dependent effects.
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Furthermore, investigating signaling mechanisms associated with beneficial and
detrimental PKC-mediated effects may lead to optimal therapeutic development by
regulating multiple isozymes.
1.8.5.1. Alterations in PKC-mediated Signaling Associated with Aging
The greatest risk factor for neurologic diseases such as ischemic stroke and AD is age.
Most preclinical studies investigating PKC-mediated effects have not considered the role
of age and the aging process. In one study that did address the effect of age on PKC in
the brain demonstrated that cPKCs are substantially down-regulated in the cortex,
striatum, and hippocampus of middle-aged animals compared to young animals. This
down-regulation drastically changes the expression of substrates normally modulated by
PKCs such as nitric oxide synthase (NOS) 146,	
   380. Ultimately, such age-related
altercations might predispose the brain to Alzheimer’s disease, dementia, or other
memory dysfunctions.
In addition to PKC downregulation, the availability of the
remaining PKC isoforms is disrupted. Most isoforms are not present in membranous
regions due to a deficit in translocation. RACKs have decreased expression, up to 50%,
in the aged brain. Without RACKs, PKCs are isolated to the cytosol of cells and cannot
translocate even if activated. This leads to deficits in PKC-mediated neuronal plasticity
and subsequent loss of LTP 333,	
   400. To further complicate matters, oxidative stress and
aluminum-induced neurotoxicity can cause PKC to transfer from the plasma membranes
to the cytosol in aged brains 401. In other tissues such as the heart, some RACKs may
be functional while others are not. When an aged heart is confronted with increased
preload, the expression of most PKCs is up-regulated. The RACKs specific for PKCβ
and PKCε are still functional and can therefore initiate translocation. Since PKCβ and
PKCε are overactive compared to the other regulatory cytosol-bound PKCs, the heart
hypertrophies and becomes fibrotic 356. Considering the potential effect of age on RACK
functionality, the ideal therapeutic would not depend on RACK function to mediate
therapeutic effects on the targeted isozyme. Several drugs have been designed for such
targets, and one specific drug of interest is Bryostatin-1. Bryostatin-1 is a potent activator
of PKCs and also aids in increased translocation of PKCα 357,	
  397.
Kostyak and colleagues demonstrated that at baseline, PKCδ levels in the mitochondria
of the heart were increased by approximately 40% in comparison to the normal adult
heart. Similarly, aged hearts contained a nearly 2-fold increase in cytosolic PKCδ in
comparison to adult heart. Perhaps most importantly, inhibition of PKCδ with KID1-1
reduced the increased infarct volume typically found in aged hearts to a level more
consistent with the adult heart 376.
1.8.5.2. Elucidating Cell-Specific and Time-Dependent Events
Investigating the pathophysiology of neurologic diseases such as ischemic stroke, as
well as developing therapeutics, is complicated by the numerous cell-types required for
both normal homeostasis as well as the response to injury and subsequent repair/
recovery. Being that each cell-type may respond differently to injury, or at least exhibit
varying sensitivity to injury, may necessitate investigation of PKC-mediated processes
independently for targeted therapeutic delivery. This idea is consistent with the varied
findings across cell-types such as the role of PKC in modulating the inflammatory
process and microglial adhesion, astrocytic control of MMP-9, and oxidative stress in
neurons 371,	
  386,	
  391,	
  402.
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Besides cell-specific events, previous work has shown time-dependent changes in PKCmediated signaling in cerebrovascular studies. For example, PKCδ is activated early in
cerebrovascular events and likely plays a greater role in the acute period whereas PKCα
may play a larger role in the chronic period after injury. Therefore, studies more
adequately addressing the timing of isozyme increases or decreases following an
injurious event may lead to more appropriate therapeutic development 403.
1.8.5.3. Understanding PKC-mediated Pathways
PKC-mediated signaling is involved in a wide array of homeostasis-associated pathways
as well as those that occur in response to injury but how precisely many cellular effects
are controlled through PKC activity remains unclear. Numerous pathways have been
implicated based on work in the brain as well as cardiovascular systems but how these
pathways all interact, and the role of various PKC isozymes in these pathways, remains
to be seen. One signaling molecule of interest is glycogen synthase kinase 3 beta
(GSK-3β), an enzyme responsible for phosphorylating glycogen synthase kinase (GSK).
Aging has been recognized as altering the ratio between phosphorylated GSK-3β and
GSK-3β, a difference that coincides with worsened cardiovascular injury in aged
subjects. Reperfusion results in a worsening of this ratio in the mitochondria of aged
hearts, an effect prevented by PKCδ inhibition 376. Vascular endothelial growth factor
(VEGF) appears to exert its mitogenic and permeability-associated effects via PKCβ
demonstrating another potential pathway of investigation 404. Lastly, the protein kinase
Akt, which has been identified as regulating apoptotic events, has been shown to
correlate with PKCδ activity in the acute period after ischemia but not after reperfusion
377. This indicates a potential link between the two pathways but also demonstrates the
inherent complexity of signaling cascades, particularly those that overlap or display timedependent effects.
1.8.6. CONCLUSION
PKC clearly plays a role in neurologic injury and represents a promising therapeutic
target based on work in numerous preclinical models of AD, ischemic stroke, and TBI.
Activity of some PKC isozymes has been demonstrated in both clinical samples and
preclinical studies at a variety of time points post-injury, likely in an isozyme-specific
fashion.
While the precise mechanism through which PKC isozymes influences
outcome following injury is unclear, evidence indicates a role for PKC in regulating
apoptosis, blood-brain barrier integrity, inflammatory cell adhesion/migration, and
multiple aspects of recovery/repair (Figure 1.19).

80

Figure 1.18.
Schematic demonstrating generic PKC activation processes and
subsequent isozymes with identified functions in neural injury/repair. Each isozyme
likely has time-dependent and isozyme-specific actions that contribute to a range of
cellular effects both during normal homeostassis as well as in response to injury.
Understanding isozyme-specific functions and how to most appropriately target these
effects remains under investigation but recent improvements in peptide-based inhibitors
provides promise in more clearly elucidating the role of a given isoform over time. As
progress continues in this regard, successful therapeutics in preclinical studies that have
progressed to clinical trials, such as Bryostatin-1, may potentially be used to carefully
target individual isoforms and likewise increase functional recovery following a variety of
neurologic injury types.
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1.9 Modeling Traumatic Brain Injury
Increased awareness of the diversity of events producing traumatic brain injury, whether
it be on the athletic or even the battlefield, or the result of accidents (automotive and
others), has led to a multitude of model systems. Models are generally classified as
open or closed, focal or global, or blast-induced. Similarly, the mechanism of injury with
regards to inciting event can also be used to classify models. The most common events
include impacts from weight-drop, fluid percussion, a pneumatic cylinder, and blast. The
advantages and disadvantages of these models have generally been well characterized
with some appreciation of injury biomechanics and relevance to human trauma. Weightdrop models, in which a weight travels down a guide tube and impacts either the
cranium or the brain directly, are generally well regarded for modeling biomechanics
similar to those experienced by humans and are more simplistic in nature than other
models. Disadvantages of these models include the potential for high mortality rates,
some of which can be avoided through experimental modification (ventilation, etc), and
issues with reproducibility. Variations of these models can be utilized to produce focal or
diffuse injury with what is known as Feeney’s model and the Shoami’s model producing
focal injury whereas Marmarou’s and Maryland’s result in diffuse injury	
  5.
Fluid percussion injury models on the other hand are highly reproducible and allow
nearly limitless adjustment of injury severity and can be applied to a broad range of
species with relative ease and only minor modifications. Unfortunately, fluid percussion
injury requires a craniotomy and uses an injury mechanism with unclear relevance to
clinical studies	
   405. Fluid percussion induces a mixed injury with focal and global
components.
Another model commonly employed is that of controlled cortical impact. In controlled
cortical impact the skull is fixed within a stereotactic frame and a craniotomy made (can
be unilateral, bilateral, and of different locales depending on type of injury desired). The
electromagnetic or pneumatic-driven cylinder is lined up with the craniotomy and the
depth of impact desired can be set. While this model exhibits high reproducibility 	
   5, it
does require craniotomy and produces a focal injury, which limits the models applicability
to the more commonly sustained closed head injury in a clinical population. Variations of
this model exist in which the impactor is fitted with a rubberized tip that is then used to
impact the intact cranium, often in a repeated manner.
Perhaps the model technique of greatest interest due to wartime conflicts in Iraq and
Afghanistan is blast injury. Blast exposure has been described as the signature injury of
war and consequently has garnered increased attention by the lay and scientific
communities alike. Many models of blast injury exist with little standardization 406. Most
commonly, for numerous practicality and regulatory reasons, compressed gas-driven
shock tubes are utilized. While these models have successfully been used to produce a
classical Friedlander curve (ideal blast wave), parameters of the wave and how these
measurements are reported varies greatly from laboratory to laboratory. Specifically, the
two main components of interest with regards to modeling blast include the peak
overpressure and the duration of the wave. While others have demonstrated the ability
to simulate a range of peak overpressures, measured in incident or reflected positions,
little emphasis has been placed on exposure duration until recently 406,	
   407. Emerging
evidence suggests that relevant exposures in rodents, based on scaling principles
derived from pulmonary lethality work across species (including humans), are far shorter
than the 4-10 ms durations commonly reported in the literature	
   406,	
   407. As such, it
remains to be seen the effect of scaled blast on neural injury in a rodent model, a key
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question that needs to be addressed for elucidation of blast injury pathophysiology and
the future development of therapeutics.
1.10 Traumatic brain injury prevention
The prevention of traumatic brain injury in potential contact scenarios, whether it is in the
general public (bicycles, motorcycles, etc), athletes (football, lacrosse, baseball, hockey,
etc), or battlefield, has always focused on the application of external protective
equipment such as helmets. While helmets have dramatically reduced the incidence of
skull fractures and have substantially improved in comfort due to improvements in
materials and design, closed head injury, namely concussion, remains a prominent
health issue in sports and on the battlefield. This is likely due to inherent shortcomings
associated with the application of helmets, specifically an inability to address differential
movement between the brain and the skull that occurs due to the floating nature of the
brain in cerebrospinal fluid within the cranial vault. As such, alternative approaches for
reducing traumatic brain injury and concussion are required going forward.
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1.11 Long-Term Consequences of Traumatic Brain Injury
Investigating neural injury using trauma as a tool has generally focused on acute
injurious events. Only recently has evidence emerged that trauma, in the form of
concussions, has lasting effects that often emerge years later. Perhaps the most wellknown of these is chronic traumatic encephalopathy, a neurodegenerative disease
diagnosed in numerous athletes and soldiers at autopsy. The fact that chronic traumatic
encephalopathy remains an autopsy-based diagnosis limits the ability to understand
disease pathophysiology and progression, as well as the development of potential
therapeutics.
This work highlights the pathological findings of chronic traumatic
encephalopathy and explores potential tools for improving detection prior to death,
through the use of imaging modalities and biomarkers.
This work was published in Frontiers Neurology.
Citation: Turner RC, Lucke-Wold BP, Robson MJ, Omalu BI, Petraglia AL and Bailes JE
(2013) Repetitive traumatic brain injury and development of chronic traumatic
encephalopathy: a potential role for biomarkers in diagnosis, prognosis, and treatment?
Front. Neur. 3: 186. doi: 10.3389/fneur.2012.00186.
ABSTRACT
The diagnosis of chronic traumatic encephalopathy (CTE) upon autopsy in a growing
number of athletes and soldiers alike has resulted in increased awareness, by both the
scientific/medical and lay communities, of the potential for lasting effects of repetitive
traumatic brain injury. While the scientific community has come to better understand the
clinical presentation and underlying pathophysiology of CTE, the diagnosis of CTE
remains autopsy-based, which prevents adequate monitoring and tracking of the
disease. The lack of established biomarkers or imaging modalities for diagnostic and
prognostic purposes also prevents the development and implementation of therapeutic
protocols. In this work the clinical history and pathologic findings associated with CTE
are reviewed, as well as imaging modalities that have demonstrated some promise for
future use in the diagnosis and/or tracking of CTE or repetitive brain injury. Biomarkers
under investigation are also discussed with particular attention to the timing of release
and potential utility in situations of repetitive traumatic brain injury. Further investigation
into imaging modalities and biomarker elucidation for the diagnosis of CTE is clearly
both needed and warranted.
1.11.1 INTRODUCTION
Increasing awareness by both medical professionals and the lay community concerning
the potential long-term effects of repetitive traumatic brain injury, such as CTE and
cognitive impairment 408-‐410, has led to the identification of a need for improved
diagnostic and prognostic tests. Investigators have focused primarily on the use of
various imaging modalities and development of blood- or CSF-based biomarkers. In the
following sections we attempt to briefly review findings associated with CTE diagnosis,
proposed disease pathophysiology, and how these findings may potentially relate to
imaging and/or biomarker discovery.
1.11.1.1. Epidemiology & Clinical Presentation
Exposure to repetitive mild traumatic brain injury (mTBI) is a common occurrence in
athletes on the playing field and soldiers on the battlefield. In fact, playing American
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football at higher levels results in documented exposure up to 1400 impacts per season
for select positions such as linemen with some players involved in both offense and
defense sustaining nearly 2000 impacts 411. Similarly, mTBI has been identified as the
most common combat-related injury in soldiers returning from present-day conflicts in
Iraq and Afghanistan and consequently, has been described as the “signature injury of
war” 412. The diagnosis of mTBI remains particularly challenging due to the usual lack of
abnormal findings on conventional CT and MR imaging 412. Lack of a diagnostic test for
mTBI is problematic considering the potential for both enduring cerebral effects
(cognitive, neurophysiological, and clinical) and for identification of those at risk for
development of CTE later in life.
CTE represents a progressive neurodegenerative disease currently diagnosed only upon
autopsy and subsequent neuropathological examination 413. Despite the lack of specific
diagnostic criteria required for pre-mortem clinical diagnosis, patients afflicted with CTE
diagnosed post-mortem are often described as suffering behavioral, cognitive, and
emotional changes or impairments prior to death 413-‐415. Notably, symptom development
occurs following a prolonged latency in most cases, although exceptions do exist 415,	
   416.
The tendency for a latent period creates a clear distinction between initial symptoms
associated with TBI and the persistent, long-term degeneration, much like other
neurodegenerative diseases such as Alzheimer’s disease (AD).
CTE has been diagnosed in a broad spectrum of individuals with a history of head
trauma, although the number of and severity of impacts is often unclear, ranging from
athletes playing American football, soccer, hockey, boxers, and wrestlers to soldiers who
have received battlefield injuries 	
   415,	
   417-‐426. Due to the variety of individuals afflicted by
CTE, emerging evidence indicates that CTE is likely more common than previously
thought 411,	
   417. Based on the experience of one group of investigators, a conservative
estimate of lifetime prevalence of CTE in American football players is at least 3.7% 413.
Estimates of CTE prevalence in retired professional boxers have been as high as 20%
419. Considering the number of individuals actively engaged in contact sports such as
football or exposed to explosive devices on the battlefield, it is clear that CTE represents
a clear public-health risk. Much of the early work involving CTE diagnosis focused on
concussion history but recent studies have documented a potential role of repetitive
subconcussive blows as well 417,	
  424.
1.11.1.2. Neuropathologic Findings of CTE
Gross
Gross neuropathologic examination of the brain in individuals afflicted with CTE may
produce a range of findings. The brain may appear grossly normal or may show minimal
lobar cortical atrophy for age without remote cortical contusions or lacerations 423. There
may be other non-specific gross pathologic changes like fenestrations of the septi
pellucidi, communicating ventriculomegaly, subcortical ganglionic atrophy, cerebellar
folial atrophy and pallor of the substantia nigra 414. In general, however, the CTE brain of
non-boxers is grossly normal without evidence of focal traumatic brain injury.
The frequent lack of gross neuroanatomical changes observed in CTE is in striking
contrast to dementia pugilistica, believed to represent a more severe form of chronic
traumatic encephalopathy observed in boxers 427-‐430. Dementia pugilistica, described
originally as ‘punch drunk’ by Martland 431, was characterized neuropathologically by
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Corsellis and colleagues based on a tetrad of findings: 1) abnormalities of the septum
pellucidum; 2) cerebellar and other scarring of the brain; 3) degeneration of the
substantia nigra; and 4) the presence of neurofibrillary tangles in a regional manner 429.
While some controversy exists concerning identification of CTE, the work of Corsellis
and colleagues is notable in that at no point is encephalopathy defined by the presence
of a fenestrated or cavum septum pellucidum and equally important, the complete tetrad
was not observed in a third of the cases characterized as dementia pugilistica 428.
Microscopic
Microscopic investigation of CTE has focused primarily on several factors: the presence
of tau, amyloid, and presence of TDP-43 proteinopathy as well as low grade diffuse
white matter rarefaction, microglial activation and presence of reactive astrocytes 414.
The presence of a tauopathy, whether it be in the form of neurofibrillary tangles (NFTs),
neuropil threads (NTs), or glial tangles (GTs), is a defining feature of CTE. While other
neurodegenerative diseases such as AD are also frequently defined and/or described by
the presence of tau, CTE is clearly unique based on the topographic distribution of
tauopathy 414. AD is characterized by a relatively uniform distribution of tau NFTs in
layers containing large projection neurons, such as layers III and V 414. In contrast, CTE
is exemplified by an irregular distribution of tau in more superficial cortical layers such as
II and III. Similarly, the progressive topographic involvement of regions of the brain as
seen in CTE differs from what is seen in other neurodegenerative diseases like AD.
While neuritic amyloid plaques are seen in AD, neuritic amyloid plaques are not defining
features of CTE, and are less frequently seen in CTE 414.
Another delineating factor between AD and CTE is the presence of neuritic beta amyloid
(Aβ) plaques. Found extensively throughout the brains of those afflicted with AD,
neuritic amyloid plaques are found in a minority of CTE sufferers. Diffuse and neuritic
amyloid plaques are found in less than 40-45% of individuals with CTE 414,	
   432.
Additionally, when found in CTE, amyloid plaques are more likely to be diffuse plaques
and not the typical neuritic plaques that are diagnostic of AD 414. The role Aβ plays in
CTE pathophysiology, and why it is present in some brains but not others, remains to be
elucidated.
Interestingly, amyloid precurosor protein (APP), which can undergo
cleavage to form Aβ, accumulates following axonal injury and likely plays a role in plaque
formation 414.
CTE has been recently associated, in greater than 80% of cases, with accumulation of
yet another phosphorylated protein aggregate, TDP-43 414. In some cases, TDP-43 has
been found extending into the anterior horns of the spinal cord, particularly in patients
exhibiting motor neuron disease symptoms similar to those of amyotrophic lateral
sclerosis 411,	
   414. While TDP-43 proteinopathy occurs as a primary or secondary
proteinopathy in a variety of neurodegenerative diseases, the significance of TDP-43
proteinopathy in CTE is presently not clear. The presence of another phosphorylated
protein in aggregate form may indicate a shared process resulting in neurodegeneration
following repetitive brain trauma 414. Being that TDP-43 has been suggested to mediate
the response of the neuronal cytoskeleton following injury, brain trauma and subsequent
axonal injury may trigger a TDP-43-mediated process involved in neurodegeneration 433.
The diversity of pathological findings associated with CTE, as represented by the varied
findings presented above, has begun to be described with four distinct phenotypes
emerging (Table 1.4) 426. The significance of these phenotypes with regards to clinical
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correlate remains to be elucidated but it is becoming increasingly clear that CTE
represents a diverse spectrum of disease, a finding consistent with the heterogeneous
nature of injury history, genetic predisposition, and a variety of other factors.
1.11.1.3. CTE Pathogenesis & Pathophysiology
The pathogenesis and pathophysiology of CTE remain unclear, as with many
neurodegenerative diseases, but is believed to be a multifactorial process initiated by
brain trauma. The development of CTE begins with sub-concussive or concussive injury.
The damage is progressive and often accelerated by the number of brain injuries that
occur in an individual. Initially, mTBI causes diffuse axonal injury (DAI), which results in
disruption of axonal transport and subsequent axonal swelling. The swelling causes a
disconnection of the axons and later Wallerian degeneration 434. This degenerative
process, a portion of which is referred to in the literature as immunoexcitotoxicity, may
lead to the development of CTE 432. It is interesting to note that the abnormal tau and
amyloid accumulations, which are seen in CTE are peptide derivatives of both
membrane and cytoskeletal proteins, which are involved in traumatic axonal injury
following concussive and subconcussive injury. This process is still relatively poorly
understood clinically with post-mortem studies on young adults revealing that repetitive
head injury is associated with the formation of NFTs and tau-based pathology
surrounding vascular elements within the cortex 435. Consequently, it is perhaps likely
that microvascular damage plays a role in formation of the classical neuropathology
associated with CTE. This is consistent with findings from classical literature exploring
dementia pugilistica in which a large percentage of ex-boxers experienced perivascular
hemorrhages with evidence of meningeal and/or subpial siderosis 427. In addition to
repetitive brain injury, there may be other identified factors that may contribute to or alter
disease development, such as presence of certain genotypes 424. Notably, anabolic
steroid use had been previously suggested as a potential contributing factor to CTE
development but the use of exogenous anabolic steroids has been shown
experimentally to not worsen mTBI 436.
While the precise pathway or mechanism via which repetitive brain trauma predisposes
to CTE development is poorly elucidated, Blaylock and Maroon posit a logical process
via which immunoexcitotoxicity mediates the transition 432. As part of this process,
microglia are primed by initial impacts and with sustained trauma as well as aging,
undergo phenotypic conversion from a non-destructive to destructive mode 413,	
   432. Once
phenotype switching occurs, this pro-inflammatory state can be maintained for prolonged
periods, consistent with neurodegenerative processes and emergence of
hyperphosphorylated tau. Similarly, mild injury has been demonstrated to damage
axons due to degenerative processes, resulting in a progressive deterioration, rather
than rapidly occurring axonal shearing. This furthers the notion of CTE as a chronic
neurodegenerative process, clearly distinct from the immediate sequelae often
associated with TBI 432.
1.11.2. IMAGING MODALITIES FOR REPETITIVE BRAIN INJURY & CHRONIC
TRAUMATIC ENCEPHALOPATHY (CTE)
A major concern for clinicians and researchers is how to detect small but important brain
changes prior to the development of CTE symptoms so that preventative measures can
be taken or treatments implemented, once available 413,	
   417. The obvious short term
deficits seen in concussive injuries such as loss of consciousness, post-traumatic
amnesia, and altered mental status have been historically hard to quantify using
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traditional imaging modalities such as computed tomography (CT) and magnetic
resonance imaging (MRI) 437,	
   438. The difficulties and shortcomings of more commonly
utilized imaging techniques have led researchers and clinicians to define concussion as
a biomechanically induced brain injury with no gross anatomic lesions 439. Despite the
lack of gross lesions, it is still necessary to look at diffuse and microscopic alterations in
the brain. Until recently, imaging techniques were not sophisticated enough to detect the
subtle changes that are the hallmark of DAI. Clinicians have previously been forced to
rely on post-mortem tissue analysis to discover mechanisms of CTE pathology 419. With
the invention and application of new imaging modalities, it is now possible to identify and
investigate more of the pathological changes that are a consequence of mTBI. The
following sections will highlight several of the new imaging modalities that are being
used successfully to study various phenomena associated with mTBI and also promising
modalities for further investigation of CTE. These modalities and potential strengths, as
well as challenges, associated with each are summarized in Table 1.5.
1.11.2.1. Diffusion Tensor Imaging (DTI)
Diffusion tensor imaging (DTI) represents one of the more thoroughly investigated
techniques for detecting axonal injury clinically 412,	
   440-‐442 and has even been shown to
correlate with long-term outcome in preclinical rodents models of TBI 443. Perhaps most
notably, preliminary studies in retired professional athletes subjected to repeat head
trauma demonstrate a correlation between history of concussion and DTI measures,
particularly in the callosal white matter 416. How DTI-based findings are altered with age
and whether these findings correlate with neurodegenerative and behavioral changes
associated with CTE remains to be seen 444. Regardless, DTI appears to be a promising
technique for detecting and tracking structural correlates of repetitive brain injury,
including those believed to be specific to CTE.
1.11.2.2. Functional Magnetic Resonance Imaging (fMRI)
Functional magnetic resonance imaging (fMRI) is unique amongst the various imaging
modalities discussed within this work due to the ability to provide insight into functional
alterations, particularly working memory, and anatomic or structural changes
simultaneously. The capability to measure brain-behavior relationships has proved
useful in other neurodegenerative diseases and appears promising for further
investigation of CTE-related changes 416. Based on blood oxygen level dependent
(BOLD) signal, fMRI is advantageous in that serial scans can be administered without
exposure to harmful ionizing radiation 445. This is particularly useful for fMRI-based
studies as baseline measurements are required for comparison due to inter-individual
variability 446. Following exposure to head trauma, deficits on fMRI are apparent in both
concussive and subconcussive injury groups with concussive injury producing a more
severe deficit 447,	
   448. Importantly, studies utilizing both fMRI and ImPACT for
neuropsychological testing have revealed deficits in working memory, even in the group
sustaining only subconcussive impacts, and these deficits appear to be related to the
number of impacts rather than the magnitude of any one impact 449. Furthermore, in a
preclinical model of TBI, fMRI response was diminished acutely and correlated with
functional deficits based on the forepaw placement test 450. The use of fMRI for
assessing the more subtle deficits produced by repetitive subconcussive impacts
warrants further investigation, and in particular, longitudinal studies investigating the
persistence of deficits on fMRI and the likelihood of further development for detecting,
diagnosing and tracking CTE.
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1.11.2.3. Magnetic Resonance Spectroscopy (MRS)
Magnetic resonance spectroscopy (MRS) is a noninvasive method that measures brain
chemistry associated with DAI and neuronal injury 412,	
   416. It is sensitive for changes
occurring with age, mTBI, and mild cognitive impairment (MCI) 451. As an imaging
modality, 1H MRS is used to detect changes in N-acetylaspartate (NAA), myoinositol
(mI), choline, lactate, and adenosine triphosphate (ATP) production in specific ROI. Nacetylaspartate is a neuronal marker and is reported as a NAA:creatinine ratio. Other
markers that may prove useful in neural injury include myoinositol, a glial marker,
choline-based compounds, indicative of membrane integrity, and lactate, an indirect
marker for ischemia 452. The metabolite levels in an injured brain are compared to levels
in a healthy brain for analysis 453. A decrease in NAA and ATP is indicative of reversible
neuronal and mitochondrial dysfunction 454. An elevation of the NAA:creatinine ratio
indicates persistent damage following mTBI 439, H2O is often measured as an internal
control in the patient during imaging 444. By monitoring the metabolites and H2O, the
progress of a patient can be tracked longitudinally 455. It is even possible to detect
changes in the brain prior to onset of symptoms such as in subconcussive injuries 456.
Furthermore, metabolite levels remain altered long after symptoms subside, which gives
credence to the idea of long-term degeneration occurring and presence of a latent period
457. As MRS utilizes current clinical MR scanners and does not administer ionizing
radiation to the patient, MRS may represent an ideal imaging modality for long-term
studies requiring repeated measurements. Furthermore, a preliminary study conducted
by Lin and colleagues demonstrated persistent changes in Cho and Glx in 5 professional
athletes, aged 31-54 years. Specifically, both Cho and Glx were significantly increased
as compared to controls 416,	
   458,	
   459. Additionally, studies have demonstrated changes in
mI consistent with MCI literature that correlate with NFT count in AD brains upon
pathological examination 444. Consequently, understanding the effect of repetitive brain
injuries on mI levels over time may be of interest for future investigation due to the
strong correlation with episodic memory deficits observed in formerly concussed athletes
444. Based on this evidence, MRS appears promising for not only elucidation of CTE
pathophysiology but also tracking the effects of repetitive brain trauma longitudinally. In
this manner, MRS may also be useful for the diagnosis of CTE in effected individuals.
1.11.2.4. Positron Emission Tomography (PET)
Positron emission tomography (PET) can be used to detect metabolic rates in a variety
of tissues of interest, including the brain 460. While PET has traditionally been used in
cases of more severe injury, recent evidence indicates a potential role in mTBI 461. In
boxers, hypometabolism was observed in regions likely affected by impacts to the side
of the head such as the portion of the frontal lobe anterior to Broca’s area 462. Similarly,
hypometabolism was observed in the posterior cingulate cortex and posterior parietal
lobes 462. In other patients afflicted with TBI, hypometabolism may be seen commonly in
the anterior temoporal lobe and orbitofrontal lobe due to rapid acceleration-deceleration
mechanisms 462. Other promising developments in PET imaging include the
development of ligands specific for disease states such as AD. For example, Pittsburgh
compound B selectively binds beta-amyloid whereas others under development nonselectively bind both beta amyloid and tau 416. While beta amyloid is not diagnostic for
CTE, this technology appears potentially promising for the imaging of CTE should tauspecific compounds be identified. Furthermore, recent studies using F18 DDNP glucose-
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Table 1.4. The diversity of pathological findings in CTE has led to the emergence of four distinct phenotypes.

PET, conducted by Dr.
Gary Small at UCLA,
show promise for
identifying tau protein
deposition in the form of
NFT’s in subjects with
potential CTE 463. F18
DDNP glucose-PET
allows for labeling of
both plaques and
tangles, as has been
shown in cases of mild
cognitive impairment as
well as AD, making this
technique exceptionally
promising in identifying
characteristic
pathological features of
CTE as they develop
This
pre-mortem 464.
effort is significant in
that it could potentially
allow, for the first-time
ever, the diagnosis of
CTE pre-mortem.
Similarly, identification
of NFT’s following brain
injury would provide
substantial insight into
the
timing
of
development and
pathophysiology of
CTE.
1.11.2.5. Single Photon
Emission Computer
Tomography (SPECT)
Single photon emission
computer tomography
(SPECT), similar to
PET in the use of
radionuclides, can be
used for measurement
of cerebral perfusion
and has been shown to
detect abnormalities in
41% of amateur boxers
in comparison to 14% of
controls. Furthermore,
abnormalities were
generally singular in the
control group yet
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multiple in the group of boxers subjected to repetitive brain trauma 465. While SPECT
has not been utilized in studies of CTE, CTE is associated with amyloid protein
deposition in a significant number of cases and amyloid is notably largely perivascular in
deposition, particularly in regions of abnormal vasculature, which could account for
abnormal findings on SPECT 465. It has also been correlated with functional deficits
revealed on neuropsychological testing (NPT).
Specifically, NPT strongly predicts
diminished perfusion on SPECT but the inverse is not true 458. The reasons for this
mismatch are currently unknown but may be due to SPECT being obtained at a resting
state while NPT requires neural activity and processing 458. In spite of this lack of
correlation and lack of specificity when considering other disease conditions, SPECT
has clear value in recovery prognostication based on previously reported findings 458.
1.11.2.6. Susceptibility Weighted Imaging (SWI)
Susceptibility weighted imaging is used to detect microhemorrhages, the intact structure
of the venous system, and oxygen saturation following neurotrauma 466 .
Microhemorrhages, venous thrombosis, and ischemia are common secondary injuries
following mTBI 467. Furthermore, the extent of blood brain barrier (BBB) disruption and
perivascular tau deposition can be mapped with SWI 417. Tau accumulates in the brain
during the progression of CTE 411. The imaging technique works by taking phase data
from a T2* weighted MRI and creating a second mapped image. This image allows both
blood oxygen levels and the amount of deoxyhemoglobin to be measured 468. It also
localizes concentrations of paramagnetic iron and detects areas of iron translocation 469.
Iron deposition may play a role in CTE symptom manifestation 470. The images produced
with SWI are highly functional, velocity-compensated, and gradient echoed 471. When
used with DTI, SWI can accurately show which areas of white matter are damaged by
microhemorrhages 472. This modality offers a unique tool to detect areas of injury early,
and provides clinicians with information on how to manage the care of the patient,
particularly in children in which SWI has been shown to predict future outcomes
following injury 416,	
   473. Unfortunately, the predictive ability is more limited in adults at
present but necessitates further study 416.
1.11.2.7. Electroencephalography (EEG)
Electroencephalography has been used to demonstrate mental processing impairment in
12 professional concussed boxers based on increased P300 latency and lessened
amplitude. P300 has been identified as a cognitive event-related potential (ERP) with a
novel amplitude and latency, making it a potentially suitable measure of brain processing
ability. Similarly, investigators have demonstrated altered components of P300, such as
P3a/P3b, decades after concussion in older athletes with a history of past concussion
compared to controls 416,	
   433. Based on these findings, EEG may have utility in assessing
long-term cognitive effects associated with concussion and therefore, may be useful in
identifying those predisposed to CTE development.
1.11.2.8. Future Directions
Advances in imaging technology and improved access provide nearly limitless
opportunities for both understanding the pathophysiology and diagnosis of CTE premortem. As such, it may be possible to initiate both treatments and preventive
measures prior to emergence of CTE. Many challenges remain such as clarifying the
role of subconcussive injury in CTE development and how to most readily identify
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Table 1.5. Numerous imaging modalities may provide insight into the development or tracking of
CTE.
suspected
subconcussive injuries on the athletic or battlefield. By utilizing techniques such as MRS
and fMRI, pathology can be correlated with functional deficits and hopefully lead to more
appropriate identification and monitoring of those with suspected injuries, regardless of
severity. Other challenges such as the need for baseline measurements remain to be
overcome as well but clearly warrant additional investigation.
1.11.3. BIOMARKERS FOR CTE: A NEW FRONTIER
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As discussed in previous sections modern imaging techniques are one way by which
diagnosing and tracking the progression of CTE may be feasible in the near future.
Unfortunately, access and economic issues associated with imaging techniques may
somewhat limit their ultimate usefulness in the diagnosis of CTE, especially during the
acute phases of injury. With CTE potentially being a large public health issue, a simple
and cost effective manner to diagnose and possibly track progression of the disease is
crucial 417.
Biomarkers represent one method by which CTE may one day be diagnosed.
Additionally, it may be possible to track disease severity and progression through the
use of a biomarker(s). Ideally, a potential biomarker for CTE would be minimally
invasive, have diagnostic potential and would correlate to disease severity, allowing care
providers to track progression of the disease. It should be sensitive enough to detect the
disease and when used in conjunction with clinical evidence of CTE symptoms and a
past history of repeated head injuries, allow for a diagnosis. As described above, there is
currently no accepted method of diagnosing CTE until post-mortem pathological analysis
has been conducted 417. A readily available biomarker with the aforementioned traits
would give practitioners a useful tool for the diagnosis and tracking of patients suffering
from CTE.
Currently there is a paucity of studies aimed at determining a biomarker(s) specifically
for CTE. Many studies aimed at elucidating biomarkers for traumatic brain injury and
other types of neurotrauma have been conducted. One difficult aspect of searching for a
CTE biomarker is that CTE symptomology can be similar to a variety of other neurologic
disorders. This may add a layer of complexity to conducting human clinical studies in an
attempt to discover suitable biomarkers. The neuropathology of CTE, however, is not
distinctly different, as hyperphosphorylated tau and TDP-43 deposition are found in a
variety of neurodegenerative diseases outside CTE 413,	
   417,	
   474. Additionally, recent
reports indicate that CTE may be associated with symptomology similar to ALS, further
complicating the likelihood of clinical diagnosis without improved diagnostic tests 474.
These reports emphasize the need for a biomarker with high specificity that can
delineate CTE from other neurologic disorders.
There are two primary body fluids where readily attainable biomarkers of CTE may be
located. These include the cerebral spinal fluid (CSF) and the blood. Blood or plasma
samples have the distinct advantage of being minimally invasive and easy to obtain.
Cerebrospinal fluid samples, however, are in more direct contact with the CNS and may
confer an advantage in this regard to the determination of suitable biomarkers for CTE.
Routine use of CSF in the diagnosis or tracking of CTE presents several obvious
problems associated with obtaining CSF samples. Therefore, ideally a biomarker aimed
at detecting CTE in the periphery would be found in serum or plasma samples obtained
via venipuncture. As discussed above, currently there is a lack of primary studies aimed
at the elucidation of biomarkers in either one of these body fluids for CTE. However,
several studies have been conducted in the realm of TBI and mTBI and these will be
discussed herein.
It may be possible that biomarkers in development for TBI may be useful during the
acute injury phase of patients at risk for CTE.
The repeated concussive and
subconcussive blows that result in CTE may alter levels of particular biomarkers studied
for TBI immediately following these events. The tracking of these acute changes,
although not specific to CTE, may give healthcare professionals insight into those
patients at the greatest risk for developing CTE later in life. Equally important though, is
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the potential utility for biomarker surveillance in patients with known or suspected postconcussion syndrome.
Many studies have been conducted aimed at determining a biomarker for TBI or mTBI in
the plasma or serum. A study conducted by Mondello et al. has determined that glial
neuronal ratio (GNR), characterized as the ratio between GFAP and ubiquitin carboxyterminal hydrolase-L1 (UCH-L1) in the serum of TBI patients is characteristic of the type
of TBI injury, focal vs. diffuse 475. It was noted by Mondello et al. that their studies may
have implications for diagnosis in TBI patients in the early acute phases of injury,
however whether these results would have implications for CTE patients has yet to be
determined 475. It is possible that after multiple concussive or subconcussive blows to
the head that the GNR may be altered and may offer insight into the extent of injury and
potential for later development of CTE.
Several other studies aimed at elucidating valuable biomarkers for TBI in the serum
have been conducted and may offer insight into the production of a biomarker(s) specific
to CTE. It has been reported that plasma bilirubin levels in TBI patients are elevated on
days subsequent to injury 476. Unfortunately, this study only determined bilirubin levels
up to 4 days post-injury. The determination as to whether the increases in plasma
bilirubin remain elevated for a significant amount of time post-injury or whether it is
specific to the acute injury phase has yet to be made. Additionally, the determination as
to whether bilirubin concentrations in the plasma would be elevated in patients at risk for
CTE has also yet to be made.
Another intriguing potential serum biomarker for CTE may be the protein neuron-specific
enolase. Zetterberg et al. have shown that this protein is increased in the serum of
boxers as compared to healthy controls after the boxers abstained from boxing for a
period of 2 months 477. Interestingly, elevated levels of neuron-specific enolase were
detected two months after a nonparticipatory period of boxing, however other biomarker
candidates for CTE such as S-100B, BDNF and heart-type fatty acid binding protein
were found to be unchanged 477. These results indicate that neuron-specific enolase
may be one protein biomarker that has the potential for use as a diagnostic tool. It is
possible that neuron-specific enolase remains elevated for an extended time period after
injury and may be a useful tool for diagnostic purposes in athletes and patients who
have suffered multiple concussive and subconcussive blows to the head.
An area of biomarker research that has received much attention is the field of microRNA.
It is possible that potential biomarkers for CTE may not only be protein-based in nature.
A recent report by Balakathiresan et al. has shown that levels of microRNA let-7i are
elevated post-blast-induced TBI in both the CSF and the serum of rats exposed to a
model of this type of TBI 478. Additionally, this group showed that the expression of 5
microRNA’s were altered post-blast TBI in the serum of these animals 478. These
included let-7i, miR-122, miR-200b, miR-340-5p and miR-874 478. Further study is
needed in both animal models, as well as humans, to validate the potential for using
microRNA’s as potential biomarkers for TBI and possibly CTE. Although this study was
conducted using a blast-TBI animal model, a recent report has shown that this model
produces pathology similar to that seen in CTE and models similar to this may be viable
animal models for the study of CTE 418. The production of validated animal models could
greatly aid in the discovery of biomarkers aimed at detecting CTE and the production of
potential clinical therapies for treating CTE. Other studies have also successfully
identified RNA-based biomarkers for mTBI based on both micro- and snoRNA in
peripheral blood mononuclear cells (PBMCs). Using a panel of 3 markers, veterans that
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experienced mTBI were detected with 89% accuracy, 82% selectivity, and 78%
specificity 479. Future studies utilizing both animal models as well as clinical samples
may reveal additional RNA-based molecules that may be viable biomarkers for detecting
and possibly tracking CTE.
One particularly interesting report recently published, studied a variety of biomarkers
aimed at detecting TBI and mTBI in Olympic boxers with an extended history of many
bouts 480. This study determined extent of increases in neurofilament light protein (NFL),
total tau (T-tau), tau phosphorylated at threonine 181 (P-tau181), heart-type fatty acid
binding protein (H-FABP), glial fibrillary acidic protein (GFAP), S-100B, and the 42 amino
acid form of amyloid β (Aβ1-42) in olympic boxers both in the acute phase after a bout
and an extended phase of two weeks post-bout and compared them to non-boxing
controls. It was found that both NFL and GFAP levels within the CSF were significantly
different from controls in both the acute and extended phase of testing 480. The
determination as to whether either of these correlated to injury severity was unable to be
conclusively made in this study 480.
However, a previous study has shown that there may be a potential correlation between
NFL levels in the CSF and injury severity 477. Zetterberg et al. showed that NFL, T-tau
and GFAP were increased in the CSF of boxers and the levels appear to be correlated to
injury severity, as boxers who received more hits in number or severity had increased
levels of these markers 477. Only NFL in these studies however, was increased for an
extended time period (tested at 3 months) as compared to controls 477. The extended
increase in NFL levels within the CSF post-injury may make it a viable candidate for a
biomarker for mTBI and CTE however whether levels of NFL within the CSF correlate to
later disease severity in the case of CTE or mTBI has yet to be conclusively made. NFL
levels however, have been shown to be altered in other types of neurologic trauma and
disorders so this may ultimately decrease its viability as a tool for detecting, diagnosing
and tracking CTE disease progression 481,	
  482.
Although levels of proteins such as NFL and tau may not be specific with regards to
CTE, a battery of various biomarker proteins combined with patient history and imaging
studies [discussed in previous sections] may result in the ability to make a pre-mortem
diagnosis of CTE via a reference fractional laboratory index using a high throughput
analytical system. In this respect, a combined battery of proteins such as tau, GFAP,
NFL, S100-B and bilirubin may offer more accurate quantitative data with regards to a
patients risk for developing CTE and when combined with other modalities of relevant
clinical data, may be used as even more accurate diagnostic indicators at some point in
the future.
1.11.4. LINKING PATHOPHYSIOLOGY TO IMAGING & BIOMARKER DISCOVERY
Perhaps the greatest challenge concerning development of biomarkers or imaging
modalities for prevention, diagnosis, and prognosis of CTE is the current lack of wellelucidated disease pathophysiology. Consequently, few clearly identifiable and specific
disease markers have been identified. Without first understanding disease development
more clearly, likely via both clinical research and utilization of animal models of repetitive
brain trauma, logical discovery of CTE-associated markers appears unlikely. Recent
work has demonstrated the presence of CTE-like neuropathology in wild-type mice
following single-blast exposure and increased formation of neurofibrillary tangles in a
transgenic mouse model following repetitive injury 418,	
   483. In a single-injury experiment,
again using transgenic mice utilized in Alzheimer’s disease models, tau and amyloid-β
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accumulation was accelerated 484. Similarly, studies have shown the presence of
phosphorylated tau and amyloid-β months after initial fluid percussion injury in the
genetically unmodified rat 485.
Despite the present lack of clear elucidation of disease pathophysiology, certain imaging
techniques such as MRS, fMRI, and tau-specific labeling compounds in PET, have
begun and will likely continue to provide insight into CTE development via longitudinal
changes in neurologic function and health via a variety of markers. Similarly, work in
other disease conditions that allows for imaging of activated microglia, consistent with
the notion of immunoexcitotoxicity, may provide further insight into disease development
and progression 461.
In addition to assisting in the diagnosis and prognosis of patients suffering from CTE,
continued improvements in imaging and biochemical assays associated with CTE
identification may promote risk factor identification and provide insight into periods of
increased risk. For example, the role of age at time of impact and associated brain
trauma in disease development is unclear. Understanding this issue warrants further
investigation as neuropathologic changes associated with CTE have been found in an
asymptomatic 18-year old high school football player and consequently, age at time of
first head injury may contribute to CTE incidence 413.
1.11.5. CONCLUSION
CTE is an emerging public-health concern due to disease prevalence likely higher than
previously recognized and continued popularity of contact sports as well as involvement
in military combat that places soldiers at risk for explosive blasts and subsequent TBI.
As CTE represents a devastating deterioration of neurologic function, a clear need for
improved diagnostic and prognostic tests exists. To accommodate this need, as well as
more clearly elucidate disease pathophysiology, imaging and/or biomarker-based tests
are required. We propose a potential work-flow for implementation of both imaging and
biomarker-based studies for improving the understanding of the role concussive and
subconcussive impacts play in long-term disease development (Figure 1.20). While the
specifics remain open to interpretation, obtaining pre-injury exposure studies as well as
after a suspected or confirmed injury parameters is likely to provide further insight into
the effects of TBI. It is only by more accurately identifying CTE pre-mortem and studying
disease progression and mechanisms that we can establish improved therapeutic
approaches.
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Figure 1.20. Imaging and biomarker studies may be useful in improving understanding
of the role of repetitive concussive and subconcussive injury in disease development.
Two experimental paradigms are presented representing a potentially more ideal, but
costly, scenario (A) and more cost-conscious approach (B).
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Chapter Two
The role of protein kinase C modulation in neural injury outcome is not well elucidated
but work completed by Sun and colleagues using a global model of ischemia, akin to
cardiac failure, has indicated the potential benefit of protein kinase C modulation via
bryostatin-1 administration. This chapter seeks to investigate this potential protective
effect in a clinically relevant thromboembolic model of ischemic stroke utilizing aged
animals and tissue plasminogen activator for reperfusion.
Characterization of
bryostatin-1-mediated effects on outcome was pursued through the use of both
histological measures (infarct volume, edema, and atrophy) as well as functional
assessments (mNSS) as outlined by the Stroke Therapy Academic Industry Roundtable
(STAIR). Insight into the mechanism of bryostatin-1 was obtained through assessment
of protein kinase C expression, specifically α and ε isozymes, post-stroke in both
neurons, astrocytes, and also endothelial cells.
Bryostatin-1 Improves Outcome in a Clinically Relevant Model of Ischemic Stroke
via Protein Kinase C Activation
Zhenjun Tan, Ryan C. Turner, Rachel L. Leon, Xinlan Li, Jarin Hongpaisan, Wen Zheng,
Aric F. Logsdon, Zachary J. Naser, Daniel L. Alkon, Charles L. Rosen, Jason D. Huber
This work is currently under revision for publication in Stroke.
ABSTRACT
Background and Purpose. Bryostatin-1, a potent protein kinase C (PKC) activator, has
demonstrated therapeutic efficacy in preclinical models of associative memory,
Alzheimer’s disease, global ischemia, and traumatic brain injury. In this study, we tested
the hypothesis that administration of bryostatin-1 provides a therapeutic benefit in
reducing brain injury and improving stroke outcome using a clinically relevant model of
cerebral ischemia with tissue plasminogen activator (tPA) reperfusion in aged rats.
Methods. Focal cerebral ischemia was produced by reversible occlusion of the right
middle cerebral artery (MCAO) in 18-20 month old female Sprague-Dawley rats using an
autologous blood clot with tPA-mediated reperfusion. Bryostatin-1 was administered at 6
h after MCAO then at 3, 6, 9, 12, 15, and 18 d after MCAO. Functional and assessment
was conducted at 1, 7, 14, and 21 d after MCAO and histological assessment was
performed at 21 d post-MCAO.
Results.
Bryostatin-1 treated rats showed improved survival following MCAO,
especially during the first 4 d. Repeated administration of bryostatin-1 following MCAO
resulted in reduced infarct volume, atrophy formation, and improved neurological
function at 21 d after MCAO. Changes in PKC alpha expression and PKC epsilon
expression in neurons were noted in bryostatin-1 treated rats at 24 h following MCAO.
Conclusions. Repeated bryostatin-1 administration following MCAO protected the brain
from severe neurological injury following MCAO. Bryostatin-1 treatment improved
survival rate, reduced infarct volume, salvaged tissue in infarcted hemisphere by
reducing necrosis and peri-infarct astrogliosis, and improved functional outcome
following MCAO.
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2.1. INTRODUCTION
There is an urgent clinical need for improved treatment of acute ischemic stroke. Despite
impressive gains in our knowledge of the mechanisms underlying ischemic brain injury,
there has been a failure in translating these promising preclinical findings into
therapeutics that improve stroke outcome. Thrombolytic treatment with recombinant
tissue plasminogen activator (tPA) remains the only FDA approved drug for treatment of
focal ischemic stroke. However, less than 2% of people suffering an ischemic stroke
receive tPA due to increased risk of secondary cerebral hemorrhage and edema
formation 486. Based on the aging population and increased stroke burden, an unmet
need exists to develop alternative approaches to treat acute ischemic stroke, either
independently of tPA or in an effort to increase the number of patients eligible for tPA.
Preclinical studies of proposed therapeutics for ischemic stroke have largely failed to
consider the greatest risk factor for stroke, age 9. Previous studies suggest that aged
rats represent a more clinically relevant model of ischemic stroke in comparison to the
younger animals typically used, a difference characterized by an altered inflammatory
response following brain injury 84,	
   487. These studies illustrate an increased severity of
ischemic injury and altered neural injury progression 30,	
   51,	
   84,	
  487. Therefore, inclusion of
aged animals may increase clinical relevance and the likelihood of bench-to-bedside
therapeutic translation.
Protein kinase C (PKC) is critical for storage of associative memory and related
synaptogenesis in normal animals 394; reducing accumulation of A Beta, synaptic loss,
cognitive deficits, and neurodegeneration in preclinical models of Alzheimer’s disease
358,	
   488; and protection against ischemic pathology 364,	
   365 and traumatic brain injury in
rodents 349. PKC isozymes alpha (α) and epsilon (ε) regulate synaptogenic and antiapoptotic signaling pathways 489, as well as critical functional pathways in the
multicellular response to ischemia-reperfusion injury 321. Individual PKC isozymes play
differing, and sometimes opposing, roles in injury response that often depend on cell
types and degree of pathophysiology 362,	
   490. Observations that PKC activation mediates
both protective and harmful messages results from different PKC isoforms being
activated by different signals that play concentration- and time- dependent roles in the
development of neuronal damage and regeneration 375,	
  394.
Bryostatin-1, an ultrapotent PKC activator may provide substantial benefit in the
treatment of focal ischemic stroke. Studied extensively as an anti-tumorogenic agent,
recent studies demonstrated that administration of bryostatin-1 following ischemic insult
resulted in curative neurogenesis, synaptogenesis, and cognitive enhancement 362. The
purpose of our current study was to investigate the pharmacological potential of
repeated administration of bryostatin-1 to improve outcome following focal ischemic
stroke in aged rats using a clinically relevant experimental stroke model.
2.2. MATERIALS AND METHODS
2.2.1. Animals and Treatment Protocol
Forty-eight female Sprague-Dawley rats (18-20 months old) were purchased from Harlan
Laboratories (Indianapolis, IN) and housed under 12-h:12-h light-dark conditions with
food and water ad libitum. All work involving rats was approved by the West Virginia
University Animal Care and Use Committee. Rats were randomly divided into two
treatment groups (N=38). Group 1 (N=19) underwent a 2 h MCAO with tPA-mediated (5
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mg/kg; i.v.) reperfusion as previously described 9,	
   10, and at 6 h was administered
bryostatin-1 (15 mg/m2; i.v.) with subsequent doses every 3 d for a total of 7 doses over
21 d. Group 2 (N=19) served as the control group and underwent the same procedures
except was administered 0.9% saline instead of bryostatin-1. A second set of rats
(N=10; 6 saline and 4 bryostatin-1 treated rats) underwent MCAO with bryostatin-1/
saline treatment at 6 h and were then euthanized at 24 h to visualize changes in PKC
isozyme (α and ε) expression in neurons, endothelial cells, and astrocytes. Ischemia
and reperfusion were defined as a minimum of 80% decrease in cerebral blood flow at
onset of ischemia and return to 80% of baseline blood flow measurement, respectively.
Rats not achieving these standards were excluded from the study 9,	
   10. Chemicals and
antibodies were acquired from specified manufacturers (Supplemental Methods; please
see http://stroke.ahajournals.org).
2.2.2. Neurological Functional Assessment
The modified Neurological Severity Scores (mNSS) was used to assess neurological
function at 1, 7, 14, and 21 d after MCAO. The mNSS is a composite score of motor,
sensory, balance and reflex measures ranging from scores of 1 to 17, with higher scores
indicating greater neurological injury 493.
2.2.3. TUNEL Staining, Immunohistochemistry, and Infarct Volume Measurement
To identify cells undergoing DNA fragmentation, TUNEL staining was performed
according to manufacturer’s instructions (Roche Applied Science). After mounting and
nuclear staining with 4',6-diamidino-2-phenylindole (DAPI), slices were visualized for
apoptotic tissue using a Zeiss LSM 510 confocal microscope.
Using alternating slices from the same brain (Supplemental Methods; please see http://
stroke.ahajournals.org), immunohistochemistry using a modified ABC procedure
(Benkovic et al., 2004) was performed with anti-GFAP (1:1000) for evaluation of
astrocyte morphology (n=7 saline and 10 bryostatin-1 treated rats). Infarction volumes
were determined using standard protocols for hematoxylin and eosin (H&E) staining as
well as cresyl violet staining. Degree of cerebral atrophy at 21 d following MCAO was
calculated from H & E stained tissue using the formula: cerebral atrophy = (LV-RV)/
LVx100%, where LV was volume of left hemisphere (mm3) and RV was volume of right
hemisphere (mm3).
Tri-labeled confocal microscopy was performed to determine immunolocalization of
αPKC (1:100) and εPKC (1:100) with neurons (1:150), endothelial cells (1:100), and
astrocytes (1:100) at 24 h following MCAO (n=4 rats per treatment). Nuclear staining
was performed on sections using DAPI and secondary antibodies were incubated at
1:200 dilution.
Expression levels of DNA damage (TUNEL), αPKC, and εPKC were evaluated based on
immunofluorescence intensity. Confocal images were quantified using ImageJ as
previously described 358.
2.2.4. Statistical Analysis
All data were compiled and analyzed by an investigator blinded to treatment and
presented as mean ± SEM. Physiologic parameters, functional data, and
immunofluorescence intensity were compared by Student’s t-test grouped by treatment
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(saline vs bryostatin-1). Mortality data were compared using Fisher’s exact test (2X2
contingency table). P<0.05 was considered statistically significant.
RESULTS
2.3.1. Administration of Bryostatin-1 Following MCAO in Aged Rats Improved Survival
Rate & Neurological Function
A total of 48 rats were used in this study. Thirty-eight rats were used to evaluate the
effects of bryostatin-1 administration on ischemic brain injury over 21 d following MCAO.
Two rats from this cohort, both saline-treated, were excluded from further study for not
meeting ischemia/reperfusion criteria. Survival rates were documented daily from 1 to 21
d (Figure 2.1A). Administration of bryostatin-1 following MCAO improved survival rates
through 21 d (N=36; 17 saline and 19 bryostatin-1 treated rats) with positive effects most
evident during the first 4 d following MCAO and a significant increase in survival
achieved from 2 to 17 d after MCAO. Although survival decreased in bryostatin-1 treated
rats after day 4, improved survival was demonstrated at 7 d (68% bryostatin-1, n=13,
versus 41% saline, n=7, treated rats), 14 d (59% bryostatin-1, n=11, versus 41% saline,
n=7, treated rats), and 21 d (53% bryostatin-1, n=10, versus 41% saline, n=7, treated
rats) after MCAO.
Neurological functional assessment revealed significant improvement in mNSS scores at
21 d post-MCAO in bryostatin-1 treated rats (2.6 ± 0.3; n=10) compared to saline-treated
rats (3.7 ± 0.2; n=7) (Figure 2.1B). No difference (p>0.05) in mNSS scores was observed
at 1 d (n=15 saline and 18 bryostatin-1 treated rats), 7 d (n=7 saline and 13 bryostatin-1
treated rats), and 14 d (n=7 saline and 11 bryostatin-1 treated rats) following MCAO.
2.3.2. Bryostatin-1 Results in Diminished Infarct Volume Post-MCAO
Quantification of infarction volume for cortex, striatum and total cerebral hemisphere
using H&E-stained and cresyl violet-stained coronal sections was measured at 21 d with
bryostatin-1 administration (n=10) resulting in a significant (p<0.05) decrease in infarct
volume in cortex (6 ± 2%), striatum (19 ± 3%), and total hemisphere (10 ± 2%) as
compared to saline-treated (n=7) rats, which showed infarct volumes in cortex (18 ± 5%),
striatum (31 ± 2%), and total (23 ± 3%) (Figure 2.2A). Measurements of cortical atrophy
revealed a significant (p<0.05) decrease in the infarcted hemisphere in bryostatin-1
treated rats (5 ± 1%; n=10) compared to saline-treated rats (14 ± 2%; n=7) (Figure
2.2B). Figure 2.2 C &D shows representative photomicrographs of the infarcted
hemisphere in saline control (n=7) and bryostatin-1 (n=10) treated aged rats at 21 d
following MCAO. The infarcted hemisphere from saline-treated rats exhibited profound
atrophy marked by necrosis and vacuolation. The peri-infact area showed intense
astrogliosis throughout the hemisphere. The infarcted hemisphere of bryostatin-1 treated
rats showed a smaller brain injury with astrogliosis confined to the MCA region.
2.3.3.
Administration of Bryostatin-1 Reduces Cellular Apoptosis and Decreases
Astrogliosis in Aged Rats at 21 Days Following MCAO
At 21 d after MCAO, a significant reduction (p<0.01) in TUNEL-positive cells,
representing those undergoing apoptosis due to DNA fragmentation, were detected in
the peri-infarct region surrounding the infarct in bryostatin-1 treated rats when compared
to saline-treated rats (n=7 saline and 10 bryostatin-1 treated rats) (Figure 2.3). This
finding was reinforced by a profound reduction in reactive astrocytes, identified by
GFAP expression, observed in bryostatin-1 treated rats, in which not only was
astrogliosis reduced but the degree of tissue destruction was markedly reduced (Figure
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2.4). Astrocytic hypertrophy with enlarged processes was evident in tissue surrounding
the necrotic zone around the infarct in saline-treated aged rats (Figure 2.4 A & B),
consistent with the astrocytic response. Bryostatin-1 attenuated this response and
reduced tissue damage in the peri-infarct area (Figure 2.4 C & D)
2.3.4. αPKC Expression Was Reduced in Neurons Surrounding the Penumbral Region
of Bryostatin-1 Treated Rats at 24 h Following MCAO
Colocalization of αPKC with neurons (NeuN), endothelial cells (CD31), and astrocytes
(GFAP) was investigated in penumbra surrounding the infarct in aged rats at 24 h after
MCAO (n=4 rats per treatment group).
αPKC immunoreactivity was observed in
neurons and endothelial cells (Figure 2.5A & 2.6A). Expression of αPKC was diffusely
localized throughout the cytoplasm of the cell. No colocalization of αPKC was shown
with GFAP-positive astrocytes (data not shown). Rats treated with bryostatin-1 showed a
significant (p<0.05) decrease in immunoreactivity of αPKC in neurons at 24 h following
MCAO (Figure 2.5A & 2.5C). No change (p>0.05) in αPKC expression was observed in
endothelial cells at 24 h following MCAO (Figure 2.6A & 2.6C).
2.3.5. Bryostatin-1 Increased εPKC Within Neurons in the Penumbra at 24 h Following
MCAO and tPA Reperfusion
Colocalization of εPKC with NeuN and CD31 in the penumbral area at 24 h after MCAO
was investigated (n=4 rats per treatment group). εPKC immunoreactivity was observed
in neurons and endothelial cells (Figure 2.5B & 2.6B). Expression of εPKC was punctate
along cytoplasmic edge of the plasma membrane of the cell. No colocalization of εPKC
was shown with GFAP-positive astrocytes. Rats treated with bryostatin-1 showed a
significant (p<0.05) increase in immunoreactivity of PKC in neurons at 24 h following
MCAO (Figure 2.5B & 2.5C).
2.4. DISCUSSION
The primary finding of this study was that administration of bryostatin-1 after MCAO and
tPA reperfusion decreased mortality over 21 d, with marked improvement during the first
4 d. Additionally, we are the first to report that bryostatin-1 administration improved
recovery from ischemic brain injury and functional outcome up to 21 d after MCAO in
aged animals. Use of bryostatin-1 attenuated both necrotic and apoptotic cell death.
The reduced degree of atrophy observed in aged rats treated with bryostatin-1 at 21 d
suggests the potential for both decreased inflammation and cellular death following
MCAO and tPA reperfusion. Effects measured in this study were associated with
changes in expression and localization of PKC isozymes in neurons and endothelial
cells within the peri-infarct region.
Regulation of PKC activity is the primary reported mechanism of action for bryostatin-1.
Inhibition of PKC isozymes blocked the synaptogenic and cognitive-enhancing effects of
bryostatin on normal animals 394. Therefore, it is plausible that pathological mechanisms
initiated following ischemic brain injury involve PKC-mediated pathways 33,	
   322. Results
from this study clearly show increased εPKC expression in endothelial cells and a
modest decrease in αPKC expression in neurons of bryostatin-1 treated rats at 24 h
following MCAO. The roles of PKC activity following ischemic stroke and reperfusion are
complex and poorly defined. What is known is that PKC activity mediates protective and
damaging signaling cascades during the injury and reparative phases of ischemic stroke
362,	
   490; suggesting that timing, localization, and the PKC isozyme activated play critical,
and sometimes contrasting, roles in injury response and progression of neuronal
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damage and regeneration following stroke 375,	
  394. Previous studies report that increased
εPKC activity initiates proliferative and cell survival signaling pathways following
ischemic stroke and reperfusion 321,	
   363,	
   396, while increased αPKC activity exacerbates
neuronal damage following post-stroke brain injury through initiation of anti-proliferative
and pro-apoptotic pathways 330; thus, while still inconclusive, our results suggest that
changes in PKC activity in endothelial cells and neurons may play a vital role in the
acute neuroprotective actions of bryostatin-1. It should be noted that while bryostatin
initially activates both PKC α and ε, it only causes prolonged binding of εPKC to the
critically required anchoring protein, RACK 1, that is required for prolonged activation
(unpublished data, Sun, Nelson, and Alkon).
Of particular interest, especially during the acute phase of stroke injury, is the role
different PKC isozymes play in alterations of endothelial cell function during
pathophysiological conditions. Increased PKC activity has been shown to affect
structural and functional integrity of the BBB following ischemic brain injury 382 with
αPKC and βPKC increasing BBB opening through alterations in tight junction protein
localization and εPKC enhancing BBB integrity by upregulating the expression of claudin
5 345,	
  384,	
   491. Our study showed that αPKC and εPKC were localized to both neurons and
cerebral endothelial cells. No colocalization of αPKC or εPKC was observed with GFAPpositive astrocytes; however, that does not mean that changes in PKC activity do not
have a significant influence on astrocyte reactivity as demonstrated by our study, which
showed a reduction in astrogliosis and tissue damage in bryostatin-1 treated rats. In fact,
in relation to chronic brain response following ischemic injury, attenuation of glial
response may end up being the most significant finding of this study. Gaining a better
understanding of the critical mediators and timing of this response will be a primary
focus of follow-up studies.
In conclusion, administration of bryostatin-1 following MCAO and tPA reperfusion has
neuroprotective effects on the magnitude of ischemic brain injury. A notable finding in this
study was the marked improvement in survival observed in bryostatin-treated rats,
especially during the first week following ischemic insult. While mortality increased in
the bryostatin-1 treated group during the 21 d, it must be emphasized that PKC activator
treatment, depending on dose and duration, causes three sequential consequences:
activation, downregulation (and thus inhibition), and de novo protein synthesis. Thus,
careful selection of treatment dosing and duration has a profound impact on PKCmediated phosphorylation of down-stream substrates and associated therapeutic
benefits 492. Bryostatin-1 treated rats displayed reduced ischemic brain injury following
MCAO that is characterized by increased survival, reduced infarct volume, decreased
atrophy, and improved neurological function.
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FIGURES

Figure 2.1. A.) Administration of bryostatin-1 significantly increased the survival rate of
aged rats from 2 to 17 d following MCAO and tPA reperfusion. A total of 7 out of 17
saline and 10 out of 19 bryostatin-1 treated rats survived to 21 d after MCAO. Fisher’s
exact test with two-tailed calculation of P value was performed to determine statistical
significance in mortality rate (*p<0.001; #P<0.01; †P<0.05). B.) Neurological function was
also significantly improved in bryostatin-1 treated aged rats at 21 d after MCAO as
compared to saline-treated rats. No difference in neurological score between saline and
bryostatin-1 treated rats was measured at 1, 7, and 14 d after MCAO (n=7 saline and 10
bryostatin-1 treated rats). Data presented as mean ± SEM, * p<0.05.

104

Figure 2.2. A.) Repeated administration of bryostatin-1 decreased infarct volume in the
cortex (p=0.02), striatum (p=0.01), and total cerebral hemisphere (p=0.001) of aged rats
at 21 d following MCAO (n=7 saline and 10 bryostatin-1 rats). B.) Bryostatin-1
significantly reduced cerebral atrophy in the ischemic hemisphere as compared to
saline-treated rats at 21 d after MCAO (n=7 saline and 10 bryostatin-1 rats). Data
presented as mean ± SEM, * p<0.05.
C.) Representative photomicrographs of
hematoxylin and eosin stained brains in control and bryostatin-1 treated animals,
respectively. D.) Representative photomicrographs of cresyl-violet stained brains in
control and bryostatin-1 treated animals, respectively.
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Figure 2.3. Representative photomicrographs showing TUNEL-positive cells (green) in
the peri-infarct region at 21d after MCAO in saline group (A) and bryostatin-1 treated (B)
aged rats at 21 d after MCAO. (C) A 84±15% decrease in TUNEL positive cells were
observed at 21 d following MCAO in rats treated with bryostatin-1 as compared to salinetreated rats. Data expressed as mean ± SEM. * denotes statistical significance at
p<0.05. Cell nuclei were stained using DAPI (n= 7 saline and 10 bryostatin-1 rats).
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Figure 2.4. Representative photomicrographs of GFAP-staining positive cells in saline
(A & C) and bryostatin-1 (B & D) treated aged rats at 21 d following MCAO. Arrows
(white) point to difference in astrocyte morphology observed in saline and bryostatin
treated brain at 21 d following MCAO (n=7 saline and 10 bryostatin-1 rats).
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Figure 2.5. Representative images of tri-color confocal immunofluorescent microscopy
demonstrating colocalization of NeuN with αPKC (A) and εPKC (B) in the penumbra of
the infarcted hemisphere of saline and bryostatin-1 treated aged rats at 24 h after
MCAO. (C) In neurons, a 68% decrease in αPKC expression and a 202% increase in
εPKC expression were measured at 24 h following MCAO in bryostatin-1 treated rats as
compared to saline-treated rats. Data expressed as mean ± SEM. * denotes statistical
significance at p<0.05. Cell nuclei were stained using DAPI (n=4 rats per group).
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Figure 2.6. Representative images of tri-color confocal immunofluorescent microscopy
demonstrating colocalization of CD31 (endothelial cells) with αPKC (A) and εPKC (B) in
the penumbra of the infarcted hemisphere of saline and bryostatin-1 treated aged rats at
24 h after MCAO. (C) In endothelial cells, no statistical difference (p<0.05) in αPKC and
εPKC expression were observed at 24 h following MCAO between bryostatin-1 and
saline treated rats. Data expressed as mean ± SEM. * denotes statistical significance at
p<0.05. Cell nuclei were stained using DAPI (n=4 rats per group).
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Chapter Three
Currently, tissue plasminogen activator (tPA) remains the only FDA-approved
pharmacologic for the treatment of ischemic stroke. Administration of tPA is hampered
by an extensive list of contraindications and narrow therapeutic window resulting in less
than 5% of patients receiving tPA. Consequently, there is an immense need for
pharmacological agents that can improve the safety to tPA, allowing administration in
previously contraindicated patients and those presenting outside the classically defined
therapeutic window. One potential candidate based on prior work in other disease and
animal models is apyrase. This study examines the effect of apyrase on outcome
following ischemic stroke and tPA administration at 6 hours post-stroke.
Combination Treatment of r-tPA and Apyrase Reduces Mortality Rate and
Hemorrhage Transformation in Acute Ischemic Stroke in Aged Female Rats
Zhenjun Tan, Xinlan Li, Ryan C. Turner, Aric F. Logsdon, Brandon P. Lucke-Wold,
Kenneth H. DiPasquale, Ridong Chen, Jason D. Huber, Charles L. Rosen
This work is currently in preparation for publication submission.
ABSTRACT
Thrombolytic therapy utilizing the only FDA-approved pharmacologic agent for ischemic
stroke treatment, recombinant tissue plasminogen activator (r-tPA), has a narrow time
window for administration and is therefore limited to use in a select few patients.
Furthermore, r-tPA has direct and deleterious effects on the ischemic neurovascular unit
that can substantially increase the risk of intracerebral hemorrhage and intrinsic toxicity.
These therapeutic shortcomings necessitate additional investigation of agents that can
extend the windows for safe use of thrombolytic therapy. In this study, combination of rtPA and APT 102, a novel form of the naturally occurring human apyrase/ADPase, was
investigated in a clinically relevant embolic ischemic stroke model in aged female rats to
evaluate whether the combination can safely extend the therapeutic window of r-tPA
administration. Results of our study showed that co- administration of APT 102 with rtPA significantly reduced mortality rate and decreased cortical and total hemispheric
stroke volumes. Similarly, co-administration produces significant improvement in
neurological deficit scores obtained using the modified Neurological Severity Scale
(mNSS). Decreased cortical, striatal and total hemorrhage were also observed in APT
102 plus r-tPA groups as determined by hemoglobin extravasation. These data suggest
that APT 102 can extend the therapeutic window and prevent intracerebral hemorrhage
following r-tPA treatment in aged female rats. APT 102 combined with r-tPA may have
potential utility in treating acute ischemia stroke in clinical setting. Prior work indicates
this beneficial effect may be achieved through modulation of extracellular ATP and ADP,
substances involved in platelet aggregation and endothelial activation, by APT 102.
Keywords
Acute ischemia stroke; APT 102/ apyrase; hemorrhage transformation; infarction size;
recombinant tissue plasminogen activator
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3.1. INTRODUCTION
Stroke remains a leading cause of death worldwide, consequently a tremendous clinical
need for improved acute ischemic stroke therapy exists. Despite clinical trials on
numerous drug candidates, pharmacological options for acute ischemic stroke are
limited to thrombolytic therapy 493,	
   494. Unfortunately, thrombolytic therapy is indicated in
a small subset of patients due to a narrow therapeutic window and an extensive list of
contraindications. Therefore, there is an urgent need for adjunct therapy in conjunction
with r-tPA administration that would reduce intracerebral hemorrhage, improve general
clinical outcomes, and expand the time window of eligibility for r-tPA.
Reasons for the failed translation of other therapeutics from bench-to-bedside are
presently unclear but notable contrasts exist between preclinical models of ischemic
stroke and the clinical population and may account for failed translation. Specifically,
stroke is a disease of the elderly with approximately 72% of stroke patients are over the
age of 65 495. The Stroke Therapy Academic Industry Roundtable (STAIR) committee
recommends that following evaluation of proposed therapeutics in young, healthy male
animals, further studies should be performed in aged female animals and animals with
comorbid conditions 47,	
   496. Therefore, we used a model of embolic stroke in aged
female rats to investigate whether aging alters efficacy and side effects of r-tPA in a
combination treatment paradigm with the belief that doing so may significantly contribute
to the successful translation of therapeutics from animal models to stroke patients.
In this study, combination of r-tPA and APT 102, a recombinant form of human apyrase,
was investigated in a clinically relevant embolic stroke model in aged female rats to
evaluate whether the combination can reduce cerebral infarct volume, improve
neurological deficit score, and prevent r-tPA-induced cerebral hemorrhage. Previous
studies have shown that APT 102 alone or combination with r-tPA can prevent ischemiareperfusion injury in lung infarction 497,	
   498, myocardial infarction 499,	
   500 and ischemic
stroke in young male rats 501-‐503 making APT 102 a potentially promising therapeutic for
ischemic stroke. Our general goal was to determine whether APT 102 will improve
outcome of stroke, efficacy and safety of r-tPA, and extend the therapeutic window of rtPA and the therapeutics can be translated from bench to bedside.
3.2. MATERIALS AND METHODS
3.2.1 Animals, Surgical Procedures for MCAO and Drug Treatment
Seventy-two female Sprague-Dawley rats (18-20 months old) were purchased from
Harlan Laboratories ( Indianapolis, IN) and housed under 12-h:12-h light-dark conditions
with food and water ad libitum. All work involving rats was approved by the West Virginia
University Animal Care and Use Committee. Rats were randomly divided into three
treatment groups. Saline group (N=23): TBS(Tris Buffered Saline) as an i.v. bolus at 6h
after MCAO; r-tPA group (N=30): 5mg/kg of r-tPA in TBS as an i.v. bolus at 6 h after
MCAO; r-tPA+ APT 102 group (N=19): 5mg/kg of tPA plus 2.25mg/kg of APT 102 in TBS
as an i.v. bolus at 6 h after MCAO.
Rats underwent a reversible embolic MCAO as previously described and modified 10,	
  84,	
  
504. Briefly, rats were anesthetized with 2% isoflurane in a mixture of 30% oxygen and
70% nitrous oxide. A servo-controlled homeothermic heating blanket, utilizing a rectal
thermometer, was used to maintain body temperature at 37 °C. All surgical procedures
were performed with the aid of a Leica™ Surgical Microscope. Relative regional cerebral
blood flow was monitored with a laser Doppler probe. The modified PE 50 microcatheter
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was inserted into the external carotid artery stump and advanced into the MCA.
Placement in the proximal MCA was verified by a sudden decrease in cerebral blood
flow as measured by laser Doppler. Microcatheter was withdrawn ~1 mm, allowing
cerebral blood flow to return to baseline, and then the 25mm thoroughly washed fibrinrich clot was injected. Successful MCA occlusion was confirmed by a drop in perfusion
greater than 80% of initial baseline in continuous laser Doppler monitoring.
Recanalization was noted if cerebral blood flow increased to 75% of baseline. Rats not
achieving these standards were excluded from the study.
3.2.2. Neurological Functional Assessments
Neurological functional assessments were measured at post-MCAO 24 hours. The
neurological assessments were made by an investigator blinded to the treatment group.
The modified Neurological Severity Scores (mNSS) evaluated the motor, sensory,
balance and reflex measures, with scores ranging from 1 to 17, with higher scores
indicating greater neurological injury 505.
3.2.3. TTC staining and Determination of Infarction Volume
At 24 hr following MCAO, rats were sacrificed and infarct size and stroke volume were
evaluated by 2,3,5-triphenyltetrazolium chloride (TTC; 2%) staining of 2 mm coronal
brain slices for 15 min at 37°C. Hemispheres were scanned on a flatbed scanner and
analyzed using Image J software. On each slice, the nonstained area (ischemic brain)
was marked, and the infarct volume was calculated according to the slice thickness of 2
mm per slice. The corrected infarction volume (CIV) was given by the following equation:
CIV=(CHV-[IHV-IHI])x d, where CHV was the area of the contralateral cortical or striatal
volume in mm2, IHV was the area of the ipsilateral cortical or striatal volume in mm2,
IHI was the infarct cortical or striatal area in mm2, and d was the thickness of the slice (2
mm). Edema index was calculated as follows: Edema index = ([volume of ipsilateral
hemisphere-volume of contralateral hemisphere]/volume of contralateral hemisphere)
x100% 16.
3.2.4. Spectrophotometric Assay of Hemoglobin
Hemorrhagic transformation was quantified with spectrophotometric assay of brain
hemoglobin content. At 24 hours after MCAO, the animals were perfused transcardially
with 0.1mol/L Phosphate-buffered saline under anesthetization of ketamine and xylazine
until the outflow fluid from the right atrium was colorless. MCA area in left and right
hemisphere were dissected and put in 0.1mol/L phosphate-buffered saline. Brain tissue
was then homogenized in 0.1mol/L phosphate-buffered saline. After 30-minute
centrifugation (13000g), 50µl samples (supernatant) were transferred into wells and
200µl reagent was added. After 15 minutes, optical density was measured at 400nm with
a spectrophotometer. The hemoglobin content was expressed as mg/dl tissues 506.
3.2.5 Statistical Analysis
Data are presented as mean±SEM. Physiologic parameters and functional data were
compared using two-way analysis of variance (ANVOA) and comparisons between
groups determined using Turkey’s post-hoc analysis. Level of significance was set at
p<0.05.
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3.3. RESULTS
3.3.1. APT 102 and r-tPA in Combination Significantly Decreased Mortality Rate at 24 h
Following MCAO
Mortality rate was evaluated at 24 h following MCAO. APT 102 and r-tPA in combination
significantly reduced the mortality rate from 46.67% (n=30, r-tPA group) to 15.79%
(n=19, r-tPA+ APT 102 group). The mortality rate of saline group was 34.78% (n=23,
saline group) (Figure 3.1). Animals dying prior to 24 h were autopsied. Typical findings
were larger ipsilateral hemispheric infarctions, extensive brain edema and macroscopic
hemorrhage. Animals expiring prior to 24 h were not included in the following histological
analysis.
3.3.2. APT 102 and r-tPA in Combination Reduced Cortical and Total Hemispheric but
Not Striatal Infarction Size at 24 h Following MCAO
Stroke volume of the infarct cortex, striatum, and total cerebral hemisphere were
measured at 24 h following MCAO. Cortical infarct volume was reduced significantly by
APT 102/r-tPA combination treatment compared with r-tPA alone (29.15±4.48% versus
46.87±4.72%, p<0.05). Infarct volume of total cerebral hemisphere was also significantly
reduced by
APT 102/r-tPA combination treatment compared with r-tPA alone
(33.18±3.52% versus 48.15±3.23%, p<0.05). Striatal infarct volume was not significantly
different in APT 102/r-tPA combination treatment and r-tPA alone (39.74±3.07% versus
49.90±2.19%, p>0.05). The infarction volume of cortex, striatum, total cerebral
hemisphere from saline group was 44.20±4.92%, 53.74±3.98%, 47.17±3.71%
respectively (Figure 3.2).
3.3.3. APT 102 and r-tPA in Combination Improved Neurological Function at 24 h
Following MCAO
Before MCAO, neurological score was normal (score=0) in all animals. Neurological
function (mNSS) was assessed at 24 h following MCAO. APT 102 and r-tPA in
combination significantly improved the neurological score compared with r-tPA alone
(6.78±0.82 versus 8.93±0.61, p<0.05). There was no significant difference of
neurological score between the saline group (7.73±0.49) and r-tPA group, saline group
and r-tPA +APT 102 group (Figure 3.3).
3.3.4.
APT 102 and r-tPA in Combination Significantly Decreased Hemorrhage
Transformation in Cortex, Striatum and Total Hemisphere at 24 Following MCAO
Hemoglobin levels were measured by hemoglobin assay in cortex, striatum and total
hemisphere at 24 h following MCAO. APT 102 and r-tPA combination significantly
decreased hemoglobin levels in cortex (1.394±0.084 versus 1.879±0.144 mg/dl, p<0.05),
striatum (1.368±0.101 versus 2.045±0.289 mg/dl, p<0.05), and total hemisphere
(1.37±0.080 versus 1.946±0.200 mg/dl, p<0.05) compared with r-tPA group. The
hemoglobin levels of cortex, striatum and total hemisphere from saline group were
1.850±0.142mg/dl, 1.662±0.098mg/dl, 1.759±0.098mg/dl respectively (Figure 3.4).
3.3.5 APT 102 and r-tPA in Combination Failed to Affect Edema Formation at 24 h
Following MCAO
Edema formation (brain swelling) was measured at 24 h following MCAO. There was no
significant difference between saline, r-tPA and r-tPA +APT 102 group (28.43±1.54%
versus 25.70±2.83% versus 22.35±2.29%, P>0.05) on edema formation (Figure 3.5).
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3.4. DISCUSSION
To our knowledge, this is the first report of the evaluation of a soluble apyrase in a
reproducible and clinically relevant embolic stroke model of aged female rats. This study
showed that co- administration of APT 102 with r-tPA significantly reduced mortality rate
and improved neurological functional outcome with r-tPA at 6h following MCAO. Our
findings also demonstrated that administration of APT 102 significantly improved cortical
and total infarct volume and decreased hemorrhagic transformation.
Consistent with our previous studies 10,	
   84,	
   504, higher mortality rates and large infarct
volumes were observed in aged female rats at 24h following MCAO and 6 h r-tPA
reperfusion. As a thrombolytic agent, r-tPA has direct and deleterious effects on the
neurovascular unit and brain parenchyma that substantially increase death rate,
increase infarct volume and cause severe hemorrhage when administered intravenously
following MCAO in a delayed fashion. Recent studies show 507-‐509 that aged rats are
more severely impaired by stroke than are young rats, and show diminished functional
recovery. Clinically, aging affects spontaneous recovery of stroke patients and is a risk
for fragility of the blood brain barrier and hemorrhagic transformation after thrombolytic
therapy 47.
Vascular endothelium and blood platelets maintain vascular integrity and promote
primary and secondary hemostasis following interruption of vessel continuity. Cerebral
artery occlusion and reperfusion associated with endothelial damage and activation of
platelets 498,	
   510,	
   511. ATP and ADP are released in high concentrations by activated
endothelial cells and platelets following aggregation on endothelium. In turn, ATP and
ADP further increase additional platelet aggregation, leading to microthrombus formation
and the eventual worsening of endothelial injury. Platelet and fibrin deposition
downstream of an occlusive lesion contribute significantly to the postischemic
hypoperfusion and tissue injury complicating stroke 499,	
  501,	
  512-‐515.
The beneficial effects of co-administration of APT 102 with r-tPA at 6h following MCAO
may likely be explained by the effect of apyrase. APT 102, a novel form of the naturally
occurring human apyrase/ADPase (CD 39, recombinant soluble human CD 39), can
promote the breakdown of extracellular ATP and ADP by catalyzing the removal of the
gamma phosphate from ATP and the beta phosphate from ADP 514,	
   516-‐519. APT 102 does
not act on the platelet per se but exclusively on prothrombolic mediators (ATP and ADP).
Moreover, APT 102 prevents hemorrhagic transformation by inhibiting ATP-induced
endothelial cell activation and neutrophil infiltration and re-sensitizing platelets 499-‐501,	
   510,	
  
518,	
  520.
Furthermore, the effects of exogenously administered apyrase are consistent with prior
work in cd 39-/- mice demonstrating increased cerebral infarction volumes compared
with control cd 39+/+ mice following stroke. Data also showed that endogenous CD 39 is
protective in stroke, and that administration of pharmacological doses of sol CD 39 is
effective in inhibiting thrombosis and tissue injury in strokes 513,	
  517. Since sol CD39 does
not interfere with primary GPIb-mediated platelet adhesion at the site of vessel damage,
sol CD 39 administration should not prevent a layer of platelets from forming at the site
of injury or interfere with hemostatic mechanisms that prevent intracerebral hemorrhage
501,	
   510. Compared with aspirin, sol CD39 may induce more potent inhibition of platlet
aggregation by blocking ADP-induced platelet recruitment. sol CD 39 is more efficient in
inhibiting platelet recruitment than is aspirin via blockade of the arachidonate/
thromboxane pathway. Sol CD39 disaggregates platelets under recruitment, but it does
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not have a deleterious effect on primary hemostasis. The fact may explain how sol CD
39 can inhibit microvascular thrombosis and confer cerebroprotection in ischemic stroke
without worsening intracerebral hemorrhage 499,	
  500,	
  510,	
  516.
In conclusion, combination of r-tPA and APT 102 reduces mortality rate, decreases
cerebral infarct volume, improves neurological deficit scores, and prevents r-tPA-induced
hemorrhage transformation in our highly clinical relevant ischemic stroke model in aged
female rats. APT 102 can extend the therapeutic window and prevent intracerebral
hemorrhage of r-tPA treatment by inhibiting platelet aggregation and endothelial cell
activation in aged female rats following MCAO.
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Figure 3.1. Mortality rate was evaluated at 24 h following MCAO. Results showed a
significant decrease (p<0.05) in mortality rate in the r-tPA+APT 102 group (15.79%,
n=23) compared with r-tPA group (46.67%, n=30). The mortality rate of the saline group
(n=23) was 34.78%. * represents statistical significance as determined using a p-value of
p<0.05
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Figure 3.2. Measurement of stroke volume of the infarct cortex, striatum, and total
cerebral hemisphere at 24 h following MCAO. Results showed a significant decrease in
cortical stroke volume in the r-tPA+APT 102 group (29.15 ± 4.48%, n=14) compared with
the r-tPA group (46.87 ± 4.72%, n=14, p<0.05). No significant difference in striatal stroke
volume was observed in r-tPA+APT 102 group (39.74 ± 3.07%, n=14) and the r-tPA
group (49.90 ± 2.19%, n=14, p>0.05). Results from the total cerebral hemisphere stroke
volume showed a significant (p<0.05, n=14) decrease in the r-tPA+APT 102 group
(33.18±3.52%, n=14) as compared to the r-tPA group (48.15 ± 3.25%, n=14). The
infarction volume of cortex, striatum, total cerebral hemisphere from the saline group
(n=13) was 44.20 ± 4.92%, 53.74 ± 3.98%, 47.17 ± 3.71% respectively. * represents
statistical significance as determined using a p-value of p<0.05.
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Figure 3.3. Assessment of neurological function using a 17 point mNSS following
MCAO. A significant difference (p<0.05) in mNSS scores were demonstrated between
the r-tPA+ APT 102 group (6.78 ± 0.82, n=16) and the r-tPA group (8.93 ± 0.61, n=14).
The mNSS for the saline group (n=15) was 7.73 ± 0.49. * represents statistical
significance as determined using a p-value of p<0.05
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Figure 3.4. Hemoglobin levels were measured in the cortex, striatum and total
hemisphere by hemoglobin assays at 24 h following MCAO. Results showed a
significant decrease hemoglobin levels in cortex (1.39 ± 0.08 vs 1.88 ± 0.14 mg/dl,
p<0.05), striatum (1.37 ± 0.10 vs 2.05 ± 0.29 mg/dl, p<0.05), and total hemisphere (1.37
± 0.08 vs 1.95 ± 0.20 mg/dl, p<0.05) in r-tPA+ APT 102 group (n=13) compared with rtPA group (n=12). The hemoglobin levels of cortex, striatum and total hemisphere from
saline group (n=15) were 1.85 ± 0.14mg/dl, 1.66 ± 0.10mg/dl, 1.76 ± 0.10mg/dl
respectively. * represents statistical significance as determined using a p-value of p<0.05
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Figure 3.5. Measurement of edema formation in the infarct hemisphere following MCAO.
No significant (p>0.05) difference was observed between r-tPA+APT 102 group (22.35 ±
2.29%, n=14) and r-tPA group (25.70 ± 2.83%, n=14). Edema index of saline group
(n=13) was 28.43 ± 1.54%.
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Chapter Four
Proposed neuroprotective agents developed using preclinical models of ischemic stroke
have failed to translate successfully despite over 100 clinical trials being conducted.
Extensive reflection within the stroke community has resulted in the creation of
numerous advisory groups that have outlined recommended practices to hopefully
increase the likelihood of successful translation from bench-to-bedside. Recurring
recommendations include the use of aged animals or those with comorbidities and the
implementation of functional assessments as an experimental endpoint in preclinical
studies. These suggestions have been made upon the basis that ischemic stroke is a
disease of the elderly and clinical endpoints frequently utilize functional outcomes (aka
can the patient care for themselves). Functional assessments and the use of aged
animals have not been emphasized in preclinical studies and therefore, it remains
unclear what the most appropriate functional assessments are and how these may be
impacted by age. This chapter explores this issue by comparing performance in
numerous assessments across age groups utilized in preclinical ischemic stroke work.
Effect of Aging on Behavioral Assessment Performance: Implications for Clinically
Relevant Models of Neurological Disease
This work was published in Journal of Neurosurgery.
Citation: Turner RC, Seminerio MJ, Naser ZJ, Ford JN, Martin SJ, Matsumoto RR,
Rosen CL, Huber JD (2012) Effects of aging on behavioral assessment performance:
implications for clinically relevant models of neurological disease.
Journal of
Neurosurgery 117: 629-637.
ABSTRACT
The effect of age is often disregarded despite the role of aging in neurologic and
neurodegenerative disease development. Functional assessment increases the clinical
relevance of animal models of neurologic disease and adds value beyond traditional
histologic measures. However, the relationship between age and functional impairment
has not been systematically assessed through a battery of functional tests. In the
present study, various sensorimotor and behavioral tests were used to evaluate effects
of age on functional performance. Aged (18-24 months) Sprague-Dawley rats were
found to perform significantly worse on inclined plane test and exhibited alterations in
elevated-plus maze and forced swim test compared to young adult animals (3-4
months). Specifically, aged animals exhibited reduced exploration of open arms in
elevated-plus maze and higher immobility time in forced swim test. Spatial acquisition
and reference memory was diminished in aged animals in comparison to the young adult
animals. This work illustrates clear differences between young adult and aged animals,
which may have implications in functional assessment for preclinical models of
neurologic disease.
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4.1. INTRODUCTION
The assessment of outcome from preclinical neurologic disease models has often
emphasized histologic measures and minimized functional and behavioral evaluations
521.
Functional assessment following neurologic disease onset and treatment is the
primary means of evaluating patients clinically, and therefore, is desirable for translation
of preclinical studies to clinical trials 522. In addition to being clinically relevant, functional
assays have the potential to be more sensitive to therapeutic-induced improvements
when compared to histologic measures.
One aspect of functional assays that remains poorly understood is the effect of aging on
behavior and functional performance. Aging is well documented as a leading risk factor
for numerous neurologic diseases ranging from Alzheimer’s to stroke and consequently,
the use of preclinical models utilizing aged animals has been recognized and
recommended 47,	
  523,	
  524. Preclinical studies utilizing both young and adult animals have
illustrated more severe impairment and lessened functional recovery following
neurologic injury in comparison to young animals 30,	
  33,	
  525-‐527.
Furthermore, Mehan et al recently demonstrated age-dependent effects on both motor
coordination and specific cognitive tasks before and after traumatic brain injury 528.
Similarly, Badan et al documented a 30% decrease in spontaneous activity in aged
animals compared to young animals prior to initiation of neurologic injury 30. Increased
recognition of the utility of using aged animals in preclinical models of disease creates a
need for basic understanding of behavioral differences, both before, as well as after, any
neurologic injury. This work seeks to elucidate age-dependent effects on behavior and
in doing so, establish a foundation for selecting and developing the most appropriate
assessments for aged animals. We hope to provide insight into not only the differences
in behavior associated with age, but also any similarities that may exist with young adult
animals. Lastly, this work will facilitate future work utilizing more clinically relevant
preclinical models of neurologic disease.
4.2. MATERIALS AND METHODS
4.2.1. Animals
Female Sprague-Dawley rats 3-4 months (young adult) and 18-20 months (aged adults)
were acquired from Hilltop Animal Laboratory (Scottdale, PA, USA) and housed under 12
hr light/12 hr dark conditions with food and water available ad libitum. Animals were
allowed to acclimate for one week after arrival. All procedures involving rats abided by
the policies outlined by the West Virginia University Animal Care and Use Committee.
Sprague-Dawley rats were selected based on frequent use in models of neurologic
disease, particularly stroke. Clinically, stroke more commonly affects females and
therefore, female rats were utilized. Animal weight was recorded using a standard
balance prior to conducting assessments.
4.2.2. Sensorimotor Assessment
Animals were assessed for sensorimotor ability using standard measures for strength,
balance, coordination, and overall locomotor activity. The assessments included gripstrength, inclined plane, rotarod, and locomotor activity. Each of these measures is
described in greater detail below. A baseline modified Neurologic Severity Score
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(mNSS), a scoring system widely used in neurologic assessment, particularly for stroke,
was utilized 529.
4.2.2.1. Grip-Strength
A commercially available grip-strength measurement system, the Grip Strength Meter,
was acquired from Columbus Instruments (Columbus, OH). The grip-strength apparatus
consists of a load cell and an interchangeable grip attachment. Two types of grip
attachments were utilized in this work – a T bar and a triangle bar. For each attachment,
a total of five measures were taken for forelimb grip-strength for each animal and
averaged to create a composite for each bar. Animals were grasped by the tail and nape
of the neck, forepaws placed on the bar, and pulled in a straight line away from the load
cell 530.
4.2.2.2. Inclined Plane
An inclined plane was constructed similar to that described by Rivlin, et al 531. The
device consists of an 18 cm x 18 cm platform to which a ridged rubber mat is attached.
The platform is affixed to a base via a hinge on one side, allowing rotation from 0-85°.
Animals were placed such that their body axis was perpendicular to that of the inclined
plane. The maximum incline angle was recorded at which the animal could successfully
maintain its position for 5 seconds. During this period, the animal makes corrective
adjustments to maintain a normal posture using both fore- and hind-limbs. This process
was repeated for a total of five measures per animal, which were then averaged to
create a composite value.
4.2.2.3. Locomotor Activity
Locomotor activity was measured using an automated activity monitoring system (San
Diego Instruments, San Diego, CA). The animals were given one hour to acclimate to
the testing room prior to initiation of testing. Each testing chamber consisted of a
plexiglass housing and a 16 x 16 photobeam array to detect lateral movements with a
separate 8 photobeam array to detect rearing activity. Locomotor activity was quantified
over a 30 minute period. Ambulatory, fine, and rearing movements were quantified in
order to determine total locomotor activity.
4.2.2.4. Rotarod
The rotarod test requires animals to balance on a rotating drum and is often utilized to
assess motor deficits in neurodegenerative disease models in rodents. Two variations to
the rotarod test exist – incremental fixed speeds and accelerating 532. All rotarod studies
were conducted with the OMNI-ROTOR by Omnitech, Inc (Columbus, OH).
Training animals consisted of four trials a day over the course of three consecutive days.
Animals were placed on the rotarod that was accelerated to a speed of 24 rpm over 20
seconds. The maximum duration spent at this speed was 60 seconds.
For the fixed speed test, animals were placed on the rod and tested at 12, 16, 20, 24,
28, 32, 36, and 40 rpm for a maximum of 60 seconds at each speed. The animals were
tested a total of three times at each speed with a rest of 30 minutes between each trial.
The accelerating rotarod test was set to reach a maximum speed of 50 rpm over a
period of 4.5 minutes and was repeated for a total of two trials with a 30 minute rest
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period between trials. The total test duration was 5 minutes per trial. For both the fixed
speed and accelerating rotarod tests, the latency to fall was recorded.
4.2.2.5. Modified Neurologic Severity Score (mNSS)
The mNSS, described at length by Watanabe, et al., is a widely used method for quickly
assessing severity of injury, particularly in the stroke field 529. The mNSS (Table 4.1)
includes basic measures of sensorimotor performance and reflex integrity. The balance
beam used had a square profile with rounded edges and measured 4 cm x 4 cm. The
beam was constructed of a synthetic wood alternative.
4.2.3. Elevated-Plus Maze Assessment
The elevated-plus maze test was conducted as described by Walf, et al 533. Time spent
in the open arms has been described as correlating inversely with anxiety-like behavior.
Animals were placed individually in the center of the maze facing an open arm. ANYMaze Version 4.63 video tracking software (Stoelting Co., Wood Dale, IL) was used to
record the number of entries, time, speed, and distance in open versus closed arms.
ANY-Maze software settings were as follows: test duration = 300 seconds and percent
body to be considered in arm = 90%.
4.2.4. Forced Swim Test Assessment
The forced swim test was performed as described by Porsolt et al 534,	
   535. Time spent
immobile has been identified as correlating with depressive-like activity. Rats were
habituated the day prior to testing for a period of seven minutes. On the testing day, rats
were acclimated to the testing facility for 60 minutes prior to initiation of experiments.
Animals were placed in individual cylinders of water (20 cm deep) for a total of seven
minutes. The initial two minutes served as an acclimation period and data was not
collected from this period. During the remaining five minutes, immobility time was
quantified using ANY-Maze Version 4.63 video tracking software (Stoelting Co., Wood
Dale, IL). Immobility was defined as no activity other than that required to maintain the
animal’s head above the surface of the water. In addition to immobility time, speed,
distance, and number of immobile episodes were recorded. ANY-Maze software settings
were as follows: accustomization period = 120 seconds, test duration = 300 seconds,
minimum immobility time = 2000 milliseconds, and immobility sensitivity = 75%.
4.2.5.
Maze

Spatial Acquisition & Reference Memory Assessment using the Morris Water

All Morris water maze studies were conducted in a 182 cm diameter stainless steel pool
with an opaque interior. Columbus Instruments (Columbus, OH, USA) Videomex 4.50
tracking software was utilized for all data acquisition and subsequent analysis. Water
was maintained at 19-22 °C throughout all studies and a platform made of plexiglass, 12
cm x 12 cm was used. On Days 1-5, four trials were completed per animal from four
different positions with the platform being visible on Day 1 and hidden subsequently.
Each trial lasted a maximum of two minutes with an inter-trial interval of 15 seconds.
Animals not finding the platform within a two minute period were then placed on the
platform. The animal remained on the platform for the duration of the inter-trial interval
for acquisition to occur. One week after the last acquisition trial, a probe trial was
performed in which the platform was removed. For the probe trial, animals were placed
in a novel start position facing the tank wall, 180° from the original platform position to
ensure spatial recognition and preference rather than a specific path. For the probe trial,
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the animal was removed after 60 seconds. For the probe trial, the WaterMaze v4.50
was set with a counter 300% of original platform size. The number of entries, time, and
distance in the counter zone was recorded.
4.2.6. Statistical Analysis
Data from all experiments was analyzed using GraphPad Prism 4.0 (San Diego, CA).
Two-way repeated measures analysis of variance was performed to test for differences
between young-adult and aged mice in the water maze-spatial acquisition test (both for
latency and distance) and the fixed speed rotarod test. An unpaired t test was used to
compare young-adult and aged mice in grip strength, balance beam, locomotor activity,
mNSS (placing, tail raise, and reflexes), inclined plane, accelerating rotarod, forced swim
test, and elevated plus maze. P < 0.05 was considered statistically significant for all
data analyzed.
4.3. RESULTS
4.3.1. Sensorimotor
The effect of aging on strength, balance, and locomotor ability was measured through
grip-strength recordings (Figure 4.1a), inclined plane (Figure 4.1b), and overall
locomotion (Figure 4.1c).
Statistically significant differences were observed when
comparing young-adult and aged animals in terms of grip-strength with the T-bar (t=2.17,
p<0.05), grip-strength with the triangle bar (t=3.03, p<0.01), and angle of fall on the
inclined plane (t=8.47, p<0.0001). No significant difference was seen in total locomotor
activity.
The results from two variations of rotarod testing, a fixed speed (Figure 4.2a) and
accelerating test (Figure 4.2b), are shown. No significant difference was seen between
young-adult and aged animals on either the fixed speed or the accelerating test.
The mNSS, a widely utilized scoring system for stroke, showed that aged animals
performed significantly worse than young adults animals on the balance beam
component (Figure 4.3; t=2.41, p<0.05). On the other subtests of the mNSS such as
placing, raising by the tail, and reflexes, age did not appear to alter ability.
4.3.2. Elevated Plus Maze
In the elevated plus maze, young-adult animals spent significantly more time exploring
the open arms than did aged animals (Figure 4.4a, t=2.39, p<0.05)). While not reaching
statistical significance, there was also a strong trend towards an increased number of
entries into the open arm by young animals when compared to the aged (Figure 4.4b).
Notably, there was no difference in the average speed between groups in the open arm
(Figure 4.4c). In the closed arm, the average speed was different as aged animals failed
to explore while young-adult animals moved about with greater frequency (Figure 4.4d,
t=3.77, p<0.01).
4.3.3. Forced Swim Test
In the forced swim test, significant differences were seen in total immobility time (Figure
4.5a:t=3.83,p<0.05) and the number of immobile episodes (Figure 4.5b:t=3.45,p<0.05)
between the two groups. No significant differences were seen in the total distance
traveled (Figure 4.5c), average speed (Figure 4.5d), or the latency to the first immobile
episode (Figure 4.5e).
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4.3.4. Cognitive
Two-way ANOVA of the spatial acquisition (learning) phase showed differences between
young and aged mice in their latency to find the platform (Figure 4.6a:F(4,88)=17.10,
p<0.0005) and distance (Figure 4.6b:F(4,55)=31.60, p<0.0001). Bonferroni post hoc test
confirmed a significant difference between latency on Days 3-5 (Figure 4.6a: Day 3,
t=2.958, p<0.05; Day 4, t=4.30, p<0.001; Day 5, t=3.30, p<0.01) and distance on Day 4
(Figure 4.6b: t=3.32, p<0.01).
In the probe test (reference memory assessment), conducted 7 days after the last day of
learning, aged animals exhibited a reduced number of entries (Figure 4.7a: t=3.132,
p<0.01), time spent (Figure 4.7b; t=4.93, p<0.0001), and distance traveled in the counter
area (Figure 4.7c; t=4.88, p<0.0001) compared to the young-adult rats. Aged animals
also performed more poorly than the young-adult animals based on the proximity
average, a calculation of the average distance from platform and ideal path of travel
(Figure 4.7d; t=2.33, p<0.05).
4.4. DISCUSSION
Age is often ignored despite its clinical relevance in many animal models for neurologic
or neurodegenerative disease, of which stroke and Alzheimer’s Disease are examples.
Age is the greatest known risk factor for Alzheimer’s Disease 524 and stroke 536, yet the
use of young-adult animals is pervasive throughout the literature. This clinical reality is
in sharp contrast to preclinical studies of stroke, in particular, in which the vast majority
of studies utilize young-adult animals. Furthermore, preclinical models of neurologic
disease often emphasize histologic measures despite the clinical relevance of functional
assessment.
The effect of age on common neurologic functional tests was not
systematically investigated previously, making the comparison between young and aged
models of neurologic disease difficult. This work not only compares the performance of
young and aged animals in the widest array of behavioral tests utilized in neurologic
disease research but also illustrates fundamental baseline differences, which may
provide insight into the most appropriate tasks for functional assessment going forward
in aged animal disease models.
This work addresses the effect of age on sensorimotor, anxiety-like behavior,
depressive-like behavior, spatial acquisition, and reference memory. Data presented
herein illustrate that age does not affect general locomotor activity and basic tests of
motor function. In contrast, age appears to adversely affect tasks requiring integration of
motor activity and balance as seen in the balance beam component of the mNSS and
inclined plane test. In both tests, aged animals performed worse than the young adult
animals. In one measure, grip-strength, the aged animals performed better than young
adult animals. This is likely not a true reflection of strength but rather a consequence of
increased body weight as described by Maurissen, et al 537. Young-adult animals
utilized in this work weighed 256.92 ± 1.56 grams while aged animals weighed 391.58 ±
10.53 grams (data reported as mean ± standard error of the mean).
In the elevated plus maze, aged animals made fewer entries into the open arms and
also spent less time in the open arms. This does not appear to be a consequence of
impaired motor activity based on sensorimotor results (above) and no difference in
average speed in the open arm between young-adult and aged animals. Within the
closed arms, aged animals did not explore to the same degree as the young-adult
animals, as evidenced by a reduced average speed within the closed arm.
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Changes in immobility time were reported in the forced swim test. Young-adult and aged
animals differed significantly in the number of immobile episodes and the total immobility
time. Again, this does not appear to be due to fatigue or changes in motor ability as the
total distance traveled and average speed was not different between age groups.
Similarly, total distance and average speed was not significantly different between aged
and young-adult animals, nor was latency to first immobile episode.
Animal age appears to reduce spatial acquisition and reference memory ability as
determined with the Morris Water Maze, a well-accepted and utilized cognitive test, in
terms of both learning and memory. The Morris Water Maze test revealed significant
differences in spatial acquisition between groups, both in terms of latency to find the
platform and total distance swam. While Hamm et al showed an age-related impairment
in spatial acquisition (learning) ability after traumatic brain injury, differences at baseline
were not discussed 526. Reference memory, as assessed using a probe trial, also
appears to be worsened with age. The aged animals made fewer entries, spent less
time, and traveled a shorter distance within the counter area. Furthermore, aged
animals spent less time exploring near the counter area as determined using the
proximity index. Once again, these results cannot be explained based on motor
differences as groups exhibited comparable baseline ability on Day 1 of spatial
acquisition.
These studies illustrate fundamental differences in animal behavior and function
associated with aging. The process of aging, a risk factor for numerous neurologic and
neurodegenerative diseases such as stroke, is rarely considered in preclinical models of
stroke and therefore, the effect of aging on a variety of behavioral assays utilized in poststroke assessment has been underreported. Due to behavioral differences associated
with age, it is clear that animal models seeking to compare young adult and aged
animals may need to normalize to baseline ability prior to injury/disease onset rather
than simply reporting absolute measurements post-experimental manipulation.
Furthermore, the use of aged animal models may necessitate a specifically designed
functional assessment for this population.
For example, the modified Neurologic
Severity Score (mNSS), is widely utilized in post-stroke assessment, yet has never been
validated in an aged animal model. In comparing young adult and aged animal
performance on the mNSS, striking differences emerge, particularly on the balance
beam task. Notably, in a preclinical study of traumatic brain injury by Hamm et al,
different sized balance beams were utilized for young versus aged animals to reach a
similar level of difficulty after injury 526. Other subsets of the mNSS such as placing,
raising by the tail, and reflexes did not appear to be affected by age.
4.5. CONCLUSION
As evident in this work, age affects performance on a variety of behavioral assessments
such as the inclined plane, balance beam, elevated-plus maze, forced-swim test, and
Morris Water Maze. These differences can not be explained based on motor ability
alone as aged animals exhibit similar performance on the rotarod and total locomotor
activity assessment. Rather, the data suggest an age-related impairment in the ability to
integrate sensorimotor cues such as balance on the inclined plane and balance beam
tests. This work may have implications in preclinical models of neurologic disease
employing the use of aged animals, such as stroke. Furthermore, the data indicate clear
functional differences associated with aging but the biologic causes of these differences
remain to be elucidated.
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TABLES AND FIGURES
Table 4.1. Modified Neurologic Severity Score (mNSS). The mNSS utilizes a variety of
sensorimotor, balance, and reflex tests to assign a neurologic score. One point is
assigned for the inability to perform the tests or for the lack of a tested reflex. Severe
injury is defined as 13-18 points, moderate injury 7-12 points, and mild injury 1-6 points.
Modified Neurologic Severity Score (mNSS)
Motor Tests
Muscle status - Hemiplegia
Raising by tail (normal = 0, maximum = 3)
1.) Flexion of forelimb
1.) Flexion of hindlimb
1.) Head moving more than 10 to vertical axis within 30 seconds
Placing on floor (normal = 0, maximum = 3)
0.) Normal walk
1.) Inability to walk straight
2.) Circling toward paretic side
3.) Falling down to paretic side
Sensory Tests (maximum of 2 – 1 for each test)
1.) Placing (visual and tactile test)
1.) Proprioception (deep sensation)
Beam Balance (normal = 0, maximum = 6)
0.) Balances with steady posture
1.) Grasps side of beam
2.) Hugs the beam and one limb falls down from beam
3.) Hugs the beam and two limbs fall down from beam, or spins on beam
4.) Attempts to balance on beam but falls off (>40 seconds)
5.) Attempts to balance on beam but falls off (>20 seconds)
6.) Falls off without attempting to balance or hang on to beam (<20 seconds)
Reflex absence & abnormal movements (normal = 0, maximum = 4)
1.) Pinna reflex (head shake when touching auditory meatus)
1.) Corneal reflex (eye blink when touching cornea lightly with cotton)
1.) Startle reflex (a motor response to a brief noise from snapping a clipboard paper)
1.) Seizures, myoclonus, myodystony
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Figure 4.1. The effect of age on sensorimotor assessment with A) Grip Strength Test, B)
Inclined Plane Test, and C) Total Locomotor Activity. The grip strength and inclined
plane tests were significantly different between young-adult and aged animals (p<0.05)
with aged animals exhibiting stronger grip force and young-adult animals performing
better on the inclined plane. No difference in total locomotor activity was measured.
Statistical significance determined using unpaired t-test. *, **, *** denote statistical
significance (p<0.05, p<0.01, and p<0.001).
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Figure 4.2. Fixed-speed (A) and accelerating (B) rotarod test in young-adult and aged
animals. The fixed speed test included trials at 12, 16, 20, 24, 28, 32, 36, and 40 RPM.
The accelerating test was conducted over five minutes while reaching a maximum speed
of 50 RPM. No statistically significant difference was seen between young-adult and
aged animals on either variation of rotarod testing.
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Figure 4.3. Reduced performance on the balance beam subtest (part of mNSS) in aged
animals. Aged animals were comparable to young-adult animals in all mNSS subtests
except for balance beam in which young animals excelled in contrast to aged animals.
Statistical significance determined using unpaired t-test.
* denotes statistical
significance (p<0.05).
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Figure 4.4. Effect of age on behavior using the elevated plus maze assessment. Aged
animals made fewer entries into the open arms (A), spent less time in the open arms (B),
but did not differ in average speed in the open arms (C). In the closed arms, young
animals explored more readily than the aged animals, resulting in a higher average
speed within the closed arms (D). Statistical significance determined using unpaired ttest. *, ** denote statistical significance (p<0.05 and p<0.01), respectively.
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Figure 4.5. Effect of age on total immobility time, immobile episodes, distance traveled,
and speed in the forced swim test. Aged animals spent more time immobile (A), had a
greater number of immobile episodes (B), but traveled a similar distance (C) at a similar
speed (D). There was no statistically significant difference in latency to first immobile
episode (E). Statistical significance determined using unpaired t-test. * denotes
statistical significance (p<0.05).
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Figure 4.6. The role of age in spatial acquisition determined using the Morris Water
Maze. Aged animals exhibited increased latency (A) and distance to platform (B) when
compared to young animals at later time-points, despite being nearly identical when first
exposed to the maze. Statistical significance determined using two-way ANOVA with
Bonferroni post hoc test. *, **, *** denote statistical significance (p<0.05, p<0.01, and
p<0.001).
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Figure 4.7. Reduction in reference memory in aged animals as measured in the Morris
water maze probe test. Aged animals made fewer entries (A), spent less time (B), and
traveled less distance (C) in the counter zone compared to young animals. The
proximity average (D) was lower amongst young animals, indicating greater reference
memory ability. Statistical significance determined using unpaired t-test. *, **, *** denote
statistical significance (p<0.05, p<0.01, and p<0.001).
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Chapter Five
This work builds upon the previous chapter by applying many of the previously described
functional assessments to a clinically relevant model of ischemic stroke at numerous
time points post-stroke. By correlating function and infarct volume over time, it becomes
clear that some functional assessments, such as the mNSS, correlate more strongly with
various infarcted regions, such as the striatum, at different time points. The model of
ischemic stroke utilized in this work in aged rodents produces both large cortical and
striatal strokes, whereas many studies utilizing young animals produce only striatal
strokes due to strong collateral circulation within the cortex.
Consequently, we
demonstrate the potential utility, of specific functional outcomes as an experimental
endpoint in preclinical studies to more closely replicate the clinical scenario.
The Role for Infarct Volume as a Surrogate Measure of Functional Outcome
Following Ischemic Stroke in Preclinical Studies
Ryan C. Turner, Kenneth H. DiPasquale, Aric F. Logsdon, Zhenjun Tan, Rae R.
Matsumoto, Jason D. Huber, Charles L. Rosen
This work is currently in preparation for publication submission.
ABSTRACT
The failed translation of proposed therapeutic agents for ischemic stroke from preclinical
to clinical studies has led to increased scrutiny of preclinical studies, namely the model
and outcome measures utilized. Preclinical studies routinely use infarct volume as an
experimental endpoint or measure in studies employing young-adult, healthy male
animals despite the fact that clinically, ischemic stroke is a disease of the elderly,
predominantly affecting females, and improvements in functional outcome from pre- to
post-intervention remains the most widely utilized assessment. The validity of infarct
volume as a surrogate measure for functional outcome remains unclear in clinical
studies, as well as preclinical studies, particularly those utilizing a more clinicallyrelevant, aged thromboembolic model. In this work, we addressed the relationship
between acute and subchronic functional outcome and infarct volume using a variety of
functional assessments ranging from subjective measurements such as the modified
Neurologic Severity Score (mNSS), to objective measurements such as grip strength
and performance on the inclined plane.
5.1. INTRODUCTION
Ischemic stroke remains a leading cause of morbidity and mortality worldwide and is
associated with significant direct and indirect costs 538. Present treatment of ischemic
stroke is limited to thrombolysis, achieved via either mechanical or pharmacological
means, both of which are limited to a small cohort of patients based on time of
presentation after stroke onset and an extensive list of contraindications. Consequently,
there remains a large unmet need for either alternative treatment options or a means for
The development of a successful
increasing eligibility for thrombolysis 504.
neuroprotectant, since discovery of the ischemic penumbra by Astrup and colleagues 150,	
  
539,	
   540, has been the focus of extensive research in ischemic stroke and produced over
100 candidates progressing to clinical trials based on the work of over 1000 preclinical
studies 8. Unfortunately, none of these proposed neuroprotective agents have translated
from bench-to-bedside successfully 8.
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Reasons for the failed translation remain speculative; however, advisory groups
composed of leaders in the field have identified numerous potential reasons for the lack
of successful translation 47,	
   135,	
   523,	
   541. These include the animal models and outcome
measures utilized. The vast majority of preclinical studies have employed healthy,
young-adult male animals, despite the fact that stroke is largely a disease of the elderly
and the female gender9,	
   523. The aged brain not only responds to an insult or injury
differently, but also exhibits less restorative capacity in comparison to the healthy and
young brain 9,	
   33,	
   51,	
   508,	
   542,	
   543. Additionally, preclinical studies emphasize histological
outcome measures, namely infarct volume quantification, whereas the focus of clinical
studies is on functional assessments and restoration of physical and cognitive skills 523,	
  
544. How infarct volume relates to functional outcome is a subject of controversy with
clinical studies demonstrating a moderate correlation (Spearman’s rho of 0.43 – 0.59
depending on the study) between final infarct volume and function assessed using
common scales of neural injury 381,	
   545. Preclinical studies have demonstrated a
multitude of findings depending on the model of ischemia, functional assays performed,
method of correlation, and time points assessed post-ischemia 546-‐554. Variances and
discrepancies in these findings are difficult to interpret due to the aforementioned
variables as well as the use of generally healthy, young-adult animals in the vast majority
of studies, a population that fails to replicate the clinical population afflicted with ischemic
stroke 10.
In this work, we investigate for the first time in an aged thromboembolic model of
ischemia and tPA-mediated reperfusion the relationship between infarct volume and
infarct location on functional outcome. Specifically, we address the following questions:
1) do acute decrements in functional ability following ischemia correlate with the location
or size of the infarct; 2) do chronic deficits in function equate to larger infarct volumes; 3)
do acute functional deficits correlate with larger infarcts chronically; and 4) does the time
point of assessment indicate the inclusion or exclusion of certain functional
assessments?
We seek to address these questions in what we believe represents a more clinicallyrelevant preclinical model of ischemic stroke. The use of functional assessments is
emphasized in clinical studies and therefore needs to be considered in preclinical work.
By incorporating the use of a functional assessment array in a more relevant model of
ischemia, we address for the first time using this model the relevance of histological
measures as a surrogate measure of outcome. This work illustrates the importance of
functional ability as an outcome measure in preclinical ischemic stroke studies on the
basis of more closely replicating clinical experience. A range of functional assessments
were included in an effort to address multiple components of sensorimotor ability
(strength, balance, etc).
5.2. MATERIALS AND METHODS
5.2.1. Chemicals and Animals
All chemicals used in this study were of pharmaceutical grade and purchased from
Sigma Aldrich (St. Louis, MO), unless stated otherwise. Human recombinant tPA was
gifted by Genentech (San Francisco, CA). Female Sprague-Dawley rats were acquired
from Hilltop Animal Laboratory (Scottsdale, PA). All animals used in this work were
obtained between 18-21 months of age from an aging colony established at the supplier.
Animals were housed under 12 hour light/12 hour dark conditions with food and water
available ad libitum. Animals were acclimated for a minimum of seven days prior to all
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experimental procedures. All experimental protocols were approved by the West Virginia
University Animal Care and Use Committee.
5.2.2. Surgery: Middle Cerebral Artery Occlusion (MCAO)
Rats were anesthetized using inhaled isoflurane (4% induction, 2% maintenance) from
Halocarbon (River Edge, NJ) and underwent thromboembolic MCAO as previously
described. Reperfusion was achieved through administration of human recombinant
tPA (5 mg/kg i.v., femoral vein; 30% bolus and 70% infused over 30 minutes using a
syringe drive). Ischemia was defined as a perfusion drop across the MCA territory of
>80% as determined by laser Doppler measurements. Successful reperfusion was
considered upon restoration of blood flow to >80% of baseline values within 30 minutes
of tPA administration. The time of tPA administration was varied from 2-6 hours to
produce ischemia of a multitude of severities and consequently, infarcts of different
sizes. Rats were then divided into acute and chronic assessment groups with the acute
group being sacrificed at 24 hours post-MCAO and the chronic group at 21 days postMCAO.
5.2.3. Behavioral Testing
All functional testing was performed at baseline to obtain a baseline value for
normalization on an animal-by-animal basis, based on previous experience of the
authors and the potential for weight and size-related effects 538. There was no more
than 1 week between baseline testing and induction of MCAO. Following MCAO, testing
occurred at 24 hours, 72 hours, 7 days, 14 days, and 21 days in the chronic assessment
paradigm and only at 24 hours in the acute paradigm, immediately prior to sacrifice.
5.2.3.1. Modified Neurological Severity Score (mNSS)
The mNSS, described previously by Watanabe and colleagues 529, is a widely used
method for assessing the severity of functional deficits after neurological injury in
rodents. The test includes measures of sensorimotor performance and basic reflex
integrity (Table 5.1). The balance beam used was a synthetic composite material and
possessed a square profile with rounded corners and measured 4 x 4 cm.
5.2.3.2. Grip Strength
The Grip Strength Meter was acquired from Columbus Instruments (Columbus, Ohio).
This apparatus is composed of a load cell and interchangeable grip attachment. This
work utilized the T-bar attachment. A total of 5 measures were taken for forelimb grip
strength for each rat and averaged to produce a composite score at each time point.
The rats were grasped by the tail and nape of the neck, forepaws placed onto the bar,
and pulled in a straight line away from the load cell by gripping the animal at the base of
the tail.
5.2.3.3. Activity Monitoring
Activity was recorded using an automated monitoring system from San Diego
Instruments (San Diego, CA). Rats were given 1 hour to acclimate to the testing room
prior to initiation of testing. Each chamber for testing consisted of a Plexiglass housing
surrounded by a photobeam array (16 x 16) to detect movements in the x-y plane. A
separate 8 photobeam array detected rearing activity. Activity was recorded over a
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period of 30 minutes and included measures of ambulatory, fine, rearing, and total
activity in increments of 5 minutes.
5.2.3.4. Inclined Plane
An inclined plane was constructed to model that described by Rivlin and Tator 531. The
device consisted of an 18 x 18 cm platform with a textured, rubberized coating. The
platform was affixed to a base and hinged on one side, allowing rotation from the
horizontal to 85°. Rats were placed on the apparatus such that the main axis of the
body was perpendicular to the inclined plane. The maximum incline angle at which the
rat could successfully maintain its position for 5 seconds was recorded as the plane was
elevated slowly. As the plane was elevated, the rat would make corrective adjustments
to maintain a normal posture using both fore- and hindlimbs. Rats were subjected to 5
trials on the inclined plane per assessment period with these measurements being
averaged to again produce a composite score.
5.2.4. Histology
At the time of sacrifice, animals in the acute group were saline perfused prior to brain
extraction and subsequent staining with 2% triphenyl tetrazolium chloride (TTC) as
previously described. The chronic group was perfused with 4% paraformaldehyde prior
to brain extraction and immersion in fixative for a minimum of 24 hours. Brains were
then processed using a Tissue-Tek VIP 5 automatic processor and paraffin embedded
using a Tissue-Tek TEC 5 embedding console system, both of which were acquired from
Sakura Finetek (Torrance, CA). Paraffin-embedded tissues were sectioned at 6 µm
using a Leica RM2235 microtome (Richmond, VA). Alternating sections were stained for
infarct volume assessment using standard protocols for hematoxylin & eosin (H&E) and
cresyl echt violet. Briefly, sections were deparaffinized using xylene and rehydrated
through a series of alcohol immersions progressing from 100% ethanol to 70% ethanol.
For H&E, sections were immersed in hematoxylin solution for 2.25 minutes, rinsed in
running tap water, and dipped in a 0.25% acid alcohol solution to differentiate. Slides
were again rinsed in running tap water and blued in Scott’s Tap Water Substitute for one
minute prior to immersion in 95% ethanol for 30 seconds and subsequent
counterstaining with Eosin Y for 30 seconds. For cresyl echt violet, sections were
stained in in cresyl echt violet solution (pH 2.5) for 4 minutes prior to dehydration and
clearance with xylene. These techniques allow for assessment of infarct volume despite
the presence of significant gliosis at chronic time points.
5.2.5. Infarct Volume Quantification
For quantification of TTC stained sections, images were acquired using a standard
flatbed scanner and quantified using Adobe Photoshop (San Jose, California). For
quantification of H&E and cresyl echt violet stained sections, images were acquired
using an Olympus AX-70 microscope (Center Valley, Pennsylvania) and quantified using
ImageJ (Bethesda, Maryland). All quantification was performed by a blinded observer.
5.2.6. Statistical Analysis
All data was analyzed using JMP 10 from the SAS Institute (Cary, NC). Correlations
between infarct volume and functional performance were assessed by the Spearman
rank-sum coefficient. Differences are considered to be statistically significant at the
P<0.05 level.
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5.3. RESULTS
5.3.1. Acute Impairments in Functional Performance on the mNSS Following MCAO in
Aged Rodents Correlate with Striatal Infarct Volume.
At 24 hours after MCAO, rats underwent functional assessment using the mNSS, gripstrength meter, inclined plane, and recording of spontaneous activity immediately prior to
sacrifice and infarct volume determination using TTC staining. A moderate correlation
was observed based on Spearman rank-order correlation between total mNSS score
and indirect striatal infarct volume (ρ = 0.45, P < 0.05) as well as the balance beam and
raising by the tail subtests of the mNSS (ρ = 0.41, P < 0.05; ρ = 0.36, P < 0.05;
respectively). Activity monitoring revealed a significant decline in the number of rearings
recorded post-stroke with a moderate correlation between rearing and striatal infarct
volume observed (ρ = 0.45, P < 0.05).
Both total mNSS and subtests of the mNSS universally failed to correlate with cortical
and total infarct volumes at 24 hours post-MCAO (Table 5.2). While mNSS failed to
correlate with striatal and cortical infarct volume in the acute period, both inclined plane
and grip strength indicated a strong trend towards correlation with cortical (ρ = 0.44, P =
0.05; ρ = -0.41, P = 0.07) and total (ρ = 0.42, P = 0.06; ρ = -0.42, P = 0.06) infarct
volumes but not striatal infarcts (Table 5.2).
The relationship between the various functional assessments and the edema index was
also determined as at 24 hours post-MCAO, significant edema is present and may
influence outcome as evident by the numerous proposed and tested therapeutic agents
targeting various elements of ischemic stroke pathophysiology associated with edema
development. Significant correlations were observed between total mNSS (ρ = 0.31, P <
0.05) and the inclined plane (ρ = 0.54, P < 0.05).
5.3.2. Total mNSS Scores Correlate with Cortical, Striatal, and Total Infarct Volume
When Assessed at 21 Days Post-MCAO.
Functional assessments were performed on Day 21 post-MCAO immediately prior to
sacrifice and infarct volume determination using hematoxylin and eosin (H&E) staining.
Moderate to strong correlations were observed between total mNSS and cortical (ρ =
0.56, P < 0.05), striatal (ρ = 0.62, P < 0.05), and total (ρ = 0.70, P < 0.05) infarct
volumes. Subtests such as the balance beam and raising by the tail also correlated with
various elements of infarct volume when both function and histology were assessed at
21 days post-MCAO (Table 5.3). Specifically, performance on the balance beam subtest
of the mNSS correlated with cortical and total infarct volumes (ρ = 0.75, P < 0.05; ρ =
0.75, P < 0.05; respectively) but not striatal. Raising of the tail, another subtest of the
mNSS, was related to striatal (ρ = 0.62, P < 0.05) and total (ρ = 0.54, P < 0.05) infarct
volumes but not cortical (Table 5.3).
No other assessments detected deficits or
impairments at Day 21 consistent with infarct volume (Table 5.3). The reasons for this
are unclear but likely include the gradual return of function with increased time postMCAO to a level frequently near, or approximating, the baseline.
5.3.3. Acute Deficits Determined Using the mNSS May Predict Cortical, Striatal, and
Total Infarct Volumes at 21 Days Post-MCAO in Aged Rodents.
Moderate to strong correlations were observed between total mNSS and cortical (ρ =
0.63, P < 0.05), striatal (ρ = 0.84, P < 0.05), and total (ρ = 0.81, P < 0.05) infarct volumes
in animals with functional performance assessed at 24 hours post-MCAO and infarct
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volumes determined histologically at Day 21 post-ischemia. Subtests such as the
balance beam and raising by the tail also correlated with striatal (ρ = 0.60, P < 0.05; ρ =
0.72, P < 0.05) and total (ρ = 0.59, P < 0.05; ρ = 0.53, P < 0.05) infarct volume but not
cortical infarction when function was assessed at 24 hours post-MCAO and histology
was assessed at 21 days post-MCAO (Table 5.4). No other assessments correlated with
any of the infarct measures (Table 5.4).
5.4. DISCUSSION
Failure of successful bench-to-bedside translation of proposed therapeutics for ischemic
stroke, namely neuroprotectants, has resulted in an extensive array of recommendations
for preclinical studies going forward. Some of the most notable and agreed upon
guidelines include the incorporation of functional and histological endpoints, prolonged
survival times post-MCAO, and perhaps most importantly, the consideration of more
clinically relevant models that address aging and/or comorbidities frequently afflicting
patients with ischemic stroke. This work shows for the first time in a thromboembolic
model of ischemic stroke using aged animals, the relationship between infarct volume
and functional impairment at both acute and chronic time points. Moderate to strong
correlations were observed between neurological scoring systems such as the mNSS
and infarct volume at numerous time points. Perhaps most notable is the strength and
persistence of this correlation between total mNSS score and striatal infarct volumes at
both Day 1 and Day 21. This finding is in contrast to comparisons between total mNSS
and cortical infarct volumes in which no correlation was observed at 24 hours postMCAO between function and volume, but a moderate to strong correlation was found at
21 days post-MCAO and when using Day 1 function as a predictor of Day 21 infarct
volume.
Why cortical infarct volumes do not correlate with function acutely remains unclear but
potential reasons include the impact of edema acutely following MCAO and disruption of
the functional circuitry as a consequence of striatal damage regardless of cortical
integrity. Edema occurs rapidly following ischemia and subsequent blood-brain barrier
disruption, likely reaching a maximum within the first five days post-ischemia and has
been shown to be associated with various neurological deficits identified in otherwise
healthy young-adult, male rats 555,	
   556. These findings are consistent with work presented
here in which edema correlated with the total mNSS score and inclined plane. Perhaps
more importantly, the striatum serves as a relay for numerous connections related to
motor and sensorimotor function in the rat. The striatum, composed of the caudate
nucleus, putamen, and ventral striatum (a combination of the nucleus accumbens and
surrounding areas), receives afferent connections from the cortex, substantia nigra, and
thalamic nuclei (centromedian and parafascicular). Efferent connections originating in
the striatum pass to the thalamus and substantia nigra, in addition to numerous intrastriatal connections (caudate to the putamen, putamen to the globus pallidus, etc).
Consequently, any lesion within the striatum can alter function of other brain regions and
result in anatomical changes outside of the ischemic territory such as thalamic
shrinkage. Therefore, impairments in function are likely regardless of cortical health,
diminishing the likelihood of strong volume-function correlations with regards to cortical
and total volumes acutely 557. This is particularly true with regards to the aged rodent
model utilized herein as cortical volumes are typically larger in this model due to reduce
collateralization with age and therefore, increased tissue susceptibility to ischemia 558.
There is less discrepancy in collateral flow with regards to the striatum between young
and aged rodents, resulting in more uniformity when considering striatal infarct volumes.
Delayed assessments post-stroke, such as those conducted within this work, generally
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display an improvement or recovery in function, a finding consistent with significant
plasticity of the rodent brain.
While the inclusion of functional assessments has been identified as a recommended
experimental endpoint in preclinical studies, there is little to no consensus as to the most
appropriate assessments. A variety of assays have been used in young-adult models
using primarily acute time points and have been shown to correlate with infarct volume
but have never been applied to an aged thromboembolic model with long-term
assessments. We demonstrate herein the applicability of the mNSS but undoubtedly
other tests may want to be explored, particularly those that are sensitive to higher order
functions such as cognition and complex sensorimotor behaviors. Importantly, the lack
of significant correlation between infarct volume and functional outcome at certain time
points with certain tests is not entirely surprising but indicates a need for more sensitive
functional measures following MCAO that display persistent deficits, a particular problem
in the likely less relevant but far more widely used young-adult models of ischemic
stroke. Similarly, the plasticity of the rodent brain that allows for functional recovery
may necessitate an array of functional assessments dependent on time post-infarct of
interest in order to capture both initial deficits and return of function prior to saturation
(generally baseline).
Limitations
There is an inherent bias within preclinical ischemic stroke work, particulary in aged
animals, with regards to long-term survival studies as animals with presumably the
largest infarctions expire prior to assessment at delayed time points, thus preventing
acquisition of data. Animals that survive for weeks post-MCAO generally have smaller
infarcts, as was the case within this work. Specifically, animals surviving to 21 days had
a total mNSS score of 6.39 ± 2.68 on Day 1 post-MCAO, consistent with a mild to
moderate impairment rather than a severe deficit. The lack of rodents exhibiting more
severe deficits chronically post-stroke is likely a product of minimal post-operative care
relative to the clinical scenario. Patients afflicted with stroke are often monitored
continuously both during and after ischemia with extensive critical care, intervention, and
rehabilitation support 564, a striking contrast to preclinical studies in which pain
medication and nutritional support are applied but little else. Consequently, severely
afflicted patients may survive whereas this is unlikely in animals.
Similarly, the eloquence of human behavior, a vital component of post-stroke
assessment in which patients are asked to communicate, both verbally and written, as
well as perform simple drawings and motor tasks, allows for the observation of abilities
the emphasize primarily motor, sensory, or cognition. In rodents most, if not all,
functional assessments require extensive motor ability. As such, when significant tissue
damage occurs within the striatum or motor-associated parts of the cortex, assessments
may be impaired due to reduced movement despite the fact that sensory and cognitive
abilities are in tact.
Without access to small animal imaging, this work required histological quantification of
infarct volumes and therefore necessitated animal sacrifice. As such, we were unable to
assess how acute infarct volume influences chronic functional assessments. Future
studies may want to address this question in a clinically relevant model of ischemia.
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TABLES

Table 5.1.
Description of the mNSS scoring system for neural injury that
incorporates assessments of reflex and sensorimotor abilities. Scores from each
subsection are summed to produce a cumulative score representing the overall
level of impairment. A score of 1-6 represents mild, 7-12 moderate, and 13-18
severe injury. Rats were assessed at baseline, day 1, day 3, day 7, day 14, and
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Table 5.2. Spearman correlation coefficients between histologic measures (edema index, cortical, striatal, and total
infarct volume) and functional assessments (mNSS, grip strength, inclined plane, and activity monitoring) at 24 hours
post-MCAO. A P < 0.05 was considered statistically significant. Data is presented as spearman correlation coefficient
(top) and P value (below).
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Table 5.3. Spearman correlation coefficients between histologic measures (edema index, cortical, striatal, and total infarct
volume) and functional assessments (mNSS, grip strength, inclined plane, and activity monitoring) at 21 days post-MCAO.
A P < 0.05 was considered statistically significant. Data is presented as spearman correlation coefficient (top) and P value
(below).
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Table 5.4. Spearman correlation coefficients between histologic measures (edema index, cortical, striatal, and total infarct
volume) determined at 21 days post-MCAO and functional assessments (mNSS, grip strength, inclined plane, and activity
monitoring) conducted at 24 hours post-MCAO. A P < 0.05 was considered statistically significant. Data is presented as
spearman correlation coefficient (top) and P value (below).
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Chapter Six
Traumatic brain injury, particularly repetitive traumatic brain injury in the form of
concussions, has been associated with the development of neurodegenerative disease
such as chronic traumatic encephalopathy. This is inherently alarming to those charged
with leading or representing certain athletic bodies and hence there are numerous
parties attempting to create distance between inherently dangerous activities and health
risk.
Consequently, alternative explanations have been proposed as precipitating
neurologic decline following repetitive trauma, perhaps the most prevalent being a
potential role for anabolic steroids. This work investigates this issue by administering
steroids in different paradigms, pre- and post-injury, and assessing a well-documented
marker of neural and axonal injury, amyloid precursor protein.
Anabolic Steroids and Head Injury
This work was published in Neurosurgery.
Citation: Mills JD, Bailes JE, Turner RC, Dodson SC, Sakai J, Maroon JC (2012)
Anabolic Steroids and Head Injury. Neurosurgery 70 (1): 205-210.
ABSTRACT
Background. The suggestion has been made that the neurologic changes seen in the
syndrome of chronic traumatic encephalopathy (CTE) may be due to exogenous
anabolic steroid use rather than traumatic brain injury (TBI).
Objective. The purpose of this study is to determine if the administration of anabolic
steroids alters the pathophysiology of traumatic brain injury.
Methods. Sixty adult male Sprague-Dawley rats were used. A linear acceleration model
of traumatic brain injury was used. Experimental groups were as follows: 1) pre-injury
anabolic steroids, 2) pre-injury placebo carrier, 3) anabolic steroids without injury, 4) no
steroids and no injury, 5) post-injury placebo carrier, 6) post-injury anabolic steroids.
Following a 30-day recovery period, rats were sacrificed and brainstem white matter
tracts underwent fluorescent immunohistochemical processing and labeling of beta
amyloid precursor protein, a marker of axonal injury. Digital imaging and statistical
analyses were used to determine if anabolic steroid administration resulted in a
significant change in the number of injured axons.
Results. There was no statistically significant difference in number of APP-positive
axons by immunohistochemical analysis between the pre-injury anabolic steroid group
and the pre-injury placebo carrier group. The same is true when comparing the steroids
+no injury with the no steroids+no injury groups and the post-injury steroids with the
post-injury placebo carrier groups.
Conclusion. Using a standard acceleration-deceleration laboratory model of mild
traumatic brain injury (MTBI), we have shown successful visualization of traumatically
injured axons with antibody staining of APP. Our results indicate there is no statistically
significant effect of anabolic steroids on the number of APP positive axons in the normal
(no linear acceleration injury) rodent corticospinal tract or medial lemniscus, nor is there
any statistically significant difference in the number following traumatic brain injury. Using
this model and within its limitations, we see no adverse effect or causative role of
anabolic steroid administration on the brain following MTBI using APP counts as a
marker for anatomical injury.
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6.1. INTRODUCTION
While the causal mechanisms of traumatic brain injury (TBI) cross a spectrum from
sports-related head impacts to blunt high speed motor vehicle injuries, the underlying
pathophysiology remains similar. Autopsy studies from patients with injury classifications
ranging from mild traumatic brain injury (MTBI) or concussion to severe traumatic brain
injury demonstrate diffuse injury to white matter tracts coursing from the cortex to the
brainstem. Initially, traumatic axonal injury (TAI) was thought to involve immediate axonal
tearing through the direct action of forces associated with the traumatic insult.
Recent experiments employing anterograde tracers have revealed that TAI is a
progressive event involving a focal impairment of axoplasmic transport leading to axonal
swelling and ultimate disconnection in the subsequent hours to days 559. Initial disruption
of the axon plasma membrane results in ion channel dysregulation and loss of calcium
homeostasis. Thereafter, a series of calcium dependent cascades are activated,
resulting in mitochondrial damage and cytochrome c release, activating a caspase-3
mediated apoptotic cascade of proteolytic cleavage of cytoskeletal substrates resulting
in the axonal disconnection characteristic of TAI 560, 561. The extent of TAI is a principal
determinant of morbidity and mortality following traumatic brain injury.
To date, no published study has been performed investigating the role of anabolic
steroids in the pathophysiology of TBI. The purpose of this study was to determine if
chronic administration of anabolic steroids prior to diffuse axonal injury in rats alters the
pathophysiology of traumatic brain injury. Furthermore, this study provides insight into
the suggestion that anabolic steroid use may be responsible for the pathological
alterations seen in Chronic Traumatic Encephalopathy (CTE).
6.2. MATERIALS AND METHODS
A total of six experimental groups were utilized in this work. Experimental groups were
as follows: 1) pre-injury anabolic steroids, 2) pre-injury placebo carrier, 3) anabolic
steroids without injury, 4) no steroids and no injury, 5) post-injury placebo carrier, 6) postinjury anabolic steroids. Following a 30-day recovery period, rats were sacrificed and
brainstem white matter tracts underwent fluorescent immunohistochemical processing
and labeling of beta amyloid precursor protein, a marker of axonal injury. Digital imaging
and statistical analyses were used to determine if anabolic steroid administration
resulted in a significant change in the number of injured axons. The experimental
groups and methodology is described in greater detail in subsequent sections.
6.2.1. Pre-Injury Steroid Administration
Four groups of ten (n=40) adult male Sprague-Dawley rats received anabolic steroids
(nandrolone) at a dosage of 15mg/kg/week for 12 weeks, or received a carrier placebo.
The animals were then subjected to an impact acceleration injury (or sham procedure)
resulting in TAI. The four groups therefore were: 1) anabolic steroids with impact injury;
2) anabolic steroids without impact injury; 3) impact injury without steroids; 4) no steroids
and no impact injury.
6.2.2. Post-Injury Steroid Administration
Two groups of ten (n=20) adult male Sprague-Dawley rats received either nandrolone at
a dosage of 15mg/kg/week or a carrier placebo for four weeks following an impact
acceleration injury. At one month post-injury, rats were sacrificed and following
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transcardial perfusion, their brainstems harvested and sagittal sections were prepared.
Immunohistochemical processing was performed to detect abnormal concentration of
amyloid precursor protein, the standard marker of TAI. Stereologic microscopic analysis
was performed to calculate the density of injured axons within the corticospinal tract and
medial lemnsicus.
6.2.3. Continuous Steroid Infusion
Subcutaneous continuous osmotic pumps were prefilled with nandrolone or carrier and
surgically implanted in rats. Animals received induction anesthesia using a modified
medical anesthesia machine. The animals were then shaved and prepared in sterile
fashion for surgery, followed by subcutaneous injection of local anesthetic into the
planned incision site. A 1cm midline incision between the scapulae was made and a
subcutaneous pocket was opened using hemostats. The osmotic infusion pump (Azlet;
Cupertino, California) was inserted into the pocket and the skin incision was closed. The
process was repeated at 6 weeks to obtain 12 weeks of nandrolone or carrier infusion.
6.2.4. Marmarou Impact Acceleration Injury 562
The rats were subjected to an impact acceleration injury (or sham injury procedure)
resulting in reproducible MTBI. Rats weighing between 350 and 400 grams received
induction anesthesia followed by endotracheal intubation and were maintained on
inhaled anesthetic using a modified medical anesthesia machine. The animals were then
shaved and prepared in sterile fashion for surgery, followed by subcutaneous injection of
local anesthetic into the planned incision site. A 3 cm midline incision in the scalp was
made, periosteal membranes were separated, exposing the bregma and lambda
sutures. A metal disk 10 mm in diameter and 3 mm thick was attached to the skull with
cyanoacrylate and centered between bregma and lambda. The animal was placed prone
on a foam bed with the metal disk directly under a plexiglas tube. A 450-gram brass
weight was dropped through the tube from a height of 2 meters striking the disk. The
animal was then ventilated on 100% O2 while the skull was inspected and the incision
repaired. When the animal recovered spontaneous respirations, the endotracheal tube
was removed and the animal was returned to its cage for postoperative observation.
Animals in the sham injury groups underwent an identical procedure with the exception
of the weight drop onto the skull. All procedures involving live animals were approved by
the Institutional Animal Care and Use Committee of West Virginia University, and were
performed according to the principles of the Guide for the Care and Use of Laboratory
Animals, published by the Institute of Laboratory Resources, National Research Council
(NIH publication 85-23-2985). The animals were housed in the small animal vivarium
under veterinary staff supervision. Each group received rat chow ad lib.
6.2.5. Tissue Processing and Immunohistochemical Analysis
Following 30 day post-injury survival, animals were euthanized with a lethal dose
injection of 0.5ml Ketamine and 0.5ml Xylazine. The animals were immediately perfused
transcardially with 200ml cold 0.9% saline to wash out all blood. This was followed by
4% paraformaldehyde in Millonigs buffer for 40 minutes. The entire brain, brainstem, and
rostral spinal cord were removed and immediately placed in 4% paraformaldehyde for 24
hours. Following 24 hours fixation, the brain was blocked by cutting the brainstem above
the pons, cutting the cerebellar peduncles, and then making sagittal cuts lateral to the
pyramids. The resulting tissue containing the corticospinal tracts and the medial
lemnisci, areas shown previously to yield traumatically injured axons, was then sagittally
cut on a vibratome into 40-micron sections. The tissue then underwent temperature
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controlled microwave antigen retrieval using previously described techniques 563569. The
tissue was pre-incubated in a solution containing 10% normal goat serum (NGS) and
0.2% Triton X in PBS for 40 minutes.
The tissue was incubated in polyclonal antibody raised in rabbit against beta amyloid
precursor protein (APP) at a dilution of 1:200 in 1% NGS in PBS overnight. Following
incubation in primary antibody, the tissue was washed 3 times in 1% NGS in PBS, then
incubated in a secondary anti-rabbit IgG antibody conjugated with Alexa 488 fluorophore
(Molecular Probes; Carlsbad, California) for two hours. The tissue underwent a final
wash in 0.1M phosphate buffer and then was mounted to a glass slide using an anti-fade
agent and a coverslip applied. The slides were sealed with acrylic and stored in the dark
in a laboratory refrigerator 564.
A stereological method was used to determine an unbiased estimate of the number of
APP positive axons per cubic mm in the corticospinal tract and medial lemniscus. The
optical fractionator technique utilitizing StereoInvestigator 7.0 (MBF Bioscience;
Williston, Vermont) and a Nikon Eclipse microscope with 4x and 20x objectives was
performed. Sagittal APP stained specimens were examined with low magnification and
regions of interest were drawn incorporating the corticospinal tract and medial
lemniscus. The software then selected random 50 mm2 counting frames with depth of 15
mm, and APP positive axons were marked. The volume of the ROI was determined
using the Cavalieri method, the volume of the sum of the counting frames was
calculated, the sum total of injured axons within the counting frames was calculated, and
an estimate of the number of APP positive axons per cubic mm was calculated.
6.3. RESULTS
In sham injured animals receiving either nandrolone or carrier, axons throughout the
medullary corticospinal tract and medial lemniscus demonstrated a paucity of labeling for
APP. These rare labeled axons did not demonstrate vacuolization, swelling, or
breakdown; typical characteristics of traumatic axonal injury. In comparison, evaluation
of axons from animals 30 days post-injury demonstrated focal labeling of APP within
swollen contiguous and terminal axon segments, consistent with previous findings
suggestive of impaired axoplasmic transport in traumatic axonal injury. These APP
positive injured axons had similar appearance irrespective of the pre-injury treatment
with nandrolone or carrier (Figure 6.1).
The stereologic optical fractionator method was utilized to determine an unbiased
estimate of the number of APP positive axons per cubic mm within the corticospinal tract
and medial lemnsicus. This demonstrated no statistically significant quantitative
difference between the injured animals receiving either carrier or nandrolone; 29,757 ±
6,185 and 27,301 ± 3,772 axons per mm3 respectively, (Figure 6.2). Likewise, there was
no significant difference between sham injured animals receiving either nandrolone or
carrier; 1,554 ± 759 and 1,632 ± 827 axons per mm3 respectively. As expected, a
significant difference was observed between the sham injured and injured animals,
irregardless of nandrolone or carrier.
To determine if nandrolone would effect injury mechanisms and cellular recovery
following injury, the second experimental design was deployed. Again, the stereologic
method was utilized to determine an unbiased estimate of the number of APP positive
axons per cubic mm. This demonstrated no significant quantitative difference between
the injured animals receiving either carrier or nandrolone; 28,136 ± 7,160 and 25,448 ±
6,955 axons per mm3 respectively, (Figure 6.3). Additionally, there was no significant
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difference between the four groups of injured animals, irrespective of the timing or
exposure to nandrolone.
6.4. DISCUSSION
This work is necessitated by the fact that the use of anabolic-androgenic steroids (AAS)
has increased in recent decades, particularly among athletes seeking a competitive
advantage 565-567. According to vandenBerg et al., approximately 1.5% to 2.5% of US
adolescents routinely use anabolic steroids 568. The rate of use escalates to between
15% and 30% amongst community weight trainers 569. Worse yet is that this issue is far
from isolated to adult athletes - 10% of users are teens according to recent estimates,
with the majority being young males 569. Use among male adolescents reaches 4.5%,
with school sponsored sport participants more likely to use anabolic steroids 570. Not
surprisingly, this same group is most likely to suffer TBI.
Sports or recreational activity-associated MTBI is now believed to occur in at least 1.7
million people annually in the United States 571 with some estimating the prevalence as
two to three times greater. Additionally, football-specific studies report that 47% of high
school football players sustain a concussion annually 572. Players suffering a concussion
are likely to suffer a second concussion, and multiple concussions are associated with
slower recovery of neurologic function 573. Recent evidence from a survey of retired NFL
players indicates that multiple concussions have long term neurologic consequences,
including increased risks of clinical depression 574. The suggestion has been made that
the long-term neurologic changes seen in retired NFL players and other competitive
athletes is due to the increased prevalence of steroid use, which would appear plausible
due to the 9.1% self-reported use of anabolic steroids during the playing careers of nowretired professional football players 575.
The syndrome of CTE has been recognized as an important consequence of repetitive
MTBI in contact sports 	
  420, particularly football. It is believed to represent a milder form of
exposure to multiple head contacts or violent collisions than is dementia pugilistica which
is present in approximately 17% of retired professional boxers 	
   421,	
   576. The
neurobehavioral syndrome of CTE affects the brain’s emotional circuitry, expressed as
mood lability, depression, failed business and personal relationships, alcohol and drug
abuse, and suicide 	
  410,	
   574. Using antibody staining for tau protein, the neuropathological
picture of CTE has been firmly delineated as tauopathy expressed as neurofibrillary
tangles and neuritic plaques 	
  423. These NFTs and NTs have been shown to be the result
of repetitive MTBI in several models, and brain trauma is the only known cause of these
typical NFTs and NTs.
The suggestion has been made that the pathologic alterations in CTE could instead be
attributed to the interaction of exogenous anabolic steroids, however, to date no
experimental paradigm has been carried out to attempt to discern the effects on the
mammalian brain of a maintenance administration of testosterone combined with a TBI.
Since a controlled clinical trial is unlikely to be performed, we attempted to answer, in a
straightforward manner, the question of whether a potentially synergistic effect exists
between anabolic steroids and MTBI. Using a standard acceleration-deceleration
laboratory model of MTBI, we have shown successful visualization of traumatically
injured axons with antibody staining of APP. Our results disclosed no effect on the
number of APP positive axons in the rodent corticospinal tract or medial lemniscus, nor
was there any difference in the number following traumatic brain injury.
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To the best of our knowledge, the available scientific and medical literature does not
contain any studies which incriminate anabolic steroids in causing neuronal damage,
loss, or vulnerability following TBI. In conclusion, using this model and within its
limitations, we see no adverse effect or causative role of anabolic steroid administration
on the brain following MTBI using APP counts as a marker for anatomical injury. To the
contrary, our clinical research has shown that the risk of CTE is most likely related to
exposure to repetitive MTBI with a tendency towards a genetic predisposition,
specifically the presence of the ApoE3 allele	
  422,	
  423,	
  426.
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FIGURES

Figure 6.1. Micrographs of sagittal sections through rat corticospinal tract following
immunohistochemical processing for APP. Injured axons, represented by arrows, had
similar appearance in rats receiving either 12 weeks of continuous steroid infusion or
carrier infusion. Panel 1a.) steroids and injury, 1b.) no steroids and injury, 1c.) steroids
and no injury, 1d.) no steroids and no injury.
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Figure 6.2. Graph demonstrating the density of APP positive axons in corticospinal
tracts and medial lemnisci in sham impact injured animals receiving either carrier of
nandrolone prior to injury. There was no statistical significance between carrier and
steroid-treated groups within any of the respective treatment paradigms (P > 0.05).
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Figure 6.3. Graph demonstrating the density of APP positive axons in corticospinal
tracts and medial lemnisci in rats receiving either post-injury steroids or post-injury
carrier. There was no statistical significance between carrier and steroid-treated groups
within any of the respective treatment paradigms (P > 0.05).
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Chapter Seven
Traumatic brain injury and concussion specifically, remain a major issue on the athletic
and battlefield despite significant improvements in technology and materials that have
been incorporated in helmets.
As such, alternative measures of prevention are
desirable. One area of traumatic brain injury that remains uninvestigated, particularly
with regards to diffuse axonal injury, is how to restrict brain movement within the cranial
vault, thus reducing axonal injury and coup-contrecoup impacts. In this chapter we
apply observations from nature, specifically the woodpecker, that may prevent brain
movement and neural injury following trauma.
Internal Jugular Vein Compression Mitigates Traumatic Axonal Injury in Rat Model
by Reducing Intracranial Slosh Effect
This work was published in Neurosurgery.
Citation: Smith DW, Bailes JE, Fisher JA, Robles J, Turner RC, Mills JD (2012) Internal
Jugular Vein Compression Mitigates Traumatic Axonal Injury in a Rat Model by Reducing
the Intracranial Slosh Effect. Neurosurgery 70 (3): 740-746.
ABSTRACT
Background. Traumatic brain injury (TBI) remains a devastating condition for which
traditionally extra-cranial protection has been utilized in the form of helmets, which
largely fail to protect against intracranial injury.
Objective. The purpose of this study was to determine if the pathologic outcome after
TBI can be improved via slosh mitigation by internal jugular vein (IJV) compression.
Methods. Two groups of 10 adult male Sprague-Dawley rats were subjected to impactacceleration traumatic brain injury.
One group underwent IJV compression via
application of a collar prior to injury while the second group did not. Intracranial pressure
(ICP) and intraocular pressure (IOP) were measured before and after IJV compression
to assess collar performance. All rats were sacrificed after a 7-day recovery period, and
brainstem white matter tracts underwent fluorescent immunohistochemical processing
and labeling of beta amyloid precursor protein (APP), a marker of axonal injury. Digital
imaging and statistical analyses were used to determine if IJV compression resulted in a
diminished number of injured axons.
Results. IJV compression resulted in an immediate 30% increase in IOP and ICP. Most
notably, IJV compression resulted in greater than 80% reduction in the number of APPpositive axons as indicated by immunohistochemical analysis.
Conclusion. Using a standard acceleration-deceleration laboratory model of mild TBI,
we have shown successful prevention of axonal injury following IJV compression as
indicated by immunohistochemical staining of APP. We argue that IJV compression
reduces slosh-mediated brain injury by increasing intracranial blood volume, which can
be indirectly measured by intracranial and intraocular pressure.
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7.1. INTRODUCTION
Traumatic brain injury (TBI) continues to be one of the most common causes of death
and morbidity in persons under age 45, even in western societies. A reported 1.7 million
people suffer from TBI annually in the United States alone, resulting in an estimated per
annum total cost of over $60 billion	
   571. Historically, prevention of skull and brain injury
has focused on the use of helmets as external cranial protection. We believe this
approach is fundamentally flawed as irrespective of the benefits helmets have provided
for major penetrating brain injuries and skull fractures, both military personnel and
athletes are subjected to high velocity, acceleration-deceleration mechanisms which lead
to concussive injury 	
  577. In large part, the human brain’s relative freedom of movement
within the cranial cavity predisposes to both linear and rotational force vectors, with
resultant axonal tearing	
   578. We believe that helmets fail to address the linear and
rotational forces imparted on the brain following impact and therefore are inadequate for
prevention of traumatic axonal injury (TAI) and concussion.
The skull and spinal canal contains only nervous tissue, connective tissue and fat cells
and their interstitium, blood, and cerebrospinal fluid (CSF). These fluid contents do not
completely fill the rigid container delimited by the skull and bony spinal canal, leaving a
‘reserve volume’. The change in volume inside a container for a given change in
pressure is termed ‘compliance’. Increases in volume of the contents of the skull and
bony spinal canal, within the range of reserve volume, occur at low container pressures
(due to the high compliance of the system). In the presence of reserve volume, as is
seen in a normal physiologic state, acceleration to the skull can result in a differential
acceleration between the skull and its contents. As a consequence, the brain and fluids
collide with the inside of the skull	
   578. Considering the semi-solid properties of the
mammalian brain, we will refer to this effect as ‘slosh’.
While helmets are effective in preventing the infrequent penetration or fracture of the
skull, they have little ability to limit slosh effects. We believe that mitigating slosh by filling
the reserve volume (exhausting compliance) will significantly reduce the propensity for
differential motion between the skull and its contents. We reasoned that by mitigating
slosh, an accelerating force to the skull would tend to move the skull and its contents in
unison, preventing collisions amongst intracranial contents and therefore, avoiding brain
kinetic and vibrational energy absorption.
In an attempt to mitigate intracranial slosh it is important to recognize that the single
intracranial compartment that is most amenable to rapid, reversible change in volume
and pressure is the blood. The simplest and most rapid means of increasing the blood
compartment is to inhibit its outflow by mechanically obstructing the draining veins in the
neck. As such, the aim of this study was to test the hypothesis that reducing intracranial
and spinal canal compliance would mitigate brain injury due to acute skull acceleration
or deceleration (impact). We used a standardized mild TBI rat model to study the effects
of internal jugular vein (IJV) compression on brain injury	
  562,	
  579-‐581.
7.2. Materials and Methods
7.2.1. Animals
In this work two groups of ten (total of 20) male Sprague-Dawley rats weighing between
350 and 400 grams were used. Animals were acquired from Hilltop Animal Laboratory
(Scottdale, PA, USA) and housed under 12 hour light/12 hour dark conditions with rat
chow and water available ad libitum. All procedures involving live animals were approved
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by the Institutional Animal Care and Use Committee of West Virginia University, and
were performed according to the principles of the Guide for the Care and Use of
Laboratory Animals, published by the Institute of Laboratory Resources, National
Research Council (National Institutes of Health publication 85-23-2985).
7.2.2. Marmarou Impact Acceleration Injury Model 562 in Rats
Anesthesia was induced and maintained with isoflurane using a modified medical
anesthesia machine. Body temperature was controlled during the approximately 10
minute procedures using a homeothermic heating blanket with rectal probe, and
adequate sedation was confirmed by evaluation of response to heel tendon pinch. The
animals were shaved and prepared in sterile fashion for surgery, followed by
subcutaneous injection of 1% lidocaine local anesthetic into the planned incision site. A 3
cm midline incision in the scalp was made, and periosteal membranes separated,
exposing bregma and lambda. A metal disk 10 mm in diameter and 3 mm thick was
attached to the skull with cyanoacrylate and centered between bregma and lambda. The
animal was placed prone on a foam bed with the metal disk directly under a plexiglas
tube. A 450-g brass weight was dropped a single time through the tube from a height of
2 m, striking the disk. The animal was then ventilated on 100% oxygen while the skull
was inspected, the disk removed, and the incision repaired. When the animal recovered
spontaneous respirations, anesthesia was discontinued and the animal was returned to
its cage for post-operative observation 562, 579-581. Buprenorphine was used for postoperative analgesia.
7.2.3. Experimental Protocol
This work involved two groups, each consisting of 10 animals for a total of 20 animals.
Two groups were utilized, a control injury group and an experimental injury group. In the
experimental injury group the rats were fitted with a 15 mm wide collar, with two
compressive beads designed to overlay the IJVs and was tightened sufficiently to
provide mild compression of the veins without compromising the airway. The collar was
then fixed in circumference with a Velcro fastener. The collar was left in position for
three minutes prior to administrating experimental brain injury.
7.2.4. Assessment of Intracranial Reserve Volume
7.2.4.1. Intracranial Pressure (ICP) Measurement
ICP was measured in five animals using the FOP-MIV pressure sensor (FISO
Technologies; Quebec, Canada) as described by Chavko, et al 	
  582. The head of the rat
was shaved and prepped in sterile fashion for surgery. The rat was fixed in a stereotaxic
apparatus (model 962; Dual Ultra Precise Small Animal Stereotaxic Instrument;, Kopf
Instruments, Germany) and a 3 cm midline incision in the scalp was made. Periosteal
membranes were separated, exposing both bregma and lambda. A 2 mm burr hole was
drilled 0.9 mm caudal from bregma and 1.5 mm from the midline. The fiberoptic probe
was then inserted to a depth of 3 mm into the cerebral parenchyma.
7.2.4.2. Intraocular Pressure (IOP) Measurement
IOP was measured in all animals using the TonoLab rebound tonometer (Colonial
Medical Supply; Franconia, New Hampshire) as described in the literature	
   582-‐584. IOP
measurements were taken after induction of anesthesia in all animals and a second time
in the experimental group following application of the novel IJV compression device.
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Following application of the IJV compression device in the experimental injury group,
IOP readings were taken every 30 seconds while the compression device was in place.
7.2.5. Tissue Preparation and Immunhistochemical Labeling
At 7 days post-injury all animals (n=20) were anesthetized and immediately perfused
transcardially with 200 ml cold 0.9% saline to wash out all blood. This was followed by
4% paraformaldehyde infusion in Millonigs buffer for 40 minutes. The entire brain,
brainstem, and rostral spinal cord were removed and immediately placed in 4%
paraformaldehyde for 24 hours. Following 24 hours fixation, the brain was blocked by
cutting the brainstem above the pons, cutting the cerebellar peduncles, and then making
sagittal cuts lateral to the pyramids. The resulting tissue, containing the corticospinal
tracts and the medial lemnisci, areas shown previously to yield traumatically injured
axons, was then sagitally cut on a vibratome into 50 micron thick sections. The tissue
underwent temperature controlled microwave antigen retrieval using previously
described techniques 563. The tissue was preincubated in a solution containing 10%
normal serum and 0.2% Triton X in PBS for 40 minutes.
For amyloid precursor protein (APP) labeling, the tissue was incubated in polyclonal
antibody raised in rabbit against beta APP (#51-2700, Zymed, Inc.; San Francisco,
California) at a dilution of 1:200 in 1% NGS in PBS overnight. Following incubation in
primary antibody, the tissue was washed 3 times in 1% NGS in PBS, then incubated in a
secondary anti-rabbit IgG antibody conjugated with Alexa 488 fluorophore (A11008,
Molecular Probes; Eugene, Oregon), diluted at 1:200 for two hours. The tissue
underwent a final wash in 0.1M phosphate buffer and then was mounted using an
antifade agent and cover slipped. The slides were sealed with acrylic and stored in the
dark in a laboratory refrigerator 569.
7.2.6. Fluorescent Microscopy and Image Analysis
The tissue was examined and images acquired using a Olympus AX70 fluorescence
microscope system (Olympus; Tokyo, Japan). Ten digital images were obtained from the
tissue of each animal and images were then randomized. Individual injured axons were
independently counted and data was stored in a spreadsheet (Microsoft
Corp.,;Redmond, Washington). Differences between group means were determined
using paired t-tests and considered significant if the probability value was less than 0.05.
7.2.7. Stereological Quantification of Axonal Injury
A stereological method was used to determine an unbiased estimate of the number of
APP positive axons per cubic mm in the corticospinal tract and medial lemniscus. The
optical fractionator technique utilizing a StereoInvestigator 9.0 (MBF Bioscience,
Inc.,;Williston, Vermont) and a Olympus AX70 microscope with 4x and 40x objectives
was performed. Sagittal APP stained specimens were examined with low magnification
and regions of interest were drawn incorporating the corticospinal tract and medial
lemniscus. The software then selected random 50 micron counting frames with depth of
15 microns, and APP positive axons were marked. The volume of the region of interest
(ROI) was determined using the Cavalieri method, the volume of the sum of the counting
frames was calculated, the sum total of injured axons within the counting frames was
calculated, and an estimate of the number of APP positive axons per cubic mm was
calculated.
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7.3. RESULTS
7.3.1. Assessment of Intracranial Reserve Volume
7.3.1.1. Intracranial Pressure (ICP) Measurement
ICP was assessed both prior to and after application of the IJV compression device. The
baseline ICP was 10.23 ± 1.68 mmHg and was increased to 16.63 ± 2.00 mmHg
following IJV compression (Figure 7.1: p<0.01). Notably, this increase of greater than
30% from baseline occurred within seconds following IJV compression.
7.3.1.2. Intraocular Pressure (IOP) Measurement
IOP measurements were taken both before and after application of the IJV compression
device, similar to ICP recordings. The baseline IOP was 11.18 ± 2.27 mmHg and was
elevated to 16.27 ± 3.20 mmHg following IJV compression (Figure 7.2: p<0.01). The
increase of 31% seen in IOP following IJV compression is strikingly similar to that seen
in ICP following IJV compression, both in magnitude and rapidity of response (Figure
7.3).
7.3.2. TBI - Impact Acceleration Model
None of the animals died from the head trauma. Animals tolerated collar application
without any observed untoward effects for the duration of the experiment. Specifically,
there were no outward or visible signs of discomfort, intolerance, or respiratory difficulty.
All recovered without complication and exhibited normal behavioral and feeding habits
up until the day of sacrifice. At necropsy, the brains were grossly normal in appearance.
7.3.3. Stereologic Analysis of APP Positive Axons
To determine the density of injured axons in the corticospinal tracts and medial lemnisci,
the stereological optical fractionator method was used.
Compared to the normal
anatomy found in previous experiments with sham animals, control animals without the
collar demonstrated focal labeling of APP within many swollen contiguous and terminal
axon segments, consistent with impaired axoplasmic transport in traumatic axonal injury.
Following microscopic digital image acquisition from multiple areas within the
corticospinal tract and medial lemnisci from multiple tissue slices, counting of APP
positive axons in animals who received the IJV compression collar demonstrated much
fewer APP positive axons, at a frequency much more similar to sham animals, compared
to those undergoing injury without IJV compression (Figure 7.4). These abnormal axons
demonstrated typical morphological characteristics of traumatic injury, primarily swelling
and disconnection. By qualitative analysis, the experimental group showed (m ± sd)
13,540 ± 9808 vs. 77,474 ± 25,325 (p<0.01) APP positive axons/mm3 in the control
group (Figure 7.5).
7.4. DISCUSSION
7.4.1. Internal versus External Brain Protection
The main finding of this study is that compression of the IJVs for 3 min prior to head
trauma, led to physiological alterations in intracranial compliance, as evidenced by
modest increases in ICP and IOP, while simultaneously and markedly reducing the
pathologic index of primary neuronal injury in a standardized rat model of TBI. We had
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reasoned that the reduction in brain volume compliance would prevent the differential
motions between the cranium and the brain that lead to energy absorption and neuronal
primary and secondary injuries. These pathological changes include axonal tearing that
disrupt axoplasmic transport resulting in axonal swelling and activation of the apoptotic
cascades, as evidenced in this model by a statistically significant reduction in APP
counts of injured axons.
To date, no effective pharmacological treatment has been discovered for TBI. Although
omega-3 fatty acids such as docosahexaenoic acid (DHA), and progesterone	
   581, show
some promise in animal studies, efficacy in humans has not been proven, emphasizing
the importance of prevention in TBI	
   579,	
   580,	
   585. Heretofore, standard prophylactic
measures designed to protect the brain against injury in the case of head trauma have
emphasized external cranial prevention through the use of helmets. As effective as they
may be in preventing penetrating injuries and fractures, helmets have limitations in their
protective abilities, especially for concussion and axonal injury	
   577. The explanation may
be furthered by an analogy to automobiles: placing additional armor on the outside of
the car may not be as effective in preventing passenger injuries during collisions as
simply wearing a seat belt, or filling up the passenger compartment with an activated
airbag. To counteract this reality, our approach involves increasing resistance to venous
return and increasing intracranial blood volume, theoretically preventing or reducing the
brain movement inside the skull resulting from impact. The energy imparted to a nonsloshing brain space traverses its contents as a series of elastic collisions between
molecules--rather than being absorbed in the form of frictional, acoustic, and kinetic
energies associated with relative motion (shear and collision) between compartments. A
well known example of elastic collisions is that of Newton’s cradle (Figure 7.6) where the
energy imparted by striking of the first ball-bearing in a series of contiguous suspended
ball-bearings is transmitted through the series of contiguous ball-bearings to the last,
without apparent motion of those in between.
In our animal model, applying the collar increased intracranial volume as indicated by an
increase in ICP and IOP by 30% and 31%, respectively. In humans, safe, gentle
compression of IJVs dates back to 1918 when Quenkenstedt developed a simple test to
prove patency of the spinal column. In this maneuver, a spinal needle is placed in the
lumbar subdural space and then the IJVs are compressed causing a rise in spinal
pressure. IJV compression may also occur upon placement of tight fitting neck
stabilization collars, and have been shown to increase ICP	
   586, whereas wearing shirts
with tight collars or neckties, has also been shown to increase IOP	
   587. Notably, only mild
compressive pressure is required to partially occlude the IJVs as they are a low pressure
system, often with . As the inflow of cerebral arterial blood continues after partial cerebral
venous outlet obstruction, the intracerebral and venous pressure will increase until the
jugular venous resistance is overcome or the blood drainage is redirected to other
venous channels. In either case there is a reduction in intracranial compliance and a
modest increase in ICP.
7.4.2. Implications to Humans
Increasing intracranial blood volume to provide brain protection from head trauma and
blast injuries, in sports or on the battlefield, could be readily implemented by wearing an
elastic collar-type device (Figure 7.7). Mild compression of the IJVs, particularly if
applied along some length of the vein, would not pose any danger of airway or carotid
compression. Clothing and jewelry, some of which are restrictive in nature and may
apply some compression of the neck, are ubiquitously worn without any known adverse
effects.
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7.4.3. Do Analogous Mechanisms Exist in Nature to Limit Brain Trauma?
In terms of biological-inspired discovery, another species exposed to repeated head
trauma is the woodpecker. This bird experiences forces of 1500 G per peck, for 12,000
pecks a day, totaling about 85 million head impacts over its average lifespan	
   588. Its
protective mechanisms are all reminiscent of preventing slosh.
It restricts eye
movement by closing its thick inelastic eyelids on impact. A pectin structure within the
globe increases pressure and volume and thus prevents relative movement of the
vitreous and retina. Its CSF space is remarkably small resulting in low intracranial
volume compliance. Finally, woodpeckers have a hyoid and omohyoid structure similar
to that in man	
   589. Due to the direct proximity of the omohyoid atop the IJVs it is
intriguing to speculate that upon contraction of the omohyoid, perhaps with each peck,
the IJVs may be partially occluded and intracranial compliance exhausted.
7.4.4. Limitations
This was a pilot and proof of concept study which had sufficient power to identify a
difference between the treatment and control group in a cohort of 20 animals because of
the magnitude of the difference in outcome. This is a standardized measure of axonal
injury that may or may not be translatable to other types of trauma and axonal damage
in rats, much less other species, including man. Nevertheless, the immunohistochemical
technique we employed is specific for axonal damage and results in a reliable range of
measured damaged neurons.
In addition, the Marmarou model of accelerationdeceleration injury 	
  562 is an accepted and well-studied methodology by which to quantify
the extent of TBI, in which we, and others, have published experience	
   579,	
   580,	
   585. A
hallmark of this model is the ability to cause diffuse axonal injury as a consequence of
not only the initial impact but also the rebound experienced following injury as the animal
is placed on a foam pad with known spring constant. An essential component of this is
an unimpeded range of motion of the head and neck regions in particular. The IJV
compression device utilized in this work (Figure 7), composed primarily of an elastic
band with compression beads overlying the IJVs rather than a rigid material, did not
impair or alter the biomechanics of the model. The reduction in damaged axons, as
evidenced by a marked reduction in APP counts, in the experimental group with the IJV
compression device is highly statistically significant (p<0.01).
Additionally, we measured the change in ICP after applying the collar in five rats. There
may have been a variation of increase in ICP in the remaining test rats, but if anything,
this would be expected to reduce the variability within experimental groups. Our results
show that every study rat had a reduction in axonal injury greater than the 95%
confidence interval of the control group. We did not test the protective effect of
increasing intracranial volume from blast injury; however, the rationale for its
effectiveness is the same.
7.5. CONCLUSIONS
We conclude that venous compression in the neck reduced the extent of axonal injury in
a standardized mild TBI model in rodents. We suggest that our mechanism restricted
brain venous drainage and increased its blood volume, thus shifting intracranial
physiology to the steep part of the volume-compliance curve. The lack of compliance
inside the confines of the skull and spinal canal prevented slosh energy absorption and
the resultant axonal injury by causing them to approach a more elastic collision when the
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skull was struck during the weight drop method. Further research is needed to ascertain
whether higher species, including humans, may benefit from slosh mitigation during TBI.
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Figures

Figure 7.1.: Change in intracranial pressure (ICP) as a consequence of IJV
compression, p-value <0.01.
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Figure 7.2.: Change in intraocular pressure (IOP) as a consequence of IJV
compression, p-value <0.01.
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Figure 7.3.: Representative tracing of physiologic changes seen in intracranial pressure
(ICP) and intraocular pressure (IOP) over a 15 minute period caused by
application (arrow on left) and removal of IJV compression (arrow on right). Of
note is the rapid response seen in both ICP and IOP following IJV compression
as well as the duration for which these changes are sustained.
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Figure 7.4.: Corticospinal tracts stained for APP post-injury (a) control (b) application of
IJV compression device. Arrows represent injured axons.
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Figure 7.5.: Effect of IJV compression on axonal injury as indicated by APP staining, pvalue <0.01.
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Figure 7.6.: Newton’s cradle
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Figure 7.7.: IJV Compression Device (A) Actual device used in this study applied to a rat
traversing a blance beam. No observable changes in behavior were noted
following collar application with the rat.
(B & C) Artistic rendering of a
comparable device applied to a soldier on the battlefield and an athlete on the
football field, respectively.
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Chapter Eight
In this work, we build upon prior observations of reduced axonal injury associated with
internal jugular vein compression (Chapter Seven) by exploring the effect on neural
degeneration and glial activation. We also explore additional brain regions such as the
cortex, striatum, hippocampus, and cerebellum, whereas prior work focused only on the
corticospinal tracts.
Effect of Slosh Mitigation on Histologic Markers of Traumatic Brain Injury
This work was published in Journal of Neurosurgery.
Citation: Turner RC, Naser ZJ, Bailes JE, Smith DW, Fisher JA, Rosen CL (2012) Effect
of slosh mitigation on histologic markers of traumatic brain injury.
Journal of
Neurosurgery 117: 1110-1118.
ABSTRACT
Background. Helmets successfully prevent most cranial fracture and skull trauma but
TBI and concussion continue to occur with frightening frequency, despite the widespread
use of helmets on the athletic and battlefield. Protection against such injury is needed.
Objective. To determine if slosh mitigation reduces neural degeneration, gliosis, and
neuroinflammation.
Methods. Two groups of 10 adult male Sprague-Dawley rats underwent an impactacceleration traumatic brain injury. To one group a collar, inducing internal jugular vein
(IJV) compression, was applied prior to injury whereas the second group received no
manipulation prior to injury. All rats were sacrificed 7 days post-injury and the brains
fixed and paraffin-embedded. Sections were processed and stained for markers of
neural degeneration (Fluoro-Jade B), gliosis (Glial Fibrillary Acidic Protein), and
neuroinflammation (Ionized Calcium Binding Adapter Molecule 1).
Results. Compared to control animals, animals undergoing IJV compression resulted in
a reduction of degenerative neurons by 48.7-59.1%, reactive astrocytes by 36.8-45.7%,
and microglial activation by 44.1-65.3%.
Conclusion. We conclude that IJV compression, a form of slosh mitigation, markedly
reduces markers of neurologic injury in a common model of TBI. We believe slosh
mitigation may have potential for preventing TBI in the clinical population based on these
findings and those of previous studies.
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8.1. INTRODUCTION
Traumatic brain injury (TBI) remains an immense public health problem and a leading
cause of morbidity and mortality in those under 45 years old in the United States and
industrialized countries 590. Treatment options for TBI remain relatively limited in scope,
emphasizing control of edema and intracranial pressure (ICP) and subsequent
rehabilitation. While numerous therapeutic agents such as progesterone 581,	
   591-‐593 and
DHA 579,	
   580,	
   585 have been found to be neuroprotective in preclinical models, and some
are presently in clinical trials, few alternatives presently exist for the clinical management
of TBI. Furthermore, it is unlikely any treatment aimed at injury reversal will be as
effective as injury prevention.
Efforts aimed at preventing TBI have continued to focus on extra-cranial protection in the
form of helmets and improved helmet technology such as innovative shapes, shell
materials, and padding. Emphasis on helmet technology may not be ideal due to
limitations of helmets in preventing the acceleration-deceleration forces causing axonal
injury and subsequent concussion. Drawing on lessons from nature, such as the
woodpecker, may provide insight into protective mechanisms from repetitive TBI.
The woodpecker anatomy is notable for a multitude of reasons ranging from a small
subdural space to a unique tongue structure 594-‐596. The tongue is notable in that it
extends posteriorly from the base of the mouth, around the neck, over the occiput, and
into the right nostril 594. This arrangement, in which a muscular sling is formed in the
neck, has been identified as a possible shock absorber by limiting motion in the neck 594.
In fact, the long tongue and hyoid bone experience significant stress during collision, as
evident in biomechanical studies 595. The hyoid bone has been described by Wang, et al
as playing the role of a safety belt for the head of the woodpecker 595.
While human anatomy clearly differs from that of the woodpecker, some correlates do
exist in preventing TBI. For example, professional boxers are capable of sustaining
forces of large magnitude when prepared for the impact but suffer deleterious
consequences when the blow is unexpected.
Much of this has been attributed to a
tightening of the neck muscles, one of which is the omohyoid muscle. The omohyoid is
unique in that it consists of two muscle bellies joined by a tendon and closely overlies
and crosses the internal jugular vein (IJV), a rare anatomic relationship. Notably,
contraction of the omohyoid muscle upon yawning results in IJV compression and
Therefore, the
subsequent changes to intracerebral venous hemodynamics 597.
contraction of the omohyoid muscle, as well as other muscles in the neck, may serve a
protective effect in humans through stabilization of the neck, much like the tongue/hyoid
bone in the woodpecker. Furthermore, contraction of the omohyoid alters intracerebral
hemodynamics, which may serve as a protective mechanism by increasing intracranial
volume and reducing intracranial movement, minimizing the collisions experienced by
the brain within the skull.
As such, Smith et al postulated that a reduction in intracranial compliance via increased
intra-cerebral volume would result in reduced brain injury 598. This theory, based on the
concept of slosh, has been thoroughly investigated in other applications, such as rocket
propellants, by groups such as NASA. Ibrahim et al describe slosh as the motion of a
given liquids’ free surface within a container 599. Upon colliding with the surface
container, energy transfer occurs amongst the involved surfaces 599. Notably, fluid
density must be considered when calculating energy dissipation and motion as it relates
to slosh. In the previous work by Smith, et al, intracranial slosh was believed to be
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prevented through IJV compression, thought to result in increased intracranial vascular
volume as evident based on correlative physiologic measures such as intracranial and
intraocular pressure.
Consequently, reduced motion of the cranial contents was
believed to occur during trauma, reducing measures of axonal injury by 83% 598.
While axonal injury was markedly reduced via internal jugular vein (IJV) compression,
presumably due to a reduction in associated slosh mitigation, it was previously unclear
to what extent IJV compression alters the response of glial cells to neurologic injury
following TBI. Glial cells are likely to influence outcome after TBI significantly as it is well
known that astrocytes, oligodendrocytes, and microglia are known to outnumber neurons
in humans, and play a clear role in maintaining homeostasis and normal function within
the brain 600,	
  601.
8.2. MATERIALS AND METHODS
Tissue samples were obtained from the animals studied by Smith et al. 598 All
procedures involving live animals were approved by the Institutional Animal Care and
Use Committee of West Virginia University, and were performed according to the
principles of the Guide for the Care and Use of Laboratory Animals, published by the
Institute of Laboratory Resources, National Research Council (National Institutes of
Health publication 85-23-2985).
8.2.1. Experimental Protocol
In brief, twenty male Sprague Dawley rats weighing between 350 and 400 g were tested.
Anesthesia was induced and maintained with isoflurane and temperature regulated with
a homeothermic heating blanket. The experimental injury group (10 rats) were fitted with
a 15 mm wide collar, with two compressive beads designed to overlay the IJVs and was
tightened sufficiently to produce mild compression of the IJVs without compromising the
airway. Increases in intraocular and intracranial pressure confirmed IJV compression
598. The remaining rats were the control group. The collar was left in position for three
minutes prior to administrating experimental brain injury. All animals were subjected to a
standardized acceleration-deceleration head injury model in which a 450-gram weight
was dropped from a height of 2 meters, striking a brass disk previously surgically affixed
to the skull 562,	
  602.
8.2.2. Tissue Preparation for Histology and Immunohistochemistry
At 7 days post-injury all animals (n=20) were anesthetized and immediately perfused
transcardially with 200 ml cold 0.9% saline. This was followed by 4% paraformaldehyde
infusion in Millonigs buffer for 40 minutes. The entire brain, brainstem, and rostral spinal
cord were removed and immediately placed in 4% paraformaldehyde for 24 hours.
Following 24 hours fixation, the brain was blocked into 2 mm thick sections. The first
section, from the forebrain, was taken from 1.72-3.72 mm from bregma. The second
section, from the cerebellum, was taken from 9.12-11.12 mm from bregma. The resulting
tissue was then processed using the Tissue Tek-VIP 5 Automatic Tissue Processor
(Sakura Finatek; Torrence, California) and embedded into paraffin using a Tissue-Tek
Tec 5: Tissue Embedding Console system (Sakura Finatek; Torrence, California). These
embedded tissues were then sliced at a thickness of 6 µm using a Leica RM2235
microtome (Leica Microscopes; Buffalo Grove, Illinois) and the slices were mounted on
glass slides for staining. All slides were heat-fixed and de-paraffinized via a series of
xylene and alcohol washes.
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8.2.3. Cresyl Violet
For cresyl violet staining, the tissue was incubated in 0.1% cresyl violet solution for 10
minutes. Following the incubation, the tissue was rinsed in dH20 and differentiated in
95% ethyl alcohol for 30 seconds. Following the differentiation, the tissue was washed 2
times in xylene and then mounted using an antifade agent. The slides were then cover
slipped, sealed with acrylic, and stored in the dark in a laboratory refrigerator.
8.2.4. Hematoxylin & Eosin (H&E)
Tissue was incubated in hematoxylin (Gill’s 1X) for 5 minutes prior to rinsing in deionized
water until water is clear (approximately 5 minutes). Sections were then dunked 2-3
times in acid alcohol (1% HCl in 70% EtOH). The sections should be pink following this
step. Sections were then rinsed for 5 minutes prior to placement in ammonia water (1
mL NH4OH in 1 L H2O), resulting in sections darkening significantly. The tissue was then
rinsed for 5 minutes in deionized water and then placed in Eosin Y for 1 minute prior to
final rinses and cover-slipping.
8.2.5. Fluoro-Jade B (FJB)
For FJB labeling, the tissue was incubated in 0.06% potassium permanganate for 10
minutes after rehydrating with a series of alcohol and deionized water rinses. Slides
were washed for 2 minutes in deionized water prior to incubation for 20 minutes in
0.0004% FJB in 0.1% acetic acid. Following incubation in the antibody, the tissue was
washed 3 times in dH2O and then mounted using an antifade agent. The slides were
then cover slipped, sealed with acrylic, and stored in the dark in a laboratory refrigerator.
8.2.6. Glial Fibrillary Acidic Protein (GFAP)
For GFAP labeling, the tissue was incubated in polyclonal antibody raised in rabbit
against anti-cow GFAP (Dako, Glostrup, Denmark) at a dilution of 1:500 in 4% horse
serum in DPBS overnight. Following the incubation in primary antibody, the tissue was
washed 3 times in DPBS and then incubated in a secondary Biotinylated anti-rabbit IgG
antibody (Vector Laboratories, Burlingame, CA) diluted at 1:10000 in 4% horse serum in
DPBS for 4 hours. Following the incubation in the secondary antibody, the tissue was
then incubated in Avidin D-HRP (Vector Laboratories, Burlingame, CA) diluted at 1:1000
in DPB for 1 hour. Following the incubation in the Avidin D-HRP, the tissue was rinsed 3
times in DPBS and then Chromagen solution DAB (Vector Laboratories, Burlingame,
CA) for 5 minutes. The tissue was then rinsed 3 times in DPBS and left out to dry
overnight. The tissue underwent a final wash in xylene and then was mounted using an
antifade agent and cover slipped. The slides were sealed with acrylic and stored in the
dark in a laboratory refrigerator.
8.2.7. Ionized Calcium Binding Adapter Molecule (Iba-1)
For Iba-1 labeling, the tissue was processed identically to GFAP with the following
exceptions: the primary antibody was rabbit anti-Iba 1 (Wako Chemicals
USA,;Richmond, Virginia) at a dilution of 1:500 and the chromagen solution was Nova
Red (Vector Laboratories; Burlingame, California).
8.2.8. Stereological Quantification
A stereological method was used to determine an unbiased estimate of the number of
each staining marker per cubic mm in the hippocampus, striatum, cortex and cerebellum
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areas. The optical fractionator technique utilizing a StereoInvestigator 9.0 (MBF
Bioscience, Inc.; Williston, Vermont) and a Olympus AX70 microscope with 4x-100x
objectives was performed. Specimens were examined with low magnification and
regions of interest were drawn. The software then selected random 75 micron counting
frames with depth of 6 microns, and the object of interest was marked. The volume of
the region of interest (ROI) was determined using the Cavalieri method, the volume of
the sum of the counting frames was calculated, the sum total of the object of interest
within the counting frames was calculated, and an estimate of the number per cubic mm
was calculated.
All microscopy was performed by an observer blinded to the
experimental treatment.
8.2.9. Statistics
Data from all experiments was analyzed using GraphPad Prism 4.0 (San Diego,
California). An unpaired t test was used to compare between control animals and those
undergoing IJV compression for FJB-positive neurons, GFAP-positive astrocytes, and
Iba-1-positive microglia. P < 0.05 was considered statistically significant for all data
analyzed.
8.3. RESULTS
8.3.1. Histopathology
At one week after TBI, no gross or histopathological abnormalities were seen in either
experimental group (IJV compression or control).
Cresyl violet (Figure 8.1) and
hematoxylin and eosin (Figure 8.2) staining revealed no contusions or cortical cell loss
underlying the impact site, no hippocampal cell loss, and no noticeable difference in
striatal or cerebellum integrity.
8.3.2. Neural Degeneration
Fluoro-Jade B, a marker of neural degeneration, was utilized to visualize and quantify
degenerating neurons. A difference between control animals and those undergoing IJV
compression was grossly apparent in all tissue regions visualized (Figure 8.3) and was
confirmed with stereologic quantification (Figure 8.4). Statistical analysis comparing
control animals to those undergoing IJV compression showed a significant difference in
cortex (t=8.522, p<0.0001), hippocampus (t=8.835, p<0.0001), striatum (t=9.439,
p<0.0001), and cerebellum (t=6.302, p<0.0001).
8.3.3. Glial Proliferation
Astrocyte reactivity has been previously described as both a precursor to neural injury as
well as a marker of neural repair. At one week after traumatic brain injury, control
animals exhibited increased numbers of reactive astrocytes, at each location assessed
using GFAP as a marker, in comparison to animals receiving TBI with IJV compression
and slosh mitigation (Figures 8.5-8.6). Statistical analysis comparing control animals to
those undergoing IJV compression showed a significant difference in cortex (t=8.201,
p<0.0001), hippocampus (t=9.334, p<0.0001), striatum (t=8.296, p<0.0001), and
cerebellum (t=8.600, p<0.0001).
8.3.4. Inflammation & Immune Reactivity
Microglial activation following traumatic brain injury was assessed using Ionized Calcium
Binding Adapter Molecule 1 (Iba-1) as a marker of microglia. Microglia morphology
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varies between resting and activated microglia, with the later exhibiting hypertrophic,
bushy, and ameboid morphology. At one-week post-TBI, slosh mitigation significantly
reduced the number of activated microglia at all locations measured (Figures 8.7-8.8).
Statistical analysis comparing control animals to those undergoing IJV compression
showed a significant difference in cortex (t=12.60, p<0.0001), hippocampus (t=9.176,
p<0.0001), striatum (t=9.133, p<0.0001), and cerebellum (t=8.979, p<0.0001).
8.4. DISCUSSION
In this study we confirmed the protective effect of IJV compression, which we believe
leads to slosh mitigation 598, on neuronal damage by using an alternative marker of
neural degeneration, Fluoro-Jade B 603 which has previously been shown to be elevated
in numerous TBI models 604-‐608. We further corroborated these findings by showing an
associated marked reduction in post-traumatic glial activation in the experimental group.
Degenerating neurons were visualized by Fluoro-Jade B and were reduced between
48.7-59.1% depending on location within the brain. Similarly, reactive astrocytes, which
were measured using GFAP, were reduced between 36.8-45.7%. Microglial activation,
indicated by Iba-1 staining, was reduced 44.1-65.3%. Notably, activated microglia were
seen throughout the brain in a diffuse nature, consistent with findings in ‘focal’ injury
models such as ‘controlled-cortical impact’ 606.
Astrocytes, the most abundant type of glial cell, are essential in maintaining homeostasis
in the healthy brain and also play a critical role in response to injury. Astrocytes have
previously been shown to reduce neuronal death in co-culture models of ischemia when
compared to neuron-only cultures 609. The notion of astrocytes facilitating neuronal
survival has been furthered by the observation that loss of astrocytes following TBI
precedes neuronal degeneration 608. It is believed that astrogliosis, which is usually
initiated shortly after CNS injury, is involved in the process of restoring CNS homeostasis
610. However, in excess, it may result in glial scarring which may impede neural repair
and contribute to axonal degeneration 611.
Similarly, microglia are capable of secreting both neurotrophic as well as
neurodegenerative factors 612-‐614. While it is unclear whether or not microglial activation
precedes or is a consequence of axonal injury, it is known to occur in both the acute and
chronic phases following TBI, and is therefore a suitable marker for neurologic injury 613.
8.5. CONCLUSION
Our findings suggest that IJV compression, and associated slosh mitigation, may be a
powerful technique for reducing TBI. This technique reduces not only axonal injury as
previously reported, but also the number of degenerating neurons, reactive astrocytes,
and activated microglia. While axonal injury is a well-documented pathological finding
after TBI, and one for which current preventative techniques are inadequate, injury to
neurons and associated axons hardly exists in isolation. Rather than taking a neuroncentered approach to TBI prevention and treatment, it seems likely that the neuron-glial
interaction must be considered. Microglia and astrocytes are intimately involved in not
only the initial injury process and subsequent inflammation, but also the long-term repair
and recovery that occurs. We believe that IJV compression, and presumably slosh
mitigation, offers a novel form of TBI prevention and addresses the intracranial
environment more effectively than extracranial protective devices such as helmets. IJV
compression likely leads to not only increased retention of blood in the cranium but also
may alter the density gradients amongst structures, reducing energy displacement in
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brain tissue based on the concept of slosh in fluid dynamics. More research is needed
to verify that our initial findings may translate to clinical applications and be of benefit
based on various TBI outcome measures used clinically.
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Figures

Figure 8.1. Cresyl violet staining illustrated no abnormalities following TBI in control
animals (panels a-h) or those undergoing IJV compression (panels i-p). Low-power view
of cortex (a,i), hippocampus (c,k), striatum (e,m), and cerebellum (g,o) in control and IJV
compression animals, respectively. High-power view of cortex (b,j), hippocampus (k,l),
striatum (m,n), and cerebellum (o,p) in control and IJV compression animals,
respectively.
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Figure 8.2. Hematoxylin and eosin staining showed no abnormalities following TBI in
control animals (panels a-h) or those undergoing IJV compression (panels i-p). Lowpower view of cortex (a,i), hippocampus (c,k), striatum (e,m), and cerebellum (g,o) in
control and IJV compression animals, respectively. High-power view of cortex (b,j),
hippocampus (k,l), striatum (m,n), and cerebellum (o,p) in control and IJV compression
animals, respectively.
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Figure 8.3. Fluoro-Jade B staining showed a significant reduction in degenerating
neurons in animals undergoing IJV compression (panels i-p) compared to control
animals (panels a-h). Low-power view of cortex (a,i), hippocampus (c,k), striatum (e,m),
and cerebellum (g,o) in control and IJV compression animals, respectively. High-power
view of cortex (b,j), hippocampus (k,l), striatum (m,n), and cerebellum (o,p) in control
and IJV compression animals, respectively. Arrows represent degenerating neurons.
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Figure 8.4. Stereologic quantification of degenerating neurons stained with Fluoro-Jade
B. A significant reduction in neural degeneration was seen in IJV compression animals
at all tissue locations visualized and quantified (p<0.0001).
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Figure 8.5. GFAP staining showed a significant reduction in reactive astrocytes in
animals undergoing IJV compression (panels i-p) compared to control animals (panels ah). Low-power view of cortex (a,i), hippocampus (c,k), striatum (e,m), and cerebellum
(g,o) in control and IJV compression animals, respectively. High-power view of cortex
(b,j), hippocampus (k,l), striatum (m,n), and cerebellum (o,p) in control and IJV
compression animals, respectively. Arrows represent reactive astrocytes.
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Figure 8.6. Stereologic quantification of reactive astrocytes stained with GFAP. A
significant reduction in reactive astrocytes was seen in IJV compression animals at all
tissue locations visualized and quantified (p<0.0001).
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Figure 8.7. Iba-1 staining showed a significant reduction in activated microglia in
animals undergoing IJV compression (panels e-h) compared to control animals (panels
a-d). High-power view of cortex (a,e), hippocampus (b,f), striatum (c,e), and cerebellum
(d,h) in control and IJV compression animals, respectively.
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Figure 8.8. Stereologic quantification of activated microglia stained with Iba-1. A
significant reduction in activated microglia was seen in IJV compression animals at all
tissue locations visualized and quantified (p<0.0001).
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Chapter Nine
In addition to diffuse axonal injury following impact with another object, blast-induced
neurotrauma has received increased attention due to involvement in military conflicts
around the globe. Prior work modeling blast has failed to adequately scale the exposure
for rodents based on pulmonary lethality curves 406. In this work, we present a novel
blast model capable of simulating relevant parameters based on scaling concepts,
namely overpressure duration. We also show a graded response in many neural injury
markers associated with the level of peak overpressure exposure. This work sets the
stage for further investigation of blast injury pathophysiology and potential preventative
or treatment measures.
Modeling Clinically Relevant Blast Parameters Based on Scaling Principles
Produces Functional & Histological Deficits in Rats
Ryan C. Turner, Zachary J. Naser, Aric F. Logsdon, Kenneth H. DiPasquale, Garrett J.
Jackson, Matthew J. Robson, Robert T. Gettens, Rae R. Matsumoto, Jason D. Huber,
Charles L. Rosen
This work is under consideration for publication in Experimental Neurology.
ABSTRACT
Blast-induced traumatic brain injury represents a leading cause of injury in modern
warfare with injury pathogenesis poorly understood. Preclinical models of blast injury
remain poorly standardized across laboratories and the clinical relevance is unclear
based upon pulmonary injury scaling laws. Models capable of high peak overpressures
with short durations may better replicate clinical exposure when scaling principles are
considered. In this work, we demonstrate a tabletop shock tube model capable of high
peak overpressures of short duration.
By varying the thickness of the polyester
membrane, peak overpressure can be controlled. We used membranes with a thickness
of 0.003, 0.005, 0.007, and 0.010 inches to generate peak reflected overpressures of
31.47, 50.72, 72.05, and 90.10 PSI, respectively.
Blast exposure was shown to
decrease total activity and produce neural degeneration as indicated by fluoro-jade B
staining. Similarly, blast exposure resulted in increased glial activation as indicated by
an increase in the number of glial fibrillary acidic protein expressing astrocytes
compared to control within the corpus calllosum, the region of greatest apparent injury
following blast exposure based on previous reports. Similar findings were observed with
regards to activated microglia, some of which displayed phagocytic-like morphology
within the corpus callosum following blast exposure, particularly with higher peak
overpressures. Furthermore, hematoxylin and eosin staining showed the presence of
red blood cells within the parenchyma and red, swollen neurons following blast injury.
Exposure to blast with 90.10 PSI peak reflected overpressure resulted in immediate
mortality associated with extensive intracranial bleeding. This work demonstrates one of
the first examples of blast-induced brain injury in the rodent when exposed to a blast
wave scaled from human exposure based on scaling principles derived from pulmonary
injury lethality curves.
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9.1. INTRODUCTION
Blast-induced traumatic brain injury has been described as the hallmark injury of modern
warfare 615,	
  616 with ~25,000 members of the armed services (U.S. and Coalition forces)
injured or killed by explosive devices in Iraq and Afghanistan conflicts in the past decade
617.
The prevalence of blast exposure is associated with an immense financial and
societal burden with estimates of 13-22% of combat veterans having sustained a
traumatic brain injury (TBI) during time in service 406,	
   618,	
   619. Consequently, there is a
clear clinical need for increased understanding of blast injury pathogenesis and the
development of improved therapeutics for the treatment, or prevention, of blast-induced
brain injury. Increasing efforts to study blast injury has resulted in the propagation of
numerous preclinical models of blast injury with the shock tube representing the most
widely used model type. Despite the extensive use of shock tube models, model
parameters such as size of the driver and driven sections, membrane material and
thickness, and gas used seem to vary across laboratories. As such, the shock waves
produced vary significantly in peak overpressure and duration.
Recent work by Panzer and colleagues has identified potential discrepancies between
many preclinical models and real-world recorded blast parameters with models often
exposing small rodents to long duration blasts 406. Assuming the same scaling principles
apply as those discovered with regards to pulmonary blast injury, many current rodent
models, in which overpressure exposure durations frequently exceed 4 ms and in some
cases as much as 10 ms or more, may be subjecting animals to the equivalent of a
human exposed to detonation of 27,000-kg of trinitrotoluene (TNT) explosive from over
70 m away 406. In other words, many preclinical models may be exposing animals to the
equivalent of long-duration nuclear blasts rather than the more common high explosive
Therefore, a preclinical blast model capable of delivering high peak
blasts 407.
overpressures over a short duration may be of value, particularly should similar scaling
laws exist in the brain, as is the case in pulmonary-based work.
In this work, we demonstrate the ability to model blast injury with clinically relevant peak
overpressure and duration based on scaling laws from humans to rodents with a novel,
tabletop shock tube model. Furthermore, we show the ability to model blast injury of
varying severity with different polyethylene terephthalate (PET) membranes that result in
reflected peak overpressures ranging from approximately 30-90 PSI while consistently
being of short duration (< 3 ms). Animals exposed to blast-induced TBI across this
range of pressures exhibit alterations in total activity as well as clear histological
changes as determined utilizing common markers of neural injury.
9.2. MATERIALS AND METHODS
9.2.1. Animals
All procedures involving live animals were approved by the Institutional Animal Care and
Use Committee of West Virginia University and were performed according to the
principles of the Guide for the Care and Use of Laboratory Animals. This worked used
thirty-eight 350 gram male Sprague-Dawley rats acquired from Hilltop Lab Animals
(Hilltop Lab Animals, Inc.; Scottdale, Pennsylvania). Animals were acclimated for the
week prior to experimental use and were housed under 12-hour light/12-hour dark
conditions with food and water available ad libitum.
9.2.2. Design of Blast Model
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A four-piece, machined aluminum shock tube apparatus was constructed and driven
using compressed nitrogen gas. The driver and driven sections were separated by clear
polyester membranes (Ridout Plastics Co.; San Diego, California) of varying thickness
(0.003”-0.010”) to achieve a range of peak overpressure exposures. A tapered design of
the driver section (Figure 1) was included in an effort to minimize wave reflection and
alterations of the blast wave by the expansion wave. This feature is similar in nature to
blast tubes utilizing explosives in which the explosive is often detonated in a conical or
parabolic-shaped driver section. The driver section was kept short in length in an effort
to reduce the amount of gas required for membrane rupture and subsequent blast
duration. The overpressure duration and impulse are reduced as described previously
due to the shortened driver section 407. For additional details concerning design of the
blast model, please see Appendix.
9.2.3. Blast Waveform Acquisition & Analysis
Shock wave pressures were detected using piezoelectric sensors (PCB Piezotronics;
Depew, New York) that were placed in both reflected and incident positions at the exit of
the shock tube (Figure 9.1). Data was acquired and processed using the National
Instruments input module (NI 9223) connected to the National Instruments receiver USB
chassis (CDAQ-9171). Signals were recorded using a custom-designed Labview 12.0
program and the NI data acquisition system (National Instruments; Austin, Texas) with a
sampling rate of 500 kHz as described previously 620,	
  621.
9.2.4. Blast Exposure
Prior to blast exposure, animals were anesthetized by intraperitoneal injection of
ketamine (90 mg/kg; Webster Veterinary; Devens, Massachusetts) and xylazine (5 mg/
kg; Webster Veterinary). Animals were oriented with the long axis of the animal
perpendicular to the blast front. In other words, the blast was delivered side-on to the
head only as the thorax and abdomen were protected using rigid shielding, creating an
experimental setup (Figure 9.1) similar to that used by Shridharani and colleagues 622.
With the animal placed directly at the exit of the tube, the effect of expansion waves on
the planar conditions of the blast front is minimized as described by Bass and colleagues
407.
Animals (n=38) were divided into the following groups: control (n=10), 0.003
membrane blast exposure (n=6), 0.005 membrane blast exposure (n=10), 0.007
membrane blast exposure (n=9), and 0.010 membrane blast exposure (n=3).
Immediately following blast exposure, animals were returned to a holding cage equipped
with a homeothermic heating blanket equipped with a rectal thermometer to maintain
body temperature at 37 °C. Once basic reflexes were restored, animals were returned
to the home cage.
9.2.5. Total Activity Measurements
Animal activity was measured using an automated activity monitoring system (San Diego
Instruments; San Diego, California). Rats were given the hour to acclimate to the testing
room prior to initiation of testing. Each testing chamber consisted of a 16 x 16
photobeam array surrounding a Plexiglass chamber to record lateral movements. A
separate 8 photobeam array to detect rearing activity was located above the 16 x 16
array. Activity was quantified over a 30 minute period 24 hours post-blast exposure with
total activity, ambulatory, and fine activity reported based on default settings of the data
acquisition software (PAS, San Diego Instruments; San Diego, California).
9.2.6. Histological Preparations
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At 72 hours post-blast exposure, a total of 24 animals (6 control and 6 from each blast
exposure group) were anesthetized as described above and perfused transcardially with
cold 0.9% saline followed by 10% formalin for a total of 10 minutes. The brain was then
extracted and placed into fresh 10% formalin for a minimum of 24 hours. After 24 hours
of fixation, the brain was blocked into sections and paraffin embedded as previous
described 623. Briefly, tissues were processed using the Tissue-Tek VIP 5 automatic
tissue processor (Sakura Finatek; Tokyo, Japan) and embedded in paraffin using the
Tissue-Tek TEC 5 embedding system (Sakura Finatek; Tokyo, Japan). Tissues were
sliced using a Leica RM2235 microtome (Leica Microsystems; Wetzlar, Germany) and
slices mounted on slides for staining.
Standard protocols were utilized for staining with hematoxylin and eosin (H&E),
fluorojade-B (Millipore; Billerica, Massachusetts), which was used as a marker of neural
degeneration, glial fibrillary acidic protein (GFAP) (Dako; Glostrup, Denmark), which was
used as a marker of reactive astrocytes, and ionized calcium binding adapter molecule
(Wako; Osaka, Japan), which was used as a marker of activated microglia.
Images were acquired from the S1BF region of the cortex, corpus callosum, striatum,
hippocampus, and cerebellum. Imaging was performed using a Zeiss Axio Imager 2
(Carl Zeiss AG; Oberkochen, Germany) for all brightfield and fluorescent images shown.
9.2.7. Histological Quantification
Stereology and the optical fractionator technique were used to quantify histological
results as previously described 598,	
  624,	
  625. Briefly, a region of interest encompassing the
corpus callosum was drawn at low power using an Olympus AX70 microscope
(Olympus; Tokyo, Japan) and StereoInvestigator software (MBF Bioscience; Williston,
Vermont). The software then selected random 75-µm counting frames with a depth of 6
µm, and the object of interest marked by an observed blinded to treatment. The volume
of the region of interest previously identified was then determined by the software and
the number of cells marked by the observer returned.
9.2.8. Quantitative Real-Time PCR
A total of 8 animals were used for quantitative real-time polymerase chain reaction
(PCR) and included 4 control animals and 4 animals exposed to blast using the 0.005
membrane.
Total RNA was extracted from the brain tissue (cortex, striatum,
hippocampus, and cerebellum) of saline-perfused animals using Trizol reagent
(Invitrogen; Carlsbad, California) according to the manufacturer’s instructions. Sample
concentration was determined by spectral absorption and the purity confirmed using a
260/280 ratio of 1.8-2.0. Samples of cDNA were prepared via reverse transcription
using commercially available kits (Applied Biosystems; Carlsbad, California). Sample
reactions included MultiScribe TM Reverse Transcriptase and random primers, with
thermal cycle conditions set as follows: step 1 at 25° C for 10 minutes, step 2 at 37° C
for 120 minutes, step 3 at 85° C for 5 seconds, and step 4 at 4° C for 10 minutes. For
PCR amplification, TaqMan® Universal PCR Master Mix and the following probes were
obtained from Applied Biosystems: 18s (Hs99999901_s1) for use as an endogenous
control gene, GFAP (Rn00566603_m1), and Iba-1 (Rn00574125_g1). The reaction
mixture was prepared based on manufacturer’s instructions and the following thermal
cycling conditions used: initial holding at 50° C for 2 minutes to allow for optimal
AmpErase® UNG activity, followed by a first denaturing step at 95° C for 10 minutes,
then 45 cycles at 95° C for 15 seconds, and at 60° C for 1 minute. Changes in gene
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expression were determined using the ΔΔCT method and a threshold value of 0.2.
Threshold cycle values of each gene were normalized to 18s rRNA.
9.2.9. Data Analysis
Data were analyzed using GraphPad Prism 5.0 (GraphPad Software, Inc.; San Diego,
California). A one-way analysis of variance (ANOVA) with post-hoc Tukey’s test was
used to compare across control and various blast-exposed groups. For gene expression
work, a student’s t-test was utilized for comparing control and the blast-exposure group
(0.005 membrane).
P < 0.05 was considered statistically significant for all data
analyzed.
9.3. RESULTS
9.3.1. The Model is Capable of Producing a Characteristic Friedlander-type Blast Across
a Range of Peak Overpressures with Short Duration of Exposure.
The ideal blast wave in an open area, also known as the Friedlander curve, consists of a
near-instantaneous pressure rise followed by an exponential decay of the overpressure
407. With all membranes tested utilizing the shock tube apparatus (Figure 9.1), ideal
blast waves were obtained with a representative curve shown (Figure 9.2a). Peak
overpressure increased in a linear fashion with membrane thickness with both reflected
(r2 = 0.92) and incident (r2 = 0.93) sensor orientations allowing for the simulation of
multiple peak overpressures in the experiment (Figure 9.2b,c).
9.3.2. High Peak Vverpressure Blast, Even of Short Duration, Is Associated with High
Mortality and Extensive Intracranial Bleeds.
While reflected pressures of 31.47 ± 3.049 and 50.72 ± 3.368 PSI failed to produce any
mortality, exposure to 72.05 ± 1.212 PSI blast was associated with mortality in 3 of 9
experimental animals (33%) while 90.10 ± 1.030 PSI blast exposures produced mortality
in all 3 animals tested (100%). Surviving animals failed to exhibit large hematomas at 72
hours post-blast (Figure 9.3a,b) but evidence of microvascular dysfunction and the
potential for intraparenchymal bleeds was present (Figure 9.3c,d). Animals exposed to
survivable moderate peak overpressures in this work displayed small hematomas
immediately following blast exposure (Figure 9.3c), consistent with the work of Reneer
and colleagues 626. Mortality was associated with the production of intracranial bleeds in
the cortex, particularly on the contrecoup side as well as in the brainstem (Figure 9.3e,f).
Similar findings have been observed utilizing explosives such as TNT in rat models in
which animals placed in close range exhibit increased mortality rates associated with
brain contusions, lacerations, and hematomas 627.
9.3.3. Blast-induced Brain Injury Results in the Presence of Intraparenchymal Red
Blood Cells, Swollen Neurons, and Activated Microglia.
To further examine the effect of blast exposure on neural injury and microvascular
dysfunction, particularly considering the presence of hematomas and parenchymal blood
on gross examination, brain sections underwent H&E staining. The intraparenchymal
blood was confirmed with H&E staining and red blood cells clearly passed into the
parenchyma and were no longer confined to the vasculature (Figure 9.4a). Evidence of
neural injury and swollen, red axons was apparent in some animals (Figure 9.4b). The
presence of red neurons indicated a potential anoxic/ischemic insult 628, consistent with
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the presence of microvascular dysfunction observed following blast exposure 629. The
presence of activated microglia, capable of releasing an array of inflammatory
mediators, was also seen with blast exposure and prompted further investigation of
astro- and microgliosis.
9.3.4. Neural Degeneration Occurs in a Dose-response Manner Consistent with Blast
Severity.
Blast-induced brain injury resulted in increased neural degeneration measured using
Fluoro-Jade B staining in the S1BF region of the cortex on both the coup (F(3,23) =
47.03, P < 0.0001) and contrecoup (F(3,23) = 110.7, P < 0.0001) sides when analyzed
by one-way ANOVA (Figure 9.5a-d). Post hoc tests revealed that blast-induced brain
injury produced increases in neural degeneration compared to control at 31.47 ± 3.049
PSI on the contrecoup side (q = 4.51, P < 0.05), 50.72 ± 3.368 PSI on both coup (q =
10.29, P < 0.0001) and contrecoup (q = 13.69, P < 0.0001) sides, and 72.05 ± 1.212 PSI
on both coup (q = 15.13, P < 0.001) and contrecoup (q = 23.76, P < 0.0001) sides
(Figure 9.5e-f). Neural degeneration following blast exposure was also observed within
other brain regions including the striatum, hippocampus, cerebellum and regions
surrounding the corpus callosum (Appendix).
9.3.5. Blast Injured Brains Demonstrate Increased Glial Activation with Increasing Peak
Over-pressure.
Reactive astrocytes, identified by GFAP staining, were elevated significantly within the
corpus callosum on the coup (F(3,23) = 26.08, P < 0.0001) and contrecoup (F(3,23) =
8.03, P < 0.001) sides of the brain following blast-induced neurotrauma, consistent with
findings from other blast injury models 629, when analyzed using one-way ANOVA
(Figure 9.6a-d). Post hoc tests showed that blast injury resulted in elevated astrocyte
reactivity at 50.72 ± 3.37 PSI on the contrecoup side (q = 5.13, P < 0.01) and at 72.05 ±
1.21 PSI on both the coup (q = 11.28, P < 0.0001) and contrecoup (q = 6.03, P < 0.01)
sides (Figure 9.6e-f). Similar findings were observed concerning microglial activation,
identified with Iba-1 staining, with increased levels of microglial activation relative to
control on both coup (F(3,23) = 83.12, P < 0.0001) and contrecoup (F(3,23) = 25.37, P <
0.0001) sides (Figure 9.7a-d). Again, although microglial presence was detected
throughout the brain and appeared increased throughout, microglial activation was most
prominent throughout the corpus callosum and internal capsule, consistent with other
Notably, microglia appeared more rounded or amoeboid, typical of
studies 628.
phagocytic microglia, within these white matter tracts consistent with white matter
damage observed in human subjects following trauma 630. Previous reports in swine
exposed to blast and assessed primarily at two weeks failed to identify extensive
microglial activation, a potential reason for the discrepancy between studies 628. Post
hoc tests revealed increased microglial activation following 31.47 ± 3.049 PSI blast on
the contrecoup side (q = 4.71, P < 0.05), 50.72 ± 3.37 PSI blast on both coup (q = 8.37,
P < 0.0001) and contrecoup (q = 7.85, P < 0.0001) sides, and 72.05 ± 1.212 PSI blast on
both coup (q = 20.49, P < 0.0001) and contrecoup (q = 11.92, P < 0.0001) sides as well
(Figure 9.7e-f).
Gene expression of GFAP (Figure 9.8a) was increased at 24 hours following blast
exposure in the cortex (t = 2.41, P < 0.05) but not in the striatum (t = 0.02, P > 0.05),
hippocampus (t = 1.08, P > 0.05), or cerebellum (t = 0.63, P > 0.05). The lack of
difference in GFAP gene expression in regions outside of the cortex was in contrast to
the visible differences seen in these regions at 72 hours based on
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immunohistochemistry (Appendix).
No difference in Iba-1 gene expression (Figure
9.8b) was detected in the cortex (t = 0.43, P > 0.05), striatum (t = 0.90, P > 0.05),
hippocampus (t = 0.38, P > 0.05), or cerebellum (t = 0.45, P > 0.05), consistent with
immunohistochemical findings (Appendix).
9.3.6.
Blast-induced Traumatic Brain Injury Produces Deficits in Total Activity
Regardless of Severity.
Total activity of the experimental subjects was decreased at 24 hours post-blast in all
injured groups. The total activity level post-injury did not vary based on injury severity
with all injury groups demonstrating similar impairments (Figure 9.9a). The deficits in
total activity were due to a decrease in ambulatory activity associated with blast
exposure (Figure 9.9b). Blast exposure did not alter measures of fine activity (Figure
9.9c).
9.4. DISCUSSION
Efforts to model blast injury have been plagued by the lack of standardization across
laboratories and the appropriate scaling of blast parameters to the animal species used
based on data obtained from human studies. Preclinical studies are varied with regards
to animal placement within or outside of the shock tube, orientation to the blast front,
protection of the thorax, and blast parameters, namely peak overpressure and duration
of exposure. Studies in soldiers revealed common IED exposures producing blast injury
result from detonation of 105-mm and 155-mm artillery rounds at a distance of 5-10
meters 406. Use of the Conventional Weapons Effects Program (CONWEP) 631 allows
for interpretation of these exposures in relation to blast wave parameters with a peak
overpressure of 50-1000 kPA (7.25-145.03 PSI) and an exposure duration of 2-10 ms
406. As such, utilizing these parameters and scaling appropriately to preclinical animal
species used may represent a more clinically-relevant blast exposure and allow for
improved elucidation of blast-induced injury pathophysiology and evaluation of proposed
therapeutics.
The concept of scaling blast injury to animal models is based largely upon previous
works assessing pulmonary injury and primary blast survival across animal species.
Richmond and colleagues identified, in various species, the effect of blast duration on
lethality with longer duration blasts requiring a lower peak overpressure to produce
mortality when compared to short duration blasts that required a significantly higher peak
overpressure 632. A clear relationship between mass and blast parameters associated
with lethality exists, particularly with regards to the more clinically-relevant short duration
blast 632. In fact, classical work by Bowen and colleagues investigated pulmonary injury
in relation to blast exposure and created a model system in which scaling is based upon
the height of burst divided by the cubed root of the mass 633. This has been simplified to
an equation utilizing the cubed root of the reference mass (human) divided by the mass
of the experimental subject 406,	
   407,	
   622. The scaling equations developed have displayed
significant utility in development of injury risk functions based upon the high level of
agreement with pre-existing experimental data concerning blast survival and injury risk.
As such, while scaling of blast injury and associated blast parameters based on subject
weight has not been related to neural injury 634, scaling represents a logical step forward
in more closely replicating clinically relevant exposures in laboratory models 406,	
  635,	
  636.
To address the question of how scaling affects blast-induced brain injury a shock tube
capable of producing a range of peak overpressures with short durations was designed
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and utilized within this work. Furthermore, the model was designed to simulate openfield blast with the rat placed outside of the shock tube in order to increase clinical
relevance. Notably, the model produced clear neuropathological changes indicative of
neural degeneration and glial reactivity. These findings were consistent with work by
Goldstein and colleagues in which single-blast exposure produced neurodegenerative
changes consistent with chronic traumatic encephalopathy (CTE) 418 as well as other
work utilizing scaling principles 622. Similarly, neuropathological changes were observed
throughout the cortex as previously described 418 but were most prominent with the
corpus callosum and internal capsule, consistent with previous findings in other blast
It remains unclear why specific brain regions may be more
injury models 634.
susceptible to blast-induced brain injury but one logical explanation is that of spallation.
Spallation refers to the interface-based disruption that occurs between tissues of
different densities upon a compression wave in the denser medium reflecting at the
interface resulting in displacement and fragmentation of the denser medium into the less
dense medium 637-‐639. Spalling has been identified as a leading cause of endothelial
injury and activation of microglia 640, consistent with our findings. Similarly, endothelial
damage results in a loss of tight junction integrity and consequently the potential for
increased blood-brain barrier permeability (BBB) and microvascular injury 640. Notably,
increased BBB permeability has been found as late as one month following blastinduced brain injury in a preclinical rodent model, indicating the presence of lasting
microvascular dysfunction 641. Furthermore, blast-induced BBB disruption has been
observed to occur more extensively on the contralateral side, as well as at fluid-tissue
interfaces such as that surrounding the lateral ventricles 642, consistent with the findings
reported within this study in which the contralateral side was more severely injured in
comparison to the ipsilateral side based on standard markers of neural degeneration,
astrocyte reactivity, and microglial activation 643.
The clear neuroinflammatory response, characterized by a graded glial response based
on peak overpressure exposure, observed in this work is consistent with findings by
Cernak and colleagues in which mild and moderate blast exposure produced increases
in GFAP, as well as ED1, a marker of microglia, at numerous time points 644.
Importantly, activated microglia in other blast exposure studies have been associated
with changes in neuron appearance such as darkened dendrites 645 and in vitro work
has demonstrated a mild activation of microglia following overpressure exposure with
pulse duration altering microglial gene expression 646. Interestingly, gene expression
studies did not entirely match immunohistochemical studies with regard to GFAP and
Iba-1 expression. The reason for this discrepancy is not entirely clear but may be due to
consideration of the entirety of brain sections for gene expression studies when
immunohistochemistry reveals findings largely located at the interface of regions and the
gray-white matter junction. Another possibility explaining the discrepancy between
immunohistochemical and gene expression findings is the time of analysis. Only one
time point for each assay was included and therefore, changes in gene expression could
have occurred rapidly following blast and already declined to baseline by 24 hours.
In addition to the neuropathological findings, the model utilized in this work produced
deficits in total activity at 24 hours post-blast, regardless of experimental group. How
blast-injury models affect behavioral functions in rodents is poorly understood but of
clear interest based on clinical findings associated with blast that include retrograde
amnesia, confusion, loss of conscioussness, depression, post-traumatic stress disorder
(PTSD), vertigo, balance disorders, anxiety, apathy, and difficulty concentrating and
performing executive functions 636,	
   641,	
   647-‐649. Previous reports have demonstrated
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impairment on the accelerating rotarod following direct cranial blast injury 650 and on the
balance beam following whole body blast exposure 620 while others have shown that
shielding of the torso prevents neural injury and associated behavioral deficits following
blast 651. While the significance of these findings is unclear and how these findings
translate from one model to another, let alone to the clinical population, there is a clear
need for further studies in standardized, clinically-relevant models.
It is clear that future studies, in addition to understanding the effect of scaled blast
exposure on functional ability and behavior-related changes, need to better characterize
the inflammatory processes associated with blast exposure and how these relate to
neural injury and neurodegeneration.
While it is unlikely blast exposure can be
completely prevented, particularly in civilians exposed to terrorist-type attacks, it may be
possible to improve therapeutic options.
The need for improved therapeutics is
particularly clear in the military in which evacuation of blast-exposed troops is often
delayed by hours to several days due to the nature of conflict. As such, secondary
responses within the brain often occur and may represent a potential target as described
previously 652.
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FIGURES

Figure 9.1. Experimental setup utilized in this work demonstrating the novel shock tube
apparatus for simulating blast-induced brain injury and data acquisition procedures. The
shock tube utilizes a tapered driver section to reduce wave reflection and alterations of
the shock wave by the expansion wave. The driver section was kept short to reduce the
volume of gas required to produce membrane rupture and therefore, reduced
overpressure duration and impulse. The abdomen and thorax of animals was protected
using a rigid apparatus.
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Figure 9.2. A.) Sample shock wave recording (reflected sensor) representing a classical
Friedlander wave of short duration. B.) Peak reflected overpressure recorded as a
function of membrane thickness. C.) Peak incident overpressure recorded as a function
of membrane thickness.

197

Figure 9.3. Gross examination of single blast-exposed brains. A.) Brain of a perfused
control animal, B.) 31.47 ± 3.049 PSI (reflected) blast-exposed brain at 72 hours postblast following perfusion demonstrating no apparent hematomas or gross changes, C.)
Presence of hematomas and contusion immediately following exposure to 50.72 ± 3.368
PSI (reflected) blast on the contrecoup side, D.) At 72 hours post-blast, 72.05 ± 1.212
PSI (reflected) blast exposure results in the appearance of parenchymal blood and an
overall husky appearance on the contrecoup side, E.) Immediately following 90.10 ±
1.030 PSI (reflected) blast, clear evidence of bleeds on the cortex, and F.) Immediately
following 90.10 ± 1.030 (reflected) PSI blast, brainstem bleeds were apparent and
associated with mortality.
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Figure 9.4. Blast exposure, particularly at high peak overpressures, was associated
with microvascular damage and neural injury on H&E staining. A.) Presence of red
blood cells within the parenchyma at 72 hours following 72.05 ± 1.212 PSI (reflected)
blast. B.) Swollen, red neuron at 72 hours following 72.05 ± 1.212 (reflected) PSI blast.
Red neurons typically are associated with anoxic/ischemic injury indicating the presence
of secondary damage, likely related to microvascular dysfunction, following blast injury.
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Figure 9.5. Blast exposure produced neural degeneration within the S1BF region of the
cortex at 72 hours post-exposure as indicated with fluoro-jade B staining. A.) 31.47 ±
3.049 PSI (reflected) blast on the coup side, B.) 50.72 ± 3.368 PSI blast on the coup
side, C.) 31.47 ± 3.049 PSI blast on the contrecoup side, and D.) 72.05 ± 1.212 PSI
blast on the contrecoup side. Quantification of Fluoro-Jade B (FJB) positive neurons
using stereology demonstrated a graded response based on peak overpressure
exposure in the S1BF region of the cortex on coup (F(3,23) = 47.03, P<0.0001) and
contrecoup (F(3,23) = 110.70, P<0.0001) sides (E and F, respectively). Post hoc
analysis showed that blast exposure resulted in increased neural degeneration relative
to control with 31.47 ± 3.049 PSI on the contrecoup side (q = 4.51, P < 0.05), 50.72 ±
3.368 PSI on both coup (q = 10.29, P < 0.0001) and contrecoup (q = 13.69, P < 0.0001)
sides, and 72.05 ± 1.212 PSI on both coup (q = 15.13, P < 0.001) and contrecoup (q =
23.76, P < 0.0001) sides.
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Figure 9.6. Blast exposure produced extensive astrocyte reactivity within the corpus
callosum at 72 hours post-exposure as indicated with glial fibrillary acidic protein (GFAP)
staining. A.) 31.47 ± 3.049 PSI blast on the coup side, B.) 72.05 ± 1.212 PSI blast on
the coup side, C.) control (no blast exposure) on the contrecoup side, and D.) 72.05 ±
1.212 PSI blast on the contrecoup side. Quantification of Glial Fibrillary Acidic Protein
(GFAP) positive astrocytes using stereology demonstrated a graded response based on
peak overpressure exposure in the corpus callosum on the coup (F(3,23) = 26.08,
P<0.0001) and contrecoup (F(3,23) = 8.03, P<0.001) sides (E and F, respectively). Post
hoc analysis showed that blast exposure resulted in increased astrocyte reactivity
relative to control with 50.72 ± 3.368 PSI on the contrecoup side (q = 5.13, P < 0.01) and
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at 72.05 ± 1.212 PSI on both the coup (q = 11.28, P < 0.0001) and contrecoup (q = 6.03,
P < 0.01) sides.
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Figure 9.7. Blast exposure produced microglial changes within the corpus callosum at
72 hours post-exposure as indicated with ionized calcium-binding adapter molecule 1
(Iba-1) staining. A.) Control (no blast exposure) on the coup side, B.) 50.72 ± 3.368 PSI
blast on the coup side, C.) 31.47 ± 3.049 PSI blast on the contrecoup side, and D.)
72.05 ± 1.212 PSI blast on the contrecoup side. Quantification of Ionized Calciumbinding Adapter Molecule 1 (Iba-1) positive microglia using stereology demonstrated a
graded response based on peak overpressure exposure in the corpus callosum on the
coup (F(3,23) = 83.12, P<0.0001) and contrecoup (F(3,23) = 25.37, P<0.0001) sides (E
and F, respectively).
Post hoc analysis showed that blast exposure resulted in
increased microglial activation relative to control with 31.47 ± 3.049 PSI blast on the
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contrecoup side (q = 4.71, P < 0.05), 49 PSI blast on both coup (q = 8.37, P < 0.0001)
and contrecoup (q = 7.85, P < 0.0001) sides, and 72.05 ± 1.212 PSI blast on both coup
(q = 20.49, P < 0.0001) and contrecoup (q = 11.92, P < 0.0001) sides as well.
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Figure 9.8. Effect of 50.72 PSI blast exposure on gene expression at 24 hours postinjury. A.) Gene expression of glial fibrillary acidic protein (GFAP) was increased within
the cortex (t = 2.412, P < 0.05) but not in the striatum, hippocampus, or cerebellum. B.)
Gene expression of ionized calcium binding adapter molecule (Iba-1) was not changed
within any of the brain regions studied at 24 hours post-blast.
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Figure 9.9. Effect of blast exposure on total, ambulatory, and fine activity levels at 24
hours post-injury. A.) Total activity was significantly altered with blast exposure (F(3,23)
= 6.55, P<0.05) with post hoc analysis identifying a reduction relative to control with
31.47 ± 3.049 PSI blast (q = 4.50, P<0.05), 50.72 ± 3.368 PSI blast (q = 5.28, P<0.05),
and 72.05 ± 1.212 PSI blast (q = 5.40, P<0.05). B.) Ambulatory activity was reduced
with blast exposure (F(3,23) = 6.74, P<0.05) with post hoc analysis identifying a
reduction relative to control with 31.47 ± 3.049 PSI blast (q = 4.59, P<0.05), 50.72 ±
3.368 PSI blast (q = 5.34, P<0.05), and 72.05 ± 1.212 PSI blast (q = 5.47, P<0.05)
exposures.
C.) Fine activity failed to demonstrate differences across any group
comparisons (F(3,23) = 0.17, P>0.05).

206

Chapter Ten
As neurotrauma has been associated with long-term neurodegeneration, there is
increasing interest in rapid identification of persons sustaining even ‘mild’ neurotrauma
on the athletic or battlefields. The diagnosis of concussion currently relies largely upon
self-reported symptoms, as no consistent positive findings are observed with standard
medical imaging procedures.
As such, numerous tests, both physical and
neuropsychological in nature, have been developed in an attempt to assist in concussion
diagnosis and return-to-play guidelines. Study of trauma and concussion in preclinical
studies has relied largely upon mortality rate and histological markers of damage rather
than functional impairment. Therefore, it remains unclear the level or severity of injury
truly being studied as impairments are not well-characterized. In this work, we address
this issue using a clinically-relevant model of diffuse axonal injury and an array of
functional assessments conducted in the acute period, typical of when symptoms
associated with concussion present.
Elucidating the Severity of Preclinical Traumatic Brain Injury Models: A Role for
Functional Assessment?
This work is currently in preparation for publication submission.
ABSTRACT
Concussion remains a symptom-based diagnosis clinically, yet preclinical studies
investigating traumatic brain injury emphasize histological endpoints with functional
assessments often minimized or ignored all together. Recently, clinical studies have
identified the importance of cognitive and neuropsychiatric symptoms, in addition to
somatic complaints, following concussion.
How these findings may translate to
preclinical studies is unclear at present. This work addresses the contrasting endpoints
utilized clinically compared to those in preclinical studies and the potential role of
functional assessments in a commonly used model of diffuse axonal injury (DAI), the
impact-acceleration model. We show, despite the suggestion that this model represents
concussive injury, no functional impairments as determined using common measures of
motor, sensorimotor, cognitive, and neuropsychiatric function following injury over the
course of one week.
The lack of functional deficits is in sharp contrast to
neuropathologic findings indicating neural degeneration, astrocyte reactivity, and
microglial activation. Future studies are needed to identify functional assessments,
neurophysiologic techniques, and imaging assessments more apt to distinguish
differences following so-called ‘mild’ traumatic brain injury (TBI) in preclinical models and
determine whether these models are truly studying concussive or subconcussive injury.
These studies are needed to not only understand mechanisms of injury and production
of subsequent deficits, but also for rigorous evaluation of potential therapeutic agents.
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10.1 INTRODUCTION
The diagnosis of concussion remains challenging due to the lack of definitive diagnostic
tests such as imaging, neuropsychological assessments, accelerometer recordings 653,
or the identification of biomarkers. While advances have been made in the research
environment in many of these areas as evidenced by the advent of diffusion tensor
imaging (DTI) for imaging axonal injury 440,	
   654 and the identification of biomarkers such
as neuron-specific enolase, S100B, and glial fibrillary acidic protein, clinical diagnosis of
concussion continues to rely largely on the self-reported symptoms of the patient 653,	
   655.
Despite this reliance on clinically observed and measured, or self-reported, symptoms
for the diagnosis of concussion in humans, preclinical studies modeling mild traumatic
brain injury (TBI) or concussion continue to emphasize histologic measures of injury for
characterizing model severity, revealing a clear disconnect between preclinical and
clinical studies. Consequently, it remains unclear the precise severity of preclinical
models and how accurately these models replicate concussive injury in humans. While
variations of the fluid percussion injury model, a commonly used preclinical model of TBI
suspected to potentially replicate concussion with the use of ‘mild’ settings, have been
characterized to varying degrees using both behavioral and histological endpoints, the
same cannot be said of the impact-acceleration model, another widely used preclinical
model of TBI and one that has been described as potentially more relevant based on the
ability to model closed head injury and acceleration-deceleration biomechanics
associated with concussion 656,	
  657. Furthermore, this model produces significant diffuse
axonal injury, a common pathological feature of concussion and one that may correlate
to cognitive performance 658. As the diagnosis of concussion clinically represents a
symptom-based diagnosis without the presence of gross anatomical changes, it remains
unclear how adequate current preclinical models are at replicating a concussive-like
state and associated pathophysiology.
This deficiency will likely limit meaningful
translation of therapeutics and preventative measures from bench-to-bedside and for
these reasons, the suggestion has been made that studies should clearly characterize
how concussion is defined within the context of a preclinical model with regards to
behavioral deficits produced 656.
10.1.1. Clinical Diagnosis of Concussion
The definition of concussion has evolved over time with recent work and policy
statements moving away from previous definitions that required a period of loss of
consciousness to one in which concussion is described as a temporary disturbance in
function associated with a complex pathophysiological process induced via impact or
trauma to the head or body 659,	
   660. Despite reports indicating just short of four million
concussions occurring yearly in the United States, diagnosis relies on self-reported
symptoms with no definitive diagnostic test available and specifically, no structural injury
detected with standard neuroimaging protocols 660. Commonly reported symptoms
include physical, cognitive, emotional, and sleep-related complaints ranging from
headaches to dizziness to difficulty concentrating or confusion to irritability, sadness, and
changes in sleep patterns 659. Other symptoms related to mood disorders, namely
anxiety and depression, have also been reported following concussion, but are
frequently difficult to distinguish from larger neuropsychiatric disorders and therefore the
clinical significance is difficult to interpret 661-‐663.
As such, it is clear that the clinical diagnosis of concussion relies on behavioral and
functional changes rather than any imaging or histological findings. This is in sharp
contrast to preclinical studies in which injury severity is based largely on histological
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findings and mortality rates, while functional outcomes and behavioral analyses, if even
included, are not emphasized.
10.1.2. Preclinical Functional and Behavioral Assessments of TBI
While proposed diagnostic tools in the clinic for concussive injury have grown
increasingly technically advanced, particularly when considering neuroimaging and
neuropsychological testing, preclinical assessments used in TBI models have historically
been largely simplistic in nature. Frequently measured modalities include sensorimotor
assessments, learning and memory, and less frequently, anxiety-like or depressive-like
behaviors. Increasing emphasis has been placed in recent years on the incorporation of
more advanced tests and those addressing neurobehavioral disorders as these are one
of the most prominent long-term consequences of TBI exposure clinically 661. Motor
function can be assessed with activity measurements and open field exploration while
balance/coordination has been assayed using the rotarod, inclined plane, beam walk,
and balance beam 663-‐673. Learning and memory have been evaluated following TBI
using various iterations of the Morris water maze 528,	
   658,	
   665,	
   668,	
   673-‐686, radial arm maze
665,	
   670,	
   672, T-maze 686,	
   687, and avoidance tasks 673,	
   686,	
   688,	
   689. Anxiety-like measures
utilized previously include the elevated-plus maze and measures of peripheral versus
central exploratory activity within the open field test 658,	
  663,	
   672,	
   685,	
  689-‐693. Depressive-like
activity has been assessed in the forced swim test and tail suspension test 673,	
  685,	
  686,	
  688,	
  
689,	
   692,	
   694.
How these various behavioral measures are affected following TBI is
dependent on numerous factors including, but not limited to, the severity of injury,
location of injury, type of injury (global versus focal, open versus closed), age at time of
injury, and the length of recovery period prior to assessment. Characterization of these
deficits or changes following injury may allow for better understanding of model severity
and relationship to clinical practice rather than the more commonly utilized histological
measures that are limited to controlled preclinical studies.
10.1.3. Role of Aging in Concussive Injury
Preclinical studies have largely neglected to consider the role of the aging process in the
severity of injury sustained and subsequent recovery characteristics. While TBI is
generally thought to be a condition associated with the adolescent and young-adult
population, the prolonged careers of athletes and military personnel, two populations at
high risk for sustaining a concussive injury, alike in recent years necessitates the
consideration of age as an experimental variable or paradigm. Previous preclinical work
assessing the effect of aging on outcome from TBI, as well as other forms of neurologic
injury, has generally revealed a greater initial injury severity and prolonged deficits in
comparison to young-adult animals 525,	
   526. These studies largely utilized models
requiring craniotomy 525,	
   659,	
   668 rather than simulating true closed-head injury more
analogous to that sustained on the athletic or battlefield in the form of a concussion.
Consequently, it remains unclear how age alters functional and histological outcomes
following diffuse axonal injury.
10.1.4. Summary
In this work, we address the discrepancy between clinical diagnosis of concussion and
the potential role of functional and behavioral measures in the preclinical study of TBI
and more specifically, DAI produced using the impact-acceleration model. We also
investigate the effect of aging on the injury process and how this may influence
behavioral and functional deficits. We perform a basic characterization of neural injury
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following impact-acceleration injury and relate observed changes to those, or lack
thereof, observed with behavioral/functional studies.
10.2. MATERIALS AND METHODS
10.2.1. Animals
Two age groups, one 3-4 months (n=16) and the other 9-12 months (n=15), of male,
Sprague Dawley rats were utilized in this work. All animals utilized in this work were
acquired from Hilltop (Hilltop Lab Animals, Inc.; Scottsdale, Pennsylvania) at 3-4 months
of age and housed in the West Virginia University vivarium for aging when required.
Animals were given standard rat chow and water ad libitum. All work involving live
animals was approved by the Institutional Animal Care and Use Committee of West
Virginia University and was performed according to the principles of the Guide for the
Care and Use of Laboratory Animals, published by the Institute of Laboratory Resources,
National Research Council (National Institutes of Health publication 85-23-2985).
10.2.2. Induction of Traumatic Brain Injury
Each age cohort of animals was divided into two groups, with animals receiving either a
sham surgery or impact-acceleration injury. Anesthesia was induced and maintained
using isoflurane at a 4% and 2% concentration, respectively. Adequate anesthesia was
confirmed by evaluating the response to heel tendon pinch. Body temperature was
controlled during the approximately 10-minute procedure with a homeothermic heating
blanket and rectal probe. Animals were prepared in sterile fashion and received an
impact-acceleration injury as described previously 436,	
   580,	
   585. Briefly, a 10 mm diameter
and 3 mm thick stainless steel disk was affixed to the skull between bregma and lambda
with cyanoacrylate. The animal was placed in a prone position on a foam bed with the
metal disk directly beneath a 2 m tall plexiglass tube. A 450-gram weight was dropped
from the top of the tube, striking the metal disk. The disk was then removed, the skull
inspected, and the wound sutured. The animal was then returned to its cage and
monitored post-operatively.
10.2.3. Functional Characterization
10.2.3.1. Locomotor Activity
Total activity was assessed using an automated activity monitoring system (San Diego
Instruments; San Diego, California) that records photobeam breaks in the x, y, and z
planes. Animals were acclimated to the room for one hour prior to initiation of testing.
Each testing chamber consists of a square Plexiglass housing and 16 x 16 photobeam
array to detect lateral movements. An 8 x 8 array, located above the 16 x 16 array,
detects rearing-associated movements. Activity was quantified over 30 minutes with
fine, ambulatory, and rearing photobeam breaks summed to produce the total
photobeam breaks.
10.2.3.2. Rotarod
Two versions of rotarod testing were conducted, a fixed speed and an accelerating
variant. All studies were conducted using the OMNI-ROTOR (Omnitech Electronics,
Inc.; Columbus, Ohio). Rats were trained over a period of five consecutive days with 5
trials per day. Animals were placed on the rotarod and the rotarod was accelerated to a
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maximum of 24 RPM over a period of 20 seconds.
maximum time allowed per trial was 60 seconds.

Once reaching 24 RPM, the

For the fixed speed testing, animals were tested at speeds of 12, 16, 20, 24, 28, 32, 36,
and 40 RPM for up to 60 seconds. Three trials were conducted at each speed with a
rest period of 30 minutes between each trial. For accelerated testing, the rotarod was
set to reach a maximum speed of 50 RPM over a period of four minutes with a total test
duration of five minutes per trial. The accelerated test was repeated twice for each
animal. For both fixed and accelerating tests, the latency to fall was recorded.
10.2.3.3. Elevated Plus Maze
The elevated plus maze, a measure of anxiety-related activity, was conducted as
previously described 533,	
   544. Animals were placed one at a time in the center of the
maze, facing an open arm. Data was recorded over a period of five minutes using ANYMaze Version 4.63 video tracking software (Stoelting Co; Wood Dale, Illinois.).
Specificallly, time spent in open versus closed arms, number of entries into each arm
type, speed within given arms, and distance traveled was recorded. A body percentage
of 90% was required to be in a given arm to register a change in arm presence.
10.2.3.4. Forced Swim Test
The forced swim test, described at length by Porsolt et al, has been used as a measure
of depressive-like activity 534,	
   535. Animals were acclimated to the testing room for 60
minutes prior to initiation of testing. On the day before testing, animals were habituated
to the water-filled testing cylinder for seven minutes, a length of time consistent with the
testing period. During the testing period, animals were placed in the water for a total of
sevenminutes, the first two of which served as an acclimation period. Data related to
immobility time, speed, distance traveled, and number of immobile episodes was
recorded over the subsequent five minutes using ANY-Maze Version 4.63 video tracking
software.
10.2.3.5. Morris Water Maze
The Morris water maze was used to assess memory as previously described. Animals
were trained prior to induction of injury and tested post-injury for the ability to recall the
platform location. All trials were conducted in a 182-cm diameter pool using Videomex
4.50 tracking software (Columbus Instruments, Columbus, Ohio) for data acquisition.
The water temperature was maintained at 19-22 °C and a platform (12 cm x 12 cm)
made of plexiglass was used. Animals were trained on Days 1-6 via a series of four
trials per day, each from a different location around the pool, and each with a maximum
time of two minutes. Once animals found the platform, 15 seconds was allowed to
elapse for spatial acquisition to occur. If animals were unsuccessful in finding the
platform after two minutes, they were placed on the platform for 15 seconds. After
induction of injury, on Day 1, a one-trial test with the platform in place was utilized to
assess memory. Once the platform was discovered, animals were removed immediately
to prevent additional learning. On Day 6, a traditional probe trial was performed in which
the platform was removed and time spent in each quadrant and the counter zone
recorded.
Functional testing was performed beginning 24 hours post-injury over a one-week
period. Testing was spread over various days to minimize the level of exertion required
by the animal in an effort to reduce the potential for fatigue, consistent with the work of

211

Shultz and colleagues 658. Assays requiring more extensive exertion or those of longer
duration were the only task completed on a given day. At 24 hours post-injury, animals
underwent activity monitoring and a single trial in the Morris water maze. At 48 hours,
the elevated-plus maze and the first rotarod fixed speed test were conducted. At 72
hours, the accelerating rotarod test was conducted. At 96 hours, the forced swim test
was performed and at 120 hours, activity monitoring was conducted. The final day prior
to sacrifice, Day 6 (144 hours), the probe trial in the water maze was performed along
with the second fixed speed rotarod test.
10.2.4. Histology
10.2.4.1. Tissue Preparation
At the conclusion of functional testing, seven days after injury, all surviving animals were
anesthetized and immediately perfused transcardially with physiologic saline followed by
4% paraformaldehyde.
The entire brain, brainstem, and rostral spinal cord were
extracted and placed in 4% paraformaldehyde for 24 hours. Following fixation, the brain
was blocked into 2 mm thick sections and processed using the Tissue-Tek VIP 5
Automatic Tissue Processor (Sakura Finatek; Torrence, CA). Processed tissues were
paraffin-embedded with the Tissue-Tek Tec 5 embedding system (Sakura
Finatek,;Torrence, CA) and sliced (6 µm) using a Leica RM2235 microtome (Leica
Microscopes, Buffalo Grove, IL). Sections were mounted on glass slides and heat-fixed.
Immediately prior to staining, tissues were de-paraffinized using a series of xylene and
alcohol washes as described previously 623.
10.2.4.2. Fluoro-Jade B (FJB) Staining
FJB staining was used to identify neural degeneration. For FJB labeling, slides were
incubated in 0.06% potassium permanganate for 10 minutes following rehydration
through a series of alcohol and deionized (dH2O) water rinses. After incubation in
potassium permanganate, slides were rinsed for 2 minutes in dH2O water and then
incubated for 20 minutes with FJB in 0.1% acetic acid. Slides were washed three times
in dH2O.
10.2.4.3. Glial Fibrillary Acidic Protein (GFAP) Staining
Slides were incubated in rabbit anti-cow GFAP antibody (Dako, Glostrup, Denmark) at a
dilution of 1:500 in 4% horse serum in dulbecco’s phosphate-buffered saline (DPBS)
overnight. Tissues were then washed 3 times in DPBS and incubated in biotinylated
anti-rabbit immunoglobulin G (IgG) antibody (Vector Laboratories, Burlingame, CA)
diluted at 1:10,000 in 4% horse serum in DPBS for 4 hours. Following secondary
antibody incubation, Avidin D horseradish peroxidase (HRP) (Vector Laboratories,
Burlingame, CA) diluted at 1:1,000 in DPBS for 1 hour was applied.
3,3’diaminobenzidine (DAB) chromagen solution (Vector Laboratories, Burlingame, CA) was
applied for 5 minutes. Tissues were then rinsed 3 times in DPBS and dried overnight.
10.2.4.4. Ionized Calcium Binding Adapter Molecule 1 (IBA-1) Staining
IBA-1 labeling of activated microglia utilized an identical protocol as that used for GFAP
staining with the following exceptions: the primary antibody was rabbit anti-Iba 1 (Wako
Chemicals USA, Richmond, VA) at a dilution of 1:500 and the chromagen solution was
Nova Red (Vector Laboratories, Burlingame, CA).
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10.2.4.5. Statistical Analysis
Data were analyzed using GraphPad Prism version 4.0. One-way analysis of variance
(ANOVA) with Tukey’s post-hoc tests were performed to determine differences between
experimental groups on the accelerating rotarod, elevated plus maze, forced swim test,
and Morris water maze. Two-way ANOVA with repeated measures was utilized for fixed
speed rotarod testing analysis.
A p-value of <0.05 was considered statistically
significant.
10.3. RESULTS
10.3.1. Diffuse Axonal Injury Induced Using the Impact-Acceleration Model Produces
Neural Degeneration, Reactive Astrocytes, and Microglial Activation in Both Age Groups.
Fluoro-Jade B staining of brain sections revealed diffuse degeneration of neurons
throughout the cortex and striatum as indicated by increased fluorescent labeling (Figure
10.1).
While injury induced clear degeneration in both age groups examined in
comparison to control (Figure 10.1a,c), young-adult specimens (Figure 10.1b) exhibited
qualitatively diminished damage whereas older animals exhibited a qualitatively more
severe response and level of damage (Figure 10.1d). A diffuse proliferation and
hypertrophy of astrocytes, visualized using GFAP staining, was also seen across tissue
regions in young and old groups relative to control (Figure 10.2). Microglial activation
was enhanced post-injury in both age groups as indicated by Iba-1 staining (Figure
10.3). Microglia in the injured brain exhibit increased ramification of processes as well
as overall hypertrophy.
10.3.2. Impact-Acceleration Injury Fails to Produce Deficits in Total Activity and Motor
Coordination Across Multiple Time Points in Either Age Group up to One-Week PostInjury.
Analysis using a one-way ANOVA and Tukeyʼs post-hoc of total activity indicated by
beam breaks revealed no significant difference between injury and control groups within
respective age groups, at both Day 1 (Figure 10.4a) and Day 5 (Figure 10.4b) postinjury, although differences were observed across age groups on Day 1 [Day 1: F(3,29)
= 10.26, P < 0.05; Young: q=2.07, P>0.05; Old: q=2.78, P>0.05 and Day 5: F(3,29) =
2.12, P > 0.05; Young: q=0.02, P>0.05; Old: q=1.118, P>0.05]. More complex motor
function or coordination was assessed using two variations of the rotarod – accelerating
(Figure 10.4c) and fixed speed (Figure 10.4d,e). The fixed speed test conducted on Day
2 post-injury demonstrated no significant interaction between speed and experimental
group using two-way ANOVA and a Bonferroni post-hoc test when comparing within a
respective age group (Table 10.1). When repeated on Day 6, the fixed speed test again
failed to demonstrate significant deficits between respective age groups (Table 10.2).
The accelerating rotarod test, conducted on Day 3 post-injury, did not reveal any deficits
across groups [F(3,23)=1.165, P>0.05; Young: q=0.11, P>0.05; Old: q=0.22, P>0.05].
10.3.3. Diffuse Axonal Injury Does Not Alter Reference Memory in Both Acute and
Subacute Periods as Determined Using the Morris Water Maze.
Acute analysis of reference memory using the Morris water maze at 24 hours post-injury
(Figure 10.5) showed no deficits as a consequence of injury in either the young or aged
groups [F(3,27)=3.78, P>0.05; Young: q=2.58, P>0.05; Old: q=2.62, P>0.05]. Similar
findings to those at 24 hours were observed in a probe trial conducted on Day 6 post-
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injury. Specifically, no difference between the injured and non-injured groups within
respective age groups was seen with regards to time spent in the counter region, the
region in which the platform previously was placed [F(3,27)=0.58, P>0.05; Young:
q=1.61, P>0.05; Old: q=0.01, P>0.05].
10.3.4. Measures of Anxiety-like and Depressive-like Behaviors Are Unaltered Following
Injury.
The elevated-plus maze, a commonly utilized measure of anxiety-like behavior, failed to
show differences between control and injured animals within respective age groups on
Day 2 post-injury (Figure 10.6a,b). Time spent in the open arms [F(3,29)=5.00, P<0.05;
Young: q=0.55, P>0.05; Old: q=3.00, P>0.05] and number of entries into the open arms
[F(3,29)=2.15, P>0.05; Young: q=0.05, P>0.05; Old: q=1.97, P>0.05] were specifically
analyzed. The forced swim test, a measure of depressive-like activity, was conducted on
Day 4 post-injury. Again, no significant differences were observed between injured and
control groups within respective age groups (Figure 10.6c,d). Both total immobility time
[F(3,28)=6.67, P<0.05; Young: q=0.33, P>0.05; Old: q=3.70, P>0.05] and total number of
immobile episodes [F(3,28)=1.02, P>0.05; Young: q=0.12, P>0.05; Old: q=0.28; P>0.05]
were assessed.
10.3.5. Aging Alters Select Behavioral Measures at Baseline and Post-injury in Male
Animals.
While no differences were observed in total activity within respective age groups at both
24 hours and Day 4, comparisons across age groups showed reduced activity in the
older cohort of animals subjected to injury when compared to both younger control
animals [F(3,29)=10.26, P<0.05; q=7.21, P<0.0001] and younger injured animals [F
(3,29)=10.26, P<0.05; q=5.95, P<0.05] at 24 hours post-injury (Figure 10.4a). At Day 4
post-injury, no difference in total activity was observed between any groups (Figure
10.4b). Evaluation of fixed-speed rotarod performance revealed a similar phenomena in
that at Day 2 post-injury (Figure 10.4c), no difference was observed within respective
age groups or between control groups, but older injured animals performed worse than
both younger controls (12 RPM: t=2.73, P>0.05; 16 RPM: t=1.83, P>0.05; 20 RPM:
t=2.31, P>0.05; 24 RPM: t=1.41, P>0.05; 28 RPM: t=3.15, P<0.05; 32 RPM: t=3.80,
P<0.01; 36 RPM: t=3.27, P<0.05; 40 RPM: t=2.14, P>0.05) and younger injured animals
(12 RPM: t=2.65, P>0.05; 16 RPM: t=1.22, P>0.05; 20 RPM: t=1.63, P>0.05; 24 RPM:
t=1.26, P>0.05; 28 RPM: t=3.14, P<0.05; 32 RPM: t=3.34, P<0.01; 36 RPM: t=3.29,
P<0.01; 40 RPM: t=2.25, P>0.05) at higher speeds. On Day 6, deficits were still
observed when contrasting older injured animals with both younger controls (12 RPM:
t=0.34, P>0.05; 16 RPM: t=0.03, P>0.05; 20 RPM: t=0.09, P>0.05; 24 RPM: t=1.29,
P>0.05; 28 RPM: t=2.47, P>0.05; 32 RPM: t=2.40, P>0.05; 36 RPM: t=2.58, P>0.05; 40
RPM: t=3.41, P<0.01) and younger injured animals (12 RPM: t=0.12, P>0.05; 16 RPM:
t=0.67, P>0.05; 20 RPM: t=0.96, P>0.05; 24 RPM: t=0.63, P>0.05; 28 RPM: t=2.26,
P>0.05; 32 RPM: t=2.97, P<0.05; 36 RPM: t=2.97, P<0.05; 40 RPM: t=3.12, P<0.05).
On the accelerating version of rotarod testing, neither aging nor injury affected the
latency to fall [F(3,23)=1.17, P>0.05].
Reference memory at 24 hours was reduced in the older injured group in comparison to
the younger injured group as determined by latency to platform measurements using the
Morris water maze [F(3,27)=3.78, P<0.05; q=4.65; P<0.05]. On Day 6 post-injury, no
differences were seen between any of the control or treatment groups with regard to
time spent in the counter region, irrespective of age [F(3,27)=0.58, P>0.05].
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Aging appears to alter anxiety-like and depressive-like behaviors as indicated by the
elevated-plus maze and forced swim test, respectively. Older control animals spent
more time in the open arm of the elevated-plus maze than both younger controls
(q=4.82, P<0.05) and younger injured animals (q=4.81, P<0.05). No difference was
observed when comparing younger and older injured groups (q=2.09, P>0.05). In the
forced swim test, older injured animals spent more time immobile than both younger
controls (q=4.72, P<0.05) and younger injured animals (q=5.79, P<0.05).
10.4 DISCUSSION
We have demonstrated a lack of functional and behavioral deficits despite evidence of
histologic changes utilizing the impact-acceleration model of TBI, and more specifically,
diffuse axonal injury (DAI).
Preclinical studies of TBI and DAI have consistently
emphasized histologic measures for assessing the severity of injury despite the fact that
concussion is a clinical diagnosis based on the observation or reporting of somatic as
well as cognitive or neuropsychologic function.
It would seem logical then that
preclinical studies need to incorporate functional assays as not only an experimental
endpoint but also to reconcile preclinical models with the severity and clinical relevance
of injury being studied. Others have explored this concept, primarily using the fluid
percussion model of TBI, and have shown impaired hippocampal spatiotemporal
representation in the absence of histological changes 687. Similarly, a study using lowlevel fluid percussion injury has identified the presence of neuroinflammation after injury
despite no difference in axonal injury and no functional impairments 695.
By observing no effect of injury on an array of behavioral and functional measures
following impact-acceleration injury, even though changes in injury markers were
observed on post-mortem histopathology, additional questions are raised. One, is the
impact-acceleration (Marmarou) model utilized herein truly a model of concussive injury
or rather, would it be more appropriately termed a model of subconcussive injury?
Second, what preclinical behavioral measures are most appropriate for detecting the
subtleties of injury progression and how do these emulate and approximate those used
clinically?
Third, how does symptom expression relate to neurologic health or
neurodegeneration? Four, how are neuropathological findings and functional analysis
altered by aging?
10.4.1. Subconcussive Injury: An Emerging Phenomenon
Emerging evidence indicates the presence of long-term neurodegeneration upon
neuropathological examination of persons with no history of concussion 411,	
   417.
Importantly, Talavage and colleagues have identified for the first time persons failing to
exhibit symptoms associated with concussion but clear deficits on neurocognitive
(ImPACT) and neuropsychologic (fMRI) measures 448. This work, completed in high
school football players, indicates changes in neurologic function and health without
evidence of concussive injury but rather repetitive subconcussive blows 448. As these
players did not exhibit obvious injury, participation and exposure to further injury
continued, consistent with some biomechanical analyses suggesting potential
accumulation of injury and altered neurophysiology consistent with the number of
The notion of
subconcussive impacts rather than the shear magnitude 448,	
   449.
pathological changes occurring in the brain in the absence of clinical presentation of
concussion is particularly alarming and indicates the need for further research as does
identification of persistent deficits in working memory months after initial TBI 696,	
  697.
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As clinically measured subconcussive injury likely requires the utilization of increasingly
advanced testing modalities such as ImPACT, fMRI, or force accelerometers, translation
of this work to preclinical models based on functional assessments will likely necessitate
an advanced array of assessment modalities. ImPACT incorporates symptom reporting
as well as measurements of verbal and visual memory, processing speed, and reaction
time. As such, future preclinical studies may want to incorporate more specific and
sensitive studies designed to evaluate similar parameters, when possible, in the rat that
may be key in determining concussive versus subconcussive injury. This notion may be
true irrespective of preclinical model utilized as our work was consistent with others
using the mild fluid percussion injury model in that no functional deficits were observed
using locomotor activity, elevated-plus maze, and the forced swim test despite the
presence of neuroinflammatory changes 695. Other measures of behavior, specifically
those assessing reaction time and processing or attention deficits, may more closely
measure, in preclinical models, the deficits observed in clinic in patients following
concussion. While the methodology of these techniques is beyond the scope of this
work, various tests assessing these parameters have been extensively reviewed
elsewhere 698,	
   699. The same can be said of more advanced measures of learning and
memory such as shuttle avoidance and operant conditioning.
10.4.2. Symptom Expression as a Correlate of Neuropatholgy
While the acute effects of clinically defined concussive injury are apparent based upon a
combination of self-reported symptoms by the patient and a thorough neurologic
assessment by a trained clinician, diagnosis of concussion has historically been viewed
as a transient neurologic disturbance with no long-term effects. This view has radically
changed in recent years with the emergence of chronic traumatic encephalopathy (CTE),
a neurodegenerative condition associated with repetitive head injury – both of the
concussive and subconcussive types 700. CTE is notable in that a history of repetitive
head trauma proceeds by years, often decades, development of disease-related
symptoms 700. While the disease pathophysiology remains to be elucidated, it has been
hypothesized that the initial brain trauma initiates degenerative processes that emerge
slowly over time, hence the existence of a latent period between trauma and symptom
emergence 432. The role the quantity, severity, type, and location of impacts plays in
symptom development and severity remain unknown, but it is apparent that more
sensitive measures to detect neural damage may be required. In this work, we’ve
shown the lack of acute deficits across a spectrum of functional assays, despite the
presence of neuropathological findings. The existence of neural degeneration and glial
responses without corresponding symptom expression, albeit using a limited battery of
relatively simplistic rodent behavioral tests, indicates the potential for induction of neural
damage without clear deficits clinically, at least in the acute period. How deficits develop
over time, as well as how neuropathological findings progress, remains to be seen, but
may provide further insight into the development of long-term neurodegenerative
diseases such as CTE and warrants future study.
Prior work has demonstrated learning impairments utilizing the Morris water maze, a
spatial acquisition task, following TBI. These deficits appear largely time and model
dependent though as controlled cortical impact has repeatedly been reported to produce
acquisition deficits 528,	
   673,	
   674,	
   685 while fluid percussion injury generally appears to
produce impairments only at more moderate and severe levels. In fact, 1.0 atmosphere
(atm) fluid percussion injury has been reported to produce histological damage upon
microscopic analysis, without any associated water maze deficits 668. This is in contrast
to 1.5 and 1.7-2.0 atm fluid percussion injury producing acquisition and memory-related

216

deficits 668,	
   684 and 1.2 atm causing impairment not on original platform trials but in
reversal studies 658. Work using variations of the weight-drop model, some of which
produce more linear acceleration while others are rotational in nature, have resulted in
reports of similar variability with regards to deficits, with some identifying acquisition
deficits at one week post-injury and beyond 675-‐677,	
   686 whereas others demonstrate
deficits only with heavier weights 678, no deficits in acquisition 679, or no deficits in
memory 665. Our work is notably different in that we focused on the acute period after
injury, based on the period in which patients most commonly report symptoms following
concussion, whereas prior studies have generally employed longer periods between
injury and functional assessment. Similarly, animals were trained in the acquisition task
of the maze prior to injury with memory assessed following injury, hence an evaluation of
retrograde amnesia. Retrograde amnesia has been described as likely time-dependent
in nature with longer intervals between training and injury allowing for enhanced
consolidation and therefore greater likelihood of retention 701.
Other tests of learning and memory may demonstrate greater sensitivity for detecting
deficits or distinguishing between injury severity following neurotrauma. Depending on
the location and severity of injury, fluid percussion has been shown to produce deficits in
the radial arm maze for as few as 5 days after mild injury, 15 days after moderate injury,
and more persistent deficits in others 665,	
   670. In contrast, a modified weight-drop
procedure fails to produce differences in response latency or number of visits to the
baited arms or all arms at any time point post-injury, although an increase in working
memory errors on Day 3 and reference memory errors at Day 5 post-injury were
reported 672. Non-spatial memory, such as that assessed by the novel object recognition
test has successfully demonstrated deficits both acutely and chronically with some ability
to distinguish between varying severities or number of impacts in the case of repetitive
injury models 673,	
   702. Passive avoidance and other avoidance tasks have revealed
impairments following various forms of injury, namely controlled cortical impact (CCI)
and modified weight-drop, at numerous time points, particularly those beyond 1-2 weeks
673,	
   688,	
   689. Some discrepancy is impairment with one study utilizing a modified weightdrop reporting a lack of deficit at 7, 60, and 90 days but diminished memory at 30 days
686. Lastly, other cognitive assessments have also demonstrated utility for distinguishing
between sham and injured animals. This includes fear conditioning 663,	
  703, the swim Tmaze 686,	
   687, and the dig task 686. Whether these other techniques for assessing
learning and memory would reveal deficits in the acute period using the standard weightdrop model is unclear but may represent more sensitive indices of behavioral
assessment going forward.
Furthermore, emerging evidence from clinical studies on concussed patients identifies
the potential for neuropsychiatric changes. We investigated anxiety-like and depressivelike behaviors using the elevated plus maze and forced swim test respectively. While we
did not identify injury-dependent deficits within respective age groups in the acute
period, it is possible the lack of difference between groups is a product of either the time
of assessment, model utilized, and/or severity of injury. Previous work has reported
contrasting findings with some indicating an increase in anxiety-like behavior 663,	
   692,	
   693
whereas others report anxiolytic-like effects of traumatic brain injury 658,	
   685. Notably,
multiple studies have identified no difference in anxiety-like behaviors following TBI when
assessed within one week of injury 672,	
   690-‐692, furthering illustrating the potential timedependency of functional changes following injury. Likewise, injury severity may greatly
influence findings as mild modified weight-drop injury has been shown to produce
anxiety-like behavior, but the same study failed to demonstrate findings in moderate- and
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severely-injured animals 689.
Depressive-like behavior was reported to increase
following modified weight-drop in mice 686,	
   688,	
   689,	
   694, although this finding was not
always consistent over time 686 and in one instance was detected only on tail suspension
but not forced swim test 689. Interestingly, depressive-like behavior (forced swim test)
and anhedonia (sucrose preference test) were not altered following severe fluidpercussion injury (FPI) 692 while CCI resulted in depressive-like behavior at both Day 21
and 24 post-injury 673,	
  685.
More simplistic functional tests, mainly those assessing motor and/or balance, have also
been used following injury in preclinical models of TBI. These tests display a range of
findings with many failing to report deficits with more mild variations of injury or deficits
that resolve within a short period of time post-injury 663-‐668,	
   670-‐672. More severe injury
models, such as CCI, have been reported as producing lasting deficits 673.
The frequent lack of functional deficits observed following injury in preclinical models is
perhaps most alarming considering the frequently reported histological damage
indicating lasting effects of brain injury, even when injury is below the threshold of
detection based on commonly used functional and behavioral assays 695. Clinical
studies have identified similar discrepancies between symptom resolution and metabolic
disturbances. Specifically, Vagnozzi and colleagues showed a resolution of symptoms
by Day 15 post-concussion in all athletes studied, yet metabolite ratios did not normalize
until Day 30 453.
10.4.3. Role of Aging in Neuropathology & Functional Deficits Post-TBI
Aging has been attributed, via clinical experience, with poorer outcomes post-TBI 528,	
   704,	
  
705. Consequently, there has been an increased emphasis on understanding the effects
of aging post-TBI in recent years in an effort to improve the translation of therapeutics
from bench-to-bedside. In preclinical studies, aging has been associated with an
increase in mortality rate as well as prolonged suppression of reflexes 525,	
   706.
Importantly, aging has also been associated with diminished functional performance both
before 528,	
   544, and after, injury 525,	
   528,	
   544,	
   681. While the injury models and functional/
behavioral measures utilized across studies vary, it is clear that older animals exhibit
diminished learning and memory, and often complex sensorimotor abilities, in
comparison to young-adult animals. In work by Mehan and colleagues, 20 month-old
animals performed worse in the Morris water maze and beam walking tasks compared to
young-adult animals following laterally administered controlled cortical impact injury 528,	
  
544. Use of the impact-acceleration model has produced similar findings in that aged
animals, despite being subjected to a less severe injury in terms of energy transferred,
exhibited a markedly worse impairment in the water maze at 1 week, 3 weeks, and 5
weeks post-injury in comparison to young-adult animals 681. Others have identified
similar deficits in middle-aged animals compared to young-adult animals with cortical
contusion producing more severe deficits in the bilateral tactile adhesive removal test
and acquisition, as well as memory, of a reference-based task 707. Similarly, aging has
been associated with larger lesion cavities following CCI 707 and an altered biochemical
response as demonstrated by age-dependent changes in protein expression post-injury
528,	
   706. Why the aged brain appears more susceptible to brain injury remains unclear
and necessitates further investigation.
10.4.4. Future Directions
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Future studies need to elucidate the effect of TBI across a spectrum of time points to
address the possibility of delayed effects and the development of deficits over time.
While this work demonstrates the lack of detectable functional deficits following a single
injury using an array of behavioral measures during the acute and subacute period,
chronic deficits that may take longer to develop were not studied. Clinically, changes in
affect and cognitive abilities generally arise years after sustaining concussive injury, at
least in those cases associated with a diagnosis of CTE 417,	
   422-‐424,	
   708. This reality
further indicates the need for long-term preclinical studies to assess not only behavioral
changes but also pathological changes.
In addition to the need for longer-term single impact studies, perhaps more importantly,
long-term studies incorporating repetitive injury are warranted based on clinical
indications and injury paradigms potentially experienced on the athletic or battlefields,
frequent locations of concussive injury. Unfortunately, at this point in time preclinical
models of disease processes associated with a history of repetitive-concussive injury,
such as CTE, have not been established. The lack of representative animal models for
these increasingly diagnosed conditions, both in terms of functional/behavioral changes
as well as histolgic changes observed on post-mortem analysis, has limited elucidation
of disease pathophysiology and therapeutic development.
While numerous models have been utilized to study TBI in rodent models, how these
models replicate the clinical scenario, particularly of such a heterogeneous injury as TBI,
is unclear. Emerging evidence in preclinical as well as clinical literature indicates a
potential role for magnetic resonance spectroscopy (MRS) to gain insight into the
biochemistry and pathophysiology of the injury process. Similarly, diffusion tensor
imaging (DTI) has been utilized for identification of axonal injury post-TBI. Application of
technologies such as these to preclinical models may allow for an enhanced
understanding of injury pathophysiology and the severity of injury induced using various
models.
10.4.5. Limitations
Animals were not assessed until 24 hours post-injury to minimize the potential for
anesthetic influences on behavior. By waiting until one day post-injury this issue was
avoided. Future studies are likely needed to assess the effect of TBI in this immediate
post-injury period. Despite the delay in initial assessments, one would have expected if
this was truly a model of concussive injury that some deficits may be detected based on
the persistence of symptoms clinically beyond one day in many cases, even though
80-90% of those afflicted with concussion report resolution of symptoms within 7 days.
How the recovery period and resolution of symptoms correlates between clinical and
preclinical studies remains to be seen. Furthermore, animals were sacrificed at one
week post-injury for neuropathological analysis, preventing the study of potentially late
developing deficits weeks or months post-injury.
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FIGURES

Figure 10.1. Impact-acceleration injury resulted in neural degeneration as evident by
Fluoro-Jade B staining in both 3-4 month and 9-12 month-old male rats. Representative
sections from sham 3-4 month-old (A), injured 3-4 month-old (B), sham 9-12 month-old
(C), and injured 9-12 month-old (D) rats. Arrows indicate degenerating neurons.
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Figure 10.2. Impact-acceleration injury resulted in reactive astrocytes as evident by glial
fibrillary acidic protein (GFAP) staining in both 3-4 month and 9-12 month-old male rats.
Representative sections from sham 3-4 month-old (A), injured 3-4 month-old (B), sham
9-12 month-old (C), and injured 9-12 month-old (D) rats. Arrows represent reactive
astrocytes and insets represent high-powered view of the corresponding panel.
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Figure 10.3. Impact-acceleration injury resulted in microglial activation as evident by
ionized calcium binding adapter molecule 1 (Iba-1) staining in both 3-4 month and 9-12
month-old male rats. Representative sections from sham 3-4 month-old (A), injured 3-4
month-old (B), sham 9-12 month-old (C), and injured 9-12 month-old (D) rats. Arrows
represent reactive microglia and insets represent high-powered views of the
corresponding panel.
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Figure 10.4. Diffuse axonal injury (DAI), produced through impact-acceleration injury,
did not result in sensorimotor deficits. Total activity was not altered within respective age
groups on Day 1 (A) or Day 5 (B) post-injury. Similar findings were seen in the
accelerated rotarod test on Day 3 post-injury (C) and the fixed speed rotarod test
conducted on Day 2 (D) and Day 6 (E) post-injury.
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Figure 10.5. Diffuse axonal injury did not produce retrograde amnesia on Day 1 (A) or
Day 6 (B) post-injury as determined using the Morris water maze.
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Figure 10.6. Impact-acceleration injury was not associated with changes in anxiety- or
depressive-like behavior as determined using the elevated-plus maze and forced swim
test, respectively. Both the time spent in open arms (A) and number of entries into open
arms (B) were not significantly altered within respective age groups when comparing
injured and sham animals. Similar findings were observed in the forced swim test with
regards to immobility time (C) and number of immobile episodes (D).
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TABLES

Table 10.1. Fixed speed rotarod testing on Day 2 post-DAI does not reveal deficits
between injured and sham animals within respective age groups. Deficits are seen
when comparing injured aged animals to younger animals (both control and injured) at
higher speeds.
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Table 10.2. Fixed speed rotarod testing on Day 6 post-DAI does not reveal deficits
between injured and sham animals within respective age groups. Deficits are seen
when comparing injured aged animals to younger animals (both control and injured) at
higher speeds.
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Chapter Eleven
11.1. SUMMARY
In summary, the studies that have been presented herein demonstrate the following:
• Modulating protein kinase c (PKC) via bryostatin-1 administration reduces
mortality, infarct volume, and improves functional outcome following stroke.
• APT102 safely extended the therapeutic window for tPA in a clinically relevant
animal model of ischemic stroke while significantly reducing the mortality rate.
• Functional endpoints are emphasized in clinical trials yet are often not utilized in
preclinical studies. The correlation between functional and histological endpoints
is likely age-dependent.
• Traumatic brain injury and axonal injury specifically, resulting from impactacceleration injury, can be reduced through manipulation of intracranial vascular
volume.
• Glial activation likely significantly contributes to not only initial injury, but also long
term repair and recovery following traumatic brain injury.
• Blast models have frequently failed to consider exposure duration as a clinically
relevant parameter and consequently, models have not been scaled
appropriately.
Scaling to clinically-relevant parameters revealed significant
neural injury in a pressure-dependent fashion.
11.2. FUTURE STUDIES and DIRECTIONS
11.2.1. Bryostatin-1 Administration for Neural Injury – Isoform Specificity in Injury?
While we’ve shown a clear beneficial role for PKC modulation following ischemic stroke,
as others have in other neural injury and neurodegenerative conditions 349,	
  358,	
  359,	
  364,	
   365,	
  
394,	
   397,	
   488,	
   492, it remains unclear the contribution of various PKC isoforms.
While
bryostatin-1 is believed to be primarily a PKCε activator, other PKC isoforms such as
PKCα and PKCδ are affected by ischemic stroke and may be altered by bryostatin-1
treatment. To address this issue, isoform-specific compounds or conditional knockouts
will need to be developed for future studies. Similarly, the precise mechanism via which
PKC modulation improves outcome is unclear. Prior work has primarily focused on
neuronal effects and largely ignored glial effects, despite the well-documented role of
glia in neural injury and degeneration. Furthermore, the role of PKC in specific cell types
(neurons, astrocytes, microglia, etc) and across time remains unclear and is of interest
considering increased recognition of biphasic signaling events post-injury that may be
deleterious initially, but beneficial in recovery and repair or vice-versa. How bryostatin-1
alters outcome in other neural injury conditions, such as blast injury, is another future
avenue of investigation.
11.2.2. APT 102 Extends the Window of Opportunity for tPA Administration but How?
We’ve shown a reduced risk of hemorrhagic transformation when tPA is administered at
6 hours post-stroke in combination with APT 102, but the mechanism is not wellelucidated. While others have shown effects on prothrombotic mediators, such as
extracellular ATP and ADP 709, it remains unclear how APT 102 may promote
maintenance or restoration of endothelial integrity through direct or indirect effects on
platelets and other mediators of thrombosis.
11.2.3. Preventing Traumatic Brain Injury: Alternative Mechanisms?
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Biologically-inspired discovery led to the revelation of internal jugular vein compression
as a preventative measure for diffuse axonal injury through a reduction in not only
axonal injury, but also glial activation. Other animals, besides the woodpecker cited as
the prime example within this work, experience significant impacts in nature with no
apparent deleterious effects, raising the possibility of alternative protective mechanisms
existing in nature that could potentially be applied to humans. Such species include big
horn sheep and diving gannets, both of which possess respiratory tracts with extensive
dead space and exhibit increased levels of arterial pCO2. This altered respiratory gas
composition, due to the well-documented effects of increased pCO2, may lead to
increased intracranial vascular volume and diminished brain movement within the cranial
vault upon impact. Therefore, future studies may administer exogenous CO2 prior to
trauma to elucidate the role of increased pCO2 in preventing traumatic brain injury.
Other mechanisms exist for increasing intracranial blood flow as well by increasing pCO2
such as pharmacological manipulation with acetazolamide, a carbonic anhydrase
inhibitor.
Another potential prevention mechanism lies in the red blood cell and hemoglobin
molecule. Traumatic brain injury, particularly diffuse axonal injury associated with closed
head injury and concussion, has been notoriously difficult to image regardless of
modality utilized. Recent work has shown the potential utility of diffusion tensor imaging
(DTI) and tractography for detection of diffuse axonal injury 710. This detection is based
primarily on the detection of iron, the majority of which is found in the heme molecule
within hemoglobin.
Interestingly, DTI is particularly sensitive for the detection of
methemoglobin, the form of hemoglobin incapable of transporting oxygen.
Methemoglobin is elevated following trauma according to numerous reports, particularly
those associated with blast exposure, in both preclinical and clinical studies indicating a
potential role in injury pathogenesis, particularly with regards to free radical production.
The conversion of hemoglobin to methemoglobin is notable in that it can be reversed by
the enzyme NADH methemoglobin reductase 711, an enzyme that can be modulated
through administration of methylene blue, which acts as an exogenous electron acceptor
for the enzyme.
11.2.4. Elucidating Blast Injury Pathophysiology
Development of a clinically relevant blast model, as described herein, will allow for the
investigation of neurotrauma pathophysiology and perhaps of most interest and
relevance to the general public, elucidation of the role of trauma in neurodegenerative
disease development risk with a particular interest in chronic traumatic encephalopathy
(CTE).
As CTE is characterized by the presence of neurofibrillary tangles,
hyperphosphorylated tau, and glial changes, these pathological features represent
logical starting points for study and the evaluation of potential therapeutics 700.
Emerging evidence from clinical and preclinical studies alike has implicated endoplasmic
reticulum stress in the hyperphosphorylation of tau 712-‐715, a precursor to tangle
formation. Specifically, components of the PERK-mediated ER stress pathway have
been shown to colocalize with pretangle neurons at autopsy in patients afflicted with
Alzheimer’s disease and other tauopathies 713,	
   715. While colocalization does not
indicate causation, the proximity does indicate a potential role for PERK-mediated ER
stress in neuropathological changes, whether direct or indirect in nature. How PERKmediated ER stress is involved in neurotrauma, and the potential for long-term
neurodegenerative disease development, remains unclear due to lack of investigation.
Studies in other neural injury models, particularly ischemic stroke 716, indicate a role for
PERK-mediated ER stress in pathology.
Therefore, PERK-mediated ER stress
represents a novel and potentially promising therapeutic target for neural injury and blast
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injury in particular. Numerous pharmacologic modulators exist, such as tunicamycin ,
thapsigargin, and salubrinal, and have been used extensively in the literature offering
further promise for future investigation.
Reconciling Preclinical and Clinical Studies: Integrating Functional and Behavioral
Measures with Traditional Histological Studies
Attempts to improve preclinical studies of neural injury, whether it be stroke or
neurotrauma, have identified numerous shortcomings in preclinical studies and
mechanisms to address these issues. Two of the main weaknesses of preclinical
studies include failure to consider age and the use of histological endpoints despite the
importance of functional assessments clinically. We’ve presented in this work the effect
of age on behavior and the correlation between infarct volume and functional
performance in a clinically relevant model of ischemic stroke using aged female rodents.
This correlation is particularly strong when using striatal infarct volumes and noticeably
weaker when using cortical volumes. It remains to be seen whether this phenomenon
holds up in the clinical population as expected, considering the role of the striatum in
signal integration and transmission from various brain regions.

231

REFERENCES
1.
Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in
stroke. Nature Reviews Neuroscience. May 2003;4(5):399-415.
2.
Candelario-Jalil E. Injury and repair mechanisms in ischemic stroke:
considerations for the development of novel neurotherapeutics. Curr Opin Investig
Drugs. Jul 2009;10(7):644-654.
3.
Jordan J, Segura T, Brea D, Galindo MF, Castillo J. Inflammation as therapeutic
objective in stroke. Curr Pharm Des. 2008;14(33):3549-3564.
4.
Hinzman JM, Thomas TC, Burmeister JJ, et al. Diffuse brain injury elevates tonic
glutamate levels and potassium-evoked glutamate release in discrete brain regions at
two days post-injury: an enzyme-based microelectrode array study. J Neurotrauma. May
2010;27(5):889-899.
5.
Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. Nat Rev
Neurosci. Feb 2013;14(2):128-142.
6.
Lin Y, Wen L. Inflammatory response following diffuse axonal injury. Int J Med
Sci. 2013;10(5):515-521.
7.
Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory
cytokines and chemokines in the pathophysiology of traumatic brain injury.
Neurotherapeutics. Jan 2010;7(1):22-30.
8.
O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells
DW. 1,026 experimental treatments in acute stroke. Ann Neurol. Mar 2006;59(3):
467-477.
9.
Rosen CL, Dinapoli VA, Nagamine T, Crocco T. Influence of age on stroke
outcome following transient focal ischemia. J Neurosurg. Oct 2005;103(4):687-694.
10.
Dinapoli VA, Rosen CL, Nagamine T, Crocco T. Selective MCA occlusion: a
precise embolic stroke model. J Neurosci Methods. Jun 30 2006;154(1-2):233-238.
11.
Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV.
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke.
Mol Neurodegener. 2011;6(1):11.
12.
Roof RL, Schielke GP, Ren X, Hall ED. A comparison of long-term functional
outcome after 2 middle cerebral artery occlusion models in rats. Stroke. Nov 2001;32
(11):2648-2657.
13.
Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of
bone marrow stromal cells after cerebral ischemia in rats. Stroke. Apr 2001;32(4):
1005-1011.
14.
Boltze J, Kowalski I, Forschler A, et al. The stairway: a novel behavioral test
detecting sensomotoric stroke deficits in rats. Artif Organs. Oct 2006;30(10):756-763.
15.
DeVries AC, Nelson RJ, Traystman RJ, Hurn PD. Cognitive and behavioral
assessment in experimental stroke research: will it prove useful? Neurosci Biobehav
Rev. Jun 2001;25(4):325-342.
16.
Yang Y, Shuaib A, Li Q. Quantification of infarct size on focal cerebral ischemia
model of rats using a simple and economical method. J Neurosci Methods. Oct 1
1998;84(1-2):9-16.
17.
Thore CR, Anstrom JA, Moody DM, Challa VR, Marion MC, Brown WR.
Morphometric analysis of arteriolar tortuosity in human cerebral white matter of preterm,
young, and aged subjects. J Neuropathol Exp Neurol. May 2007;66(5):337-345.
18.
Jucker M, Battig K, Meier-Ruge W. Effects of aging and vincamine derivatives on
pericapillary microenvironment: stereological characterization of the cerebral capillary
network. Neurobiol Aging. Jan-Feb 1990;11(1):39-46.
19.
Shao WH, Li C, Chen L, et al. Stereological investigation of age-related changes
of the capillaries in white matter. Anat Rec (Hoboken). Aug 2010;293(8):1400-1407.

232

20.
Anstrom JA, Brown WR, Moody DM, Thore CR, Challa VR, Block SM. Anatomical
analysis of the developing cerebral vasculature in premature neonates: absence of
precapillary arteriole-to-venous shunts. Pediatr Res. Oct 2002;52(4):554-560.
21.
Chen JJ, Rosas HD, Salat DH. Age-associated reductions in cerebral blood flow
are independent from regional atrophy. Neuroimage. Mar 15 2011;55(2):468-478.
22.
Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and
neurodegeneration. Neuropathol Appl Neurobiol. Feb 2011;37(1):56-74.
23.
Drake CT, Iadecola C. The role of neuronal signaling in controlling cerebral blood
flow. Brain Lang. Aug 2007;102(2):141-152.
24.
Takano T, Tian GF, Peng W, et al. Astrocyte-mediated control of cerebral blood
flow. Nat Neurosci. Feb 2006;9(2):260-267.
25.
Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of
endothelium and potassium channels. Physiol Rev. Jan 1998;78(1):53-97.
26.
Russo T, Felzani G, Marini C. Stroke in the Very Old: A Systematic Review of
Studies on Incidence, Outcome, and Resource Use. Journal of Aging Research.
2011;2011.
27.
Toescu EC. Normal brain ageing: models and mechanisms. Philos Trans R Soc
Lond B Biol Sci. Dec 29 2005;360(1464):2347-2354.
28.
Buchhold B, Mogoanta L, Suofu Y, et al. Environmental enrichment improves
functional and neuropathological indices following stroke in young and aged rats. Restor
Neurol Neurosci. 2007;25(5-6):467-484.
29.
Buga AM, Vintilescu R, Pop OT, Popa-Wagner A. Brain Aging and Regeneration
after Injuries: an Organismal approach. Aging Dis. Feb 2011;2(1):64-79.
30.
Badan I, Buchhold B, Hamm A, et al. Accelerated glial reactivity to stroke in aged
rats correlates with reduced functional recovery. J Cereb Blood Flow Metab. Jul 2003;23
(7):845-854.
31.
Zhao CS, Puurunen K, Schallert T, Sivenius J, Jolkkonen J. Behavioral and
histological effects of chronic antipsychotic and antidepressant drug treatment in aged
rats with focal ischemic brain injury. Behav Brain Res. Mar 30 2005;158(2):211-220.
32.
Di Napoli M, Shah IM. Neuroinflammation and cerebrovascular disease in old
age: a translational medicine perspective. J Aging Res. 2011;2011:857484.
33.
Popa-Wagner A, Buga AM, Kokaia Z. Perturbed cellular response to brain injury
during aging. Ageing Res Rev. Jan 2011;10(1):71-79.
34.
Buga AM, Sascau M, Pisoschi C, Herndon JG, Kessler C, Popa-Wagner A. The
genomic response of the ipsilateral and contralateral cortex to stroke in aged rats. J Cell
Mol Med. Dec 2008;12(6B):2731-2753.
35.
van Uden IW, van Norden AG, de Laat KF, et al. Depressive Symptoms and
Amygdala Volume in Elderly with Cerebral Small Vessel Disease: The RUN DMC Study.
J Aging Res. 2011;2011:647869.
36.
Teggi R, Fabiano B, Recanati P, Limardo P, Bussi M. Case reports on two
patients with episodic vertigo, fluctuating hearing loss and migraine responding to
prophylactic drugs for migraine. Meniere's disease or migraine-associated vertigo? Acta
Otorhinolaryngol Ital. Aug 2010;30(4):217.
37.
Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental
deterioration in the elderly. Lancet. Jul 27 1974;2(7874):207-210.
38.
Enciu AM, Constantinescu SN, Popescu LM, Muresanu DF, Popescu BO.
Neurobiology of vascular dementia. J Aging Res. 2011;2011:401604.
39.
Thome J, Coogan AN, Woods AG, Darie CC, Hassler F. CLOCK Genes and
Circadian Rhythmicity in Alzheimer Disease. J Aging Res. 2011;2011:383091.
40.
Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for
trials of acute stroke therapy. Lancet Neurol. Mar 2009;8(3):261-269.
41.
Floel A, Warnecke T, Duning T, et al. Granulocyte-colony stimulating factor (GCSF) in stroke patients with concomitant vascular disease--a randomized controlled trial.
PLoS One. 2011;6(5):e19767.

233

42.
Montaner J, Alvarez-Sabin J, Molina C, et al. Matrix metalloproteinase
expression after human cardioembolic stroke: temporal profile and relation to
neurological impairment. Stroke. Aug 2001;32(8):1759-1766.
43.
Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo
K. The impact of the aging population on coronary heart disease in the United States.
Am J Med. Sep 2011;124(9):827-833 e825.
44.
Taussky P, Tawk RG, Daugherty WP, Hanel RA. Medical therapy for ischemic
stroke: review of intravenous and intra-arterial treatment options. World Neurosurg. Dec
2011;76(6 Suppl):S9-15.
45.
Dronne MA, Grenier E, Chapuisat G, Hommel M, Boissel JP. A modelling
approach to explore some hypotheses of the failure of neuroprotective trials in ischemic
stroke patients. Prog Biophys Mol Biol. May 2008;97(1):60-78.
46.
Schmidt S, Bruehl C, Frahm C, Redecker C, Witte OW. Age dependence of
excitatory-inhibitory balance following stroke. Neurobiol Aging. Jul 2012;33(7):
1356-1363.
47.
Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy
academic industry roundtable preclinical recommendations. Stroke. Jun 2009;40(6):
2244-2250.
48.
Shah IM, Ghosh SK, Collier A. Stroke presentation in Type 2 diabetes and the
metabolic syndrome. Diabetes Res Clin Pract. Jan 2008;79(1):e1-4.
49.
Liu F, Yuan R, Benashski SE, McCullough LD. Changes in experimental stroke
outcome across the life span. J Cereb Blood Flow Metab. Apr 2009;29(4):792-802.
50.
Cotrina ML, Nedergaard M. Astrocytes in the aging brain. J Neurosci Res. Jan 1
2002;67(1):1-10.
51.
Dinapoli VA, Benkovic SA, Li X, et al. Age exaggerates proinflammatory cytokine
signaling and truncates signal transducers and activators of transcription 3 signaling
following ischemic stroke in the rat. Neuroscience. Oct 13 2010;170(2):633-644.
52.
Guevara R, Gianotti M, Oliver J, Roca P. Age and sex-related changes in rat
brain mitochondrial oxidative status. Exp Gerontol. Aug 12 2011.
53.
Nakanishi H, Wu Z. Microglia-aging: roles of microglial lysosome- and
mitochondria-derived reactive oxygen species in brain aging. Behav Brain Res. Jul 19
2009;201(1):1-7.
54.
Nakase T, Maeda T, Yoshida Y, Nagata K. Ischemia alters the expression of
connexins in the aged human brain. J Biomed Biotechnol. 2009;2009:147946.
55.
Popa-Wagner A, Carmichael ST, Kokaia Z, Kessler C, Walker LC. The response
of the aged brain to stroke: too much, too soon? Curr Neurovasc Res. Aug 2007;4(3):
216-227.
56.
Tripathy D, Yin X, Sanchez A, Luo J, Martinez J, Grammas P. Cerebrovascular
expression of proteins related to inflammation, oxidative stress and neurotoxicity is
altered with aging. J Neuroinflammation. 2010;7:63.
57.
Tirilazad mesylate in acute ischemic stroke: A systematic review. Tirilazad
International Steering Committee. Stroke. Sep 2000;31(9):2257-2265.
58.
Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute
stroke: a need for more rigorous testing of neuroprotective agents in animal models of
stroke. Exp Neurol. May 2007;205(1):20-25.
59.
Kelly KA, Li X, Tan Z, VanGilder RL, Rosen CL, Huber JD. NOX2 inhibition with
apocynin worsens stroke outcome in aged rats. Brain Res. Oct 6 2009;1292:165-172.
60.
Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary
perspective on immunosenescence. Ann N Y Acad Sci. Jun 2000;908:244-254.
61.
Hein AM, O'Banion MK. Neuroinflammation and cognitive dysfunction in chronic
disease and aging. J Neuroimmune Pharmacol. Mar 2012;7(1):3-6.
62.
Pizza V, Agresta A, D'Acunto CW, Festa M, Capasso A. Neuroinflamm-aging and
neurodegenerative diseases: an overview. CNS Neurol Disord Drug Targets. Aug
2011;10(5):621-634.

234

63.
von Bernhardi R, Tichauer JE, Eugenin J. Aging-dependent changes of microglial
cells and their relevance for neurodegenerative disorders. J Neurochem. Mar 2010;112
(5):1099-1114.
64.
Rosano C, Marsland AL, Gianaros PJ. Maintaining brain health by monitoring
inflammatory processes: a mechanism to promote successful aging. Aging Dis. Feb
2012;3(1):16-33.
65.
Bitto A, Sell C, Crowe E, et al. Stress-induced senescence in human and rodent
astrocytes. Exp Cell Res. Oct 15 2010;316(17):2961-2968.
66.
Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H.
Astrocytes in the aging brain express characteristics of senescence-associated
secretory phenotype. Eur J Neurosci. Jul 2011;34(1):3-11.
67.
Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Aging-induced
proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J. Jun
2003;17(9):1183-1185.
68.
Brown DR. Role of microglia in age-related changes to the nervous system.
ScientificWorldJournal. 2009;9:1061-1071.
69.
Luo XG, Ding JQ, Chen SD. Microglia in the aging brain: relevance to
neurodegeneration. Mol Neurodegener. 2010;5:12.
70.
Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ. Ex vivo
cultures of microglia from young and aged rodent brain reveal age-related changes in
microglial function. Neurobiol Aging. Jan 2012;33(1):195 e191-112.
71.
Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive
senescent cells delays ageing-associated disorders. Nature. Nov 10 2011;479(7372):
232-236.
72.
Harry GJ, Kraft AD. Microglia in the developing brain: a potential target with
lifetime effects. Neurotoxicology. Mar 2012;33(2):191-206.
73.
Hart AD, Wyttenbach A, Perry VH, Teeling JL. Age related changes in microglial
phenotype vary between CNS regions: grey versus white matter differences. Brain
Behav Immun. Jul 2012;26(5):754-765.
74.
Murphy KJ, Miller AM, Thelma R, Cowley F, Cox FF, Lynch MA. The age- and
amyloid-beta-related increases in Nogo B contribute to microglial activation. Neurochem
Int. Feb 2011;58(2):161-168.
75.
Jurgens HA, Johnson RW. Dysregulated neuronal-microglial cross-talk during
aging, stress and inflammation. Exp Neurol. Jan 2012;233(1):40-48.
76.
Cox FF, Carney D, Miller AM, Lynch MA. CD200 fusion protein decreases
microglial activation in the hippocampus of aged rats. Brain Behav Immun. Jul 2012;26
(5):789-796.
77.
Gemma C, Bachstetter AD, Bickford PC. Neuron-Microglia Dialogue and
Hippocampal Neurogenesis in the Aged Brain. Aging Dis. Dec 1 2010;1(3):232-244.
78.
Kim HJ, Kim JY, Sun W. Age-dependent changes in the subcallosal zone
neurogenesis of mice. Neurochem Int. Nov 2012;61(6):879-884.
79.
McGinn MJ, Colello RJ, Sun D. Age-related proteomic changes in the
subventricular zone and their association with neural stem/progenitor cell proliferation. J
Neurosci Res. Jun 2012;90(6):1159-1168.
80.
Morrison JH, Baxter MG. The ageing cortical synapse: hallmarks and implications
for cognitive decline. Nat Rev Neurosci. Apr 2012;13(4):240-250.
81.
Chadwick W, Martin B, Chapter MC, et al. GIT2 acts as a potential keystone
protein in functional hypothalamic networks associated with age-related phenotypic
changes in rats. PLoS One. 2012;7(5):e36975.
82.
Dotson V, Horak K, Alwardt C, Larson DF. Relationship of aging and cardiac
IL-10. J Extra Corpor Technol. Jun 2004;36(2):197-201.
83.
Meador BM, Krzyszton CP, Johnson RW, Huey KA. Effects of IL-10 and age on
IL-6, IL-1beta, and TNF-alpha responses in mouse skeletal and cardiac muscle to an
acute inflammatory insult. J Appl Physiol. Apr 2008;104(4):991-997.

235

84.
DiNapoli VA, Huber JD, Houser K, Li X, Rosen CL. Early disruptions of the bloodbrain barrier may contribute to exacerbated neuronal damage and prolonged functional
recovery following stroke in aged rats. Neurobiol Aging. May 2008;29(5):753-764.
85.
Lee P, Kim J, Williams R, et al. Effects of aging on blood brain barrier and matrix
metalloproteases following controlled cortical impact in mice. Exp Neurol. Mar 2012;234
(1):50-61.
86.
Itoh T, Imano M, Nishida S, et al. Increased apoptotic neuronal cell death and
cognitive impairment at early phase after traumatic brain injury in aged rats. Brain Struct
Funct. Jan 2013;218(1):209-220.
87.
Popa-Wagner A, Stocker K, Balseanu AT, et al. Effects of granulocyte-colony
stimulating factor after stroke in aged rats. Stroke. May 2010;41(5):1027-1031.
88.
Caballero B, Coto-Montes A. An insight into the role of autophagy in cell
responses in the aging and neurodegenerative brain. Histol Histopathol. Mar 2012;27(3):
263-275.
89.
Liu X, Wu Z, Hayashi Y, Nakanishi H. Age-dependent neuroinflammatory
responses and deficits in long-term potentiation in the hippocampus during systemic
inflammation. Neuroscience. Aug 2 2012;216:133-142.
90.
Bruce-Keller AJ, White CL, Gupta S, et al. NOX activity in brain aging:
exacerbation by high fat diet. Free Radic Biol Med. Jul 1 2010;49(1):22-30.
91.
Knecht S, Ellger T, Levine JA. Obesity in neurobiology. Prog Neurobiol. Jan
2008;84(1):85-103.
92.
Katsiki N, Ntaios G, Vemmos K. Stroke, obesity and gender: a review of the
literature. Maturitas. Jul 2011;69(3):239-243.
93.
Savopoulos C, Michalakis K, Apostolopoulou M, Miras A, Hatzitolios A.
Adipokines and stroke: a review of the literature. Maturitas. Dec 2011;70(4):322-327.
94.
Hishinuma A, Majima M, Kurabayashi H. Insulin resistance in patients with stroke
is related to visceral fat obesity and adipocytokines. J Stroke Cerebrovasc Dis. Jul-Aug
2008;17(4):175-180.
95.
Jackson RS, Black JH, 3rd, Lum YW, et al. Class I obesity is paradoxically
associated with decreased risk of postoperative stroke after carotid endarterectomy. J
Vasc Surg. May 2012;55(5):1306-1312.
96.
Kastorini CM, Panagiotakos DB. The obesity paradox: methodological
considerations based on epidemiological and clinical evidence--new insights. Maturitas.
Jul 2012;72(3):220-224.
97.
Pan W, Kastin AJ. Tumor necrosis factor and stroke: role of the blood-brain
barrier. Prog Neurobiol. Dec 2007;83(6):363-374.
98.
Orosco M, Rouch C, Meile MJ, Nicolaidis S. Spontaneous feeding-related
monoamine changes in rostromedial hypothalamus of the obese Zucker rat: a
microdialysis study. Physiol Behav. Jun 1995;57(6):1103-1106.
99.
Subramanian R, MacLeod KM. Age-dependent changes in blood pressure and
arterial reactivity in obese Zucker rats. Eur J Pharmacol. Sep 12 2003;477(2):143-152.
100. Langdon KD, Clarke J, Corbett D. Long-term exposure to high fat diet is bad for
your brain: exacerbation of focal ischemic brain injury. Neuroscience. May 19
2011;182:82-87.
101. Amantea D, Corasaniti MT, Mercuri NB, Bernardi G, Bagetta G. Brain regional
and cellular localization of gelatinase activity in rat that have undergone transient middle
cerebral artery occlusion. Neuroscience. Mar 3 2008;152(1):8-17.
102. Deutsch C, Portik-Dobos V, Smith AD, Ergul A, Dorrance AM. Diet-induced
obesity causes cerebral vessel remodeling and increases the damage caused by
ischemic stroke. Microvasc Res. Jun 2009;78(1):100-106.
103. Berg GD, Wadhwa S. Diabetes disease management in a community-based
setting. Manag Care. Jun 2002;11(6):42, 45-50.

236

104. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:
estimates for the year 2000 and projections for 2030. Diabetes Care. May 2004;27(5):
1047-1053.
105. Mahler RJ, Adler ML. Clinical review 102: Type 2 diabetes mellitus: update on
diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab. Apr 1999;84(4):
1165-1171.
106. Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes
mellitus. Am Fam Physician. Jan 1 2009;79(1):29-36.
107. Herder C, Roden M. Genetics of type 2 diabetes: pathophysiologic and clinical
relevance. Eur J Clin Invest. Jun 2011;41(6):679-692.
108. Medici F, Hawa M, Ianari A, Pyke DA, Leslie RD. Concordance rate for type II
diabetes mellitus in monozygotic twins: actuarial analysis. Diabetologia. Feb 1999;42(2):
146-150.
109. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of
type 2 diabetes. Diabetes Care. Mar 2004;27(3):813-823.
110. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an
innate immune system response in human adipose tissue in obesity and type 2 diabetes.
Am J Physiol Endocrinol Metab. Mar 2007;292(3):E740-747.
111. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of prediabetes on future risk of stroke: meta-analysis. BMJ. 2012;344:e3564.
112. Mukherjee D. Peripheral and cerebrovascular atherosclerotic disease in diabetes
mellitus. Best Pract Res Clin Endocrinol Metab. Jun 2009;23(3):335-345.
113. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased
adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin
resistance. J Clin Invest. May 1995;95(5):2409-2415.
114. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabet Med. Apr
2005;22(4):359-370.
115. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an
overview. Indian J Med Res. Mar 2007;125(3):451-472.
116. Walder KR, Fahey RP, Morton GJ, Zimmet PZ, Collier GR. Characterization of
obesity phenotypes in Psammomys obesus (Israeli sand rats). Int J Exp Diabetes Res.
2000;1(3):177-184.
117. Axen KV, Li X, Fung K, Sclafani A. The VMH-dietary obese rat: a new model of
non-insulin-dependent diabetes mellitus. Am J Physiol. Mar 1994;266(3 Pt 2):R921-928.
118. Fan X, Qiu J, Yu Z, et al. A rat model of studying tissue-type plasminogen
activator thrombolysis in ischemic stroke with diabetes. Stroke. Feb 2012;43(2):567-570.
119. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of
hypertension in the United States, 1988-2000. JAMA. Jul 9 2003;290(2):199-206.
120. Inoue R, Ohkubo T, Kikuya M, et al. Stroke risk in systolic and combined systolic
and diastolic hypertension determined using ambulatory blood pressure. The Ohasama
study. Am J Hypertens. Oct 2007;20(10):1125-1131.
121. Hjelstuen A, Anderssen SA, Holme I, Seljeflot I, Klemsdal TO. Markers of
inflammation are inversely related to physical activity and fitness in sedentary men with
treated hypertension. Am J Hypertens. Jul 2006;19(7):669-675; discussion 676-667.
122. Nilupul Perera M, Ma HK, Arakawa S, et al. Inflammation following stroke. J Clin
Neurosci. Jan 2006;13(1):1-8.
123. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent
stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J
Hypertens. Sep 2004;17(9):817-822.
124. Hisham NF, Bayraktutan U. Epidemiology, Pathophysiology, and Treatment of
Hypertension in Ischaemic Stroke Patients. J Stroke Cerebrovasc Dis. Jun 8 2012.
125. Inoue I, Chen L, Zhou L, Zeng X, Wang H. Reproduction of scalp acupuncture
therapy on strokes in the model rats, spontaneous hypertensive rats-stroke prone (SHRSP). Neurosci Lett. Nov 29 2002;333(3):191-194.

237

126. Masineni SN, Chander PN, Singh GD, Powers CA, Stier CT, Jr. Male gender and
not the severity of hypertension is associated with end-organ damage in aged strokeprone spontaneously hypertensive rats. Am J Hypertens. Jun 2005;18(6):878-884.
127. Shimizu M, Ishikawa J, Yano Y, Hoshide S, Shimada K, Kario K. The relationship
between the morning blood pressure surge and low-grade inflammation on silent
cerebral infarct and clinical stroke events. Atherosclerosis. Nov 2011;219(1):316-321.
128. Sironi L, Maria Calvio A, Bellosta S, et al. Endogenous proteolytic activity in a rat
model of spontaneous cerebral stroke. Brain Res. Jun 6 2003;974(1-2):184-192.
129. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus
document on hypertension in the elderly: a report of the American College of Cardiology
Foundation Task Force on Clinical Expert Consensus Documents developed in
collaboration with the American Academy of Neurology, American Geriatrics Society,
American Society for Preventive Cardiology, American Society of Hypertension,
American Society of Nephrology, Association of Black Cardiologists, and European
Society of Hypertension. J Am Soc Hypertens. Jul-Aug 2011;5(4):259-352.
130. McCullough LD, Alkayed NJ, Traystman RJ, Williams MJ, Hurn PD. Postischemic
estrogen reduces hypoperfusion and secondary ischemia after experimental stroke.
Stroke. Mar 2001;32(3):796-802.
131. Toung TJ, Traystman RJ, Hurn PD. Estrogen-mediated neuroprotection after
experimental stroke in male rats. Stroke. Aug 1998;29(8):1666-1670.
132. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical
trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. Oct 25
2001;345(17):1243-1249.
133. Braeuninger S, Kleinschnitz C. Rodent models of focal cerebral ischemia:
procedural pitfalls and translational problems. Exp Transl Stroke Med. 2009;1:8.
134. Durukan A, Strbian D, Tatlisumak T. Rodent models of ischemic stroke: a useful
tool for stroke drug development. Curr Pharm Des. 2008;14(4):359-370.
135. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR. Rodent Stroke Model
Guidelines for Preclinical Stroke Trials (1st Edition). J Exp Stroke Transl Med. Jan 1
2009;2(2):2-27.
136. Orset C, Haelewyn B, Vivien K, Vivien D, Young A. Rodent Models of
Thromboembolic Stroke. In: Dirnagl U, ed. Rodent Models of Stroke. Vol 47: Springer
Science; 2010:55-70.
137. Lo EH. Experimental models, neurovascular mechanisms and translational
issues in stroke research. Brit J Pharmacol. Mar 2008;153:S396-S405.
138. Lacy CR, Suh DC, Bueno M, Kostis JB. Delay in presentation and evaluation for
acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology
(S.T.R.O.K.E.). Stroke. Jan 2001;32(1):63-69.
139. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental
rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol
Biochem Behav. May 2007;87(1):179-197.
140. Goodman E, Li C, Tu YK, Ford E, Sun SS, Huang TT. Stability of the factor
structure of the metabolic syndrome across pubertal development: confirmatory factor
analyses of three alternative models. J Pediatr. Sep 2009;155(3):S5 e1-8.
141. Kawai K, Sakairi T, Harada S, et al. Diet modification and its influence on
metabolic and related pathological alterations in the SHR/NDmcr-cp rat, an animal
model of the metabolic syndrome. Exp Toxicol Pathol. May 2012;64(4):333-338.
142. Kim SY, Park HJ, Choi JS, et al. Ischemic preconditioning-induced expression of
gp130 and STAT3 in astrocytes of the rat hippocampus. Brain Res Mol Brain Res. Oct
22 2004;129(1-2):96-103.
143. Ahonen TM, Saltevo JT, Kautiainen HJ, Kumpusalo EA, Vanhala MJ. The
association of adiponectin and low-grade inflammation with the course of metabolic
syndrome. Nutr Metab Cardiovasc Dis. Mar 2012;22(3):285-291.

238

144. Maritano D, Sugrue ML, Tininini S, et al. The STAT3 isoforms alpha and beta
have unique and specific functions. Nat Immunol. Apr 2004;5(4):401-409.
145. Adibhatla RM, Hatcher JF. Secretory phospholipase A2 IIA is up-regulated by
TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat. Brain Res.
Feb 23 2007;1134(1):199-205.
146. La Porta CA, Comolli R. Age-dependent modulation of PKC isoforms and NOS
activity and expression in rat cortex, striatum, and hippocampus. Exp Gerontol. Nov
1999;34(7):863-874.
147. Sajan MP, Nimal S, Mastorides S, et al. Correction of metabolic abnormalities in
a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors
of hepatic protein kinase C-iota. Metabolism. Apr 2012;61(4):459-469.
148. Sun MK, Alkon DL. Pharmacology of protein kinase C activators: cognitionenhancing and antidementic therapeutics. Pharmacol Ther. Jul 2010;127(1):66-77.
149. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients
excluded from TPA therapy? An analysis of patient eligibility. Neurology. Apr 24 2001;56
(8):1015-1020.
150. Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and
extracellular K+ and H+ at critical levels of brain ischemia. Stroke. Jan-Feb 1977;8(1):
51-57.
151. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat
Med. May 2008;14(5):497-500.
152. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of
cardiovascular disease in the United States: a policy statement from the American Heart
Association. Circulation. Mar 1 2011;123(8):933-944.
153. Stankowski JN, Gupta R. Therapeutic targets for neuroprotection in acute
ischemic stroke: lost in translation? Antioxid Redox Signal. May 15 2011;14(10):
1841-1851.
154. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx. Jan
2004;1(1):46-70.
155. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. Part I:
Pathophysiology. J Neurosurg. Aug 1992;77(2):169-184.
156. Albers GW, Goldstein LB, Hall D, Lesko LM. Aptiganel hydrochloride in acute
ischemic stroke: a randomized controlled trial. JAMA. Dec 5 2001;286(21):2673-2682.
157. Meadows ME, Fisher M, Minematsu K. Delayed Treatment with a Noncompetitive
Nmda Antagonist, Cns-1102, Reduces Infarct Size in Rats. Cerebrovasc Dis. Jan-Feb
1994;4(1):26-31.
158. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and
pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with
acute stroke. Dextrorphan Study Group. Stroke. Feb 1995;26(2):254-258.
159. Du C, Hu R, Hsu CY, Choi DW. Dextrorphan reduces infarct volume, vascular
injury, and brain edema after ischemic brain injury. J Neurotrauma. Apr 1996;13(4):
215-222.
160. Graham SH, Chen J, Simon RP. A dose-response study of dextrorphan in
permanent focal ischemia. Neurosci Lett. Sep 17 1993;160(1):21-23.
161. Muir KW. Magnesium in stroke treatment. Postgrad Med J. Nov 2002;78(925):
641-645.
162. Saver JL, Kidwell C, Eckstein M, Starkman S. Prehospital neuroprotective
therapy for acute stroke: results of the Field Administration of Stroke TherapyMagnesium (FAST-MAG) pilot trial. Stroke. May 2004;35(5):e106-108.
163. Yang Y, Li Q, Ahmad F, Shuaib A. Survival and histological evaluation of
therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke
model of rat. Neurosci Lett. May 12 2000;285(2):119-122.
164. Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke : possible
neurotoxic effects of an NMDA antagonist. Stroke. Feb 2000;31(2):347-354.

239

165. Madden KP, Clark WM, Zivin JA. Delayed therapy of experimental ischemia with
competitive N-methyl-D-aspartate antagonists in rabbits. Stroke. Jul 1993;24(7):
1068-1071.
166. Phase II studies of the glycine antagonist GV150526 in acute stroke : the North
American experience. The North American Glycine Antagonist in Neuroprotection (GAIN)
Investigators. Stroke. Feb 2000;31(2):358-365.
167. Bordi F, Pietra C, Ziviani L, Reggiani A. The glycine antagonist GV150526
protects somatosensory evoked potentials and reduces the infarct area in the MCAo
model of focal ischemia in the rat. Exp Neurol. Jun 1997;145(2 Pt 1):425-433.
168. Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in
neuroprotection (GAIN International) in patients with acute stroke: a randomised
controlled trial. GAIN International Investigators. Lancet. Jun 3 2000;355(9219):
1949-1954.
169. De Ryck M, Keersmaekers R, Duytschaever H, et al. Lubeluzole protects
sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J
Pharmacol Exp Ther. Nov 1996;279(2):748-758.
170. Diener HC, Cortens M, Ford G, et al. Lubeluzole in acute ischemic stroke
treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg
daily dose of lubeluzole with placebo. Stroke. Nov 2000;31(11):2543-2551.
171. Weiser T. AMPA receptor antagonists for the treatment of stroke. Curr Drug
Targets CNS Neurol Disord. Apr 2005;4(2):153-159.
172. Suzuki M, Sasamata M, Miyata K. Neuroprotective effects of YM872
coadministered with t-PA in a rat embolic stroke model. Brain Res. Jan 3 2003;959(1):
169-172.
173. Lyden P, Shuaib A, Ng K, et al. Clomethiazole Acute Stroke Study in ischemic
stroke (CLASS-I): final results. Stroke. Jan 2002;33(1):122-128.
174. Marshall JW, Cross AJ, Ridley RM. Functional benefit from clomethiazole
treatment after focal cerebral ischemia in a nonhuman primate species. Exp Neurol. Mar
1999;156(1):121-129.
175. Shuaib A, Ijaz S, Kanthan R. Clomethiazole protects the brain in transient
forebrain ischemia when used up to 4 h after the insult. Neurosci Lett. Sep 8 1995;197
(2):109-112.
176. Mauler F, Horvath E. Neuroprotective efficacy of repinotan HCl, a 5-HT1A
receptor agonist, in animal models of stroke and traumatic brain injury. J Cereb Blood
Flow Metab. Apr 2005;25(4):451-459.
177. Semkova I, Wolz P, Krieglstein J. Neuroprotective effect of 5-HT1A receptor
agonist, Bay X 3702, demonstrated in vitro and in vivo. Eur J Pharmacol. Oct 23
1998;359(2-3):251-260.
178. Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M. A randomized, doubleblind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and
pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous
repinotan in patients with acute ischemic stroke: modified Randomized Exposure
Controlled Trial (mRECT). Stroke. Nov 2009;40(11):3518-3525.
179. Cheney JA, Weisser JD, Bareyre FM, et al. The maxi-K channel opener
BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after
experimental brain injury. J Cereb Blood Flow Metab. Apr 2001;21(4):396-403.
180. Jensen BS. BMS-204352: a potassium channel opener developed for the
treatment of stroke. CNS Drug Rev. Winter 2002;8(4):353-360.
181. Mizoguchi H, Leitermann RJ, Narita M, Nagase H, Suzuki T, Tseng LF. Regiondependent G-protein activation by kappa-opioid receptor agonists in the mouse brain.
Neurosci Lett. Feb 12 2004;356(2):145-147.
182. Clark WM, Raps EC, Tong DC, Kelly RE. Cervene (Nalmefene) in acute ischemic
stroke : final results of a phase III efficacy study. The Cervene Stroke Study
Investigators. Stroke. Jun 2000;31(6):1234-1239.

240

183. Faden AI, Shirane R, Chang LH, James TL, Lemke M, Weinstein PR. Opiatereceptor antagonist improves metabolic recovery and limits neurochemical alterations
associated with reperfusion after global brain ischemia in rats. J Pharmacol Exp Ther.
Nov 1990;255(2):451-458.
184. Hossmann KA. Pathophysiological basis of translational stroke research. Folia
Neuropathol. 2009;47(3):213-227.
185. Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke. Mar 1998;29(3):
705-718.
186. Nakamura H, Strong AJ, Dohmen C, et al. Spreading depolarizations cycle
around and enlarge focal ischaemic brain lesions. Brain. Jul 2010;133(Pt 7):1994-2006.
187. Hossmann KA. Pathophysiology and therapy of experimental stroke. Cell Mol
Neurobiol. Oct-Nov 2006;26(7-8):1057-1083.
188. Kunz A, Dirnagl U, Mergenthaler P. Acute pathophysiological processes after
ischaemic and traumatic brain injury. Best Pract Res Clin Anaesthesiol. Dec 2010;24(4):
495-509.
189. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative
stress as mediators of ischemic brain injury. Cell Calcium. Sep-Oct 2004;36(3-4):
257-264.
190. Smith WS. Pathophysiology of focal cerebral ischemia: a therapeutic perspective.
J Vasc Interv Radiol. Jan 2004;15(1 Pt 2):S3-12.
191. Horn J, de Haan RJ, Vermeulen M, Limburg M. Very Early Nimodipine Use in
Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke. Feb
2001;32(2):461-465.
192. Fogelholm R, Erila T, Palomaki H, Murros K, Kaste M. Effect of nimodipine on
final infarct volume after acute ischemic stroke. Cerebrovasc Dis. May-Jun 2000;10(3):
189-193.
193. Roda JM, Carceller F, Diez-Tejedor E, Avendano C. Reduction of infarct size by
intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible
brain focal ischemia. Stroke. Oct 1995;26(10):1888-1892.
194. Vibulsresth S, Dietrich WD, Busto R, Ginsberg MD. Failure of nimodipine to
prevent ischemic neuronal damage in rats. Stroke. Jan-Feb 1987;18(1):210-216.
195. Hellstrom HO, Wanhainen A, Valtysson J, Persson L, Hillered L. Effect of tirilazad
mesylate given after permanent middle cerebral artery occlusion in rat. Acta Neurochir
(Wien). 1994;129(3-4):188-192.
196. Meden P, Overgaard K, Pedersen H, Boysen G. Effect of Early Treatment with
Tirilazad (U74006F) Combined with Delayed Thrombolytic Therapy in Rat Embolic
Stroke. Cerebrovasc Dis. 1996;6(3):141-148.
197. Shuaib A, Hussain MS. The past and future of neuroprotection in cerebral
ischaemic stroke. Eur Neurol. 2008;59(1-2):4-14.
198. Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke:
pooled analysis of the SAINT I and II Trials. Stroke. Jun 2008;39(6):1751-1758.
199. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic
stroke. N Engl J Med. Aug 9 2007;357(6):562-571.
200. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral
ischemia. Stroke. May 2009;40(5):e331-339.
201. MacManus JP, Buchan AM. Apoptosis after experimental stroke: fact or fashion?
J Neurotrauma. Oct 2000;17(10):899-914.
202. Zipfel GJ, Babcock DJ, Lee JM, Choi DW. Neuronal apoptosis after CNS injury:
the roles of glutamate and calcium. J Neurotrauma. Oct 2000;17(10):857-869.
203. Bredesen DE. Apoptosis: overview and signal transduction pathways. J
Neurotrauma. Oct 2000;17(10):801-810.
204. Wang X, Han W, Du X, et al. Neuroprotective effect of Bax-inhibiting peptide on
neonatal brain injury. Stroke. Sep 2010;41(9):2050-2055.

241

205. Nuttall ME, Lee D, McLaughlin B, Erhardt JA. Selective inhibitors of apoptotic
caspases: implications for novel therapeutic strategies. Drug Discov Today. Jan 1 2001;6
(2):85-91.
206. Robertson GS, Crocker SJ, Nicholson DW, Schulz JB. Neuroprotection by the
inhibition of apoptosis. Brain Pathol. Apr 2000;10(2):283-292.
207. Joly LM, Mucignat V, Mariani J, Plotkine M, Charriaut-Marlangue C. Caspase
inhibition after neonatal ischemia in the rat brain. J Cereb Blood Flow Metab. Jan
2004;24(1):124-131.
208. Johnson EM, Jr., Greenlund LJ, Akins PT, Hsu CY. Neuronal apoptosis: current
understanding of molecular mechanisms and potential role in ischemic brain injury. J
Neurotrauma. Oct 1995;12(5):843-852.
209. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J
Neuroimmunol. Mar 2007;184(1-2):53-68.
210. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral
ischemia. Surg Neurol. Sep 2006;66(3):232-245.
211. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain
barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissuetype plasminogen activator. Neurobiol Dis. Jun 2010;38(3):376-385.
212. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of
inflammatory cells. J Leukoc Biol. May 2010;87(5):779-789.
213. Rossi DJ, Brady JD, Mohr C. Astrocyte metabolism and signaling during brain
ischemia. Nat Neurosci. Nov 2007;10(11):1377-1386.
214. Carmignoto G, Gomez-Gonzalo M. The contribution of astrocyte signalling to
neurovascular coupling. Brain Res Rev. May 2010;63(1-2):138-148.
215. Zonta M, Angulo MC, Gobbo S, et al. Neuron-to-astrocyte signaling is central to
the dynamic control of brain microcirculation. Nat Neurosci. Jan 2003;6(1):43-50.
216. Takano T, Oberheim N, Cotrina ML, Nedergaard M. Astrocytes and ischemic
injury. Stroke. Mar 2009;40(3 Suppl):S8-12.
217. Hayakawa K, Nakano T, Irie K, et al. Inhibition of reactive astrocytes with
fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia
in mice. J Cereb Blood Flow Metab. Apr 2010;30(4):871-882.
218. Pettigrew LC, Kasner SE, Albers GW, et al. Safety and tolerability of arundic acid
in acute ischemic stroke. J Neurol Sci. Dec 21 2006;251(1-2):50-56.
219. Sorbera LA, Castaner J, Castaner RM. Arundic Acid. Drugs of the Future.
2004;29(5):441-449.
220. Tateishi N, Mori T, Kagamiishi Y, et al. Astrocytic activation and delayed infarct
expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic
activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation
of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood
Flow Metab. Jun 2002;22(6):723-734.
221. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute
Stroke Trial. Neurology. Oct 23 2001;57(8):1428-1434.
222. Becker KJ. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab
(R6.5) in acute stroke. Curr Med Res Opin. 2002;18 Suppl 2:s18-22.
223. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing
leukocyte activation reduce experimental neurologic injury and enhance efficacy of
thrombolytic therapy. Neurology. Apr 1995;45(4):815-819.
224. Yenari MA, Kunis D, Sun GH, et al. Hu23F2G, an antibody recognizing the
leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal
cerebral ischemia. Exp Neurol. Oct 1998;153(2):223-233.
225. Fagan SC, Cronic LE, Hess DC. Minocycline Development for Acute Ischemic
Stroke. Transl Stroke Res. Jun 1 2011;2(2):202-208.

242

226. Hayakawa K, Mishima K, Nozako M, et al. Delayed treatment with minocycline
ameliorates neurologic impairment through activated microglia expressing a highmobility group box1-inhibiting mechanism. Stroke. Mar 2008;39(3):951-958.
227. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an openlabel, evaluator-blinded study. Neurology. Oct 2 2007;69(14):1404-1410.
228. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review
and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow
Metab. Jun 2005;25(6):713-721.
229. Maeda M, Furuichi Y, Noto T, Matsuoka N, Mutoh S, Yoneda Y. Tacrolimus
(FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic
ischemia stroke model. Brain Res. Feb 13 2009;1254:99-108.
230. Switzer JA, Hess DC, Ergul A, et al. Matrix metalloproteinase-9 in an exploratory
trial of intravenous minocycline for acute ischemic stroke. Stroke. Sep 2011;42(9):
2633-2635.
231. Takamatsu H, Tsukada H, Noda A, et al. FK506 attenuates early ischemic
neuronal death in a monkey model of stroke. J Nucl Med. Dec 2001;42(12):1833-1840.
232. Burns TC, Steinberg GK. Stem cells and stroke: opportunities, challenges and
strategies. Expert Opin Biol Ther. Apr 2011;11(4):447-461.
233. del Zoppo GJ. The neurovascular unit in the setting of stroke. J Intern Med. Feb
2010;267(2):156-171.
234. Pilegaard K, Ladefoged O. Total number of astrocytes in the molecular layer of
the dentate gyrus of rats at different ages. Anal Quant Cytol Histol. Aug 1996;18(4):
279-285.
235. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the
molecular mechanisms. Nature Reviews Neuroscience. Jan 2007;8(1):57-69.
236. Hayakawa K, Qiu J, Lo EH. Biphasic actions of HMGB1 signaling in inflammation
and recovery after stroke. Ann N Y Acad Sci. Oct 2010;1207:50-57.
237. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in
development, plasticity, disease and injury. Nat Rev Neurosci. Mar 2007;8(3):221-232.
238. Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ. The cytokine
response to human traumatic brain injury: temporal profiles and evidence for cerebral
parenchymal production. J Cereb Blood Flow Metab. Feb 2011;31(2):658-670.
239. Marz P, Herget T, Lang E, Otten U, Rose-John S. Activation of gp130 by IL-6/
soluble IL-6 receptor induces neuronal differentiation. Eur J Neurosci. Dec 1997;9(12):
2765-2773.
240. Derouet D, Rousseau F, Alfonsi F, et al. Neuropoietin, a new IL-6-related cytokine
signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci U S A. Apr
6 2004;101(14):4827-4832.
241. Fann MJ, Patterson PH. Neuropoietic cytokines and activin A differentially
regulate the phenotype of cultured sympathetic neurons. Proc Natl Acad Sci U S A. Jan
4 1994;91(1):43-47.
242. Bravo J, Heath JK. Receptor recognition by gp130 cytokines. EMBO J. Jun 1
2000;19(11):2399-2411.
243. Sriram K, O'Callaghan JP. Signaling Mechanisms Underlying Toxicant-Induced
Gliosis. In: Aschner M, Costa LG, eds. The Role of Glia in Neurotoxicity. Second ed:
CRC Press; 2005:141-171.
244. Ihle JN, Thierfelder W, Teglund S, et al. Signaling by the cytokine receptor
superfamily. Ann N Y Acad Sci. Dec 11 1998;865:1-9.
245. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine
signaling. Adv Immunol. 1995;60:1-35.
246. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the
JAK/STAT pathway, recent advances and future challenges. Gene. Feb 20 2002;285
(1-2):1-24.

243

247. Briscoe J, Kohlhuber F, Muller M. JAKs and STATs branch out. Trends Cell Biol.
Sep 1996;6(9):336-340.
248. Matsuda T, Feng J, Witthuhn BA, Sekine Y, Ihle JN. Determination of the
transphosphorylation sites of Jak2 kinase. Biochem Biophys Res Commun. Dec 10
2004;325(2):586-594.
249. Barahmand-Pour F, Meinke A, Groner B, Decker T. Jak2-Stat5 interactions
analyzed in yeast. J Biol Chem. May 15 1998;273(20):12567-12575.
250. Gupta S, Yan H, Wong LH, Ralph S, Krolewski J, Schindler C. The SH2 domains
of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals.
EMBO J. Mar 1 1996;15(5):1075-1084.
251. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell.
Aug 6 1999;98(3):295-303.
252. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway
induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. Apr 12
2007;26(17):2435-2444.
253. Tian Y, Zhang W, Xia D, Modi P, Liang D, Wei M. Postconditioning inhibits
myocardial apoptosis during prolonged reperfusion via a JAK2-STAT3-Bcl-2 pathway. J
Biomed Sci. 2011;18:53.
254. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene
leads to early embryonic lethality. Proc Natl Acad Sci U S A. Apr 15 1997;94(8):
3801-3804.
255. Herrmann JE, Imura T, Song B, et al. STAT3 is a critical regulator of astrogliosis
and scar formation after spinal cord injury. J Neurosci. Jul 9 2008;28(28):7231-7243.
256. Okada S, Nakamura M, Katoh H, et al. Conditional ablation of Stat3 or Socs3
discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med. Jul 2006;12
(7):829-834.
257. Kang SH, Yu MO, Park KJ, Chi SG, Park DH, Chung YG. Activated STAT3
regulates hypoxia-induced angiogenesis and cell migration in human glioblastoma.
Neurosurgery. Nov 2010;67(5):1386-1395; discussion 1395.
258. Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, Van Meir EG. Regulation of
interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene.
Feb 18 1999;18(7):1447-1456.
259. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible
factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J
Biol Chem. Dec 20 2002;277(51):50081-50086.
260. Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF
upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell
invasion. Lab Invest. Dec 2006;86(12):1221-1232.
261. Seki Y, Kai H, Shibata R, et al. Role of the JAK/STAT pathway in rat carotid artery
remodeling after vascular injury. Circ Res. Jul 7 2000;87(1):12-18.
262. Manea A, Tanase LI, Raicu M, Simionescu M. Jak/STAT signaling pathway
regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells.
Arterioscler Thromb Vasc Biol. Jan 2010;30(1):105-112.
263. Byfield G, Budd S, Hartnett ME. The role of supplemental oxygen and JAK/STAT
signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis
Sci. Jul 2009;50(7):3360-3365.
264. Jung JE, Kim GS, Chan PH. Neuroprotection by Interleukin-6 Is Mediated by
Signal Transducer and Activator of Transcription 3 and Antioxidative Signaling in
Ischemic Stroke. Stroke. Sep 22 2011.
265. Jung JE, Kim GS, Chen H, et al. Reperfusion and neurovascular dysfunction in
stroke: from basic mechanisms to potential strategies for neuroprotection. Mol Neurobiol.
Jun 2010;41(2-3):172-179.

244

266. Jung JE, Kim GS, Narasimhan P, Song YS, Chan PH. Regulation of Mnsuperoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral
ischemia. J Neurosci. May 27 2009;29(21):7003-7014.
267. Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J. Impaired inflammatory
response and increased oxidative stress and neurodegeneration after brain injury in
interleukin-6-deficient mice. Glia. Dec 2000;32(3):271-285.
268. Tuna M, Yilmaz DM, Erman T, Arslan A, Ozgur H, Polat S. Effect of neutralization
of rat interleukin 6 bioactivity on inducible nitric oxide synthase up-regulation and
cerebral ischemic damage. Neurol Res. Sep 2009;31(7):714-720.
269. Fagan SC, Waller JL, Nichols FT, et al. Minocycline to improve neurologic
outcome in stroke (MINOS): a dose-finding study. Stroke. Oct 2010;41(10):2283-2287.
270. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal
transducers and activators of transcription 3 reverses immune tolerance in malignant
glioma patients. Cancer Res. Oct 15 2007;67(20):9630-9636.
271. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression
in activated and resting primary macrophages by IL-10. J Immunol. Sep 1 2002;169(5):
2253-2263.
272. Lin T, Bost KL. STAT3 activation in macrophages following infection with
Salmonella. Biochem Biophys Res Commun. Sep 3 2004;321(4):828-834.
273. O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and
proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and independent pathways. EMBO J. Feb 16 1998;17(4):1006-1018.
274. Jacoby JJ, Kalinowski A, Liu MG, et al. Cardiomyocyte-restricted knockout of
STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with
advanced age. Proc Natl Acad Sci U S A. Oct 28 2003;100(22):12929-12934.
275. Wen Z, Zhong Z, Darnell JE, Jr. Maximal activation of transcription by Stat1 and
Stat3 requires both tyrosine and serine phosphorylation. Cell. Jul 28 1995;82(2):
241-250.
276. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and
activator of transcription-3, inflammation, and cancer: how intimate is the relationship?
Ann N Y Acad Sci. Aug 2009;1171:59-76.
277. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB. Rapid inhibition of
interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein
kinases. Proc Natl Acad Sci U S A. Sep 15 1998;95(19):11107-11112.
278. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by
ERK-dependent and -independent pathways negatively modulates its tyrosine
phosphorylation. Mol Cell Biol. Nov 1997;17(11):6508-6516.
279. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and
maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target
mTOR. Curr Biol. Jan 13 2000;10(1):47-50.
280. Greengard P. The neurobiology of slow synaptic transmission. Science. Nov 2
2001;294(5544):1024-1030.
281. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell
Sci. Mar 15 2004;117(Pt 8):1281-1283.
282. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat
Rev Immunol. Nov 2003;3(11):900-911.
283. Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. Bioessays. Jan
1999;21(1):47-52.
284. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F.
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. Aug
15 2003;374(Pt 1):1-20.
285. Justicia C, Gabriel C, Planas AM. Activation of the JAK/STAT pathway following
transient focal cerebral ischemia: signaling through Jak1 and Stat3 in astrocytes. Glia.
May 2000;30(3):253-270.

245

286. Wen TC, Peng H, Hata R, Desaki J, Sakanaka M. Induction of phosphorylatedStat3 following focal cerebral ischemia in mice. Neurosci Lett. May 11 2001;303(3):
153-156.
287. Yamashita T, Sawamoto K, Suzuki S, et al. Blockade of interleukin-6 signaling
aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation
in the protection of neurons. J Neurochem. Jul 2005;94(2):459-468.
288. Yagi T, Yoshioka H, Wakai T, Kato T, Horikoshi T, Kinouchi H. Activation of signal
transducers and activators of transcription 3 in the hippocampal CA1 region in a rat
model of global cerebral ischemic preconditioning. Brain Res. Nov 8 2011;1422:39-45.
289. Shakarishvili R, Beridze M. Proinflammatory reactants as determinants of stroke
severity in elderly. Georgian Med News. Sep 2008(162):23-27.
290. Ley EJ, Clond MA, Singer MB, Shouhed D, Salim A. IL6 deficiency affects
function after traumatic brain injury. J Surg Res. Oct 2011;170(2):253-256.
291. Oliva AA, Jr., Kang Y, Sanchez-Molano J, Furones C, Atkins CM. STAT3
Signaling after Traumatic Brain Injury. J Neurochem. Dec 6 2011.
292. Zhao JB, Zhang Y, Li GZ, Su XF, Hang CH. Activation of JAK2/STAT pathway in
cerebral cortex after experimental traumatic brain injury of rats. Neurosci Lett. Jul 8
2011;498(2):147-152.
293. Hergenroeder GW, Moore AN, McCoy JP, Jr., et al. Serum IL-6: a candidate
biomarker for intracranial pressure elevation following isolated traumatic brain injury. J
Neuroinflammation. 2010;7:19.
294. Bluyssen HA, Rastmanesh MM, Tilburgs C, et al. IFN gamma-dependent SOCS3
expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6
mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol. Aug
2010;299(2):C354-362.
295. Cayetanot F, Nygard M, Perret M, Kristensson K, Aujard F. Plasma levels of
interferon-gamma correlate with age-related disturbances of circadian rhythms and
survival in a non-human primate. Chronobiol Int. Dec 2009;26(8):1587-1601.
296. Liu RY, Snider WD. Different signaling pathways mediate regenerative versus
developmental sensory axon growth. J Neurosci. Sep 1 2001;21(17):RC164.
297. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene. May 15
2000;19(21):2628-2637.
298. Kovarik P, Mangold M, Ramsauer K, et al. Specificity of signaling by STAT1
depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation,
differentially affecting specific target gene expression. EMBO J. Jan 15 2001;20(1-2):
91-100.
299. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises
in the Jak/Stat pathway. Cell. Apr 2002;109 Suppl:S121-131.
300. Sriram K, Benkovic SA, Hebert MA, Miller DB, O'Callaghan JP. Induction of
gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes
up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in
vivo? J Biol Chem. May 7 2004;279(19):19936-19947.
301. Haroon F, Drogemuller K, Handel U, et al. Gp130-dependent astrocytic survival is
critical for the control of autoimmune central nervous system inflammation. J Immunol.
Jun 1 2011;186(11):6521-6531.
302. Dziennis S, Alkayed NJ. Role of signal transducer and activator of transcription 3
in neuronal survival and regeneration. Rev Neurosci. 2008;19(4-5):341-361.
303. Nicolas CS, Peineau S, Amici M, et al. The Jak/STAT pathway is involved in
synaptic plasticity. Neuron. Jan 26 2012;73(2):374-390.
304. Fukuda S, Abematsu M, Mori H, et al. Potentiation of astrogliogenesis by STAT3mediated activation of bone morphogenetic protein-Smad signaling in neural stem cells.
Mol Cell Biol. Jul 2007;27(13):4931-4937.

246

305. Tsuda M, Kohro Y, Yano T, et al. JAK-STAT3 pathway regulates spinal astrocyte
proliferation and neuropathic pain maintenance in rats. Brain. Apr 2011;134(Pt 4):
1127-1139.
306. Dominguez E, Mauborgne A, Mallet J, Desclaux M, Pohl M. SOCS3-mediated
blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord
neuroinflammation and mechanical allodynia after peripheral nerve injury. J Neurosci.
Apr 21 2010;30(16):5754-5766.
307. Sofroniew MV. Reactive astrocytes in neural repair and protection.
Neuroscientist. Oct 2005;11(5):400-407.
308. Girolami EI, Bouhy D, Haber M, Johnson H, David S. Differential expression and
potential role of SOCS1 and SOCS3 in Wallerian degeneration in injured peripheral
nerve. Exp Neurol. May 2010;223(1):173-182.
309. Beurel E, Jope RS. Differential regulation of STAT family members by glycogen
synthase kinase-3. J Biol Chem. Aug 8 2008;283(32):21934-21944.
310. Buller B, Liu X, Wang X, et al. MicroRNA-21 protects neurons from ischemic
death. FEBS J. Oct 2010;277(20):4299-4307.
311. Gabriely G, Wurdinger T, Kesari S, et al. MicroRNA 21 promotes glioma invasion
by targeting matrix metalloproteinase regulators. Mol Cell Biol. Sep 2008;28(17):
5369-5380.
312. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of
miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking
inflammation to cancer. Mol Cell. Aug 27 2010;39(4):493-506.
313. Ziu M, Fletcher L, Rana S, Jimenez DF, Digicaylioglu M. Temporal differences in
microRNA expression patterns in astrocytes and neurons after ischemic injury. PLoS
One. 2011;6(2):e14724.
314. Niemand C, Nimmesgern A, Haan S, et al. Activation of STAT3 by IL-6 and IL-10
in primary human macrophages is differentially modulated by suppressor of cytokine
signaling 3. J Immunol. Mar 15 2003;170(6):3263-3272.
315. Beurel E, Jope RS. Lipopolysaccharide-induced interleukin-6 production is
controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation.
2009;6:9.
316. Gorina R, Petegnief V, Chamorro A, Planas AM. AG490 prevents cell death after
exposure of rat astrocytes to hydrogen peroxide or proinflammatory cytokines:
involvement of the Jak2/STAT pathway. J Neurochem. Feb 2005;92(3):505-518.
317. Planas AM, Gorina R, Chamorro A. Signalling pathways mediating inflammatory
responses in brain ischaemia. Biochem Soc Trans. Dec 2006;34(Pt 6):1267-1270.
318. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to
medicine. Arthritis Res. 2002;4 Suppl 3:S233-242.
319. Satriotomo I, Bowen KK, Vemuganti R. JAK2 and STAT3 activation contributes to
neuronal damage following transient focal cerebral ischemia. J Neurochem. Sep
2006;98(5):1353-1368.
320. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune
regulation. Nat Rev Immunol. Jun 2007;7(6):454-465.
321. Bright R, Mochly-Rosen D. The role of protein kinase C in cerebral ischemic and
reperfusion injury. Stroke. Dec 2005;36(12):2781-2790.
322. Selvatici R, Marino S, Piubello C, et al. Protein kinase C activity, translocation,
and selective isoform subcellular redistribution in the rat cerebral cortex after in vitro
ischemia. J Neurosci Res. Jan 1 2003;71(1):64-71.
323. Battaini F. Protein kinase C isoforms as therapeutic targets in nervous system
disease states. Pharmacol Res. Nov 2001;44(5):353-361.
324. Li X, Pabla N, Wei Q, et al. PKC-delta promotes renal tubular cell apoptosis
associated with proteinuria. J Am Soc Nephrol. Jul 2010;21(7):1115-1124.

247

325. Muller KM, Tveteraas IH, Aasrum M, et al. Role of protein kinase C and
epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon
carcinoma cells. BMC Cancer. 2011;11:421.
326. Yang K, Taft WC, Dixon CE, Todaro CA, Yu RK, Hayes RL. Alterations of protein
kinase C in rat hippocampus following traumatic brain injury. J Neurotrauma. Fall
1993;10(3):287-295.
327. da Rocha AB, Mans DR, Regner A, Schwartsmann G. Targeting protein kinase C:
new therapeutic opportunities against high-grade malignant gliomas? Oncologist. 2002;7
(1):17-33.
328. Hussain S, Assender JW, Bond M, Wong LF, Murphy D, Newby AC. Activation of
protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9
secretion from rabbit smooth muscle cells and inhibits proliferation. J Biol Chem. Jul 26
2002;277(30):27345-27352.
329. B r i g h t R , S t e i n b e r g G K , M o c h l y - R o s e n D . D e l t a P K C m e d i a t e s
microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress
in vivo. Brain Res. May 4 2007;1144:146-155.
330. Shirai Y, Adachi N, Saito N. Protein kinase Cepsilon: function in neurons. FEBS
J. Aug 2008;275(16):3988-3994.
331. Schaffel R, Morais JC, Biasoli I, et al. PKC-beta II expression has prognostic
impact in nodal diffuse large B-cell lymphoma. Mod Pathol. Mar 2007;20(3):326-330.
332. Gruber T, Hermann-Kleiter N, Pfeifhofer-Obermair C, et al. PKC theta cooperates
with PKC alpha in alloimmune responses of T cells in vivo. Mol Immunol. Jun 2009;46
(10):2071-2079.
333. Pascale A, Govoni S, Battaini F. Age-related alteration of PKC, a key enzyme in
memory processes: physiological and pathological examples. Mol Neurobiol. Feb
1998;16(1):49-62.
334. Qvit N, Mochly-Rosen D. Highly Specific Modulators of Protein Kinase C
Localization: Applications to Heart Failure. Drug Discov Today Dis Mech. Summer
2010;7(2):e87-e93.
335. Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune
cell signalling. Biochem J. Dec 15 2003;376(Pt 3):545-552.
336. Corsini E, Battaini F, Lucchi L, et al. A defective protein kinase C anchoring
system underlying age-associated impairment in TNF-alpha production in rat
macrophages. J Immunol. Sep 15 1999;163(6):3468-3473.
337. Standaert ML, Avignon A, Arnold T, et al. Insulin translocates PKC-epsilon and
phorbol esters induce and persistently translocate PKC-beta 2 in BC3H-1 myocytes. Cell
Signal. Jun 1996;8(4):313-316.
338. Lahn M, Paterson BM, Sundell K, Ma D. The role of protein kinase C-alpha
(PKC-alpha) in malignancies of the gastrointestinal tract. Eur J Cancer. Jan 2004;40(1):
10-20.
339. Dorn GW, 2nd, Mochly-Rosen D. Intracellular transport mechanisms of signal
transducers. Annu Rev Physiol. 2002;64:407-429.
340. Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated
signal transduction. Oncogene. Oct 1 2001;20(44):6339-6347.
341. Duquesnes N, Lezoualc'h F, Crozatier B. PKC-delta and PKC-epsilon: foes of the
same family or strangers? J Mol Cell Cardiol. Nov 2011;51(5):665-673.
342. Yang T, Roder KE, Bhat GJ, Thekkumkara TJ, Abbruscato TJ. Protein kinase C
family members as a target for regulation of blood-brain barrier Na,K,2Cl-cotransporter
during in vitro stroke conditions and nicotine exposure. Pharm Res. Feb 2006;23(2):
291-302.
343. Wang J, Bright R, Mochly-Rosen D, Giffard RG. Cell-specific role for epsilon- and
betaI-protein kinase C isozymes in protecting cortical neurons and astrocytes from
ischemia-like injury. Neuropharmacology. Jul 2004;47(1):136-145.

248

344. Smeda JS, King S, Harder DR. Cerebrovascular alterations in protein kinase Cmediated constriction in stroke-prone rats. Stroke. Mar 1999;30(3):656-661.
345. Fleegal MA, Hom S, Borg LK, Davis TP. Activation of PKC modulates blood-brain
barrier endothelial cell permeability changes induced by hypoxia and posthypoxic
reoxygenation. Am J Physiol Heart Circ Physiol. Nov 2005;289(5):H2012-2019.
346. Dave KR, Raval AP, Purroy J, et al. Aberrant deltaPKC activation in the spinal
cord of Wobbler mouse: a model of motor neuron disease. Neurobiol Dis. Feb 2005;18
(1):126-133.
347. Latchoumycandane C, Anantharam V, Jin H, Kanthasamy A. Dopaminergic
neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of
PKCdelta in cell culture and animal models of Parkinson's disease. Toxicol Appl
Pharmacol. Nov 1 2011;256(3):314-323.
348. Nakai M, Tanimukai S, Yagi K, et al. Amyloid beta protein activates PKC-delta
and induces translocation of myristoylated alanine-rich C kinase substrate (MARCKS) in
microglia. Neurochem Int. Jun 2001;38(7):593-600.
349. Zohar O, Lavy R, Zi X, et al. PKC activator therapeutic for mild traumatic brain
injury in mice. Neurobiol Dis. Feb 2011;41(2):329-337.
350. Qi X, Disatnik MH, Shen N, Sobel RA, Mochly-Rosen D. Aberrant mitochondrial
fission in neurons induced by protein kinase C{delta} under oxidative stress conditions in
vivo. Mol Biol Cell. Jan 15 2011;22(2):256-265.
351. Budas GR, Churchill EN, Disatnik MH, Sun L, Mochly-Rosen D. Mitochondrial
import of PKCepsilon is mediated by HSP90: a role in cardioprotection from ischaemia
and reperfusion injury. Cardiovasc Res. Oct 1 2010;88(1):83-92.
352. Inagaki K, Chen L, Ikeno F, et al. Inhibition of delta-protein kinase C protects
against reperfusion injury of the ischemic heart in vivo. Circulation. Nov 11 2003;108(19):
2304-2307.
353. Chen L, Hahn H, Wu G, et al. Opposing cardioprotective actions and parallel
hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. Sep 25
2001;98(20):11114-11119.
354. Churchill EN, Ferreira JC, Brum PC, Szweda LI, Mochly-Rosen D. Ischaemic
preconditioning improves proteasomal activity and increases the degradation of
deltaPKC during reperfusion. Cardiovasc Res. Jan 15 2010;85(2):385-394.
355. Facchinetti MM, de Boland AR. Effect of ageing on the expression of protein
kinase C and its activation by 1,25(OH)2-vitamin D3 in rat skeletal muscle. Cell Signal.
Jan 1999;11(1):39-44.
356. Ferreira JC, Brum PC, Mochly-Rosen D. betaIIPKC and epsilonPKC isozymes as
potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell
Cardiol. Oct 2011;51(4):479-484.
357. Sun MK, Alkon DL. Bryostatin-1: pharmacology and therapeutic potential as a
CNS drug. CNS Drug Rev. Spring 2006;12(1):1-8.
358. Hongpaisan J, Sun MK, Alkon DL. PKC epsilon activation prevents synaptic loss,
Abeta elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J
Neurosci. Jan 12 2011;31(2):630-643.
359. Nelson TJ, Alkon DL. Neuroprotective versus tumorigenic protein kinase C
activators. Trends Biochem Sci. Mar 2009;34(3):136-145.
360. Shimohata T, Zhao H, Sung JH, Sun G, Mochly-Rosen D, Steinberg GK.
Suppression of deltaPKC activation after focal cerebral ischemia contributes to the
protective effect of hypothermia. J Cereb Blood Flow Metab. Aug 2007;27(8):1463-1475.
361. Sieber FE, Traystman RJ, Brown PR, Martin LJ. Protein kinase C expression and
activity after global incomplete cerebral ischemia in dogs. Stroke. Jul 1998;29(7):
1445-1452; discussion 1452-1443.
362. Matsumoto S, Shamloo M, Matsumoto E, Isshiki A, Wieloch T. Protein kinase Cgamma and calcium/calmodulin-dependent protein kinase II-alpha are persistently

249

translocated to cell membranes of the rat brain during and after middle cerebral artery
occlusion. J Cereb Blood Flow Metab. Jan 2004;24(1):54-61.
363. Bright R, Sun GH, Yenari MA, Steinberg GK, Mochly-Rosen D. epsilonPKC
confers acute tolerance to cerebral ischemic reperfusion injury. Neurosci Lett. Aug 15
2008;441(1):120-124.
364. Sun MK, Hongpaisan J, Alkon DL. Postischemic PKC activation rescues
retrograde and anterograde long-term memory. Proc Natl Acad Sci U S A. Aug 25
2009;106(34):14676-14680.
365. Sun MK, Hongpaisan J, Nelson TJ, Alkon DL. Poststroke neuronal rescue and
synaptogenesis mediated in vivo by protein kinase C in adult brains. Proc Natl Acad Sci
U S A. Sep 9 2008;105(36):13620-13625.
366. Li J, Niu C, Han S, et al. Identification of protein kinase C isoforms involved in
cerebral hypoxic preconditioning of mice. Brain Res. Oct 26 2005;1060(1-2):62-72.
367. Bu X, Zhang N, Yang X, et al. Proteomic analysis of cPKCbetaII-interacting
proteins involved in HPC-induced neuroprotection against cerebral ischemia of mice. J
Neurochem. Apr 2011;117(2):346-356.
368. Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic
mechanisms, functional effects, and pathological considerations. Am J Physiol Regul
Integr Comp Physiol. Jan 2007;292(1):R18-36.
369. Majumder PK, Mishra NC, Sun X, et al. Targeting of protein kinase C delta to
mitochondria in the oxidative stress response. Cell Growth Differ. Sep 2001;12(9):
465-470.
370. Kanthasamy AG, Kitazawa M, Kanthasamy A, Anantharam V. Role of proteolytic
activation of protein kinase Cdelta in oxidative stress-induced apoptosis. Antioxid Redox
Signal. Oct 2003;5(5):609-620.
371. Maher P. How protein kinase C activation protects nerve cells from oxidative
stress-induced cell death. J Neurosci. May 1 2001;21(9):2929-2938.
372. Kahles T, Kohnen A, Heumueller S, et al. NADPH oxidase Nox1 contributes to
ischemic injury in experimental stroke in mice. Neurobiol Dis. Oct 2010;40(1):185-192.
373. Thamilselvan V, Menon M, Thamilselvan S. Oxalate-induced activation of PKCalpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular
epithelial cells. Am J Physiol Renal Physiol. Nov 2009;297(5):F1399-1410.
374. Wei H, Mi X, Ji L, et al. Protein kinase C-delta is involved in induction of NOX1
gene expression by aldosterone in rat vascular smooth muscle cells. Biochemistry
(Mosc). Mar 2010;75(3):304-309.
375. Reshef A, Sperling O, Zoref-Shani E. Activation and inhibition of protein kinase C
protect rat neuronal cultures against ischemia-reperfusion insult. Neurosci Lett. Nov 28
1997;238(1-2):37-40.
376. Kostyak JC, Hunter JC, Korzick DH. Acute PKCdelta inhibition limits ischaemiareperfusion injury in the aged rat heart: role of GSK-3beta. Cardiovasc Res. May 1
2006;70(2):325-334.
377. Bright R, Raval AP, Dembner JM, et al. Protein kinase C delta mediates cerebral
reperfusion injury in vivo. J Neurosci. Aug 4 2004;24(31):6880-6888.
378. Dave KR, Bhattacharya SK, Saul I, et al. Activation of protein kinase C delta
following cerebral ischemia leads to release of cytochrome C from the mitochondria via
bad pathway. PLoS One. 2011;6(7):e22057.
379. Qi X, Inagaki K, Sobel RA, Mochly-Rosen D. Sustained pharmacological
inhibition of deltaPKC protects against hypertensive encephalopathy through prevention
of blood-brain barrier breakdown in rats. J Clin Invest. Jan 2008;118(1):173-182.
380. Monti M, Donnini S, Giachetti A, Mochly-Rosen D, Ziche M. deltaPKC inhibition
or varepsilonPKC activation repairs endothelial vascular dysfunction by regulating eNOS
post-translational modification. J Mol Cell Cardiol. Apr 2010;48(4):746-756.

250

381. Yoo J, Nichols A, Song JC, et al. Bryostatin-1 attenuates TNF-induced epithelial
barrier dysfunction: role of novel PKC isozymes. Am J Physiol Gastrointest Liver Physiol.
Apr 2003;284(4):G703-712.
382. Willis CL, Meske DS, Davis TP. Protein kinase C activation modulates reversible
increase in cortical blood-brain barrier permeability and tight junction protein expression
during hypoxia and posthypoxic reoxygenation. J Cereb Blood Flow Metab. Nov 2010;30
(11):1847-1859.
383. Ding Q, Chai H, Mahmood N, Tsao J, Mochly-Rosen D, Zhou W. Matrix
metalloproteinases modulated by protein kinase Cepsilon mediate resistin-induced
migration of human coronary artery smooth muscle cells. J Vasc Surg. Apr 2011;53(4):
1044-1051.
384. Sonobe Y, Takeuchi H, Kataoka K, et al. Interleukin-25 expressed by brain
capillary endothelial cells maintains blood-brain barrier function in a protein kinase
Cepsilon-dependent manner. J Biol Chem. Nov 13 2009;284(46):31834-31842.
385. Wang Z, Xue Y, Jiao H, Liu Y, Wang P. Doxycycline-mediated protective effect
against focal cerebral ischemia-reperfusion injury through the modulation of tight
junctions and PKCdelta signaling in rats. J Mol Neurosci. May 2012;47(1):89-100.
386. Arai K, Lee SR, Lo EH. Essential role for ERK mitogen-activated protein kinase in
matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia. Sep 2003;43(3):
254-264.
387. McLennan SV, Fisher E, Martell SY, et al. Effects of glucose on matrix
metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic
nephropathy. Kidney Int Suppl. Sep 2000;77:S81-87.
388. Alexander JP, Acott TS. Involvement of protein kinase C in TNFalpha regulation
of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci. Nov
2001;42(12):2831-2838.
389. Esteve PO, Chicoine E, Robledo O, et al. Protein kinase C-zeta regulates
transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in
glioma cells via NF-kappa B. J Biol Chem. Sep 20 2002;277(38):35150-35155.
390. Sariahmetoglu M, Crawford BD, Leon H, et al. Regulation of matrix
metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J. Aug 2007;21(10):
2486-2495.
391. Carpenter AC, Alexander JS. Endothelial PKC delta activation attenuates
neutrophil transendothelial migration. Inflamm Res. May 2008;57(5):216-229.
392. Kaneda H, Ikeno F, Inagaki K, Mochly-Rosen D. Preserved coronary endothelial
function by inhibition of delta protein kinase C in a porcine acute myocardial infarction
model. Int J Cardiol. Apr 3 2009;133(2):256-259.
393. Gonthier B, Koncina E, Satkauskas S, et al. A PKC-dependent recruitment of
MMP-2 controls semaphorin-3A growth-promoting effect in cortical dendrites. PLoS One.
2009;4(4):e5099.
394. Hongpaisan J, Alkon DL. A structural basis for enhancement of long-term
associative memory in single dendritic spines regulated by PKC. Proc Natl Acad Sci U S
A. Dec 4 2007;104(49):19571-19576.
395. Kim J, Koyanagi T, Mochly-Rosen D. PKCdelta activation mediates angiogenesis
via NADPH oxidase activity in PC-3 prostate cancer cells. Prostate. Jun 15 2011;71(9):
946-954.
396. Zhao CT, Li K, Li JT, et al. PKCdelta regulates cortical radial migration by
stabilizing the Cdk5 activator p35. Proc Natl Acad Sci U S A. Dec 15 2009;106(50):
21353-21358.
397. Kuzirian AM, Epstein HT, Gagliardi CJ, et al. Bryostatin enhancement of memory
in Hermissenda. Biol Bull. Jun 2006;210(3):201-214.
398. Sun MK, Alkon DL. Synergistic effects of chronic bryostatin-1 and alphatocopherol on spatial learning and memory in rats. Eur J Pharmacol. Apr 28 2008;584
(2-3):328-337.

251

399. Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase C isozymes
and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol. Sep
2000;279(3):L429-438.
400. Van der Zee EA, Palm IF, O'Connor M, Maizels ET, Hunzicker-Dunn M, Disterhoft
JF. Aging-related alterations in the distribution of Ca(2+)-dependent PKC isoforms in
rabbit hippocampus. Hippocampus. 2004;14(7):849-860.
401. Sharma D, Sethi P, Hussain E, Singh R. Curcumin counteracts the aluminiuminduced ageing-related alterations in oxidative stress, Na+, K+ ATPase and protein
kinase C in adult and old rat brain regions. Biogerontology. Aug 2009;10(4):489-502.
402. Milner R, Campbell IL. Cytokines regulate microglial adhesion to laminin and
astrocyte extracellular matrix via protein kinase C-dependent activation of the
alpha6beta1 integrin. J Neurosci. Mar 1 2002;22(5):1562-1572.
403. Ansar S, Edvinsson L. Subtype activation and interaction of protein kinase C and
mitogen-activated protein kinase controlling receptor expression in cerebral arteries and
microvessels after subarachnoid hemorrhage. Stroke. Jan 2008;39(1):185-190.
404. Meier M, King GL. Protein kinase C activation and its pharmacological inhibition
in vascular disease. Vasc Med. 2000;5(3):173-185.
405. Albert-Weissenberger C, Siren AL. Experimental traumatic brain injury. Exp
Transl Stroke Med. 2010;2(1):16.
406. Panzer MB, Matthews KA, Yu AW, Morrison B, 3rd, Meaney DF, Bass CR. A
Multiscale Approach to Blast Neurotrauma Modeling: Part I - Development of Novel Test
Devices for in vivo and in vitro Blast Injury Models. Front Neurol. 2012;3:46.
407. Bass CR, Panzer MB, Rafaels KA, Wood G, Shridharani J, Capehart B. Brain
injuries from blast. Ann Biomed Eng. Jan 2012;40(1):185-202.
408. Daneshvar DH, Baugh CM, Nowinski CJ, McKee AC, Stern RA, Cantu RC.
Helmets and mouth guards: the role of personal equipment in preventing sport-related
concussions. Clin Sports Med. Jan 2011;30(1):145-163, x.
409. Gavett BE, Stern RA, Cantu RC, Nowinski CJ, McKee AC. Mild traumatic brain
injury: a risk factor for neurodegeneration. Alzheimers Res Ther. 2010;2(3):18.
410. Guskiewicz KM, Marshall SW, Bailes J, et al. Association between recurrent
concussion and late-life cognitive impairment in retired professional football players.
Neurosurgery. Oct 2005;57(4):719-726; discussion 719-726.
411. Stern RA, Riley DO, Daneshvar DH, Nowinski CJ, Cantu RC, McKee AC. Longterm consequences of repetitive brain trauma: chronic traumatic encephalopathy. PM R.
Oct 2011;3(10 Suppl 2):S460-467.
412. Shenton ME, Hamoda HM, Schneiderman JS, et al. A review of magnetic
resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury.
Brain Imaging Behav. Jun 2012;6(2):137-192.
413. Saulle M, Greenwald BD. Chronic traumatic encephalopathy: a review. Rehabil
Res Pract. 2012;2012:816069.
414. Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential
late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med.
Jan 2011;30(1):179-188, xi.
415. Omalu B, Hammers JL, Bailes J, et al. Chronic traumatic encephalopathy in an
Iraqi war veteran with posttraumatic stress disorder who committed suicide. Neurosurg
Focus. Nov 2011;31(5):E3.
416. Gavett BE, Cantu RC, Shenton M, et al. Clinical appraisal of chronic traumatic
encephalopathy: current perspectives and future directions. Curr Opin Neurol. Dec
2011;24(6):525-531.
417. Baugh CM, Stamm JM, Riley DO, et al. Chronic traumatic encephalopathy:
neurodegeneration following repetitive concussive and subconcussive brain trauma.
Brain Imaging Behav. 2012;6:244-254.

252

418. Goldstein LE, Fisher AM, Tagge CA, et al. Chronic traumatic encephalopathy in
blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med.
May 16 2012;4(134):134ra160.
419. Lakhan SE, Kirchgessner A. Chronic traumatic encephalopathy: the dangers of
getting "dinged". SpringerPlus. 2012;1(2).
420. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in
athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol.
Jul 2009;68(7):709-735.
421. Omalu BI, Bailes J, Hammers JL, Fitzsimmons RP. Chronic traumatic
encephalopathy, suicides and parasuicides in professional American athletes: the role of
the forensic pathologist. Am J Forensic Med Pathol. Jun 2010;31(2):130-132.
422. Omalu BI, DeKosky ST, Hamilton RL, et al. Chronic traumatic encephalopathy in
a national football league player: part II. Neurosurgery. Nov 2006;59(5):1086-1092;
discussion 1092-1083.
423. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH.
Chronic traumatic encephalopathy in a National Football League player. Neurosurgery.
Jul 2005;57(1):128-134; discussion 128-134.
424. Omalu BI, Fitzsimmons RP, Hammers J, Bailes J. Chronic traumatic
encephalopathy in a professional American wrestler. J Forensic Nurs. Fall 2010;6(3):
130-136.
425. Omalu BI, Hamilton RL, Kamboh MI, DeKosky ST, Bailes J. Chronic traumatic
encephalopathy (CTE) in a National Football League Player: Case report and emerging
medicolegal practice questions. J Forensic Nurs. Spring 2010;6(1):40-46.
426. Omalu B, Bailes J, Hamilton RL, et al. Emerging histomorphologic phenotypes of
chronic traumatic encephalopathy in American athletes. Neurosurgery. Jul 2011;69(1):
173-183; discussion 183.
427. Adams CW, Bruton CJ. The cerebral vasculature in dementia pugilistica. J Neurol
Neurosurg Psychiatry. May 1989;52(5):600-604.
428. Casson IR, Pellman EJ, Viano DC. Chronic traumatic encephalopathy in a
National Football League player. Neurosurgery. May 2006;58(5):E1003; author reply
E1003; discussion E1003.
429. Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol
Med. Aug 1973;3(3):270-303.
430. Millspaugh JA. DEMENTIA PUGILISTICA. U.S. Naval Medical Bulletin. 1937;35
(3):297-303.
431. Martland HS. PUNCH DRUNK. JAMA. 1928;91(15):1103-1107.
432. Blaylock RL, Maroon J. Immunoexcitotoxicity as a central mechanism in chronic
traumatic encephalopathy-A unifying hypothesis. Surg Neurol Int. 2011;2:107.
433. Costanza A, Weber K, Gandy S, et al. Review: Contact sport-related chronic
traumatic encephalopathy in the elderly: clinical expression and structural substrates.
Neuropathol Appl Neurobiol. Oct 2011;37(6):570-584.
434. Johnson VE, Stewart W, Smith DH. Axonal pathology in traumatic brain injury.
Exp Neurol. Jan 20 2012.
435. Geddes JF, Vowles GH, Nicoll JA, Revesz T. Neuronal cytoskeletal changes are
an early consequence of repetitive head injury. Acta Neuropathol. Aug 1999;98(2):
171-178.
436. Mills JD, Bailes JE, Turner RC, Dodson SC, Sakai J, Maroon JC. Anabolic
steroids and head injury. Neurosurgery. Jan 2012;70(1):205-209; discussion 209-210.
437. McCrory P. Sports concussion and the risk of chronic neurological impairment.
Clin J Sport Med. Jan 2011;21(1):6-12.
438. Prichep LS, McCrea M, Barr W, Powell M, Chabot RJ. Time Course of Clinical
and Electrophysiological Recovery After Sport-Related Concussion. J Head Trauma
Rehabil. May 14 2012.

253

439. Signoretti S, Lazzarino G, Tavazzi B, Vagnozzi R. The pathophysiology of
concussion. PM R. Oct 2011;3(10 Suppl 2):S359-368.
440. Mac Donald CL, Dikranian K, Song SK, Bayly PV, Holtzman DM, Brody DL.
Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of
traumatic brain injury. Exp Neurol. May 2007;205(1):116-131.
441. Shah S, Yallampalli R, Merkley TL, et al. Diffusion tensor imaging and volumetric
analysis of the ventral striatum in adults with traumatic brain injury. Brain Inj. 2012;26(3):
201-210.
442. Smits M, Houston GC, Dippel DW, et al. Microstructural brain injury in postconcussion syndrome after minor head injury. Neuroradiology. Aug 2011;53(8):553-563.
443. Maller JJ, Thomson RH, Lewis PM, Rose SE, Pannek K, Fitzgerald PB.
Traumatic brain injury, major depression, and diffusion tensor imaging: making
connections. Brain Res Rev. Sep 2010;64(1):213-240.
444. Tremblay S, De Beaumont L, Henry LC, et al. Sports Concussions and Aging: A
Neuroimaging Investigation. Cereb Cortex. May 10 2012.
445. Sanchez-Carrion R, Fernandez-Espejo D, Junque C, et al. A longitudinal fMRI
study of working memory in severe TBI patients with diffuse axonal injury. Neuroimage.
Nov 15 2008;43(3):421-429.
446. Rosenbaum SB, Lipton ML. Embracing chaos: the scope and importance of
clinical and pathological heterogeneity in mTBI. Brain Imaging Behav. Jun 2012;6(2):
255-282.
447. McDonald BC, Saykin AJ, McAllister TW. Functional MRI of mild traumatic brain
injury (mTBI): progress and perspectives from the first decade of studies. Brain Imaging
Behav. Jun 2012;6(2):193-207.
448. Talavage TM, Nauman E, Breedlove EL, et al. Functionally-Detected Cognitive
Impairment in High School Football Players Without Clinically-Diagnosed Concussion. J
Neurotrauma. Oct 1 2010.
449. Breedlove EL, Robinson M, Talavage TM, et al. Biomechanical correlates of
symptomatic and asymptomatic neurophysiological impairment in high school football. J
Biomech. Apr 30 2012;45(7):1265-1272.
450. Henninger N, Sicard KM, Li Z, et al. Differential recovery of behavioral status and
brain function assessed with functional magnetic resonance imaging after mild traumatic
brain injury in the rat. Crit Care Med. Nov 2007;35(11):2607-2614.
451. Tshibanda L, Vanhaudenhuyse A, Galanaud D, Boly M, Laureys S, Puybasset L.
Magnetic resonance spectroscopy and diffusion tensor imaging in coma survivors:
promises and pitfalls. Prog Brain Res. 2009;177:215-229.
452. Signoretti S, Vagnozzi R, Tavazzi B, Lazzarino G. Biochemical and
neurochemical sequelae following mild traumatic brain injury: summary of experimental
data and clinical implications. Neurosurg Focus. Nov 2010;29(5):E1.
453. Vagnozzi R, Signoretti S, Cristofori L, et al. Assessment of metabolic brain
damage and recovery following mild traumatic brain injury: a multicentre, proton
magnetic resonance spectroscopic study in concussed patients. Brain. Nov 2010;133
(11):3232-3242.
454. Henry LC, Tremblay S, Leclerc S, et al. Metabolic changes in concussed
American football players during the acute and chronic post-injury phases. BMC Neurol.
2011;11:105.
455. Bigler ED, Maxwell WL. Neuropathology of mild traumatic brain injury:
relationship to neuroimaging findings. Brain Imaging Behav. Jun 2012;6(2):108-136.
456. Henry LC, Tremblay S, Boulanger Y, Ellemberg D, Lassonde M. Neurometabolic
changes in the acute phase after sports concussions correlate with symptom severity. J
Neurotrauma. Jan 2010;27(1):65-76.
457. Kleindienst A, Tolias CM, Corwin FD, et al. Assessment of cerebral S100B levels
by proton magnetic resonance spectroscopy after lateral fluid-percussion injury in the
rat. J Neurosurg. Jun 2005;102(6):1115-1121.

254

458. Lin AP, Liao HJ, Merugumala SK, Prabhu SP, Meehan WP, 3rd, Ross BD.
Metabolic imaging of mild traumatic brain injury. Brain Imaging Behav. Jun 2012;6(2):
208-223.
459. Lin A, Ramadan S, Box H, Stanwell P, Stern R. Neurochemical changes in
athletes with chronic traumatic encephalopathy. Paper presented at: Radiological
Society of North America2010; Chicago, IL.
460. Price P, Jones T. Can positron emission tomography (PET) be used to detect
subclinical response to cancer therapy? The EC PET Oncology Concerted Action and
the EORTC PET Study Group. Eur J Cancer. Nov 1995;31A(12):1924-1927.
461. Venneti S, Wagner AK, Wang G, et al. The high affinity peripheral
benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of
traumatic brain injury: implications for PET imaging. Exp Neurol. Sep 2007;207(1):
118-127.
462. Provenzano FA, Jordan B, Tikofsky RS, Saxena C, Van Heertum RL, Ichise M.
F-18 FDG PET imaging of chronic traumatic brain injury in boxers: a statistical
parametric analysis. Nucl Med Commun. Nov 2010;31(11):952-957.
463. Wagner K. Can Science See Inside An NFL Player's Skull Before It's Too Late?
BAD BRAINS 2012; http://deadspin.com/5920006/can-science-see-inside-an-nfl-playersskull-before-its-too-late. Accessed August 20, 2012, 2012.
464. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild
cognitive impairment. N Engl J Med. Dec 21 2006;355(25):2652-2663.
465. Kemp PM, Houston AS, Macleod MA, Pethybridge RJ. Cerebral perfusion and
psychometric testing in military amateur boxers and controls. J Neurol Neurosurg
Psychiatry. Oct 1995;59(4):368-374.
466. Shen Y, Kou Z, Kreipke CW, Petrov T, Hu J, Haacke EM. In vivo measurement of
tissue damage, oxygen saturation changes and blood flow changes after experimental
traumatic brain injury in rats using susceptibility weighted imaging. Magn Reson
Imaging. Feb 2007;25(2):219-227.
467. Aiken AH, Gean AD. Imaging of head trauma. Semin Roentgenol. Apr 2010;45
(2):63-79.
468. McCrea RP, Harder SL, Martin M, Buist R, Nichol H. A comparison of rapidscanning X-ray fluorescence mapping and magnetic resonance imaging to localize brain
iron distribution. Eur J Radiol. Dec 2008;68(3 Suppl):S109-113.
469. Cheng JL, Yang YJ, Li HL, Wang J, Wang MH, Zhang Y. In vivo tracing of
superparamagnetic iron oxide-labeled bone marrow mesenchymal stem cells
transplanted for traumatic brain injury by susceptibility weighted imaging in a rat model.
Chin J Traumatol. Jun 1 2010;13(3):173-177.
470. Zhang J, Zhang Y, Wang J, et al. Characterizing iron deposition in Parkinson's
disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res. May 12
2010;1330:124-130.
471. Meoded A, Poretti A, Northington FJ, Tekes A, Intrapiromkul J, Huisman TA.
Susceptibility weighted imaging of the neonatal brain. Clin Radiol. Aug 2012;67(8):
793-801.
472. Kou Z, Benson RR, Gattu R, Haacke EM. Susceptibility Weighted Imaging
Complements to Diffusion Tensor Imaging in Traumatic Brain Injury. Neuroimage.
2009;47:S68.
473. Ashwal S, Babikian T, Gardner-Nichols J, Freier MC, Tong KA, Holshouser BA.
Susceptibility-weighted imaging and proton magnetic resonance spectroscopy in
assessment of outcome after pediatric traumatic brain injury. Arch Phys Med Rehabil.
Dec 2006;87(12 Suppl 2):S50-58.
474. McKee AC, Gavett BE, Stern RA, et al. TDP-43 proteinopathy and motor neuron
disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. Sep 2010;69
(9):918-929.

255

475. Mondello S, Jeromin A, Buki A, et al. Glial neuronal ratio: a novel index for
differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma.
Apr 10 2012;29(6):1096-1104.
476. Dohi K, Satoh K, Ohtaki H, et al. Elevated plasma levels of bilirubin in patients
with neurotrauma reflect its pathophysiological role in free radical scavenging. In Vivo.
Sep-Oct 2005;19(5):855-860.
477. Zetterberg H, Tanriverdi F, Unluhizarci K, Selcuklu A, Kelestimur F, Blennow K.
Sustained release of neuron-specific enolase to serum in amateur boxers. Brain Inj. Aug
2009;23(9):723-726.
478. Balakathiresan N, Bhomia M, Chandran R, Chavko M, McCarron RM,
Maheshwari RK. MicroRNA let-7i is a promising serum biomarker for blast-induced
traumatic brain injury. J Neurotrauma. May 1 2012;29(7):1379-1387.
479. Pasinetti GM, Ho L, Dooley C, Abbi B, Lange G. Select non-coding RNA in blood
components provide novel clinically accessible biological surrogates for improved
identification of traumatic brain injury in OEF/OIF Veterans. Am J Neurodegener Dis.
May 30 2012;1(1):88-98.
480. Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J.
CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma.
PLoS One. 2012;7(4):e33606.
481. Avsar T, Korkmaz D, Tutuncu M, et al. Protein biomarkers for multiple sclerosis:
semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different
forms of multiple sclerosis. Mult Scler. Jan 17 2012.
482. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament
light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease
severity and progression. Eur J Neurol. Jun 11 2012.
483. Yoshiyama Y, Uryu K, Higuchi M, et al. Enhanced neurofibrillary tangle formation,
cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a
transgenic tauopathy mouse model. J Neurotrauma. Oct 2005;22(10):1134-1141.
484. Tran HT, Sanchez L, Esparza TJ, Brody DL. Distinct temporal and anatomical
distributions of amyloid-beta and tau abnormalities following controlled cortical impact in
transgenic mice. PLoS One. 2011;6(9):e25475.
485. Hoshino S, Tamaoka A, Takahashi M, et al. Emergence of immunoreactivities for
phosphorylated tau and amyloid-beta protein in chronic stage of fluid percussion injury in
rat brain. Neuroreport. Jun 1 1998;9(8):1879-1883.
486. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM.
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch
Neurol. Mar 2004;61(3):346-350.
487. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as
a therapeutic target in traumatic brain injury. Nat Rev Neurol. Jul 2010;6(7):393-403.
488. Etcheberrigaray R, Tan M, Dewachter I, et al. Therapeutic effects of PKC
activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A. Jul 27
2004;101(30):11141-11146.
489. Quattrone A, Pascale A, Nogues X, et al. Posttranscriptional regulation of gene
expression in learning by the neuronal ELAV-like mRNA-stabilizing proteins. Proc Natl
Acad Sci U S A. Sep 25 2001;98(20):11668-11673.
490. Skaper SD, Facci L, Strijbos PJ. Neuronal protein kinase signaling cascades and
excitotoxic cell death. Ann N Y Acad Sci. Jun 2001;939:11-22.
491. Krizbai I, Szabo G, Deli M, et al. Expression of protein kinase C family members
in the cerebral endothelial cells. J Neurochem. Jul 1995;65(1):459-462.
492. Alkon DL, Sun MK, Nelson TJ. PKC signaling deficits: a mechanistic hypothesis
for the origins of Alzheimer's disease. Trends Pharmacol Sci. Feb 2007;28(2):51-60.
493. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous
alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS,
NINDS, and EPITHET trials. Lancet. May 15 2010;375(9727):1695-1703.

256

494. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke
statistics--2010 update: a report from the American Heart Association. Circulation. Feb
23 2010;121(7):e46-e215.
495. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke:
a guideline from the American Heart Association/American Stroke Association Stroke
Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease
Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology
Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and
Outcomes Research Interdisciplinary Working Group. Circulation. Jun 20 2006;113
(24):e873-923.
496. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in
patients with ischemic stroke or transient ischemic attack: a statement for healthcare
professionals from the American Heart Association/American Stroke Association Council
on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention:
the American Academy of Neurology affirms the value of this guideline. Stroke. Feb
2006;37(2):577-617.
497. Eckle T, Fullbier L, Wehrmann M, et al. Identification of ectonucleotidases CD39
and CD73 in innate protection during acute lung injury. J Immunol. Jun 15 2007;178(12):
8127-8137.
498. Sugimoto S, Lin X, Lai J, et al. Apyrase treatment prevents ischemia-reperfusion
injury in rat lung isografts. J Thorac Cardiovasc Surg. Sep 2009;138(3):752-759.
499. Kohler D, Eckle T, Faigle M, et al. CD39/ectonucleoside triphosphate
diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/
reperfusion injury. Circulation. Oct 16 2007;116(16):1784-1794.
500. Moeckel D, Baum P, Nguyen A, Jeong S, Chen R, Abendschein D. A Novel
Human Apyrase Prevents Reocclusion and Substantially Decreases Infarct Size Without
Bleeding Time Prolongation After Coronary Fibrinolysis in Dogs. Paper presented at:
Arteriosclerosis, thrombosis and vascular biology 20112011; Orlando, Florida.
501. Belayev L, Khoutorova L, Deisher TA, et al. Neuroprotective effect of SolCD39, a
novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats.
Stroke. Mar 2003;34(3):758-763.
502. Sun G, Zhao X, Grotta J, Savitz SI, Chen C, Aronowski J. Apyrase, APT102,
improves the rt-PA beneficial effect in thromboembolic stroke model. Paper presented at:
International Stroke Conference2011; Los Angeles, California.
503. Wang C, Shabanzadeh AP, He C, Pegg CC. APT102 protects the ischemically
injured brain in rats. Paper presented at: Neuroscience2010; San Diego, California.
504. Tan Z, Li X, Kelly KA, Rosen CL, Huber JD. Plasminogen activator inhibitor type
1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological
function in aged rats following middle cerebral artery occlusion. Brain Res. Jul 24
2009;1281:84-90.
505. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in
neurological outcome after administration of atorvastatin following experimental
intracerebral hemorrhage in rats. J Neurosurg. Jul 2004;101(1):104-107.
506. Christoforidis GA, Slivka A, Mohammad Y, Karakasis C, Avutu B, Yang M. Size
matters: hemorrhage volume as an objective measure to define significant intracranial
hemorrhage associated with thrombolysis. Stroke. Jun 2007;38(6):1799-1804.
507. Popa-Wagner A, Badan I, Vintilescu R, Walker L, Kessler C. Premature cellular
proliferation following cortical infarct in aged rats. Rom J Morphol Embryol. 2006;47(3):
215-228.
508. Popa-Wagner A, Badan I, Walker L, Groppa S, Patrana N, Kessler C.
Accelerated infarct development, cytogenesis and apoptosis following transient cerebral
ischemia in aged rats. Acta Neuropathol. Mar 2007;113(3):277-293.

257

509. Popa-Wagner A, Dinca I, Yalikun S, Walker L, Kroemer H, Kessler C. Accelerated
delimitation of the infarct zone by capillary-derived nestin-positive cells in aged rats. Curr
Neurovasc Res. Feb 2006;3(1):3-13.
510. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. Role of CD39 (NTPDase-1) in
thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost. Apr
2005;31(2):234-246.
511. Marcus AJ, Broekman MJ, Drosopoulos JH, Pinsky DJ, Islam N, Maliszewsk CR.
Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for
occlusive vascular diseases. Ital Heart J. Nov 2001;2(11):824-830.
512. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'triphosphate and adenosine as endogenous signaling molecules in immunity and
inflammation. Pharmacol Ther. Nov 2006;112(2):358-404.
513. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations
in human CD39 transgenic mice and the implications for thrombotic disease and
transplantation. J Clin Invest. May 2004;113(10):1440-1446.
514. Imai M, Takigami K, Guckelberger O, et al. CD39/vascular ATP
diphosphohydrolase modulates xenograft survival. Transplant Proc. Aug 2000;32(5):969.
515. Wang TF, Guidotti G. CD39 is an ecto-(Ca2+,Mg2+)-apyrase. J Biol Chem. Apr
26 1996;271(17):9898-9901.
516. Marcus AJ, Safier LB, Hajjar KA, et al. Inhibition of platelet function by an aspirininsensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin
Invest. Nov 1991;88(5):1690-1696.
517. Pinsky DJ, Broekman MJ, Peschon JJ, et al. Elucidation of the thromboregulatory
role of CD39/ectoapyrase in the ischemic brain. J Clin Invest. Apr 2002;109(8):
1031-1040.
518. Robson S. The therapeutic potential of CD39: interview with Dr Simon Robson by
Emma Quigley. Expert Opin Ther Targets. Oct 2006;10(5):649-652.
519. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of
CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin
Thromb Hemost. Apr 2005;31(2):217-233.
520. Guckelberger O, Sun XF, Sevigny J, et al. Beneficial effects of CD39/ectonucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion
injury. Thromb Haemost. Mar 2004;91(3):576-586.
521. Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of
ischaemia in animals been useful in the assessment of potential neuroprotective agents?
Trends Pharmacol Sci. Feb 1998;19(2):59-66.
522. Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how
relevant is the rat? Nat Rev Neurosci. Jul 2002;3(7):574-579.
523. Recommendations for standards regarding preclinical neuroprotective and
restorative drug development. Stroke. Dec 1999;30(12):2752-2758.
524. Daviglus ML, Plassman BL, Pirzada A, et al. Risk factors and preventive
interventions for Alzheimer disease: state of the science. Arch Neurol. Sep 2011;68(9):
1185-1190.
525. Hamm RJ, Jenkins LW, Lyeth BG, White-Gbadebo DM, Hayes RL. The effect of
age on outcome following traumatic brain injury in rats. J Neurosurg. Dec 1991;75(6):
916-921.
526. Hamm RJ, White-Gbadebo DM, Lyeth BG, Jenkins LW, Hayes RL. The effect of
age on motor and cognitive deficits after traumatic brain injury in rats. Neurosurgery. Dec
1992;31(6):1072-1077; discussion 1078.
527. Popa-Wagner A, Craitoiu S, Buga AM. Central nervous system aging and
regeneration after injuries. A systematic approach. Rom J Morphol Embryol. 2009;50(2):
155-167.

258

528. Mehan ND, Strauss KI. Combined age- and trauma-related proteomic changes in
rat neocortex: a basis for brain vulnerability. Neurobiol Aging. Sep 2012;33(9):
1857-1873.
529. Watanabe T, Okuda Y, Nonoguchi N, et al. Postischemic intraventricular
administration of FGF-2 expressing adenoviral vectors improves neurologic outcome
and reduces infarct volume after transient focal cerebral ischemia in rats. J Cereb Blood
Flow Metab. Nov 2004;24(11):1205-1213.
530. Pan W, Ding Y, Yu Y, Ohtaki H, Nakamachi T, Kastin AJ. Stroke upregulates
TNFalpha transport across the blood-brain barrier. Exp Neurol. Mar 2006;198(1):
222-233.
531. Rivlin AS, Tator CH. Objective clinical assessment of motor function after
experimental spinal cord injury in the rat. J Neurosurg. Oct 1977;47(4):577-581.
532. Monville C, Torres EM, Dunnett SB. Comparison of incremental and accelerating
protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J
Neurosci Methods. Dec 15 2006;158(2):219-223.
533. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxietyrelated behavior in rodents. Nat Protoc. 2007;2(2):322-328.
534. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new
model sensitive to antidepressant treatments. Eur J Pharmacol. Feb 15 1978;47(4):
379-391.
535. Porsolt RD, Brossard G, Hautbois C, Roux S. Rodent models of depression:
forced swimming and tail suspension behavioral despair tests in rats and mice. Curr
Protoc Neurosci. May 2001;Chapter 8:Unit 8 10A.
536. Sacco RL. Risk factors, outcomes, and stroke subtypes for ischemic stroke.
Neurology. Nov 1997;49(5 Suppl 4):S39-44.
537. Maurissen JP, Marable BR, Andrus AK, Stebbins KE. Factors affecting grip
strength testing. Neurotoxicol Teratol. Sep-Oct 2003;25(5):543-553.
538. Turner RC, Seminerio MJ, Naser ZJ, et al. Effects of aging on behavioral
assessment performance: implications for clinically relevant models of neurological
disease. J Neurosurg. Sep 2012;117(3):629-637.
539. Astrup J. Energy-requiring cell functions in the ischemic brain. Their critical
supply and possible inhibition in protective therapy. J Neurosurg. Apr 1982;56(4):
482-497.
540. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia - the ischemic
penumbra. Stroke. Nov-Dec 1981;12(6):723-725.
541. Dirnagl U, Macleod MR. Stroke research at a road block: the streets from
adversity should be paved with meta-analysis and good laboratory practice. Br J
Pharmacol. Aug 2009;157(7):1154-1156.
542. Petcu EB, Sfredel V, Platt D, Herndon JG, Kessler C, Popa-Wagner A. Cellular
and molecular events underlying the dysregulated response of the aged brain to stroke:
a mini-review. Gerontology. 2008;54(1):6-17.
543. Popa-Wagner A, Buga AM, Turner RC, Rosen CL, Toescu E. Cerebrovascular
disorders: role of aging. J Aging Res. 2012;2012:128146.
544. Turner RC, Seminerio MJ, Naser ZJ, et al. Effects of aging on behavioral
assessment performance: implications for clinically relevant models of neurological
disease. J Neurosurg. Jun 29 2012.
545. Saver JL, Johnston KC, Homer D, et al. Infarct volume as a surrogate or auxiliary
outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke.
Feb 1999;30(2):293-298.
546. Bouet V, Freret T, Toutain J, Divoux D, Boulouard M, Schumann-Bard P.
Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the
mouse. Exp Neurol. Feb 2007;203(2):555-567.

259

547. Encarnacion A, Horie N, Keren-Gill H, Bliss TM, Steinberg GK, Shamloo M.
Long-term behavioral assessment of function in an experimental model for ischemic
stroke. J Neurosci Methods. Mar 30 2011;196(2):247-257.
548. Freret T, Chazalviel L, Roussel S, Bernaudin M, Schumann-Bard P, Boulouard M.
Long-term functional outcome following transient middle cerebral artery occlusion in the
rat: correlation between brain damage and behavioral impairment. Behav Neurosci. Dec
2006;120(6):1285-1298.
549. Haelewyn B, Rouillon C, Risso JJ, Abraini JH. Functional (neurologic) recovery
following transient focal cerebral ischemia in the rat requires at least 80% of ipsilateral
cortical and subcortical integrity. Exp Neurol. Sep 2008;213(1):238-240.
550. Lim SH, Lee JS, Lee JI, Im S, Ko YJ, Kim HW. The quantitative assessment of
functional impairment and its correlation to infarct volume in rats with transient middle
cerebral artery occlusion. Brain Res. Sep 16 2008;1230:303-309.
551. Nedelmann M, Wilhelm-Schwenkmezger T, Alessandri B, et al. Cerebral embolic
ischemia in rats: correlation of stroke severity and functional deficit as important
outcome parameter. Brain Res. Jan 26 2007;1130(1):188-196.
552. Wahl F, Allix M, Plotkine M, Boulu RG. Neurological and behavioral outcomes of
focal cerebral ischemia in rats. Stroke. Feb 1992;23(2):267-272.
553. Yager JY, Wright S, Armstrong EA, Jahraus CM, Saucier DM. The influence of
aging on recovery following ischemic brain damage. Behav Brain Res. Oct 16 2006;173
(2):171-180.
554. Zausinger S, Hungerhuber E, Baethmann A, Reulen H, Schmid-Elsaesser R.
Neurological impairment in rats after transient middle cerebral artery occlusion: a
comparative study under various treatment paradigms. Brain Res. Apr 28 2000;863(1-2):
94-105.
555. Tominaga T, Ohnishi ST. Interrelationship of brain edema, motor deficits, and
memory impairment in rats exposed to focal ischemia. Stroke. Apr 1989;20(4):513-518.
556. Yoo AJ, Chaudhry ZA, Nogueira RG, et al. Infarct volume is a pivotal biomarker
after intra-arterial stroke therapy. Stroke. May 2012;43(5):1323-1330.
557. Trinh VT, Fahim DK, Shah K, et al. Subcortical injury is an independent predictor
of worsening neurological deficits following awake craniotomy procedures.
Neurosurgery. Feb 2013;72(2):160-169.
558. Agarwal S, Scoffings DJ, Jones PS, et al. Interaction of age with the ischaemic
penumbra, leptomeningeal collateral circulation and haemodynamic variables in acute
stroke: a pilot study. J Neurol Neurosurg Psychiatry. Mar 2013;84(3):271-276.
559. Raghupathi R, Graham DI, McIntosh TK. Apoptosis after traumatic brain injury. J
Neurotrauma. Oct 2000;17(10):927-938.
560. Buki A, Okonkwo DO, Wang KK, Povlishock JT. Cytochrome c release and
caspase activation in traumatic axonal injury. J Neurosci. Apr 15 2000;20(8):2825-2834.
561. Wang HG, Pathan N, Ethell IM, et al. Ca2+-induced apoptosis through
calcineurin dephosphorylation of BAD. Science. Apr 9 1999;284(5412):339-343.
562. Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H, Demetriadou K. A
new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J
Neurosurg. Feb 1994;80(2):291-300.
563. Stone JR, Walker SA, Povlishock JT. The visualization of a new class of
traumatically injured axons through the use of a modified method of microwave antigen
retrieval. Acta Neuropathol. Apr 1999;97(4):335-345.
564. Mills JD, Stone JR, Rubin DG, et al. Illuminating protein interactions in tissue
using confocal and two-photon excitation fluorescent resonance energy transfer
microscopy. J Biomed Opt. Jul 2003;8(3):347-356.
565. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with
testosterone administration. N Engl J Med. Jul 8 2010;363(2):109-122.

260

566. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of
testosterone on muscle size and strength in normal men. N Engl J Med. Jul 4 1996;335
(1):1-7.
567. Talih F, Fattal O, Malone D, Jr. Anabolic steroid abuse: psychiatric and physical
costs. Cleve Clin J Med. May 2007;74(5):341-344, 346, 349-352.
568. vandenBerg P, Neumark-Sztainer D, Cafri G, Wall M. Steroid use among
adolescents: longitudinal findings from Project EAT. Pediatrics. Mar 2007;119(3):
476-486.
569. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med.
Mar 2004;32(2):534-542.
570. Scott DM, Wagner JC, Barlow TW. Anabolic steroid use among adolescents in
Nebraska schools. Am J Health Syst Pharm. Sep 1 1996;53(17):2068-2072.
571. Faul M, Xu L, Wald MM, Coronado VG. Traumatic Brain Injury in the United
States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006: Centers
for Disease Control and Prevention; 2010.
572. Langburt W, Cohen B, Akhthar N, O'Neill K, Lee JC. Incidence of concussion in
high school football players of Ohio and Pennsylvania. J Child Neurol. Feb 2001;16(2):
83-85.
573. Guskiewicz KM, McCrea M, Marshall SW, et al. Cumulative effects associated
with recurrent concussion in collegiate football players: the NCAA Concussion Study.
JAMA. Nov 19 2003;290(19):2549-2555.
574. Guskiewicz KM, Marshall SW, Bailes J, et al. Recurrent concussion and risk of
depression in retired professional football players. Med Sci Sports Exerc. Jun 2007;39
(6):903-909.
575. Horn S, Gregory P, Guskiewicz KM. Self-reported anabolic-androgenic steroids
use and musculoskeletal injuries: findings from the center for the study of retired athletes
health survey of retired NFL players. Am J Phys Med Rehabil. Mar 2009;88(3):192-200.
576. Rabadi MH, Jordan BD. The cumulative effect of repetitive concussion in sports.
Clin J Sport Med. Jul 2001;11(3):194-198.
577. Benson BW, Hamilton GM, Meeuwisse WH, McCrory P, Dvorak J. Is protective
equipment useful in preventing concussion? A systematic review of the literature. Br J
Sports Med. May 2009;43 Suppl 1:i56-67.
578. Gurdjian ES. Cerebral contusions: re-evaluation of the mechanism of their
development. J Trauma. Jan 1976;16(1):35-51.
579. Bailes JE, Mills JD. Docosahexaenoic acid reduces traumatic axonal injury in a
rodent head injury model. J Neurotrauma. Sep 2010;27(9):1617-1624.
580. Mills JD, Hadley K, Bailes JE. Dietary supplementation with the omega-3 fatty
acid docosahexaenoic acid in traumatic brain injury. Neurosurgery. Feb 2011;68(2):
474-481; discussion 481.
581. Schumacher M, Guennoun R, Stein DG, De Nicola AF. Progesterone: therapeutic
opportunities for neuroprotection and myelin repair. Pharmacol Ther. Oct 2007;116(1):
77-106.
582. Chavko M, Koller WA, Prusaczyk WK, McCarron RM. Measurement of blast
wave by a miniature fiber optic pressure transducer in the rat brain. J Neurosci Methods.
Jan 30 2007;159(2):277-281.
583. Lee EJ, Park KH, Kim DM, Yoo YC, Kang SH, Kim YJ. Assessing intraocular
pressure by rebound tonometer in rats with an air-filled anterior chamber. Jpn J
Ophthalmol. Nov-Dec 2008;52(6):500-503.
584. Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasive measurement of
rodent intraocular pressure with a rebound tonometer. Invest Ophthalmol Vis Sci. Dec
2005;46(12):4617-4621.
585. Mills JD, Bailes JE, Sedney CL, Hutchins H, Sears B. Omega-3 fatty acid
supplementation and reduction of traumatic axonal injury in a rodent head injury model.
J Neurosurg. Jan 2011;114(1):77-84.

261

586. Raphael JH, Chotai R. Effects of the cervical collar on cerebrospinal fluid
pressure. Anaesthesia. May 1994;49(5):437-439.
587. Teng C, Gurses-Ozden R, Liebmann JM, Tello C, Ritch R. Effect of a tight necktie
on intraocular pressure. Br J Ophthalmol. Aug 2003;87(8):946-948.
588. May PR, Fuster JM, Haber J, Hirschman A. Woodpecker drilling behavior. An
endorsement of the rotational theory of impact brain injury. Arch Neurol. Jun 1979;36(6):
370-373.
589. Rai R, Ranade A, Nayak S, Vadgaonkar R, Mangala P, Krishnamurthy A. A study
of anatomical variability of the omohyoid muscle and its clinical relevance. Clinics (Sao
Paulo). Aug 2008;63(4):521-524.
590. Bruns J, Jr., Hauser WA. The epidemiology of traumatic brain injury: a review.
Epilepsia. 2003;44 Suppl 10:2-10.
591. Barha CK, Ishrat T, Epp JR, Galea LA, Stein DG. Progesterone treatment
normalizes the levels of cell proliferation and cell death in the dentate gyrus of the
hippocampus after traumatic brain injury. Exp Neurol. Sep 2011;231(1):72-81.
592. Shear DA, Galani R, Hoffman SW, Stein DG. Progesterone protects against
necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp
Neurol. Nov 2002;178(1):59-67.
593. Stein DG. Progesterone exerts neuroprotective effects after brain injury. Brain
Res Rev. Mar 2008;57(2):386-397.
594. May PR, Fuster JM, Newman P, Hirschman A. Woodpeckers and head injury.
Lancet. Feb 28 1976;1(7957):454-455.
595. Wang L, Cheung JT, Pu F, Li D, Zhang M, Fan Y. Why do woodpeckers resist
head impact injury: a biomechanical investigation. PLoS One. 2011;6(10):e26490.
596. Wygnanski-Jaffe T, Murphy CJ, Smith C, et al. Protective ocular mechanisms in
woodpeckers. Eye (Lond). Jan 2007;21(1):83-89.
597. Patra P, Gunness TK, Robert R, et al. Physiologic variations of the internal
jugular vein surface, role of the omohyoid muscle, a preliminary echographic study. Surg
Radiol Anat. 1988;10(2):107-112.
598. Smith DW, Bailes JE, Fisher JA, Robles J, Turner RC, Mills JD. Internal jugular
vein compression mitigates traumatic axonal injury in a rat model by reducing the
intracranial slosh effect. Neurosurgery. Mar 2012;70(3):740-746.
599. Ibrahim RD, Pilipchuk VN. Recent advances in liquid sloshing dynamics. Appl
Mech Rev. 2001;54(2):133-199.
600. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial
and neuronal control of brain blood flow. Nature. Nov 11 2010;468(7321):232-243.
601. Bignami A. Glial cells in the central nervous system1991.
602. Foda MA, Marmarou A. A new model of diffuse brain injury in rats. Part II:
Morphological characterization. J Neurosurg. Feb 1994;80(2):301-313.
603. Schmued LC, Hopkins KJ. Fluoro-Jade: novel fluorochromes for detecting
toxicant-induced neuronal degeneration. Toxicol Pathol. Jan-Feb 2000;28(1):91-99.
604. Anderson KJ, Miller KM, Fugaccia I, Scheff SW. Regional distribution of fluorojade B staining in the hippocampus following traumatic brain injury. Exp Neurol. May
2005;193(1):125-130.
605. Gao X, Deng-Bryant Y, Cho W, Carrico KM, Hall ED, Chen J. Selective death of
newborn neurons in hippocampal dentate gyrus following moderate experimental
traumatic brain injury. J Neurosci Res. Aug 1 2008;86(10):2258-2270.
606. Haselkorn ML, Shellington DK, Jackson EK, et al. Adenosine A1 receptor
activation as a brake on the microglial response after experimental traumatic brain injury
in mice. J Neurotrauma. May 2010;27(5):901-910.
607. Sato M, Chang E, Igarashi T, Noble LJ. Neuronal injury and loss after traumatic
brain injury: time course and regional variability. Brain Res. Oct 26 2001;917(1):45-54.
608. Zhao X, Ahram A, Berman RF, Muizelaar JP, Lyeth BG. Early loss of astrocytes
after experimental traumatic brain injury. Glia. Nov 2003;44(2):140-152.

262

609. Vibulsreth S, Hefti F, Ginsberg MD, Dietrich WD, Busto R. Astrocytes protect
cultured neurons from degeneration induced by anoxia. Brain Res. Oct 6 1987;422(2):
303-311.
610. Fitch MT, Doller C, Combs CK, Landreth GE, Silver J. Cellular and molecular
mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of
inflammation-induced secondary injury after CNS trauma. J Neurosci. Oct 1 1999;19
(19):8182-8198.
611. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and
molecular cues to biological function. Trends Neurosci. Dec 1997;20(12):570-577.
612. Sandhir R, Onyszchuk G, Berman NE. Exacerbated glial response in the aged
mouse hippocampus following controlled cortical impact injury. Exp Neurol. Oct
2008;213(2):372-380.
613. Shitaka Y, Tran HT, Bennett RE, et al. Repetitive closed-skull traumatic brain
injury in mice causes persistent multifocal axonal injury and microglial reactivity. J
Neuropathol Exp Neurol. Jul 2011;70(7):551-567.
614. Venkatesan C, Chrzaszcz M, Choi N, Wainwright MS. Chronic upregulation of
activated microglia immunoreactive for galectin-3/Mac-2 and nerve growth factor
following diffuse axonal injury. J Neuroinflammation. 2010;7:32.
615. Elder GA, Cristian A. Blast-related mild traumatic brain injury: mechanisms of
injury and impact on clinical care. Mt Sinai J Med. Apr 2009;76(2):111-118.
616. Nakagawa A, Manley GT, Gean AD, et al. Mechanisms of primary blast-induced
traumatic brain injury: insights from shock-wave research. J Neurotrauma. Jun 2011;28
(6):1101-1119.
617. Champion HR, Holcomb JB, Young LA. Injuries from explosions: physics,
biophysics, pathology, and required research focus. J Trauma. May 2009;66(5):
1468-1477; discussion 1477.
618. Schneiderman AI, Braver ER, Kang HK. Understanding sequelae of injury
mechanisms and mild traumatic brain injury incurred during the conflicts in Iraq and
Afghanistan: persistent postconcussive symptoms and posttraumatic stress disorder. Am
J Epidemiol. Jun 15 2008;167(12):1446-1452.
619. Terrio H, Brenner LA, Ivins BJ, et al. Traumatic brain injury screening: preliminary
findings in a US Army Brigade Combat Team. J Head Trauma Rehabil. Jan-Feb 2009;24
(1):14-23.
620. Ahlers ST, Vasserman-Stokes E, Shaughness MC, et al. Assessment of the
effects of acute and repeated exposure to blast overpressure in rodents: toward a
greater understanding of blast and the potential ramifications for injury in humans
exposed to blast. Front Neurol. 2012;3:32.
621. Chavko M, Watanabe T, Adeeb S, Lankasky J, Ahlers ST, McCarron RM.
Relationship between orientation to a blast and pressure wave propagation inside the rat
brain. J Neurosci Methods. Jan 30 2011;195(1):61-66.
622. Shridharani JK, Wood GW, Panzer MB, et al. Porcine head response to blast.
Front Neurol. 2012;3:70.
623. Turner RC, Naser ZJ, Bailes JE, Smith DW, Fisher JA, Rosen CL. Effect of slosh
mitigation on histologic markers of traumatic brain injury. J Neurosurg. Sep 21 2012.
624. Schmitz C, Hof PR. Design-based stereology in neuroscience. Neuroscience.
2005;130(4):813-831.
625. Turner RC, Naser ZJ, Bailes JE, Smith DW, Fisher JA, Rosen CL. Effect of slosh
mitigation on histologic markers of traumatic brain injury: laboratory investigation. J
Neurosurg. Dec 2012;117(6):1110-1118.
626. Reneer DV, Hisel RD, Hoffman JM, Kryscio RJ, Lusk BT, Geddes JW. A multimode shock tube for investigation of blast-induced traumatic brain injury. J Neurotrauma.
Jan 2011;28(1):95-104.
627. Cheng J, Gu J, Ma Y, et al. Development of a rat model for studying blastinduced traumatic brain injury. J Neurol Sci. Jul 15 2010;294(1-2):23-28.

263

628. de Lanerolle NC, Bandak F, Kang D, et al. Characteristics of an explosive blastinduced brain injury in an experimental model. J Neuropathol Exp Neurol. Nov 2011;70
(11):1046-1057.
629. Svetlov SI, Prima V, Glushakova O, et al. Neuro-glial and systemic mechanisms
of pathological responses in rat models of primary blast overpressure compared to
"composite" blast. Front Neurol. 2012;3:15.
630. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W.
Inflammation and white matter degeneration persist for years after a single traumatic
brain injury. Brain. Jan 2013;136(Pt 1):28-42.
631. Conventional Weapons Effects Program [computer program]. Vicksburg, MS:
United States Army Corps of Engineers; 2004.
632. Richmond DR, Damon EG, Fletcher ER, Bowen IG, White CS. The relationship
between selected blast-wave parameters and the response of mammals exposed to air
blast. Ann N Y Acad Sci. Oct 28 1968;152(1):103-121.
633. Bowen IG, Fletcher ER, Richmond DR, Hirsch FG, White CS. Biophysical
mechanisms and scaling procedures applicable in assessing responses of the thorax
energized by air-blast overpressures or by nonpenetrating missiles. Ann N Y Acad Sci.
Oct 28 1968;152(1):122-146.
634. Park E, Gottlieb JJ, Cheung B, Shek PN, Baker AJ. A model of low-level primary
blast brain trauma results in cytoskeletal proteolysis and chronic functional impairment in
the absence of lung barotrauma. J Neurotrauma. Mar 2011;28(3):343-357.
635. Rafaels KA, dale' Bass CR, Panzer MB, et al. Brain injury risk from primary blast.
J Trauma Acute Care Surg. Oct 2012;73(4):895-901.
636. Risling M, Davidsson J. Experimental animal models for studies on the
mechanisms of blast-induced neurotrauma. Front Neurol. 2012;3:30.
637. Cernak I, Noble-Haeusslein LJ. Traumatic brain injury: an overview of
pathobiology with emphasis on military populations. J Cereb Blood Flow Metab. Feb
2010;30(2):255-266.
638. Covey DC, Born CT. Blast injuries: mechanics and wounding patterns. J Surg
Orthop Adv. Spring 2010;19(1):8-12.
639. Yeh DD, Schecter WP. Primary blast injuries--an updated concise review. World J
Surg. May 2012;36(5):966-972.
640. Duckworth JL, Grimes J, Ling GS. Pathophysiology of battlefield associated
traumatic brain injury. Pathophysiology. Jun 13 2012.
641. Rubovitch V, Ten-Bosch M, Zohar O, et al. A mouse model of blast-induced mild
traumatic brain injury. Exp Neurol. Dec 2011;232(2):280-289.
642. Readnower RD, Chavko M, Adeeb S, et al. Increase in blood-brain barrier
permeability, oxidative stress, and activated microglia in a rat model of blast-induced
traumatic brain injury. J Neurosci Res. Dec 2010;88(16):3530-3539.
643. Garman RH, Jenkins LW, Switzer RC, 3rd, et al. Blast exposure in rats with body
shielding is characterized primarily by diffuse axonal injury. J Neurotrauma. Jun 2011;28
(6):947-959.
644. Cernak I, Merkle AC, Koliatsos VE, et al. The pathobiology of blast injuries and
blast-induced neurotrauma as identified using a new experimental model of injury in
mice. Neurobiol Dis. Feb 2011;41(2):538-551.
645. Kaur C, Singh J, Lim MK, Ng BL, Yap EP, Ling EA. The response of neurons and
microglia to blast injury in the rat brain. Neuropathol Appl Neurobiol. Oct 1995;21(5):
369-377.
646. Kane MJ, Angoa-Perez M, Francescutti DM, et al. Altered gene expression in
cultured microglia in response to simulated blast overpressure: possible role of pulse
duration. Neurosci Lett. Jul 26 2012;522(1):47-51.
647. Magnuson J, Leonessa F, Ling GS. Neuropathology of explosive blast traumatic
brain injury. Curr Neurol Neurosci Rep. Oct 2012;12(5):570-579.

264

648. Scheibel RS, Newsome MR, Troyanskaya M, et al. Altered brain activation in
military personnel with one or more traumatic brain injuries following blast. J Int
Neuropsychol Soc. Jan 2012;18(1):89-100.
649. Taber KH, Warden DL, Hurley RA. Blast-related traumatic brain injury: what is
known? J Neuropsychiatry Clin Neurosci. Spring 2006;18(2):141-145.
650. Kuehn R, Simard PF, Driscoll I, et al. Rodent model of direct cranial blast injury. J
Neurotrauma. Oct 2011;28(10):2155-2169.
651. Koliatsos VE, Cernak I, Xu L, et al. A mouse model of blast injury to brain: initial
pathological, neuropathological, and behavioral characterization. J Neuropathol Exp
Neurol. May 2011;70(5):399-416.
652. Dalle Lucca JJ, Chavko M, Dubick MA, et al. Blast-induced moderate
neurotrauma (BINT) elicits early complement activation and tumor necrosis factor alpha
(TNFalpha) release in a rat brain. J Neurol Sci. Jul 15 2012;318(1-2):146-154.
653. Duhaime AC, Beckwith JG, Maerlender AC, et al. Spectrum of acute clinical
characteristics of diagnosed concussions in college athletes wearing instrumented
helmets: clinical article. J Neurosurg. Dec 2012;117(6):1092-1099.
654. Mac Donald CL, Johnson AM, Cooper D, et al. Detection of blast-related
traumatic brain injury in U.S. military personnel. N Engl J Med. Jun 2 2011;364(22):
2091-2100.
655. Finnoff JT, Jelsing EJ, Smith J. Biomarkers, genetics, and risk factors for
concussion. PM R. Oct 2011;3(10 Suppl 2):S452-459.
656. Dashnaw ML, Petraglia AL, Bailes JE. An overview of the basic science of
concussion and subconcussion: where we are and where we are going. Neurosurg
Focus. Dec 2012;33(6):E5: 1-9.
657. Levin H, Robertson CS. Mild TBI in Translation. J Neurotrauma. Oct 9 2012.
658. Shultz SR, MacFabe DF, Foley KA, Taylor R, Cain DP. A single mild fluid
percussion injury induces short-term behavioral and neuropathological changes in the
Long-Evans rat: support for an animal model of concussion. Behav Brain Res. Oct 31
2011;224(2):326-335.
659. Harmon KG, Drezner JA, Gammons M, et al. American Medical Society for
Sports Medicine position statement: concussion in sport. Br J Sports Med. Jan 2013;47
(1):15-26.
660. McCullough BJ, Jarvik JG. Diagnosis of concussion: the role of imaging now and
in the future. Phys Med Rehabil Clin N Am. Nov 2011;22(4):635-652, viii.
661. Fromm L, Heath DL, Vink R, Nimmo AJ. Magnesium attenuates post-traumatic
depression/anxiety following diffuse traumatic brain injury in rats. J Am Coll Nutr. Oct
2004;23(5):529S-533S.
662. Kontos AP, Covassin T, Elbin RJ, Parker T. Depression and neurocognitive
performance after concussion among male and female high school and collegiate
athletes. Arch Phys Med Rehabil. Oct 2012;93(10):1751-1756.
663. Meyer DL, Davies DR, Barr JL, Manzerra P, Forster GL. Mild traumatic brain
injury in the rat alters neuronal number in the limbic system and increases conditioned
fear and anxiety-like behaviors. Exp Neurol. Apr 1 2012.
664. Ding Y, Yao B, Lai Q, McAllister JP. Impaired motor learning and diffuse axonal
damage in motor and visual systems of the rat following traumatic brain injury. Neurol
Res. Mar-Apr 2001;23(2-3):193-202.
665. Hallam TM, Floyd CL, Folkerts MM, et al. Comparison of behavioral deficits and
acute neuronal degeneration in rat lateral fluid percussion and weight-drop brain injury
models. J Neurotrauma. May 2004;21(5):521-539.
666. Heath DL, Vink R. Improved motor outcome in response to magnesium therapy
received up to 24 hours after traumatic diffuse axonal brain injury in rats. J Neurosurg.
Mar 1999;90(3):504-509.
667. Heath DL, Vink R. Magnesium sulphate improves neurologic outcome following
severe closed head injury in rats. Neurosci Lett. Jun 13 1997;228(3):175-178.

265

668. Hylin MJ, Orsi SA, Zhao J, et al. Behavioral and histopathological alterations
resulting from mild fluid percussion injury. J Neurotrauma. Jan 9 2013.
669. Kane MJ, Angoa-Perez M, Briggs DI, Viano DC, Kreipke CW, Kuhn DM. A mouse
model of human repetitive mild traumatic brain injury. J Neurosci Methods. Jan 15
2012;203(1):41-49.
670. Lyeth BG, Jenkins LW, Hamm RJ, et al. Prolonged memory impairment in the
absence of hippocampal cell death following traumatic brain injury in the rat. Brain Res.
Sep 3 1990;526(2):249-258.
671. Mouzon B, Chaytow H, Crynen G, et al. Repetitive mild traumatic brain injury in a
mouse model produces learning and memory deficits accompanied by histological
changes. J Neurotrauma. Dec 10 2012;29(18):2761-2773.
672. Rostami E, Davidsson J, Ng KC, et al. A Model for Mild Traumatic Brain Injury
that Induces Limited Transient Memory Impairment and Increased Levels of Axon
Related Serum Biomarkers. Front Neurol. 2012;3:115.
673. Zhao Z, Loane DJ, Murray MG, 2nd, Stoica BA, Faden AI. Comparing the
predictive value of multiple cognitive, affective, and motor tasks after rodent traumatic
brain injury. J Neurotrauma. Oct 10 2012;29(15):2475-2489.
674. Adelson PD, Fellows-Mayle W, Kochanek PM, Dixon CE. Morris water maze
function and histologic characterization of two age-at-injury experimental models of
controlled cortical impact in the immature rat. Childs Nerv Syst. Jan 2013;29(1):43-53.
675. Beaumont A, Marmarou A, Czigner A, et al. The impact-acceleration model of
head injury: injury severity predicts motor and cognitive performance after trauma.
Neurol Res. Dec 1999;21(8):742-754.
676. Beaumont A, Marmarou C, Marmarou A. The effects of human corticotrophin
releasing factor on motor and cognitive deficits after impact acceleration injury. Neurol
Res. Oct 2000;22(7):665-673.
677. Berman RF, Verweij BH, Muizelaar JP. Neurobehavioral protection by the
neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury
in rats. J Neurosurg. Nov 2000;93(5):821-828.
678. Dapul HR, Park J, Zhang J, et al. Concussive Injury before or after Controlled
Cortical Impact Exacerbates Histopathology and Functional Outcome in a Mixed
Traumatic Brain Injury Model in Mice. J Neurotrauma. Feb 20 2013.
679. DeFord SM, Wilson MS, Rice AC, et al. Repeated mild brain injuries result in
cognitive impairment in B6C3F1 mice. J Neurotrauma. Apr 2002;19(4):427-438.
680. Gurkoff GG, Giza CC, Hovda DA. Lateral fluid percussion injury in the developing
rat causes an acute, mild behavioral dysfunction in the absence of significant cell death.
Brain Res. Mar 10 2006;1077(1):24-36.
681. Maughan PH, Scholten KJ, Schmidt RH. Recovery of water maze performance in
aged versus young rats after brain injury with the impact acceleration model. J
Neurotrauma. Dec 2000;17(12):1141-1153.
682. Meehan WP, 3rd, Zhang J, Mannix R, Whalen MJ. Increasing Recovery Time
Between Injuries Improves Cognitive Outcome After Repetitive Mild Concussive Brain
Injuries in Mice. Neurosurgery. Jun 27 2012.
683. Schmidt RH, Scholten KJ, Maughan PH. Cognitive impairment and synaptosomal
choline uptake in rats following impact acceleration injury. J Neurotrauma. Dec 2000;17
(12):1129-1139.
684. Schmidt RH, Scholten KJ, Maughan PH. Time course for recovery of water maze
performance and central cholinergic innervation after fluid percussion injury. J
Neurotrauma. Dec 1999;16(12):1139-1147.
685. Washington PM, Forcelli PA, Wilkins T, Zapple DN, Parsadanian M, Burns MP.
The Effect of Injury Severity on Behavior: A Phenotypic Study of Cognitive and
Emotional Deficits after Mild, Moderate, and Severe Controlled Cortical Impact Injury in
Mice. J Neurotrauma. Aug 3 2012.

266

686. Zohar O, Rubovitch V, Milman A, Schreiber S, Pick CG. Behavioral
consequences of minimal traumatic brain injury in mice. Acta Neurobiol Exp (Wars).
2011;71(1):36-45.
687. Eakin K, Miller JP. Mild traumatic brain injury is associated with impaired
hippocampal spatiotemporal representation in the absence of histological changes. J
Neurotrauma. Apr 10 2012;29(6):1180-1187.
688. Milman A, Zohar O, Maayan R, Weizman R, Pick CG. DHEAS repeated
treatment improves cognitive and behavioral deficits after mild traumatic brain injury. Eur
Neuropsychopharmacol. Mar 2008;18(3):181-187.
689. Schwarzbold ML, Rial D, De Bem T, et al. Effects of traumatic brain injury of
different severities on emotional, cognitive, and oxidative stress-related parameters in
mice. J Neurotrauma. Oct 2010;27(10):1883-1893.
690. Cutler SM, VanLandingham JW, Murphy AZ, Stein DG. Slow-release and injected
progesterone treatments enhance acute recovery after traumatic brain injury. Pharmacol
Biochem Behav. Jul 2006;84(3):420-428.
691. Hogg S, Moser PC, Sanger DJ. Mild traumatic lesion of the right parietal cortex of
the rat: selective behavioural deficits in the absence of neurological impairment. Behav
Brain Res. Jun 1998;93(1-2):143-155.
692. Jones NC, Cardamone L, Williams JP, Salzberg MR, Myers D, O'Brien TJ.
Experimental traumatic brain injury induces a pervasive hyperanxious phenotype in rats.
J Neurotrauma. Nov 2008;25(11):1367-1374.
693. Liu YR, Cardamone L, Hogan RE, et al. Progressive metabolic and structural
cerebral perturbations after traumatic brain injury: an in vivo imaging study in the rat. J
Nucl Med. Nov 2010;51(11):1788-1795.
694. Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H. Role of
glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic
brain injury. Mol Cell Neurosci. Apr 2007;34(4):571-577.
695. Shultz SR, MacFabe DF, Foley KA, Taylor R, Cain DP. Sub-concussive brain
injury in the Long-Evans rat induces acute neuroinflammation in the absence of
behavioral impairments. Behav Brain Res. Apr 1 2012;229(1):145-152.
696. Broglio SP, Eckner JT, Paulson HL, Kutcher JS. Cognitive decline and aging: the
role of concussive and subconcussive impacts. Exerc Sport Sci Rev. Jul 2012;40(3):
138-144.
697. Gosselin N, Bottari C, Chen JK, et al. Evaluating the cognitive consequences of
mild traumatic brain injury and concussion by using electrophysiology. Neurosurg Focus.
Dec 2012;33(6):E7: 1-7.
698. Blokland A. Reaction time responding in rats. Neurosci Biobehav Rev. Oct
1998;22(6):847-864.
699. Bushnell PJ, Strupp BJ. Assessing Attention in Rodents. 2009.
700. Turner RC, Lucke-Wold BP, Robson MJ, Omalu BI, Petraglia AL, Bailes JE.
Repetitive traumatic brain injury and development of chronic traumatic encephalopathy:
a potential role for biomarkers in diagnosis, prognosis, and treatment? Front Neurol.
2012;3:186.
701. Zhou Y, Riccio DC. Concussion-induced retrograde amnesia in rats. Physiol
Behav. Jun 1995;57(6):1107-1115.
702. Prins ML, Hales A, Reger M, Giza CC, Hovda DA. Repeat traumatic brain injury
in the juvenile rat is associated with increased axonal injury and cognitive impairments.
Dev Neurosci. 2010;32(5-6):510-518.
703. Reger ML, Poulos AM, Buen F, Giza CC, Hovda DA, Fanselow MS. Concussive
brain injury enhances fear learning and excitatory processes in the amygdala. Biol
Psychiatry. Feb 15 2012;71(4):335-343.
704. Anderson J, Sandhir R, Hamilton ES, Berman NE. Impaired expression of
neuroprotective molecules in the HIF-1alpha pathway following traumatic brain injury in
aged mice. J Neurotrauma. Sep 2009;26(9):1557-1566.

267

705. Wali B, Sayeed I, Stein DG. Improved behavioral outcomes after progesterone
administration in aged male rats with traumatic brain injury. Restor Neurol Neurosci.
2011;29(1):61-71.
706. Timaru-Kast R, Luh C, Gotthardt P, et al. Influence of age on brain edema
formation, secondary brain damage and inflammatory response after brain trauma in
mice. PLoS One. 2012;7(8):e43829.
707. Hoane MR, Lasley LA, Akstulewicz SL. Middle age increases tissue vulnerability
and impairs sensorimotor and cognitive recovery following traumatic brain injury in the
rat. Behav Brain Res. Aug 12 2004;153(1):189-197.
708. McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic
traumatic encephalopathy. Brain. Jan 2013;136(Pt 1):43-64.
709. Perez de Leon AA, Tabachnick WJ. Apyrase activity and adenosine diphosphate
induced platelet aggregation inhibition by the salivary gland proteins of Culicoides
variipennis, the North American vector of bluetongue viruses. Vet Parasitol. Feb 1996;61
(3-4):327-338.
710. Bennett RE, Mac Donald CL, Brody DL. Diffusion tensor imaging detects axonal
injury in a mouse model of repetitive closed-skull traumatic brain injury. Neurosci Lett.
Apr 4 2012;513(2):160-165.
711. Jaffe ER. Methemoglobin pathophysiology. Prog Clin Biol Res. 1981;51:133-151.
712. Ho YS, Yang X, Lau JC, et al. Endoplasmic reticulum stress induces tau
pathology and forms a vicious cycle: implication in Alzheimer's disease pathogenesis. J
Alzheimers Dis. 2012;28(4):839-854.
713. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P,
Scheper W. The unfolded protein response is activated in pretangle neurons in
Alzheimer's disease hippocampus. Am J Pathol. Apr 2009;174(4):1241-1251.
714. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Scheper W.
Activation of the unfolded protein response is an early event in Alzheimer's and
Parkinson's disease. Neurodegener Dis. 2012;10(1-4):212-215.
715. Nijholt DA, van Haastert ES, Rozemuller AJ, Scheper W, Hoozemans JJ. The
unfolded protein response is associated with early tau pathology in the hippocampus of
tauopathies. J Pathol. Apr 2012;226(5):693-702.
716. Hayashi T, Saito A, Okuno S, Ferrand-Drake M, Dodd RL, Chan PH. Damage to
the endoplasmic reticulum and activation of apoptotic machinery by oxidative stress in
ischemic neurons. J Cereb Blood Flow Metab. Jan 2005;25(1):41-53.

268

APPENDIX
SUPPLEMENTAL METHODS
Design of Blast Model
A novel blast apparatus was designed to simulate a multitude of peak overpressures,
based on membrane thickness, each with a short duration (less than 3 milliseconds). To
achieve blasts of short duration, the driver, or high-pressure section of the model, is
notably short in overall length (Supplemental Figure 1). The apparatus was constructed
of machined aluminum.
Immunohistochemistry
Hematoxylin and Eosin (H&E) Staining. H&E staining was performed according to
manufacturerʼs instructions (Sigma Aldrich). After paraffin removal and rehydration,
sections were immersed in Harris Hematoxylin solution for 2.25 minutes, rinsed in
running tap water, and differentiated using a 0.25% acid alcohol solution. After rinsing in
tap water, sections were blued in Scottʼs Tap Water Substitute for one minute prior to
placement in 95% ethanol for 30 seconds and counterstaining with Eosin Y solution for
30 seconds. Slides were rinsed and coverslipped.
Fluoro-Jade B Staining (FJB). Following deparaffinization and rehydration, sections
were incubated in 0.06% potassium permanganate for 10 minutes. Slides were then
washed for 2 minutes in deionized water prior to a 20 minute incubation in 0.0004% FJB
in 0.1% acetic acid. After incubation, sections were washed three times in deionized
water (5 minutes each wash). Slides were coverslipped, sealed with acrylic, and stored
in the dark in a laboratory refrigerator.
Following deparaffinization and
Glial Fibrillary Acidic Protein (GFAP) Staining.
rehydration, endogenous peroxidases were quenched using a 10% methanol and 10%
hydrogen peroxide solution in DPBS for 15 minutes. Slides were rinsed in DPBS three
times (5 minutes each) and permeabilized for 30 minutes using a 1.8% L-lysine, 4%
horse serum, and 0.2% Triton X-100 in DPBS. Sections were then incubated in
polyclonal antibody raised in rabbit against anti-cow GFAP at a dilution of 1:500 in 4%
horse serum in DPBS overnight. Next, sections were washed three times for 5 minutes
each prior to application of biotinylated anti-rabbit IgG (1:10,000) in DPBS with 4% horse
serum for 4 hours. Slides were developed using an alkaline phosphatase and fast blue
salt as a chromagen. Slides were rinsed, coverslipped, and sealed.
Ionized Calcium Binding Adapter Molecule 1 (Iba-1) Staining. Labeling of microglia
using Iba-1 followed an identical procedure to that used for GFAP with the exception of
the antibodies utilized.
SUPPLEMENTAL RESULTS
Neural degeneration occurs in a dose-response manner consistent with blast severity.
Blast exposure was associated with an increase in neural degeneration within the cortex,
consistent with peak overpressure exposure (Figure 5). Similar findings were also seen
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in other brain regions observed such as the region surrounding and including the corpus
callosum (Supplemental Figure 2), the striatum (Supplemental Figure 3), hippocampus
(Supplemental Figure 4), and cerebellum (Supplemental Figure 5).
Blast injured brains demonstrate increased glial activation with increasing peak
overpressure. Increasing severity of blast exposure was associated with an increased
level of astrocyte reactivity, particularly within the corpus callosum (Figure 6).
Examination of the entirety of forebrain sections (Supplemental Figure 6) revealed
astrogliosis in the cortex, striatum, and hippocampus as well. Cortical examination
showed intense astrogliosis, particularly with more severe blast exposure, at the
interface with white matter tracts such as the corpus callosum (Supplemental Figure 7).
Mild astrocyte activation was also observed within the cortical mantle of blast-exposed
brains (Supplemental Figure 6 – dashed arrow), a region of interest considering the
similarities with regions of vascular dysfunction based on gross imaging post-blast
(Figure 3). In other brain regions such as the striatum and the hippocampus, similar
findings were observed to those in the cortex in that GFAP staining was more intense at
the interface of tissue regions and was increased with peak overpressure exposure
severity (Supplemental Figures 8 and 9, respectively). Astrocyte reactivity was also
seen within the cerebellum with higher power images acquired from the region identified
in Supplemental Figure 10. Again, astrocyte reactivity appeared most predominate in
fiber tracts within the cerebellum and predominated on the contrecoup side with the
intensity of staining consistent with the severity of peak overpressure exposure
(Supplemental Figure 11). High power (63X objective) examination of these brains
regions revealed both an apparent increase in the number of reactive astrocytes as well
as astrocyte hypertrophy characterized by enlarged processes and extensive branching
(Supplemental Figure 12).
Microglial activation followed similar trends to that of
astrocyte reactivity in that there was an increase in condensed, phagocytic-type
microglia within the corpus callosum following blast exposure (Figure 7). Microglial
activation was not limited to the corpus callosum though as activated microglia were also
observed within the cortex (Supplemental Figure 13), striatum (Supplemental Figure 14),
hippocampus (Supplemental Figure 15), and cerebellum (Supplemental Figure 16).
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SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1. An exploded view (not to scale) of the novel blast model
utilized within this work with an enlarged engineering sketch shown that demonstrates
the tapered design and short driver section. The length of the driver section influences
the duration of blast exposure and was kept short deliberately to produce a range of
peak overpressures, each with a short duration. Dimensions given are in inches.
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Supplemental Figure 2. Neural degeneration in the area including and directly around
the corpus callosum of A.) Control, B.) 31.47 PSI blast, C.) 50.72 PSI blast, and D.)
72.05 PSI blast-exposed animals. Images acquired using 20X objective.
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Supplemental Figure 3. Neural degeneration in the striatum of A.) Control, B.) 31.47
PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.FJB Striatum
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Supplemental Figure 4. Neural degeneration in the hippocampus of A.) Control, B.)
31.47 PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 5. Neural degeneration in the cerebellum of A.) Control, B.)
31.47 PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 6. Representative image at 72 hours post-injury with 50.72 PSI
blast of GFAP staining acquired at low power (10X objective), using image stitching
techniques, demonstrating regions from which higher power images were acquired
(boxes). While morphological and quantitative studies were conducted using higher
power objectives, the extensive GFAP reactivity is visible near the interface of large
white matter tracts, such as the corpus callosum, with other brain regions (solid arrow).
Some astrocyte reactivity is also apparent within the cortical mantle on the contrecoup
side (dashed arrow), a location consistent with the bleeds observed on gross
examination in brains exposed to moderate-severe blast (Figure 9.3).
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Supplemental Figure 7. Blast exposure was associated with extensive astrocyte
reactivity in the cortex, particularly near the interface with long white matter tracts such
as the corpus callosum. The level of reactivity appears correlated to peak overpressure
exposure, and consequently, blast severity (A. Control, B. 31.47 PSI blast, C. 50.72 PSI
blast, and D. 72.05 PSI blast). Similar immunohistochemical findings were observed in
other brain regions as well, namely the striatum (Appendix Figure 4), hippocampus
(Appendix Figure 5), and cerebellum (Appendix Figures 6 and 7). Images acquired
using 20X objective.
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Supplemental Figure 8. Astrocyte reactivity in the striatum of A.) Control, B.) 31.47
PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 9. Astrocyte reactivity in the hippocampus of A.) control, B.)
31.47 PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 10. Representative image at 72 hours post-injury with 50.72 PSI
blast of GFAP staining acquired at low power (10X objective) demonstrating region from
which higher power images were acquired (box). Visible astrocyte activation occurred
within the white matter in blast-exposed animals.
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Supplemental Figure 11. Astrocyte reactivity in the cerebellum of A.) Control, B.) 31.47
PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 12.
High power (63X objective) visualization of astrocyte
reactivity in animals exposed to blast reveals both an increase in number of astrocytes
as well as significant hypertrophy and branching regardless of brain region but most
notable within the corpus callosum. GFAP reactivity at 72 hours post-exposure to 72.05
PSI blast in the A.) corpus callosum, B.) cortex, C.) striatum, D.) hippocampus, and E.)
cerebellum.
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Supplemental Figure 13. Microglial activation in the cortex of A.) Control, B.) 31.47
PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 14. Microglial activation in the striatum of A.) Control, B.) 31.47
PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 15. Microglial activation in the hippocampus of A.) Control, B.)
31.47 PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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Supplemental Figure 16. Microglial activation in the cerebellum of A.) Control, B.)
31.47 PSI blast, C.) 50.72 PSI blast, and D.) 72.05 PSI blast-exposed animals. Images
acquired using 20X objective.
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